

radioprotective and chemoprotective agents. Processes or preg. compds. of the invention are also disclosed.

IN Reddy, Premkumar E.; Reddy, Ramana M. V.; Bell, Stanley C.

=> d ind l1

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
 IC ICM A61K
 CC 1-6 (Pharmacology)
 Section cross-reference(s): 8, 25
 ST unsatd sulfoxide prepn proliferative disorder treatment; antitumor
 radioprotectant chemoprotectant unsatd sulfoxide
 IT Bone, disease
 (Paget's; α,β -unsatd. sulfoxides for treatment of
 proliferative disorders and as radioprotectants and chemoprotectants)
 IT Fibrosis
 (Peronies and Duputren's fibrosis; α,β -unsatd. sulfoxides
 for treatment of proliferative disorders and as radioprotectants and
 chemoprotectants)
 IT Radioprotectants
 (and chemoprotectants; α,β -unsatd. sulfoxides for treatment
 of proliferative disorders and as radioprotectants and
 chemoprotectants)
 IT Antiarteriosclerotics
 (antiatherosclerotics; α,β -unsatd. sulfoxides for treatment
 of proliferative disorders and as radioprotectants and
 chemoprotectants)
 IT Neoplasm
 (bone marrow; α,β -unsatd. sulfoxides for treatment of
 proliferative disorders and as radioprotectants and chemoprotectants)
 IT Intestine, neoplasm
 (colorectal; α,β -unsatd. sulfoxides for treatment of
 proliferative disorders and as radioprotectants and chemoprotectants)
 IT Antibodies and Immunoglobulins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (conjugates, with α,β -unsatd. sulfoxides;
 α,β -unsatd. sulfoxides for treatment of proliferative
 disorders and as radioprotectants and chemoprotectants)
 IT Disease, animal
 (degenerative, chronic progressive myelodegenerative disease;
 α,β -unsatd. sulfoxides for treatment of proliferative
 disorders and as radioprotectants and chemoprotectants)
 IT Disease, animal
 (ganglioneuromatosis; α,β -unsatd. sulfoxides for treatment
 of proliferative disorders and as radioprotectants and
 chemoprotectants)
 IT Disease, animal
 Newborn
 (hemangiomas in newborn; α,β -unsatd. sulfoxides for
 treatment of proliferative disorders and as radioprotectants and
 chemoprotectants)
 IT Mitosis
 (mitotic phase cell cycle inhibitor; α,β -unsatd. sulfoxides

- for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Antibodies and Immunoglobulins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monoclonal, conjugates, with α,β -unsatd. sulfoxides;
 α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Nervous system, neoplasm
 (neurofibromatosis type 1; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Lung, neoplasm
 (non-small-cell carcinoma; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Disease, animal
 (proliferative; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Carcinoma
 (pulmonary non-small-cell; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Artery, disease
 (restenosis; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Multiple sclerosis
 (secondary progressive; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Alkaloids, biological studies
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (vinca; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Antitumor agents
 Apoptosis
 Atherosclerosis
 Bone marrow, neoplasm
 Brain, neoplasm
 Cardiovascular agents
 Cirrhosis
 Cystic fibrosis
 Cytotoxic agents
 Drug delivery systems
 Drug toxicity
 Human
 Ionizing radiation
 Keloid
 Kidney, neoplasm
 Leukemia
 Lung, neoplasm
 Mammary gland, neoplasm
 Neoplasm
 Nervous system agents
 Ovary, neoplasm
 Oxidizing agents
 Prostate gland, neoplasm
 Radiotherapy
 Sarcoidosis

Skin, neoplasm
 Testis, neoplasm
 (α, β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT Macrolides
 Taxanes
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (α, β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT Sulfoxides
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (α, β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT Sulfides, reactions
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (α, β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT 80449-01-0, Topoisomerase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; α, β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT 57-22-7, Vincristine 64-86-8, Colchicine 64-86-8D, Colchicine, derivs. 7689-03-4, Camptothecin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 65271-80-9, Mitoxantrone
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (α, β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT 852283-21-7P 852283-22-8P 852283-23-9P 852283-75-1P 852283-91-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (α, β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT 852283-15-9 852283-16-0 852283-17-1 852283-18-2 852283-19-3
 852283-20-6 852283-24-0 852283-25-1 852283-26-2 852283-27-3
 852283-28-4 852283-29-5 852283-30-8 852283-31-9 852283-32-0
 852283-33-1 852283-34-2 852283-35-3 852283-36-4 852283-37-5
 852283-38-6 852283-39-7 852283-40-0 852283-41-1 852283-42-2
 852283-43-3 852283-44-4 852283-45-5 852283-46-6 852283-47-7
 852283-48-8 852283-49-9 852283-50-2 852283-51-3 852283-52-4
 852283-53-5 852283-54-6 852283-55-7 852283-56-8 852283-57-9
 852283-58-0 852283-59-1 852283-60-4 852283-61-5 852283-62-6
 852283-63-7 852283-64-8 852283-65-9 852283-66-0 852283-67-1
 852283-68-2 852283-69-3 852283-70-6 852283-71-7 852283-72-8
 852283-73-9 852283-74-0 852283-76-2 852283-77-3 852283-78-4
 852283-79-5 852283-80-8 852283-81-9 852283-82-0 852283-83-1
 852283-84-2 852283-85-3 852283-86-4 852283-87-5 852283-88-6
 852283-89-7 852283-90-0 852283-92-2 852283-93-3 852283-94-4
 852283-95-5 852283-96-6 852283-97-7 852283-98-8 852283-99-9
 852284-00-5 852284-01-6 852284-02-7 852284-03-8 852284-04-9
 852284-05-0 852284-06-1 852284-07-2 852284-08-3 852284-09-4
 852284-10-7 852284-11-8 852284-12-9 852284-13-0 852284-14-1
 852284-15-2 852284-16-3 852284-17-4 852284-18-5 852284-19-6
 852284-20-9 852284-21-0 852284-22-1 852284-23-2 852284-24-3
 852284-25-4 852284-26-5 852284-27-6 852284-28-7 852284-29-8
 852284-30-1 852284-31-2 852284-32-3 852284-33-4 852284-34-5
 852284-35-6 852284-36-7 852284-37-8 852284-38-9 852284-39-0

852284-40-3	852284-41-4	852284-42-5	852284-43-6	852284-44-7
852284-45-8	852284-46-9	852284-47-0	852284-48-1	852284-49-2
852284-50-5	852284-51-6	852284-52-7	852284-53-8	852284-54-9
852284-55-0	852284-56-1	852284-57-2	852284-58-3	852284-59-4
852284-60-7	852284-61-8	852284-62-9	852284-63-0	852284-64-1
852284-65-2	852284-66-3	852284-67-4	852284-68-5	852284-69-6
852284-70-9	852284-71-0	852284-72-1	852284-73-2	852284-74-3
852284-75-4	852284-76-5	852284-77-6	852284-78-7	852284-79-8
852284-80-1	852284-81-2	852284-82-3	852284-83-4	852284-84-5
852284-85-6	852284-86-7	852284-87-8	852284-88-9	852284-89-0
852284-90-3	852284-91-4	852284-92-5	852284-93-6	852284-94-7
852284-95-8	852284-96-9	852284-97-0	852284-98-1	852284-99-2
852285-00-8	852285-01-9	852285-02-0	852285-03-1	852285-04-2
852285-05-3	852285-06-4	852285-07-5	852285-08-6	852285-09-7
852285-10-0	852285-11-1	852285-12-2	852285-13-3	852285-14-4
852285-15-5	852285-16-6	852285-17-7	852285-18-8	852285-19-9
852285-20-2	852285-21-3	852285-22-4	852285-23-5	852285-24-6
852285-25-7	852285-26-8	852285-27-9	852285-28-0	852285-29-1
852285-30-4	852285-31-5	852285-32-6	852285-33-7	852285-34-8
852285-35-9	852285-36-0	852285-37-1	852285-38-2	852285-39-3
852285-40-6	852285-41-7	852285-42-8	852285-43-9	852285-44-0
852285-45-1	852285-46-2	852285-47-3	852285-48-4	852285-49-5
852285-50-8	852285-51-9	852285-52-0	852285-53-1	852285-54-2
852285-55-3				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT	852285-56-4	852285-57-5	852285-58-6	852285-59-7	852285-60-0
	852285-61-1	852285-62-2	852285-63-3	852285-64-4	852285-65-5
	852285-66-6	852285-67-7	852285-68-8	852285-69-9	852285-70-2
	852285-71-3	852285-72-4	852285-73-5	852285-74-6	852285-75-7
	852285-76-8	852285-77-9	852285-80-4		

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT	68-11-1, Mercaptoacetic acid, reactions	104-83-6	619-66-9	824-94-2
	830-79-5	6378-19-4	529502-39-4	

RL: RCT (Reactant); RACT (Reactant or reagent)

(α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT	28203-55-6P	125174-87-0P	852285-78-0P	852285-79-1P
----	-------------	--------------	--------------	--------------

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

=> d que 12

L2 1 SEA FILE=WPIX ABB=ON PLU=ON US2006-574993/APPS

=> d iall code 12

YOU HAVE REQUESTED DATA FROM FILE 'WPIX' - CONTINUE? (Y)/N:y

ACCESSION NUMBER: 2005-405099 [41] WPIX
 DOC. NO. CPI: C2005-124931 [41]
 TITLE: New alpha, beta-unsaturated sulfoxide compounds used for treating proliferative disorders e.g. hemangiomas in newborn, secondary progressive multiple sclerosis, neurofibromatosis, ganglioneuromatosis and cancer
 DERWENT CLASS: B05
 INVENTOR: BELL S; BELL S C; REDDY P; REDDY P E; REDDY R; REDDY R M V; REDDY E P; REDDY M V R
 PATENT ASSIGNEE: (UTEM-C) UNIV TEMPLE; (ONCO-N) ONCONOVA THERAPEUTICS INC; (BELL-I) BELL S C; (REDD-I) REDDY E P; (REDD-I) REDDY M V R
 COUNTRY COUNT: 107

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2005046599	A2	20050526	(200541)*	EN	120	[0]
EP 1689706	A2	20060816	(200654)	EN		
AU 2004289281	A1	20050526	(200674)	EN		
US 20060280746	A1	20061214	(200701)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2005046599	A2	WO 2004-US37293	20041108
AU 2004289281	A1	AU 2004-289281	20041108
EP 1689706	A2	EP 2004-816944	20041108
EP 1689706	A2	WO 2004-US37293	20041108
US 20060280746	A1 Provisional	US 2003-520523P	20031114
US 20060280746	A1	WO 2004-US37293	20041108
US 20060280746	A1	US 2006-574993 20060406	

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1689706	A2 Based on	WO 2005046599 A
AU 2004289281	A1 Based on	WO 2005046599 A

PRIORITY APPLN. INFO: US 2003-520523P 20031114
US 2006-574993 20060406

INT. PATENT CLASSIF.:

IPC ORIGINAL: A61K0031-095 [I,C]; A61K0031-10 [I,A]; A61K0031-12 [I,A]; A61K0031-12 [I,C]; A61K0031-34 [I,A]; A61K0031-34 [I,C]; A61K0031-455 [I,A]; A61K0031-455 [I,C]; A61K0039-395 [I,A]; A61K0039-395 [I,C]; C07C0317-00 [I,C]; C07C0317-10 [I,A]; C07C0321-00 [I,C]; C07C0321-28 [I,A]
 IPC RECLASSIF.: A61K [I,S]; A61K0031-095 [I,C]; A61K0031-10 [I,A]; C07C0317-00 [I,C]; C07C0317-10 [I,A]

BASIC ABSTRACT:

WO 2005046599 A2 UPAB: 20051222
 NOVELTY - alpha,beta-unsaturated sulfoxide compounds (I), are new.
 DETAILED DESCRIPTION - alpha,beta-unsaturated sulfoxide compounds of formula (I) and their salts are new.
 A, B1 = aryl or heteroaryl (both optionally substituted);
 n = 0 or 1, and
 R1 = H, 1-8C hydrocarbyl, CN, CO2(1-6C alkyl) or halo(1-6C alkyl),

provided that when A and B1 are both phenyl, at least one of A or B1 is substituted.

The conformation of the substituents on the carbon-carbon double bond is either E- or Z- conformation. The conformation of the substituents on the sulfoxide sulfur atom is R- and/or S- conformation. The asterisk indicates that, when R1 is not H, the conformation of the substituents on the designated C-atom is R- and/or S- conformation. INDEPENDENT CLAIMS are also included for:

- (1) a conjugate (I-1) of formula (I)-L-Ab;
- (2) a composition comprising (I-1);
- (3) reducing or eliminating the effects of ionizing radiation on normal cells in an individual who has incurred or is at risk of incurring exposure to ionizing radiation which comprises administering at least one radioprotective compound (I) prior to or after exposure to ionizing radiation;
- (4) treating a proliferative disorder which comprises administering (I) and therapeutic ionizing radiation;
- (5) reducing the number of malignant cells in bone marrow which comprises removing a portion of bone marrow, administering at least one radioprotective compound (I), and irradiating the bone marrow with ionizing radiation;
- (6) protecting from cytotoxic side effects of the administration of a mitotic phase cell cycle inhibitor or a topoisomerase inhibitor which comprises administering, in advance of administration of the inhibitor, at least one cytoprotective compound (I), where the mitotic phase cell cycle inhibitor or topoisomerase inhibitor is not (I);
- (7) preparation of (I);
- (8) preparation of alpha,beta-unsaturated sulfone compounds of formula (V);
- (9) acid intermediate compounds of formula (II);
- (10) alpha,beta-unsaturated sulfanyl compounds of formula (IV), and
- (11) an isolated optical isomer of (I).

Ab = an antibody, and

L = a single covalent bond or a linking group covalently linking the (I) to the antibody.

ACTIVITY - Cytostatic; Neuroprotective; Vulnerary; Osteopathic; Antiinflammatory; Hepatotropic; Antiarteriosclerotic; Vasotropic.

In a test using the prostate tumor cell line DU-145, results showed that (E)-2,4,6-trimethoxystyryl-4-methoxy-3-aminobenzylsulfoxide (Ia) exhibited a GI50 value of 10-100 nM.

MECHANISM OF ACTION - None given.

USE - Used for inducing apoptosis of tumor cells and to treat a proliferative disorder, particularly hemangiomas in newborn, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis; ganglioneuromatosis, keloid formation, Paget's Disease of the bone, fibrocystic disease, sarcoidosis, Peronies and Duputren's fibrosis, cirrhosis, atherosclerosis and vascular restenosis, and cancer such as cancer of ovarian, breast, prostate, testicular, lung, renal, colorectal, skin, or brain or leukemia (claimed).

ADVANTAGE - (I) protects an individual from cytotoxic side effects of the administration of a mitotic phase cell cycle inhibitor or a topoisomerase inhibitor. (I) reduces or eliminates the effects of ionizing radiation on normal cells (all claimed). MANUAL CODE: CPI: B04-G05; B04-G21; B04-G22; B07-H; B10-A09B; B10-A10;

B14-C03; B14-F01G; B14-F07; B14-H01; B14-H03; B14-J01;
B14-M01; B14-N01; B14-N12; B14-N17B; B14-S01

AN 2005-405099 [41] WPIX

DC B05

IPCI A61K0031-095 [I,C]; A61K0031-10 [I,A]; A61K0031-12 [I,A]; A61K0031-12 [I,C]; A61K0031-34 [I,A]; A61K0031-34 [I,C]; A61K0031-455 [I,A]; A61K0031-455 [I,C]; A61K0039-395 [I,A]; A61K0039-395 [I,C]; C07C0317-00 [I,C]; C07C0317-10 [I,A]; C07C0321-00 [I,C]; C07C0321-28 [I,A]

IPCR A61K [I,S]; A61K0031-095 [I,C]; A61K0031-10 [I,A]; C07C0317-00 [I,C];
C07C0317-10 [I,A]

MC CPI: B04-G05; B04-G21; B04-G22; B07-H; B10-A09B; B10-A10; B14-C03;
B14-F01G; B14-F07; B14-H01; B14-H03; B14-J01; B14-M01; B14-N01;
B14-N12; B14-N17B; B14-S01

CMC UPB 20051222

M1 *98* C216 G015 G017 G100 H5 H543 H6 H601 H608 H684 H7 H721 H8 J0 J012
J2 J271 J3 J341 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321
M322 M332 M342 M344 M349 M362 M373 M391 M392 M414 M423 M431 M510
M520 M532 M540 M782 M905 M904
DCN: RAI2CY-K RAI2CY-M RAI2CY-Q
DCR: 1086022-K 1086022-M 1086022-Q

M2 *01* C216 G013 G020 G111 G221 H6 H601 H641 H7 H721 K0 K4 K442 M280
M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540 M710
M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633
P646 P714 P721 P942 M905 M904
DCN: RAI110-N RAI110-P RAI110-T
DCR: 1084222-N 1084222-P 1084222-T

M2 *02* C216 G013 G020 G111 G221 H6 H602 H641 H7 H721 K0 K4 K442 M280
M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540 M710
M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633
P646 P714 P721 P942 M905 M904
DCN: RAI11Q-N RAI11Q-P RAI11Q-T
DCR: 1084224-N 1084224-P 1084224-T

M2 *03* C216 G013 G020 G111 G221 H6 H603 H641 H7 H721 K0 K4 K442 M280
M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540 M710
M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633
P646 P714 P721 P942 M905 M904
DCN: RAI11R-N RAI11R-P RAI11R-T
DCR: 1084225-N 1084225-P 1084225-T

M2 *04* C216 G011 G020 G111 G221 H3 H341 H7 H721 K0 K4 K442 M280 M311
M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540 M710 M720
N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
P714 P721 P942 M905 M904
DCN: RAI11S-N RAI11S-P RAI11S-T
DCR: 1084226-N 1084226-P 1084226-T

M2 *05* C216 G012 G020 G111 G221 H3 H341 H7 H721 K0 K4 K442 M280 M311
M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540 M710 M720
N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
P714 P721 P942 M905 M904
DCN: RAI11T-N RAI11T-P RAI11T-T
DCR: 1084227-N 1084227-P 1084227-T

M2 *06* C216 G013 G020 G111 G221 H3 H341 H7 H721 K0 K4 K442 M280 M311
M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540 M710 M720
N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
P714 P721 P942 M905 M904
DCN: RAI11U-N RAI11U-P RAI11U-T
DCR: 1084228-N 1084228-P 1084228-T

M2 *07* C216 G015 G017 G100 H1 H100 H141 H5 H543 H8 K0 K4 K442 M210 M211
M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532
M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523
P528 P633 P646 P714 P721 P942 M905 M904
DCN: RAI127-N RAI127-P RAI127-T
DCR: 1084243-N 1084243-P 1084243-T

M2 *08* C216 G015 G017 G100 H4 H401 H441 H5 H543 H8 K0 K4 K442 M210 M211
M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532
M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523
P528 P633 P646 P714 P721 P942 M905 M904
DCN: RAI128-N RAI128-P RAI128-T
DCR: 1084244-N 1084244-P 1084244-T

=> d que l1

L1 1 SEA FILE=HCAPLUS ABB=ON PLU=ON US2006-574993/APPS

=> d ibib ed ab in l1

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:451126 HCAPLUS Full-text

DOCUMENT NUMBER: 143:1247

TITLE: α,β -Unsaturated sulfoxides for treating proliferative disorders and as radioprotective and chemoprotective agents

INVENTOR(S): Reddy, Premkumar E.; Reddy, Ramana M. V.; Bell, Stanley C.

PATENT ASSIGNEE(S): Temple University-of the Commonwealth System of Higher Education, USA; Onconova Therapeutics Inc.

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046599	A2	20050526	WO 2004-US37293	20041108
WO 2005046599	A3	20051006		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004289281	A1	20050526	AU 2004-289281	20041108
CA 2546495	A1	20050526	CA 2004-2546495	20041108
EP 1689706	A2	20060816	EP 2004-816944	20041108
R: AT, BE, CH, LI, CY, BG, CZ				
US 2006280746	A1	20061214	US 2006-574993	20060406 <--
PRIORITY APPLN. INFO.:			US 2003-520523P	P 20031114
			WO 2004-US37293	W 20041108

OTHER SOURCE(S): CASREACT 143:1247; MARPAT 143:1247

ED Entered STN: 27 May 2005

AB $\alpha\beta$ -Unsatd. sulfoxides Ar1[CH(R1)]nS(O)CH=CHAr2 [Ar1, Ar2 = (un)substituted (hetero)aryl (when Ar1 and Ar2 are both Ph, at least one of Ar1 and Ar2 is substituted); n = 0, 1; R1 = H, C1-8 hydrocarbyl, CN, etc.; conformation of substituents on carbon-carbon double bond is E or Z; conformation of substituents on sulfoxide S atom is R-, S- or any mixture of R- and S-; when R1 other than H, conformation of substituents on carbon atom to which R1 is attached is R-, S- or any mixture of R- and S-] are disclosed which are useful as antiproliferative agents including e.g. anticancer agents and as

M2 *09* C216 G015 G017 G100 H3 H341 H5 H543 H8 K0 K4 K442 M210 M211 M272
M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
P633 P646 P714 P721 P942 M905 M904
DCN: RAI129-N RAI129-P RAI129-T
DCR: 1084245-N 1084245-P 1084245-T

M2 *10* C216 C316 G015 G017 G100 H5 H543 H7 H721 H8 J0 J011 J1 J171 K0
K3 K353 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332
M342 M349 M373 M381 M391 M392 M414 M510 M520 M532 M540 M710 M720
N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
P714 P721 P942 M905 M904
DCN: RAI12A-N RAI12A-P RAI12A-T
DCR: 1084246-N 1084246-P 1084246-T

M2 *11* C216 G015 G017 G100 H5 H543 H7 H721 H8 K0 K4 K442 L2 L250 M210
M211 M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520
M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517
P523 P528 P633 P646 P714 P721 P942 M905 M904
DCN: RAI12B-N RAI12B-P RAI12B-T
DCR: 1084247-N 1084247-P 1084247-T

M2 *12* C216 G015 G017 G100 H5 H543 H7 H721 H8 J0 J012 J1 J171 J3 J341
K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332 M342
M373 M382 M391 M392 M414 M510 M520 M532 M540 M710 M720 N211 N241
N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721
P942 M905 M904
DCN: RAI12C-N RAI12C-P RAI12C-T
DCR: 1084248-N 1084248-P 1084248-T

M2 *13* C216 G015 G017 G100 H1 H102 H141 H5 H543 H7 H721 H8 J0 J011 J1
J171 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332
M342 M349 M373 M381 M391 M392 M414 M510 M520 M532 M540 M710 M720
N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
P714 P721 P942 M905 M904
DCN: RAI12D-N RAI12D-P RAI12D-T
DCR: 1084249-N 1084249-P 1084249-T

M2 *14* C216 G015 G016 G017 G100 H3 H342 H5 H543 H7 H721 H8 J0 J011 J3
J331 K0 K4 K442 M1 M121 M136 M210 M211 M272 M283 M311 M312 M321
M332 M342 M373 M392 M414 M510 M520 M533 M540 M710 M720 N211 N241
N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721
P942 M905 M904
DCN: RAI12E-N RAI12E-P RAI12E-T
DCR: 1084250-N 1084250-P 1084250-T

M2 *15* C216 G015 G016 G017 G100 H1 H100 H102 H142 H5 H543 H7 H721 H8 J0
J011 J3 J331 K0 K4 K442 M1 M121 M143 M210 M211 M272 M283 M311
M312 M321 M332 M342 M373 M392 M414 M510 M520 M533 M540 M710 M720
N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
P714 P721 P942 M905 M904
DCN: RAI12F-N RAI12F-P RAI12F-T
DCR: 1084251-N 1084251-P 1084251-T

M2 *16* C216 G015 G017 G100 H5 H543 H6 H602 H681 H7 H721 H8 J0 J011 J3
J341 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332
M342 M349 M362 M373 M391 M392 M414 M510 M520 M532 M540 M710 M720
N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
P714 P721 P942 M905 M904
DCN: RAI12G-N RAI12G-P RAI12G-T
DCR: 1084252-N 1084252-P 1084252-T

M2 *17* C216 F011 F014 F553 G015 G017 G100 H1 H182 H2 H202 H5 H543 H7
H721 H8 J0 J011 J3 J341 K0 K4 K442 M210 M211 M272 M273 M281 M283
M311 M312 M321 M322 M332 M342 M349 M373 M381 M391 M392 M413 M510
M521 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446
P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
DCN: RAI12H-N RAI12H-P RAI12H-T

DCR: 1084253-N 1084253-P 1084253-T
M2 *18* C216 G010 G015 G017 G100 H5 H543 H7 H721 H8 J0 J011 J3 J331 K0
K4 K442 M1 M121 M136 M210 M211 M272 M283 M311 M312 M321 M332
M342 M373 M392 M414 M510 M520 M533 M540 M710 M720 N211 N241 N243
N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721 P942
M905 M904
DCN: RAI2C5-N RAI2C5-P RAI2C5-T
DCR: 1085992-N 1085992-P 1085992-T
M2 *19* C216 G013 G015 G017 G100 H3 H341 H5 H543 H7 H721 H8 J0 J011 J3
J331 K0 K4 K442 M1 M121 M136 M210 M211 M272 M283 M311 M312 M321
M332 M342 M373 M392 M414 M510 M520 M533 M540 M710 M720 N211 N241
N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721
P942 M905 M904
DCN: RAI2C6-N RAI2C6-P RAI2C6-T
DCR: 1085993-N 1085993-P 1085993-T
M2 *20* C216 G013 G015 G017 G100 H1 H100 H141 H5 H543 H7 H721 H8 J0 J011
J3 J331 K0 K4 K442 M1 M121 M136 M210 M211 M272 M283 M311 M312
M321 M332 M342 M373 M392 M414 M510 M520 M533 M540 M710 M720 N211
N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714
P721 P942 M905 M904
DCN: RAI2C7-N RAI2C7-P RAI2C7-T
DCR: 1085994-N 1085994-P 1085994-T
M2 *21* C216 G013 G015 G017 G100 H3 H341 H5 H543 H7 H721 H8 K0 K4 K442
L3 L355 M1 M121 M134 M210 M211 M272 M283 M311 M312 M321 M332
M342 M373 M392 M414 M510 M520 M533 M540 M710 M720 N211 N241 N243
N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721 P942
M905 M904
DCN: RAI2C8-N RAI2C8-P RAI2C8-T
DCR: 1085995-N 1085995-P 1085995-T
M2 *22* C216 G015 G017 G100 H1 H102 H141 H5 H543 H7 H721 H8 K0 K4 K442
M210 M211 M272 M273 M281 M283 M311 M312 M321 M332 M342 M373 M392
M414 M510 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513
P420 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
DCN: RAI2C9-N RAI2C9-P RAI2C9-T
DCR: 1085996-N 1085996-P 1085996-T
M2 *23* C216 G015 G017 G100 H5 H543 H7 H721 H8 J0 J011 J3 J341 K0 K4
K442 M210 M211 M262 M272 M281 M283 M311 M312 M321 M332 M342 M373
M392 M414 M510 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512
N513 P420 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905
M904
DCN: RAI2CA-N RAI2CA-P RAI2CA-T
DCR: 1085997-N 1085997-P 1085997-T
M2 *24* C216 C316 G015 G017 G019 G100 H3 H342 H5 H543 H7 H721 H8 K0 K3
K353 K4 K442 M1 M121 M147 M210 M211 M272 M283 M311 M312 M321
M332 M342 M373 M392 M414 M510 M520 M533 M540 M710 M720 N211 N241
N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721
P942 M905 M904
DCN: RAI2CB-N RAI2CB-P RAI2CB-T
DCR: 1085998-N 1085998-P 1085998-T
M2 *25* C216 C316 G015 G017 G019 G100 H1 H101 H142 H5 H543 H7 H721 H8 K0
K3 K353 K4 K442 M1 M121 M147 M210 M211 M272 M283 M311 M312 M321
M332 M342 M373 M392 M414 M510 M520 M533 M540 M710 M720 N211 N241
N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721
P942 M905 M904
DCN: RAI2CC-N RAI2CC-P RAI2CC-T
DCR: 1085999-N 1085999-P 1085999-T
M2 *26* C216 G015 G017 G100 H1 H103 H181 H5 H543 H7 H721 H8 J0 J011 J3
J341 K0 K4 K442 M210 M211 M272 M273 M282 M283 M311 M312 M321
M322 M332 M342 M349 M373 M381 M391 M392 M414 M510 M520 M532 M540
M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528

P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2CD-N RAI2CD-P RAI2CD-T
 DCR: 1086000-N 1086000-P 1086000-T
 M2 *27* C216 G015 G017 G100 H1 H102 H141 H5 H543 H7 H721 H8 J0 J011 J1
 J171 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M331
 M332 M340 M342 M349 M373 M381 M391 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2CE-N RAI2CE-P RAI2CE-T
 DCR: 1086001-N 1086001-P 1086001-T
 M2 *28* C216 F011 F014 F553 G013 G015 G017 G100 H1 H141 H181 H2 H202 H5
 H543 H7 H721 H8 J0 J011 J3 J331 K0 K4 K442 M1 M121 M136 M210
 M211 M272 M273 M281 M283 M311 M312 M321 M332 M342 M373 M392 M413
 M510 M521 M533 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420
 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2CF-N RAI2CF-P RAI2CF-T
 DCR: 1086002-N 1086002-P 1086002-T
 M2 *29* C216 G015 G017 G100 H4 H401 H481 H5 H543 H7 H721 H8 J0 J011 J3
 J341 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332
 M342 M349 M373 M381 M391 M392 M414 M510 M520 M532 M540 M710 M720
 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
 P714 P721 P942 M905 M904
 DCN: RAI2CG-N RAI2CG-P RAI2CG-T
 DCR: 1086003-N 1086003-P 1086003-T
 M2 *30* C216 F012 F431 G015 G017 G100 H5 H543 H7 H721 H8 J0 J011 J3 J341
 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332 M342
 M372 M373 M391 M392 M413 M510 M521 M532 M540 M710 M720 N211 N241
 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721
 P942 M905 M904
 DCN: RAI2CH-N RAI2CH-P RAI2CH-T
 DCR: 1086004-N 1086004-P 1086004-T
 M2 *31* C216 G015 G017 G100 H4 H401 H481 H5 H543 H7 H721 H8 J0 J011 J3
 J341 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M331
 M332 M340 M342 M349 M373 M381 M391 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2CJ-N RAI2CJ-P RAI2CJ-T
 DCR: 1086006-N 1086006-P 1086006-T
 M2 *32* C216 G015 G017 G100 H4 H401 H481 H5 H543 H7 H721 H8 J0 J011 J3
 J341 K0 K4 K442 M210 M211 M272 M283 M311 M312 M313 M321 M331
 M332 M340 M342 M349 M373 M381 M391 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2CK-N RAI2CK-P RAI2CK-T
 DCR: 1086007-N 1086007-P 1086007-T
 M2 *33* C216 G015 G017 G100 H5 H543 H6 H685 H7 H721 H8 J0 J011 J3 J341
 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332 M342
 M344 M349 M362 M373 M391 M392 M414 M510 M520 M532 M540 M710 M720
 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
 P714 P721 P942 M905 M904
 DCN: RAI2CL-N RAI2CL-P RAI2CL-T
 DCR: 1086008-N 1086008-P 1086008-T
 M2 *34* C216 C316 G015 G017 G100 H5 H543 H6 H685 H7 H721 H8 K0 K3 K353
 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332 M342 M344
 M362 M373 M391 M392 M414 M510 M520 M532 M540 M710 M720 N211 N241
 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721
 P942 M905 M904
 DCN: RAI2CM-N RAI2CM-P RAI2CM-T
 DCR: 1086009-N 1086009-P 1086009-T
 M2 *35* C216 G015 G017 G100 H5 H543 H7 H721 H8 J0 J012 J1 J171 J3 J341

K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332 M342
 M373 M382 M391 M392 M414 M510 M520 M532 M540 M710 M720 N211 N241
 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721
 P942 M905 M904
 DCN: RAI2CN-N RAI2CN-P RAI2CN-T
 DCR: 1086011-N 1086011-P 1086011-T
 M2 *36* C017 C216 G015 G017 G100 H5 H543 H7 H721 H8 J0 J011 J3 J341 K0
 K4 K442 L5 L512 M210 M211 M272 M283 M311 M312 M321 M322 M332
 M342 M373 M382 M391 M392 M414 M510 M520 M532 M540 M710 M720 N211
 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714
 P721 P942 M905 M904
 DCN: RAI2CO-N RAI2CO-P RAI2CO-T
 DCR: 1086012-N 1086012-P 1086012-T
 M2 *37* C216 G015 G017 G100 H5 H543 H7 H721 H8 J0 J013 J1 J171 J2 J271
 J3 J341 K0 K4 K442 M210 M211 M272 M283 M311 M312 M322 M332 M342
 M349 M373 M381 M382 M391 M392 M414 M510 M520 M532 M540 M710 M720
 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
 P714 P721 P942 M905 M904
 DCN: RAI2CP-N RAI2CP-P RAI2CP-T
 DCR: 1086013-N 1086013-P 1086013-T
 M2 *38* C216 G015 G017 G100 H5 H543 H7 H721 H8 J0 J012 J1 J171 J3 J341
 K0 K4 K442 M210 M211 M272 M283 M311 M312 M313 M321 M332 M342
 M373 M382 M391 M392 M414 M510 M520 M532 M540 M710 M720 N211 N241
 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721
 P942 M905 M904
 DCN: RAI2CQ-N RAI2CQ-P RAI2CQ-T
 DCR: 1086014-N 1086014-P 1086014-T
 M2 *39* C216 G015 G017 G100 H1 H102 H141 H5 H543 H7 H721 H8 J0 J011 J1
 J171 K0 K4 K442 M210 M211 M272 M283 M311 M312 M313 M321 M332
 M342 M373 M381 M391 M392 M414 M510 M520 M532 M540 M710 M720 N211
 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714
 P721 P942 M905 M904
 DCN: RAI2CR-N RAI2CR-P RAI2CR-T
 DCR: 1086015-N 1086015-P 1086015-T
 M2 *40* M417 M423 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517
 P523 P528 P633 P646 P714 P721 P942 M905
 DCN: RA00C8-N RA00C8-P RA00C8-T
 DCR: 184587-N 184587-P 184587-T
 M2 *41* C216 G015 G017 G100 H1 H102 H141 H5 H543 H7 H721 H8 J0 J011 J1
 J171 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332
 M342 M373 M381 M391 M392 M414 M510 M520 M532 M540 M710 M720 N211
 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714
 P721 P942 M905 M904
 DCN: RAI2CS-N RAI2CS-P RAI2CS-T
 DCR: 1086016-N 1086016-P 1086016-T
 M2 *42* C216 G015 G017 G100 H5 H543 H7 H721 H8 K0 K4 K442 L4 L462 M210
 M211 M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520
 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517
 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2CT-N RAI2CT-P RAI2CT-T
 DCR: 1086017-N 1086017-P 1086017-T
 M2 *43* C216 C316 G013 G015 G017 G100 H5 H543 H7 H721 H8 K0 K3 K353 K4
 K442 M1 M121 M147 M210 M211 M272 M283 M311 M312 M321 M332 M342
 M373 M392 M414 M510 M520 M533 M540 M710 M720 N211 N241 N243 N312
 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721 P942
 M905 M904
 DCN: RAI2CU-N RAI2CU-P RAI2CU-T
 DCR: 1086018-N 1086018-P 1086018-T
 M2 *44* C216 G015 G017 G100 H5 H543 H7 H721 H8 J0 J012 J2 J271 J3 J341
 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332 M342

M373 M382 M391 M392 M414 M510 M520 M532 M540 M710 M720 N211 N241
 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721
 P942 M905 M904
 DCN: RAI2CV-N RAI2CV-P RAI2CV-T
 DCR: 1086019-N 1086019-P 1086019-T
 M2 *45* C216 G015 G017 G100 H5 H543 H7 H721 H8 J0 J012 J2 J271 J3 J341
 K0 K4 K442 M210 M211 M212 M272 M283 M311 M312 M321 M322 M332
 M342 M373 M382 M391 M392 M414 M510 M520 M532 M540 M710 M720 N211
 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646 P714
 P721 P942 M905 M904
 DCN: RAI2CW-N RAI2CW-P RAI2CW-T
 DCR: 1086020-N 1086020-P 1086020-T
 M2 *46* C216 G015 G017 G100 H5 H543 H6 H601 H608 H684 H685 H7 H721 H8 J0
 J011 J3 J341 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322
 M332 M342 M344 M349 M362 M373 M391 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2CX-N RAI2CX-P RAI2CX-T
 DCR: 1086021-N 1086021-P 1086021-T
 M2 *47* C216 G015 G017 G100 H5 H543 H6 H601 H609 H684 H689 H7 H721 H8 J0
 J012 J1 J171 J3 J341 K0 K4 K442 M210 M211 M272 M283 M311 M312
 M321 M322 M332 M342 M344 M349 M362 M373 M391 M392 M414 M510 M520
 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517
 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2CZ-N RAI2CZ-P RAI2CZ-T
 DCR: 1086023-N 1086023-P 1086023-T
 M2 *48* C216 G015 G017 G100 H1 H100 H181 H5 H543 H7 H721 H8 J0 J011 J3
 J341 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321 M322 M332
 M342 M349 M373 M381 M391 M392 M414 M510 M520 M532 M540 M710 M720
 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
 P714 P721 P942 M905 M904
 DCN: RAI2D0-N RAI2D0-P RAI2D0-T
 DCR: 1086024-N 1086024-P 1086024-T
 M2 *49* C216 G015 G017 G100 H5 H543 H6 H601 H608 H684 H7 H721 H8 J0 J012
 J1 J171 J3 J341 K0 K4 K442 M210 M211 M272 M283 M311 M312 M321
 M322 M332 M342 M344 M349 M362 M373 M391 M392 M414 M510 M520 M532
 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523
 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2D1-N RAI2D1-P RAI2D1-T
 DCR: 1086025-N 1086025-P 1086025-T
 M2 *50* C216 G015 G017 G100 H1 H103 H181 H5 H543 H6 H601 H608 H684 H7
 H721 H8 J0 J011 J3 J341 K0 K4 K442 M210 M211 M272 M273 M282 M283
 M311 M312 M321 M322 M332 M342 M344 M349 M362 M373 M391 M392 M414
 M510 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420
 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2D2-N RAI2D2-P RAI2D2-T
 DCR: 1086026-N 1086026-P 1086026-T
 M2 *51* C216 G013 G019 G100 H6 H601 H641 H7 H721 J0 J011 J1 J131 K0 K4
 K442 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532
 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523
 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2D3-N RAI2D3-P RAI2D3-T
 DCR: 1086027-N 1086027-P 1086027-T
 M2 *52* C216 G013 G019 G100 H6 H604 H641 H7 H721 J0 J011 J1 J131 K0 K4
 K442 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532
 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523
 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2D4-N RAI2D4-P RAI2D4-T
 DCR: 1086028-N 1086028-P 1086028-T
 M2 *53* C216 G013 G019 G100 H6 H602 H641 H7 H721 J0 J011 J1 J131 K0 K4

K442 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532
 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523
 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2D5-N RAI2D5-P RAI2D5-T
 DCR: 1086029-N 1086029-P 1086029-T
 M2 *54* C216 G013 G015 G100 H1 H103 H181 H6 H601 H602 H642 H7 H721 J5
 J581 K0 K4 K442 M210 M211 M273 M282 M311 M312 M321 M322 M332
 M342 M349 M373 M381 M391 M392 M414 M510 M520 M532 M540 M710 M720
 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633 P646
 P714 P721 P942 M905 M904
 DCN: RAI2D6-N RAI2D6-P RAI2D6-T
 DCR: 1086030-N 1086030-P 1086030-T
 M2 *55* C216 G013 G015 G100 H6 H601 H603 H608 H643 H7 H721 K0 K4 K442
 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2D7-N RAI2D7-P RAI2D7-T
 DCR: 1086031-N 1086031-P 1086031-T
 M2 *56* C216 G013 G015 G100 H1 H100 H141 H6 H601 H602 H642 H7 H721 K0 K4
 K442 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532
 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523
 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2D8-N RAI2D8-P RAI2D8-T
 DCR: 1086032-N 1086032-P 1086032-T
 M2 *57* C216 G013 G018 G100 H6 H601 H609 H643 H7 H721 K0 K4 K442 M280
 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540 M710
 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633
 P646 P714 P721 P942 M905 M904
 DCN: RAI2D9-N RAI2D9-P RAI2D9-T
 DCR: 1086033-N 1086033-P 1086033-T
 M2 *58* C216 G013 G018 G100 H6 H601 H602 H609 H643 H7 H721 K0 K4 K442
 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DA-N RAI2DA-P RAI2DA-T
 DCR: 1086034-N 1086034-P 1086034-T
 M2 *59* C216 G013 G018 G100 H6 H601 H603 H609 H643 H7 H721 K0 K4 K442
 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DB-N RAI2DB-P RAI2DB-T
 DCR: 1086035-N 1086035-P 1086035-T
 M2 *60* C216 G013 G018 G100 H6 H601 H609 H643 H7 H721 K0 K4 K442 M280
 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540 M710
 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633
 P646 P714 P721 P942 M905 M904
 DCN: RAI2DC-N RAI2DC-P RAI2DC-T
 DCR: 1086036-N 1086036-P 1086036-T
 M2 *61* C216 G013 G018 G100 H6 H601 H602 H609 H643 H7 H721 K0 K4 K442
 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DD-N RAI2DD-P RAI2DD-T
 DCR: 1086037-N 1086037-P 1086037-T
 M2 *62* C216 G013 G018 G100 H6 H601 H603 H609 H643 H7 H721 K0 K4 K442
 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DE-N RAI2DE-P RAI2DE-T
 DCR: 1086038-N 1086038-P 1086038-T

M2 *63* C216 G015 G018 G100 H6 H601 H602 H608 H609 H643 H7 H721 K0 K4
 K442 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532
 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523
 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DF-N RAI2DF-P RAI2DF-T
 DCR: 1086039-N 1086039-P 1086039-T

M2 *64* C216 G013 G018 G100 H6 H601 H604 H609 H643 H7 H721 K0 K4 K442
 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DG-N RAI2DG-P RAI2DG-T
 DCR: 1086040-N 1086040-P 1086040-T

M2 *65* C216 G013 G017 G100 H3 H342 H4 H401 H441 H6 H601 H641 H7 H721 H8
 K0 K4 K442 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510
 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446
 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DH-N RAI2DH-P RAI2DH-T
 DCR: 1086041-N 1086041-P 1086041-T

M2 *66* C216 G013 G017 G100 H3 H342 H4 H401 H441 H6 H603 H641 H7 H721 H8
 K0 K4 K442 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510
 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446
 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DI-N RAI2DI-P RAI2DI-T
 DCR: 1086042-N 1086042-P 1086042-T

M2 *67* C216 G013 G017 G100 H3 H342 H4 H401 H441 H6 H602 H641 H7 H721 H8
 K0 K4 K442 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510
 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446
 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DJ-N RAI2DJ-P RAI2DJ-T
 DCR: 1086043-N 1086043-P 1086043-T

M2 *68* C216 G015 G017 G100 H3 H342 H4 H401 H441 H6 H602 H608 H642 H7
 H721 H8 K0 K4 K442 M280 M311 M312 M321 M332 M342 M373 M392 M414
 M510 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420
 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DK-N RAI2DK-P RAI2DK-T
 DCR: 1086044-N 1086044-P 1086044-T

M2 *69* C216 G013 G017 G100 H5 H543 H7 H721 H8 K0 K4 K442 M210 M211 M272
 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DL-N RAI2DL-P RAI2DL-T
 DCR: 1086045-N 1086045-P 1086045-T

M2 *70* C216 G013 G017 G100 H5 H543 H7 H721 H8 K0 K4 K442 M210 M211 M240
 M272 M281 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520
 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517
 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DM-N RAI2DM-P RAI2DM-T
 DCR: 1086046-N 1086046-P 1086046-T

M2 *71* C216 G013 G017 G100 H5 H543 H7 H721 H8 K0 K4 K442 M210 M211 M272
 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DN-N RAI2DN-P RAI2DN-T
 DCR: 1086047-N 1086047-P 1086047-T

M2 *72* C216 G017 G019 G100 H3 H341 H5 H543 H7 H721 H8 K0 K4 K442 M210
 M211 M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520
 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517
 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DO-N RAI2DO-P RAI2DO-T
 DCR: 1086048-N 1086048-P 1086048-T

M2 *73* C216 G017 G019 G100 H3 H341 H5 H543 H7 H721 H8 K0 K4 K442 M210
 M211 M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520
 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517
 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DP-N RAI2DP-P RAI2DP-T
 DCR: 1086049-N 1086049-P 1086049-T

M2 *74* C216 G017 G019 G100 H3 H341 H5 H543 H7 H721 H8 K0 K4 K442 M210
 M211 M240 M272 M281 M283 M311 M312 M321 M332 M342 M373 M392 M414
 M510 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420
 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DQ-N RAI2DQ-P RAI2DQ-T
 DCR: 1086050-N 1086050-P 1086050-T

M2 *75* C216 G013 G017 G100 H6 H601 H609 H643 H7 H721 K0 K4 K442 M280
 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540 M710
 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528 P633
 P646 P714 P721 P942 M905 M904
 DCN: RAI2DR-N RAI2DR-P RAI2DR-T
 DCR: 1086051-N 1086051-P 1086051-T

M2 *76* C216 G013 G017 G100 H6 H601 H602 H609 H643 H7 H721 K0 K4 K442
 M280 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DS-N RAI2DS-P RAI2DS-T
 DCR: 1086052-N 1086052-P 1086052-T

M2 *77* C216 G013 G017 G100 H4 H401 H441 H5 H543 H7 H721 H8 K0 K4 K442
 M210 M211 M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510
 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446
 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DT-N RAI2DT-P RAI2DT-T
 DCR: 1086053-N 1086053-P 1086053-T

M2 *78* C216 G013 G018 G100 H5 H541 H6 H601 H609 H643 H7 H721 H8 K0 K4
 K442 M210 M211 M272 M281 M311 M312 M321 M332 M342 M373 M392 M414
 M510 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420
 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DU-N RAI2DU-P RAI2DU-T
 DCR: 1086054-N 1086054-P 1086054-T

M2 *79* C216 G013 G017 G100 H5 H541 H6 H601 H609 H643 H7 H721 H8 K0 K4
 K442 M210 M211 M272 M281 M311 M312 M321 M332 M342 M373 M392 M414
 M510 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420
 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DV-N RAI2DV-P RAI2DV-T
 DCR: 1086055-N 1086055-P 1086055-T

M2 *80* C216 G013 G017 G100 H3 H341 H4 H401 H441 H5 H542 H7 H721 H8 K0
 K4 K442 M210 M211 M272 M282 M311 M312 M321 M332 M342 M373 M392
 M414 M510 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513
 P420 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DX-N RAI2DX-P RAI2DX-T
 DCR: 1086057-N 1086057-P 1086057-T

M2 *81* C216 G013 G017 G100 H3 H341 H5 H543 H7 H721 H8 K0 K4 K442 M210
 M211 M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520
 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517
 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DY-N RAI2DY-P RAI2DY-T
 DCR: 1086058-N 1086058-P 1086058-T

M2 *82* C216 G013 G017 G100 H5 H543 H6 H604 H641 H7 H721 H8 K0 K4 K442
 M210 M211 M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510
 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446
 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2DZ-N RAI2DZ-P RAI2DZ-T
 DCR: 1086059-N 1086059-P 1086059-T

M2 *83* C216 G013 G017 G100 H5 H543 H6 H601 H641 H7 H721 H8 K0 K4 K442
 M210 M211 M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510
 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446
 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2E0-N RAI2E0-P RAI2E0-T
 DCR: 1086060-N 1086060-P 1086060-T

M2 *84* C216 G013 G017 G100 H4 H401 H441 H5 H543 H7 H721 H8 K0 K4 K442
 M210 M211 M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510
 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446
 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2E1-N RAI2E1-P RAI2E1-T
 DCR: 1086061-N 1086061-P 1086061-T

M2 *85* C216 G013 G017 G100 H5 H541 H7 H721 H8 K0 K4 K442 M210 M211 M240
 M272 M281 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520
 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517
 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2E2-N RAI2E2-P RAI2E2-T
 DCR: 1086062-N 1086062-P 1086062-T

M2 *86* C216 G013 G017 G100 H5 H543 H6 H602 H641 H7 H721 H8 K0 K4 K442
 M210 M211 M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510
 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446
 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2E3-N RAI2E3-P RAI2E3-T
 DCR: 1086063-N 1086063-P 1086063-T

M2 *87* C216 G013 G017 G100 H5 H542 H6 H601 H602 H642 H7 H721 H8 K0 K4
 K442 M210 M211 M272 M282 M311 M312 M321 M332 M342 M373 M392 M414
 M510 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420
 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2E4-N RAI2E4-P RAI2E4-T
 DCR: 1086064-N 1086064-P 1086064-T

M2 *88* C216 G013 G017 G100 H4 H401 H441 H5 H542 H6 H602 H641 H7 H721 H8
 K0 K4 K442 M210 M211 M272 M282 M311 M312 M321 M332 M342 M373
 M392 M414 M510 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512
 N513 P420 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905
 M904
 DCN: RAI2E5-N RAI2E5-P RAI2E5-T
 DCR: 1086065-N 1086065-P 1086065-T

M2 *89* C216 G013 G017 G100 H5 H543 H6 H603 H641 H7 H721 H8 K0 K4 K442
 M210 M211 M272 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510
 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446
 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2E6-N RAI2E6-P RAI2E6-T
 DCR: 1086066-N 1086066-P 1086066-T


M2 *90* C216 G013 G017 G100 H5 H542 H6 H601 H603 H642 H7 H721 H8 K0 K4
 K442 M210 M211 M272 M282 M311 M312 M321 M332 M342 M373 M392 M414
 M510 M520 M532 M540 M710 M720 N211 N241 N243 N312 N512 N513 P420
 P446 P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2E7-N RAI2E7-P RAI2E7-T
 DCR: 1086067-N 1086067-P 1086067-T

M2 *91* C216 G014 G017 G100 H5 H543 H7 H721 H8 K0 K4 K442 M210 M211 M272
 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2E8-N RAI2E8-P RAI2E8-T
 DCR: 1086068-N 1086068-P 1086068-T

M2 *92* C216 G017 G019 G100 H5 H543 H7 H721 H8 K0 K4 K442 M210 M211 M272
 M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
 P633 P646 P714 P721 P942 M905 M904
 DCN: RAI2E9-N RAI2E9-P RAI2E9-T

DCR: 1086069-N 1086069-P 1086069-T
M2 *93* C216 G017 G019 G100 H5 H543 H7 H721 H8 K0 K4 K442 M210 M211 M272
M283 M311 M312 M321 M332 M342 M373 M392 M414 M510 M520 M532 M540
M710 M720 N211 N241 N243 N312 N512 N513 P420 P446 P517 P523 P528
P633 P646 P714 P721 P942 M905 M904
DCN: RAI2EA-N RAI2EA-P RAI2EA-T
DCR: 1086070-N 1086070-P 1086070-T
M2 *94* C216 F010 F019 F020 F029 G001 G002 G010 G011 G012 G013 G019 G020
G021 G022 G029 G040 G100 G111 G221 G299 H600 H681 H682 H683 H7
H721 J011 J271 K0 K4 K442 L145 M210 M211 M212 M213 M214 M215
M216 M231 M232 M233 M272 M280 M281 M311 M312 M313 M314 M315 M316
M321 M322 M331 M332 M333 M334 M340 M342 M343 M344 M349 M352 M371
M373 M391 M392 M413 M414 M510 M520 M521 M522 M530 M531 M532 M540
M630 M640 M650 M710 M720 N211 N241 N243 N312 N512 N513 P420 P446
P517 P523 P528 P633 P646 P714 P721 P942 M905 M904
MCN: 0157-19401-N 0157-19401-P 0157-19401-T
M2 *95* C316 F010 F019 F020 F029 G001 G002 G010 G011 G012 G013 G019 G020
G021 G022 G029 G040 G100 G111 G221 G299 H600 H681 H682 H683 H7
H721 J011 J271 K0 K4 K442 L145 M210 M211 M212 M213 M214 M215
M216 M231 M232 M233 M272 M280 M281 M311 M312 M313 M314 M315 M316
M321 M322 M331 M332 M333 M334 M340 M342 M343 M344 M349 M352 M371
M373 M391 M392 M413 M414 M510 M520 M521 M522 M530 M531 M532 M540
M720 N301 N382 N512 M905 M904
MCN: 0157-19404-K 0157-19404-P
M2 *96* C216 F010 F020 G001 G002 G010 G011 G012 G013 G020 G021 G022 G029
G040 G100 G221 H600 H681 H682 H683 J0 J011 J012 J1 J171 J271 K0
K4 K442 L145 M210 M211 M212 M213 M214 M215 M216 M231 M232 M233
M272 M280 M281 M311 M312 M313 M314 M315 M316 M321 M322 M331 M332
M333 M334 M340 M342 M343 M344 M349 M352 M371 M373 M381 M391 M413
M414 M510 M520 M521 M530 M531 M540 M710 M730 M905 M904
MCN: 0157-19402-N 0157-19402-S
M2 *97* F010 F019 F020 F029 G001 G002 G010 G011 G012 G013 G019 G020 G021
G022 G029 G040 G100 G111 G221 G299 H5 H592 H594 H598 H600 H681
H682 H683 H7 H721 H9 J011 J271 L145 M210 M211 M212 M213 M214
M215 M216 M231 M232 M233 M272 M280 M281 M311 M312 M313 M314 M315
M316 M321 M322 M331 M332 M333 M334 M340 M342 M343 M344 M349 M352
M371 M373 M391 M392 M413 M414 M510 M520 M521 M522 M530 M531 M532
M540 M710 M720 N214 N312 N352 N512 M905 M904
MCN: 0157-19403-N 0157-19403-P
M2 *99* C216 F010 F019 F020 F029 G001 G002 G010 G011 G012 G013 G019 G020
G021 G022 G029 G040 G100 G111 G221 G299 H600 H681 H682 H683 H7
H721 J011 J271 K0 K4 K442 L145 M210 M211 M212 M213 M214 M215
M216 M231 M232 M233 M272 M280 M281 M311 M312 M313 M314 M315 M316
M321 M322 M331 M332 M333 M334 M340 M342 M343 M344 M349 M352 M371
M373 M391 M392 M413 M414 M431 M510 M520 M521 M522 M530 M531 M532
M540 M630 M640 M650 M782 M905 M904
MCN: 0157-19401-K 0157-19401-M 0157-19401-Q

=> => d que stat
L7 STR



NODE ATTRIBUTES:

CONNECT IS E3 RC AT 3
CONNECT IS E2 RC AT 4
CONNECT IS E2 RC AT 5
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 1
GGCAT IS UNS AT 6
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L8 2 SEA FILE=REGISTRY SSS SAM L7

13.6% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 286244 TO 300756
PROJECTED ANSWERS: 64 TO 522

=> d his ful

(FILE 'HOME' ENTERED AT 15:50:32 ON 12 APR 2007)

FILE 'ZCAPLUS' ENTERED AT 15:50:45 ON 12 APR 2007
E US2006-574993/APPS

FILE 'HCAPLUS' ENTERED AT 15:51:09 ON 12 APR 2007
L1 1 SEA ABB=ON PLU=ON US2006-574993/APPS
SAVE TEMP L1 NWA993HCAAPP/A

FILE 'WPIX' ENTERED AT 15:51:29 ON 12 APR 2007
L2 1 SEA ABB=ON PLU=ON US2006-574993/APPS
SAVE TEMP L2 NWA993WPIAPP/A

FILE 'STNGUIDE' ENTERED AT 15:51:47 ON 12 APR 2007
D QUE L1

FILE 'HCAPLUS' ENTERED AT 15:52:28 ON 12 APR 2007
D IBIB ED AB IN L1

FILE 'STNGUIDE' ENTERED AT 15:52:28 ON 12 APR 2007

FILE 'HCAPLUS' ENTERED AT 15:53:07 ON 12 APR 2007
D IND L1

FILE 'STNGUIDE' ENTERED AT 15:53:07 ON 12 APR 2007
D QUE L2

FILE 'WPIX' ENTERED AT 15:53:21 ON 12 APR 2007
D IALL CODE L2

FILE 'STNGUIDE' ENTERED AT 15:53:24 ON 12 APR 2007

FILE 'REGISTRY' ENTERED AT 15:58:34 ON 12 APR 2007

L3 FILE 'HCAPLUS' ENTERED AT 15:58:38 ON 12 APR 2007
TRA PLU=ON L1 1- RN : 282 TERMS

L4 FILE 'REGISTRY' ENTERED AT 15:58:41 ON 12 APR 2007
282 SEA ABB=ON PLU=ON L3
SAVE TEMP L4 NWA993REGAPP/A

FILE 'STNGUIDE' ENTERED AT 15:59:19 ON 12 APR 2007

L5 FILE 'LREGISTRY' ENTERED AT 16:38:42 ON 12 APR 2007
STR

L6 FILE 'REGISTRY' ENTERED AT 16:40:09 ON 12 APR 2007
13 SEA SSS SAM L5

FILE 'STNGUIDE' ENTERED AT 16:40:16 ON 12 APR 2007

FILE 'REGISTRY' ENTERED AT 16:42:09 ON 12 APR 2007

L7 FILE 'LREGISTRY' ENTERED AT 16:42:31 ON 12 APR 2007
STR L5

L8 FILE 'REGISTRY' ENTERED AT 16:43:02 ON 12 APR 2007
2 SEA SSS SAM L7
D SCAN

FILE 'STNGUIDE' ENTERED AT 16:43:35 ON 12 APR 2007

FILE 'LREGISTRY' ENTERED AT 16:43:38 ON 12 APR 2007
D QUE STAT
SAVE TEMP L7 NWA993STRQ/Q

FILE 'STNGUIDE' ENTERED AT 16:44:17 ON 12 APR 2007
D SAVED
D QUE STAT

FILE HOME

FILE ZCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

10/574,993

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 12 Apr 2007 VOL 146 ISS 16
FILE LAST UPDATED: 11 Apr 2007 (20070411/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Apr 2007 VOL 146 ISS 16
FILE LAST UPDATED: 11 Apr 2007 (20070411/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIX

FILE LAST UPDATED: 4 APR 2007 <20070404/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200723 <200723/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> New reloaded DWPI Learn File (LWPI) available as well <<<

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> New display format FRAGHITSTR available <<<

SEE ONLINE NEWS and

http://www.stn-international.de/archive/stn_online_news/fraghitstr_ex.pdf

>>> IPC Reform backfile reclassification has been loaded to 31 December 2006. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC and 20061231/UPIC. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

http://www.stn-international.de/stndatabases/details/ipc_reform.html and

<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf>

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX
PLEASE SEE

http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Apr 6, 2007 (20070406/UP).

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 APR 2007 HIGHEST RN 929721-97-1

DICTIONARY FILE UPDATES: 11 APR 2007 HIGHEST RN 929721-97-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:


<http://www.cas.org/ONLINE/UG/regprops.html>

FILE LREGISTRY

LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

=> => d que stat 19
L7 STR



REP G1=(0-1) CH
NODE ATTRIBUTES:
CONNECT IS E3 RC AT 3
CONNECT IS E2 RC AT 4
CONNECT IS E2 RC AT 5
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 1
GGCAT IS UNS AT 6
DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE
L9 547 SEA FILE=REGISTRY SSS FUL L7

100.0% PROCESSED 570150 ITERATIONS
SEARCH TIME: 00.00.04

547 ANSWERS


=> d que stat 112
L6 STR



NODE ATTRIBUTES:
CONNECT IS E3 RC AT 3
CONNECT IS E2 RC AT 4
CONNECT IS E2 RC AT 5
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 1
GGCAT IS UNS AT 6
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE
L7 STR



REP G1=(0-1) CH
 NODE ATTRIBUTES:
 CONNECT IS E3 RC AT 3
 CONNECT IS E2 RC AT 4
 CONNECT IS E2 RC AT 5
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 1
 GGCAT IS UNS AT 6
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L9 547 SEA FILE=REGISTRY SSS FUL L7
 L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6

100.0% PROCESSED 547 ITERATIONS
 SEARCH TIME: 00.00.01

339 ANSWERS

=> d que nos 189

L6 STR
 L7 STR
 L9 547 SEA FILE=REGISTRY SSS FUL L7
 L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
 L89 ANALYZE PLU=ON L12 1- LC : 7 TERMS

=> d 189 1-7


L89 ANALYZE L12 1- LC : 7 TERMS

TERM #	# OCC	# DOC	% DOC LC	
1	339	339	100.00	CA
2	339	339	100.00	CAPLUS
3	323	323	95.28	TOXCENTER
4	264	264	77.88	USPATFULL
5	13	13	3.83	CASREACT
6	3	3	0.88	BEILSTEIN
7	1	1	0.29	CAOLD

***** END OF L89***

=> d que stat 117

L15 STR




REP G1=(0-1) CH
 NODE ATTRIBUTES:
 CONNECT IS E3 RC AT 3
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 1
 GGCAT IS UNS AT 11
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
 L17 3 SEA FILE=CASREACT SSS FUL L15 (8 REACTIONS)

100.0% DONE 54210 VERIFIED 8 HIT RXNS 3 DOCS
 SEARCH TIME: 00.00.07

=> d que stat 119
 L15 STR



REP G1=(0-1) CH
 NODE ATTRIBUTES:
 CONNECT IS E3 RC AT 3
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 1
 GGCAT IS UNS AT 11
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
 L19 1 SEA FILE=CHEMINFORMRX SSS FUL L15 (1 REACTIONS)

100.0% DONE 11195 VERIFIED 1 HIT RXNS 1 DOCS
 SEARCH TIME: 00.00.41

=> d que stat 129

L7 STR



REP G1=(0-1) CH

NODE ATTRIBUTES:

CONNECT IS E3 RC AT 3

CONNECT IS E2 RC AT 4

CONNECT IS E2 RC AT 5

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 1

GGCAT IS UNS AT 6

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L29 0 SEA FILE=CHEMINFORMRX SSS SAM L7 (0 REACTIONS)

35.8% DONE 1000 VERIFIED 0 HIT RXNS

0 DOCS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**


BATCH **COMPLETE**

PROJECTED VERIFICATIONS: 52827 TO 59053

PROJECTED ANSWERS: 0 TO 0

=> d que stat 130

L6 STR



NODE ATTRIBUTES:

CONNECT IS E3 RC AT 3

CONNECT IS E2 RC AT 4

CONNECT IS E2 RC AT 5

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 1

GGCAT IS UNS AT 6

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L30 0 SEA FILE=CHEMINFORMRX SSS SAM L6 (0 REACTIONS)


73.9% DONE 1000 VERIFIED 0 HIT RXNS 0 DOCS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED VERIFICATIONS: 24893 TO 29267
 PROJECTED ANSWERS: 0 TO 0

=> d que stat l31

L6 STR



NODE ATTRIBUTES:

CONNECT IS E3 RC AT 3
 CONNECT IS E2 RC AT 4
 CONNECT IS E2 RC AT 5
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 1
 GGCAT IS UNS AT 6
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L31 3 SEA FILE=CHEMINFORMRX SSS FUL L6 (5 REACTIONS)


85.9% DONE 30000 VERIFIED 5 HIT RXNS 3 DOCS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.15

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **COMPLETE**

PROJECTED VERIFICATIONS: 34925 TO 34925
 PROJECTED ANSWERS: 3 TO 8

=> d que stat l26

L6 STR



NODE ATTRIBUTES:

CONNECT IS E3 RC AT 3
 CONNECT IS E2 RC AT 4
 CONNECT IS E2 RC AT 5
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 1
 GGCAT IS UNS AT 6
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L26 11 SEA FILE=BEILSTEIN SSS FUL L6

100.0% PROCESSED 99943 ITERATIONS
 SEARCH TIME: 00.00.35

11 ANSWERS

=> d que nos 127

L6 STR
 L26 11 SEA FILE=BEILSTEIN SSS FUL L6
 L27 6 SEA FILE=BEILSTEIN ABB=ON PLU=ON L26 NOT BABSAN/FA

=> d his 126-128

(FILE 'BEILSTEIN' ENTERED AT 07:30:09 ON 13 APR 2007)

L26 11 S L6 FUL
 SAVE TEMP L26 NWA993BEIP/A
 L27 6 S L26 NOT BABSAN/FA
 SELECT L26 1- BABSAN

FILE 'BABS' ENTERED AT 07:32:22 ON 13 APR 2007


L28 8 S E1-E8/AN

=> d que 128

L28 8 SEA FILE=BABS ABB=ON PLU=ON (6121948/AN OR 6011603/AN OR
 5521334/AN OR 5542760/AN OR 6443896/AN OR 5571926/AN OR
 6282045/AN OR 6294163/AN)

=> d que 188

L6 STR



NODE ATTRIBUTES:


CONNECT IS E3 RC AT 3
 CONNECT IS E2 RC AT 4
 CONNECT IS E2 RC AT 5
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 1
 GGCAT IS UNS AT 6
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L7 STR



REP G1=(0-1) CH

NODE ATTRIBUTES:

CONNECT IS E3 RC AT 3
 CONNECT IS E2 RC AT 4
 CONNECT IS E2 RC AT 5
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 1
 GGCAT IS UNS AT 6
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L9 547 SEA FILE=REGISTRY SSS FUL L7
 L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
 L32 QUE ABB=ON PLU=ON REDDY, E?/AU
 L33 QUE ABB=ON PLU=ON REDDY, P?/AU
 L34 QUE ABB=ON PLU=ON REDDY, M?/AU
 L35 QUE ABB=ON PLU=ON REDDY, R?/AU
 L36 QUE ABB=ON PLU=ON BELL, S?/AU
 L37 QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
)/CS,SO,PA
 L39 QUE ABB=ON PLU=ON PROLIFER?
 L40 QUE ABB=ON PLU=ON DISEAS? OR DISORDER? OR SYNDROM? OR
 MALADY OR SICKNESS OR ILLNESS OR CONDITION
 L41 QUE ABB=ON PLU=ON HEMANGIOMAT?
 L42 QUE ABB=ON PLU=ON MULTIPLE (W) SCLERO?
 L43 QUE ABB=ON PLU=ON MS
 L44 QUE ABB=ON PLU=ON MYELODEGENER?
 L45 QUE ABB=ON PLU=ON ?DEGENER?(3A)?MYELO?
 L46 QUE ABB=ON PLU=ON GANGLIONEUROMATO?
 L47 QUE ABB=ON PLU=ON KELOID?

L48 QUE ABB=ON PLU=ON PAGET?
 L49 QUE ABB=ON PLU=ON FIBROCYS?
 L50 QUE ABB=ON PLU=ON COLORECT?
 L51 QUE ABB=ON PLU=ON SKIN OR DERM? OR EPIDER?
 L52 QUE ABB=ON PLU=ON BRAIN?
 L53 QUE ABB=ON PLU=ON LEUKEM? OR LEUKAEM?
 L54 QUE ABB=ON PLU=ON IONIZ? OR IONIS?
 L55 QUE ABB=ON PLU=ON RADIATION
 L56 QUE ABB=ON PLU=ON OPTIC?
 L57 QUE ABB=ON PLU=ON ISOMER?
 L58 QUE ABB=ON PLU=ON THERAP? OR DRUG OR PHARM? OR MEDIC?
 L59 QUE ABB=ON PLU=ON SARCOID?
 L60 QUE ABB=ON PLU=ON PERONIES
 L61 QUE ABB=ON PLU=ON DUPUTREN
 L62 QUE ABB=ON PLU=ON FIBROSIS
 L63 QUE ABB=ON PLU=ON CIRRHOS?
 L64 QUE ABB=ON PLU=ON ?ATHEROSCLERO? OR ANIATHEROSCLER?
 L65 QUE ABB=ON PLU=ON ?VASCULAR?
 L66 QUE ABB=ON PLU=ON RESTENO?
 L67 QUE ABB=ON PLU=ON ?CANCER? OR ?CARCIN? OR ?ONCO? OR ?S
 ARCOM? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLAS? OR ?MALIGN? OR
 ?DYPLAS?
 L68 QUE ABB=ON PLU=ON ANTICANCER? OR ANTICARCIN? OR ANTISA
 RCOM? OR ANTITUM? OR ANTINEOPLAS?
 L69 QUE ABB=ON PLU=ON OVARY OR OVARIAN
 L70 QUE ABB=ON PLU=ON BREAST OR MAMMAR?
 L71 QUE ABB=ON PLU=ON PROSTAT?
 L72 QUE ABB=ON PLU=ON TESTIS OR TESTIC?
 L73 QUE ABB=ON PLU=ON LUNG
 L74 QUE ABB=ON PLU=ON PULMONAR?
 L75 QUE ABB=ON PLU=ON KIDNEY OR RENAL?
 L77 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L12
 L78 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 AND (L39 OR L40 OR L41 OR
 L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
 L51 OR L52 OR L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR L59 OR
 L60 OR L61 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68 OR
 L69 OR L70 OR L71 OR L72 OR L73 OR L74 OR L75)
 L79 QUE ABB=ON PLU=ON SYNTHES? OR SYNTH OR PREP? OR REACT?
 L80 QUE ABB=ON PLU=ON MANUFACT?
 L81 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 AND (L79 OR L80)
 L82 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 OR L78 OR L81
 L83 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L82 AND (L32 OR L33 OR L34 OR
 L35 OR L36 OR L37)
 L84 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY
 <2004 OR REVIEW/DT
 L86 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L82 NOT L83
 L87 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L86 AND L84
 L88 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L86 OR L87

=> d que nos 193

L6 STR
 L7 STR
 L9 547 SEA FILE=REGISTRY SSS FUL L7
 L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
 L32 QUE ABB=ON PLU=ON REDDY, E?/AU
 L33 QUE ABB=ON PLU=ON REDDY, P?/AU
 L34 QUE ABB=ON PLU=ON REDDY, M?/AU
 L35 QUE ABB=ON PLU=ON REDDY, R?/AU
 L36 QUE ABB=ON PLU=ON BELL, S?/AU

L37 QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
)/CS,SO,PA
 L90 264 SEA FILE=REGISTRY ABB=ON PLU=ON L12 AND USPATFULL/LC
 L91 1 SEA FILE=USPATFULL ABB=ON PLU=ON L90
 L92 1 SEA FILE=USPATFULL ABB=ON PLU=ON L91 AND (L32 OR L33 OR L34
 OR L35 OR L36 OR L37)
 L93 0 SEA FILE=USPATFULL ABB=ON PLU=ON L91 NOT L92

=> d que nos 197

L6 STR
 L7 STR
 L9 547 SEA FILE=REGISTRY SSS FUL L7
 L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
 L32 QUE ABB=ON PLU=ON REDDY, E?/AU
 L33 QUE ABB=ON PLU=ON REDDY, P?/AU
 L34 QUE ABB=ON PLU=ON REDDY, M?/AU
 L35 QUE ABB=ON PLU=ON REDDY, R?/AU
 L36 QUE ABB=ON PLU=ON BELL, S?/AU
 L37 QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
)/CS,SO,PA
 L94 323 SEA FILE=REGISTRY ABB=ON PLU=ON L12 AND TOXCENTER/LC
 L95 3 SEA FILE=TOXCENTER ABB=ON PLU=ON L94
 L96 3 SEA FILE=TOXCENTER ABB=ON PLU=ON L95 AND (L32 OR L33 OR L34
 OR L35 OR L36 OR L37)
 L97 0 SEA FILE=TOXCENTER ABB=ON PLU=ON L95 NOT L96

=> d que nos 199

L6 STR
 L7 STR
 L9 547 SEA FILE=REGISTRY SSS FUL L7
 L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
 L98 13 SEA FILE=REGISTRY ABB=ON PLU=ON L12 AND CASREACT/LC
 L99 6 SEA FILE=CASREACT ABB=ON PLU=ON L98

=> => d que nos 1101

L6 STR
 L7 STR
 L9 547 SEA FILE=REGISTRY SSS FUL L7
 L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
 L100 1 SEA FILE=REGISTRY ABB=ON PLU=ON L12 AND CAOLD/LC
 L101 1 SEA FILE=CAOLD ABB=ON PLU=ON L100

=> d his 1100-1102

(FILE 'REGISTRY' ENTERED AT 08:15:50 ON 13 APR 2007)

L100 1 S L12 AND CAOLD/LC

FILE 'CAOLD' ENTERED AT 08:16:01 ON 13 APR 2007


L101 1 S L100
 SELECT L101 1- AN

FILE 'HCAPLUS' ENTERED AT 08:16:26 ON 13 APR 2007

L102 2 S E9/OREF

=> d que nos 1102

L102 2 SEA FILE=HCAPLUS ABB=ON PLU=ON "CA59:5004B"/OREF



```
CONNECT IS E3 RC AT 3
CONNECT IS E2 RC AT 4
CONNECT IS E2 RC AT 5
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 1
GGCAT IS UNS AT 6
DEFAULT ECLEVEL IS LIMITED
```

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 7

L104 112 SEA FILE=WPIX SSS FUL L6

```
100.0% PROCESSED    14045 ITERATIONS
SEARCH TIME: 00.00.11
```

112 ANSWERS

=> d his 1104-1109

(FILE 'WPIX' ENTERED AT 08:18:03 ON 13 APR 2007)

```

L104      112 S L6 FUL
           SAVE TEMP L104 NWA993WPIS/A
L105      4 S L104/DCR
           SELECT L104 1- SDCN
L106      4 S E10-E121/DCN
L107      4 S L105 OR L106
L108      4 S L107 AND L32-L37
L109      0 S L107 NOT L108

```

=> d que nos 1109

```

L6          STR
L32         QUE  ABB=ON  PLU=ON  REDDY, E?/AU
L33         QUE  ABB=ON  PLU=ON  REDDY, P?/AU
L34         QUE  ABB=ON  PLU=ON  REDDY, M?/AU
L35         QUE  ABB=ON  PLU=ON  REDDY, R?/AU
L36         QUE  ABB=ON  PLU=ON  BELL, S?/AU
L37         QUE  ABB=ON  PLU=ON  (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
          )/CS,SO,PA
L104        112 SEA FILE=WPIX SSS FUL L6
L105        4  SEA FILE=WPIX ABB=ON  PLU=ON  L104/DCR
L106        4  SEA FILE=WPIX ABB=ON  PLU=ON  (RAI11O/DCN OR RAI11Q/DCN OR
          RAI11R/DCN OR RAI11S/DCN OR RAI11T/DCN OR RAI11U/DCN OR
          RAI12A/DCN OR RAI12B/DCN OR RAI12C/DCN OR RAI12D/DCN OR
          RAI12E/DCN OR RAI12F/DCN OR RAI12G/DCN OR RAI12H/DCN OR
          RAI2CA/DCN OR RAI2CB/DCN OR RAI2CC/DCN OR RAI2CD/DCN OR
          RAI2CE/DCN OR RAI2CF/DCN OR RAI2CG/DCN OR RAI2CH/DCN OR

```

RAI2CJ/DCN OR RAI2CK/DCN OR RAI2CL/DCN OR RAI2CM/DCN OR
 RAI2CN/DCN OR RAI2CO/DCN OR RAI2CP/DCN OR RAI2CQ/DCN OR
 RAI2CR/DCN OR RAI2CS/DCN OR RAI2CT/DCN OR RAI2CU/DCN OR
 RAI2CV/DCN OR RAI2CW/DCN OR RAI2CX/DCN OR RAI2CY/DCN OR
 RAI2CZ/DCN OR RAI2C5/DCN OR RAI2C6/DCN OR RAI2C7/DCN OR
 RAI2C8/DCN OR RAI2C9/DCN OR RAI2DA/DCN OR RAI2DB/DCN OR
 RAI2DC/DCN OR RAI2DD/DCN OR RAI2DE/DCN OR RAI2DF/DCN OR
 RAI2DG/DCN OR RAI2DH/DCN OR RAI2DI/DCN OR RAI2DJ/DCN OR
 RAI2DK/DCN OR RAI2DL/DCN OR RAI2DM/DCN OR RAI2DN/DCN OR
 RAI2DO/DCN OR RAI2DP/DCN OR RAI2DQ/DCN OR RAI2DR/DCN OR
 RAI2DS/DCN OR RAI2DT/DCN OR RAI2DU/DCN OR RAI2DV/DCN OR
 RAI2DX/DCN OR RAI2DY/DCN OR RAI2DZ/DCN OR RAI2D0/DCN OR
 RAI2D1/DCN OR RAI2D2/DCN OR RAI2D3/DCN OR RAI2D4/DCN OR
 RAI2D5/DCN OR RAI2D6/DCN OR RAI2D7/DCN OR RAI2D8/DCN OR
 RAI2D9/DCN OR RAI2EA/DCN OR RAI2E0/DCN OR RAI2E1/DCN OR
 RAI2E2/DCN OR RAI2E3/DCN OR RAI2E4/DCN OR RAI2E5/DCN OR
 RAI2E6/DCN OR RAI2E7/DCN OR RAI2E8/DCN OR RAI2E9/DCN OR
 RAJKMO/DCN OR RAJKMP/DCN OR RAJKN1/DCN OR RAJKN2/DCN OR
 RAJKN3/DCN OR RAJKOB/DCN OR RAJKOC/DCN OR RAJKOD/DCN OR
 RAJKOE/DCN OR RAJKOF/DCN OR RAJKOG/DCN OR RAJKOH/DCN OR
 RAJKOI/DCN OR RAJKOO/DCN OR RANXKV/DCN OR RANXKW/DCN OR
 RANXKX/DCN OR RANXKY/DCN OR RANXKZ/DCN OR RANXL0/DCN OR
 RANXL1/DCN OR RANXL2/DCN)

L107 4 SEA FILE=WPIX ABB=ON PLU=ON L105 OR L106
 L108 4 SEA FILE=WPIX ABB=ON PLU=ON L107 AND (L32 OR L33 OR L34 OR
 L35 OR L36 OR L37)
 L109 0 SEA FILE=WPIX ABB=ON PLU=ON L107 NOT L108

=> d his 1122

(FILE 'MEDLINE, BIOSIS, EMBASE, CABA, AGRICOLA, DRUGU, VETU, BIOTECHNO'
 ENTERED AT 08:35:55 ON 13 APR 2007)

L122 0 S L121

=> d que nos 1122

L6 STR
 L7 STR
 L9 547 SEA FILE=REGISTRY SSS FUL L7
 L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
 L121 SEL PLU=ON L12 1- CHEM : 412 TERMS
 L122 0 SEA L121

=> fil beilst

FILE 'BEILSTEIN' ENTERED AT 09:01:55 ON 13 APR 2007

COPYRIGHT (c) 2007 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON JANUARY 10, 2007

FILE COVERS 1771 TO 2006.

*** FILE CONTAINS 9,780,003 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *


NEW

* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.
* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

=> d 127 ide 1

L27 ANSWER 1 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Beilstein Records (BRN):	9699047
Chemical Name (CN):	<Rs>-(E)-2-phenylethenyl benzyl sulfoxide
Molec. Formula (MF):	C15 H14 O S
Molecular Weight (MW):	242.34
Lawson Number (LN):	5336, 5231
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	2293105
Tautomer ID (TAUTID):	2490834
Entry Date (DED):	2004/10/23
Update Date (DUPD):	2004/10/23



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
DED	Entry Date	1
DUPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d 127 rx 1

L27 ANSWER 1 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Reaction:

RX

Reaction ID (.ID): 9592691
 Reactant BRN (.RBRN): 8813116, 3588244
 Reactant (.RCT): cholesteryl (RS)-(E)-2-phenylethenesulfinate, benzylmagnesium bromide
 Product BRN (.PBRN): 9699046, 9699047
 Product (.PRO): <Ss>-(E)-2-phenylethenyl benzyl sulfoxide, <Rs>-(E)-2-phenylethenyl benzyl sulfoxide
 No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 9592691.1
 Reaction Classification (.CL): Preparation
 Solvent (.SOL): benzene
 Temperature (.T): 6 Cel
 Note(s) (.COM): Title compound not separated from

10/574,993

byproducts


Reference(s):

1. Strickler, Rick R.; Motto, John M.; Humber, Craig C.; Schwan, Adrian L., Can. J. Chem., CODEN: CJCHAG, 81(6), <2003>, 423 - 430; BABS-6443896

=> d 127, ide 2

L27 ANSWER 2 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Beilstein Records (BRN): 8114107
 Molec. Formula (MF): C21 H18 O S
 Molecular Weight (MW): 318.43
 Lawson Number (LN): 5523, 5336
 File Segment (FS): Stereo compound
 Compound Type (CTYPE): isocyclic
 Constitution ID (CONSID): 6334519
 Tautomer ID (TAUTID): 7072389
 Beilstein Citation (BSO): 6-06
 Entry Date (DED): 1999/05/06
 Update Date (DUPD): 1999/05/06



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
FS	File Segment	1
CTYPE	Compound Type	1

CONSID.	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

=> d 127 rx 2

L27 ANSWER 2 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Reaction:

RX

Reaction ID (.ID): 5010769
 Reactant BRN (.RBRN): 605461, 2088902
 Reactant (.RCT): ethynylbenzene, diphenyl-methanethiol
 Product BRN (.PBRN): 8114107
 Product (.PRO): C21H18OS
 No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 5010769.1
 Reaction Classification (.CL): Preparation
 Reagent (.RGT): 2.) MCPBA
 Note(s) (.COM): Yield given. Multistep reaction
 Reference(s):
 1. Schwan, Adrian L.; Strickler, Rick R.; Lear, Yvonne; Kalin, Mark L.;
 Rietveld, Tanya E.; et al., J.Org.Chem., CODEN: JOCEAH, 63(22), <1998>,
 7825-7832; BABS-6121948

Reaction:

RX

Reaction ID (.ID): 5039972
 Reactant BRN (.RBRN): 8114107
 Reactant (.RCT): C21H18OS
 Product BRN (.PBRN): 7514179
 Product (.PRO): 2-phenyl-ethenesulfinyl chloride
 No. of React. Details (.NVAR): 1

Reaction Details:

RX


Reaction RID (.RID): 5039972.1
 Reaction Classification (.CL): Preparation
 Reagent (.RGT): SO2Cl2
 Solvent (.SOL): CH2Cl2
 Other Conditions (.COND): 1) -78 deg C, 10 min; 2) -78 deg C --> rt,
 30 min
 Reference(s):
 1. Schwan, Adrian L.; Strickler, Rick R.; Lear, Yvonne; Kalin, Mark L.;
 Rietveld, Tanya E.; et al., J.Org.Chem., CODEN: JOCEAH, 63(22), <1998>,

7825-7832; BABS-6121948

=> d 127 ide 3

L27 ANSWER 3 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Beilstein Records (BRN): 7516650
 Molec. Formula (MF): C16 H16 O2 S
 Molecular Weight (MW): 272.36
 Lawson Number (LN): 5912, 5336, 289
 File Segment (FS): Stereo compound
 Compound Type (CTYPE): isocyclic
 Constitution ID (CONSID): 6414604
 Tautomer ID (TAUTID): 7153514
 Beilstein Citation (BSO): 6-06
 Entry Date (DED): 1996/11/12
 Update Date (DUPD): 1999/05/07



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	3
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	4
RXREA	Substance is Reaction Reactant	2
RXPRO	Substance is Reaction Product	2

=> d 127 rx 3

L27 ANSWER 3 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Reaction:

RX

Reaction ID (.ID): 5000809
 Reactant BRN (.RBRN): 1237746, 386303
 Reactant (.RCT): phenylthiirane S-oxide,
 1-bromomethyl-4-methoxy-benzene
 Product BRN (.PBRN): 7516650, 7481013
 Product (.PRO): C16H16O2S, C16H16O2S
 No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 5000809.1
 Reaction Classification (.CL): Preparation
 Reagent (.RGT): 1.) LiHMDS
 Note(s) (.COM): Yield given. Multistep reaction. Yields of
 byproduct given
 Reference(s):
 1. Schwan, Adrian L.; Strickler, Rick R.; Lear, Yvonne; Kalin, Mark L.;
 Rietveld, Tanya E.; et al., J.Org.Chem., CODEN: JOCEAH, 63(22), <1998>,
 7825-7832; BABS-6121948

Reaction:

RX

Reaction ID (.ID): 4476062
 Reactant BRN (.RBRN): 7473708, 386303
 Reactant (.RCT): C8H7OS(1-), 1-bromomethyl-4-methoxy-
 benzene
 Product BRN (.PBRN): 7516650
 Product (.PRO): C16H16O2S
 No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 4476062.1
 Reaction Classification (.CL): Preparation
 Yield (.YDT): 43 percent (BRN=7516650)
 Reference(s):
 1. Schwan, Adrian L.; Kalin, Mark L.; Vajda, Kristin E.; Xiang, Ting-Jian;
 Brillon, Denis, Tetrahedron Lett., CODEN: TELEAY, 37(14), <1996>,
 2345-2348; BABS-6011603

Reaction:

RX

Reaction ID (.ID): 5016954
 Reactant BRN (.RBRN): 7516650
 Reactant (.RCT): C16H16O2S
 Product BRN (.PBRN): 7514180
 Product (.PRO): 2-phenyl-ethenesulfinyl chloride
 No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 5016954.1

10/574,993

Reaction Classification (.CL): Preparation
Reagent (.RGT): SO2Cl2
Solvent (.SOL): CH2Cl2
Other Conditions (.COND): 1) -78 deg C, 10 min; 2) -78 deg C --> rt, 30 min

Reference(s):

1. Schwan, Adrian L.; Strickler, Rick R.; Lear, Yvonne; Kalin, Mark L.; Rietveld, Tanya E.; et al., J.Org.Chem., CODEN: JOCEAH, 63(22), <1998>, 7825-7832; BABS-6121948

Reaction:

RX

Reaction ID (.ID): 4468765
Reactant BRN (.RBRN): 7516650, 1857542
Reactant (.RCT): C16H16O2S, 3-phenyl-propan-1-ol
Product BRN (.PBRN): 7516439
Product (.PRO): 2-phenyl-ethenesulfinic acid
3-phenyl-propyl ester
No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 4468765.1
Reaction Classification (.CL): Preparation
Reagent (.RGT): 1.) SO2Cl2; 2.) K2CO3
Other Conditions (.COND): 1.) CH2Cl2, -78 deg C to r.t.; 2.) CH2Cl2, -78 deg C to r.t.

Note(s) (.COM): Yield given. Multistep reaction


Reference(s):

1. Schwan, Adrian L.; Kalin, Mark L.; Vajda, Kristin E.; Xiang, Ting-Jian; Brillon, Denis, Tetrahedron Lett., CODEN: TELEAY, 37(14), <1996>, 2345-2348; BABS-6011603

=> d 127 ide 4

L27 ANSWER 4 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Beilstein Records (BRN): 7516649
Molec. Formula (MF): C16 H16 O2 S
Molecular Weight (MW): 272.36
Lawson Number (LN): 5912, 5336, 289
File Segment (FS): Stereo compound
Compound Type (CTYPE): isocyclic
Constitution ID (CONSID): 6414604
Tautomer ID (TAUTID): 7153514
Beilstein Citation (BSO): 6-06
Entry Date (DED): 1996/11/12
Update Date (DUPD): 1999/05/07



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	3
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	4
RXREA	Substance is Reaction Reactant	2
RXPRO	Substance is Reaction Product	2

=> d 127 rx 4

L27 ANSWER 4 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Reaction:

RX

Reaction ID (.ID): 5003978
 Reactant BRN (.RBRN): 605461, 471686
 Reactant (.RCT): ethynylbenzene, (4-methoxy-phenyl)-methanethiol
 Product BRN (.PBRN): 7516649
 Product (.PRO): C16H16O2S
 No. of React. Details (.NVAR): 1

Reaction Details:

RX

10/574,993

Reaction RID (.RID): 5003978.1
Reaction Classification (.CL): Preparation
Reagent (.RGT): 2.) MCPBA
Note(s) (.COM): Yield given. Multistep reaction
Reference(s):
1. Schwan, Adrian L.; Strickler, Rick R.; Lear, Yvonne; Kalin, Mark L.;
Rietveld, Tanya E.; et al., J.Org.Chem., CODEN: JOCEAH, 63(22), <1998>,
7825-7832; BABS-6121948

Reaction:

RX

Reaction ID (.ID): 4486322
Reactant BRN (.RBRN): 6846379
Reactant (.RCT): (Z)-1-(4-Methoxybenzyl)thio-2-phenylethylene
Product BRN (.PBRN): 7516649
Product (.PRO): C16H16O2S
No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 4486322.1
Reaction Classification (.CL): Preparation
Reagent (.RGT): MCPBA
Note(s) (.COM): Yield given
Reference(s):
1. Schwan, Adrian L.; Kalin, Mark L.; Vajda, Kristin E.; Xiang, Ting-Jian;
Brillon, Denis, Tetrahedron Lett., CODEN: TELEAY, 37(14), <1996>,
2345-2348; BABS-6011603

Reaction:

RX

Reaction ID (.ID): 5016953
Reactant BRN (.RBRN): 7516649
Reactant (.RCT): C16H16O2S
Product BRN (.PBRN): 7514179
Product (.PRO): 2-phenyl-ethenesulfinyl chloride
No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 5016953.1
Reaction Classification (.CL): Preparation
Reagent (.RGT): SO2Cl2
Solvent (.SOL): CH2Cl2
Other Conditions (.COND): 1) -78 deg C, 10 min; 2) -78 deg C --> rt, 30 min
Reference(s):
1. Schwan, Adrian L.; Strickler, Rick R.; Lear, Yvonne; Kalin, Mark L.;
Rietveld, Tanya E.; et al., J.Org.Chem., CODEN: JOCEAH, 63(22), <1998>,
7825-7832; BABS-6121948

Reaction:

RX

Reaction ID (.ID): 4468764
Reactant BRN (.RBRN): 7516649, 1857542
Reactant (.RCT): C16H16O2S, 3-phenyl-propan-1-ol
Product BRN (.PBRN): 7516438
Product (.PRO): 2-phenyl-ethenesulfinic acid
3-phenyl-propyl ester

No. of React. Details (.NVAR): 1

Reaction Details:


RX

Reaction RID (.RID): 4468764.1
 Reaction Classification (.CL): Preparation
 Reagent (.RGT): 1.) SO₂Cl₂; 2.) K₂CO₃
 Other Conditions (.COND): 1.) CH₂Cl₂, -78 deg C to r.t.; 2.) CH₂Cl₂,
 -78 deg C to r.t.
 Note(s) (.COM): Yield given. Multistep reaction
 Reference(s):
 1. Schwan, Adrian L.; Kalin, Mark L.; Vajda, Kristin E.; Xiang, Ting-Jian;
 Brillon, Denis, Tetrahedron Lett., CODEN: TELEAY, 37(14), <1996>,
 2345-2348; BABS-6011603

=> d 127 ide 5

L27 ANSWER 5 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Beilstein Records (BRN): 7481958
 Chemical Name (CN): diphenylmethyl (E)-2-phenylethenyl
 sulfoxide
 Molec. Formula (MF): C₂₁ H₁₈ O S
 Molecular Weight (MW): 318.43
 Lawson Number (LN): 5523, 5336
 File Segment (FS): Stereo compound
 Compound Type (CTYPE): isocyclic
 Constitution ID (CONSID): 6334519
 Tautomer ID (TAUTID): 7072389
 Beilstein Citation (BSO): 6-06
 Entry Date (DED): 1996/11/12
 Update Date (DUPD): 2001/07/25



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1

CN	Chemical Name	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	4
RXREA	Substance is Reaction Reactant	2
RXPRO	Substance is Reaction Product	2

=> d 127 rx 5

L27 ANSWER 5 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Reaction:

RX

Reaction ID (.ID):	5014030
Reactant BRN (.RBRN):	1237746, 638544
Reactant (.RCT):	phenylthiirane S-oxide, bromo-diphenyl-methane
Product BRN (.PBRN):	7481958, 7481885
Product (.PRO):	C21H18OS, C21H18OS
No. of React. Details (.NVAR):	1

Reaction Details:

RX

Reaction RID (.RID):	5014030.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	1.) LiHMDS
Note(s) (.COM):	Yield given. Multistep reaction. Yields of byproduct given

Reference(s):

1. Schwan, Adrian L.; Strickler, Rick R.; Lear, Yvonne; Kalin, Mark L.;
Rietveld, Tanya E.; et al., J.Org.Chem., CODEN: JOCEAH, 63(22), <1998>,
7825-7832; BABS-6121948

Reaction:

RX

Reaction ID (.ID):	4485686
Reactant BRN (.RBRN):	7473708, 638544
Reactant (.RCT):	C8H7OS(1-), bromo-diphenyl-methane
Product BRN (.PBRN):	7481958
Product (.PRO):	C21H18OS
No. of React. Details (.NVAR):	1

Reaction Details:

RX

Reaction RID (.RID):	4485686.1
----------------------	-----------

Reaction Classification (.CL): Preparation

Yield (.YDT): 35 percent (BRN=7481958)

Reference(s):

1. Schwan, Adrian L.; Kalin, Mark L.; Vajda, Kristin E.; Xiang, Ting-Jian; Brillon, Denis, Tetrahedron Lett., CODEN: TELEAY, 37(14), <1996>, 2345-2348; BABS-6011603

Reaction:

RX

Reaction ID (.ID): 5016885
Reactant BRN (.RBRN): 7481958
Reactant (.RCT): diphenylmethyl (E)-2-phenylethenyl sulfoxide
Product BRN (.PBRN): 7514180
Product (.PRO): 2-phenyl-ethenesulfinyl chloride
No. of React. Details (.NVAR): 2

Reaction Details:

RX

Reaction RID (.RID): 5016885.1
Reaction Classification (.CL): Preparation
Reagent (.RGT): SO₂Cl₂
Solvent (.SOL): CH₂Cl₂
Time (.TIM): 70 min
Temperature (.T): -78 - 20 Cel
Reference(s):
1. Strickler, Rick R.; Schwan, Adrian L., Tetrahedron: Asymmetry, CODEN: TASYE3, 11(24), <2000>, 4843 - 4852; BABS-6282045

RX

Reaction RID (.RID): 5016885.2
Reaction Classification (.CL): Preparation
Reagent (.RGT): SO₂Cl₂
Solvent (.SOL): CH₂Cl₂
Other Conditions (.COND): 1) -78 deg C, 10 min; 2) -78 deg C --> rt, 30 min
Reference(s):
1. Schwan, Adrian L.; Strickler, Rick R.; Lear, Yvonne; Kalin, Mark L.; Rietveld, Tanya E.; et al., J.Org.Chem., CODEN: JOCEAH, 63(22), <1998>, 7825-7832; BABS-6121948

Reaction:

RX

Reaction ID (.ID): 4468761
Reactant BRN (.RBRN): 7481958, 1857542
Reactant (.RCT): C₂₁H₁₈O₅, 3-phenyl-propan-1-ol
Product BRN (.PBRN): 7516439
Product (.PRO): 2-phenyl-ethenesulfinic acid
3-phenyl-propyl ester
No. of React. Details (.NVAR): 1

Reaction Details:

RX


Reaction RID (.RID): 4468761.1
Reaction Classification (.CL): Preparation
Reagent (.RGT): 1.) SO₂Cl₂; 2.) K₂CO₃
Other Conditions (.COND): 1.) CH₂Cl₂, -78 deg C to r.t.; 2.) CH₂Cl₂, -78 deg C to r.t.
Note(s) (.COM): Yield given. Multistep reaction
Reference(s):
1. Schwan, Adrian L.; Kalin, Mark L.; Vajda, Kristin E.; Xiang, Ting-Jian;

Brillon, Denis, Tetrahedron Lett., CODEN: TELEAY, 37(14), <1996>, 2345-2348; BABS-6011603

=> d 127 ide 6

L27 ANSWER 6 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Beilstein Records (BRN): 2523390
 Beilstein Pref. RN (BPR): 88584-31-0
 CAS Reg. No. (RN): 88584-31-0
 Chemical Name (CN): cis-1-Benzylmercapto-2-phenyl-ethen-S-oxid
 Molec. Formula (MF): C15 H14 O S
 Molecular Weight (MW): 242.34
 Lawson Number (LN): 5336, 5231
 File Segment (FS): Stereo compound
 Compound Type (CTYPE): isocyclic
 Constitution ID (CONSID): 2293105
 Tautomer ID (TAUTID): 2490834
 Beilstein Citation (BSO): 5-06
 Entry Date (DED): 1989/07/05
 Update Date (DUPD): 1995/11/08



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
MP	Melting Point	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d 127 rx 6

L27 ANSWER 6 OF 6 BEILSTEIN COPYRIGHT 2007 BEILSTEIN MDL on STN

Reaction:

RX

Reaction ID (.ID): 4230599
 Reactant BRN (.RBRN): 605461, 605864
 Reactant (.RCT): ethynylbenzene, phenylmethanethiol
 Product BRN (.PBRN): 2523390
 Product (.PRO): cis-1-Benzylmercapto-2-phenyl-ethen-S-oxid
 No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 4230599.1
 Reaction Classification (.CL): Preparation
 Other Conditions (.COND): (i), (ii) H2O2, AcOH
 Note(s) (.COM): Multistep reaction
 Reference(s):
 1. Pasto, D.J.; Miesel, J.L., J.Amer.Chem.Soc., CODEN: JACSAT, 85, <1963>, 2118-2124

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 09:07:09 ON 13 APR 2007.
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Apr 6, 2007 (20070406/UP).

=> dup rem 188 117 119 131 128 193 197 199 1101 1102 1109 1122

L93 HAS NO ANSWERS

L97 HAS NO ANSWERS

L109 HAS NO ANSWERS

L122 HAS NO ANSWERS

DUPLICATE IS NOT AVAILABLE IN 'CHEMINFORMRX, CAOLD'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

FILE 'HCAPLUS' ENTERED AT 09:09:24 ON 13 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 09:09:24 ON 13 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CHEMINFORMRX' ENTERED AT 09:09:24 ON 13 APR 2007

COPYRIGHT (C) FIZ-CHEMIE BERLIN

FILE 'BABS' ENTERED AT 09:09:24 ON 13 APR 2007

COPYRIGHT (c) 2007 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAOLD' ENTERED AT 09:09:24 ON 13 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

PROCESSING COMPLETED FOR L88

PROCESSING COMPLETED FOR L17

PROCESSING COMPLETED FOR L19

PROCESSING COMPLETED FOR L31

PROCESSING COMPLETED FOR L28

PROCESSING COMPLETED FOR L93

PROCESSING COMPLETED FOR L97

PROCESSING COMPLETED FOR L99

PROCESSING COMPLETED FOR L101

PROCESSING COMPLETED FOR L102

PROCESSING COMPLETED FOR L109

PROCESSING COMPLETED FOR L122

L133 21 DUP REM L88 L17 L19 L31 L28 L93 L97 L99 L101 L102... (14
DUPLICATES REMOVED)

ANSWERS '1-11' FROM FILE HCAPLUS

ANSWERS '12-14' FROM FILE CASREACT

ANSWERS '15-18' FROM FILE CHEMINFORMRX

ANSWERS '19-20' FROM FILE BABS

ANSWER '21' FROM FILE CAOLD

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 09:09:29 ON 13 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Apr 6, 2007 (20070406/UP).

=> d ibib ed ab hitind hitstr

YOU HAVE REQUESTED DATA FROM FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' -
CONTINUE? (Y)/N:y

L133 ANSWER 1 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2003:613306 HCAPLUS Full-text

DOCUMENT NUMBER: 140:111018

TITLE: Stereospecific Grignard reactions of
cholesteryl 1-alkenesulfinate esters: Application of
the Andersen protocol to the preparation of
non-racemic α,β -unsaturated sulfoxides

AUTHOR(S): Strickler, Rick R.; Motto, John M.; Humber, Craig C.;
Schwan, Adrian L.

CORPORATE SOURCE: Guelph-Waterloo Centre for Graduate Work in Chemistry
and Biochemistry, Department of Chemistry and
Biochemistry, University of Guelph, Guelph, ON, N1G
2W1, Can.

SOURCE: Canadian Journal of Chemistry (2003), 81(6),
423-430

CODEN: CJCHAG; ISSN: 0008-4042

PUBLISHER: National Research Council of Canada

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:111018

ED Entered STN: 11 Aug 2003

AB Enantiomerically enriched α,β -unsatd. sulfinate esters of (-)-cholesterol
undergo stereospecific substitutions at sulfur when treated with Grignard
reagents. Sulfoxides, e.g., I, with enantiomeric excesses of 85-99.5% were
obtained when enantiopure sulfonates were used. The substitution reactions
proceed with inversion of sulfur configuration. Enantiomerically pure
cholesteryl (E)-2- carbomethoxyethenesulfinate is not a suitable reactant
under the Grignard reaction conditions. It is suggested that the ester group
induces unwanted reactions significantly lowering both the yield and sulfur
stereogenicity.

CC 23-12 (Aliphatic Compounds)

ST sulfinate ester unsatd cholesteryl stereoselective nucleophilic
substitution Grignard; sulfoxide unsatd asym synthesis

IT Asymmetric synthesis and induction
(asym. synthesis of α,β -unsatd. sulfoxides via
nucleophilic substitution of chiral cholesteryl alkenesulfonates with
Grignard reagents)

IT Grignard reagents

RL: RCT (Reactant); RACT (Reactant or reagent)

(asym. synthesis of α,β -unsatd. sulfoxides via
nucleophilic substitution of chiral cholesteryl alkenesulfonates with
Grignard reagents)

IT Sulfinic acids

RL: RCT (Reactant); RACT (Reactant or reagent)

(esters; asym. synthesis of α,β -unsatd. sulfoxides
via nucleophilic substitution of chiral cholesteryl alkenesulfonates
with Grignard reagents)

IT Substitution reaction, nucleophilic

(stereoselective; asym. synthesis of α,β -unsatd.
sulfoxides via nucleophilic substitution of chiral cholesteryl
alkenesulfonates with Grignard reagents)

IT Vinyl compounds, preparation

- RL: SPN (Synthetic preparation); PREP (Preparation)
(sulfoxides; asym. synthesis of α,β -unsatd. sulfoxides via nucleophilic substitution of chiral cholesteryl alkenesulfinates with Grignard reagents)
- IT Sulfoxides
RL: SPN (Synthetic preparation); PREP (Preparation)
(vinyl; asym. synthesis of α,β -unsatd. sulfoxides via nucleophilic substitution of chiral cholesteryl alkenesulfinates with Grignard reagents)
- IT 110-00-9, Furan
RL: RCT (Reactant); RACT (Reactant or reagent)
(Grignard preparation; asym. synthesis of α,β -unsatd. sulfoxides via nucleophilic substitution of chiral cholesteryl alkenesulfinates with Grignard reagents)
- IT 147461-00-5P
RL: BYP (Byproduct); PREP (Preparation)
(asym. synthesis of α,β -unsatd. sulfoxides via nucleophilic substitution of chiral cholesteryl alkenesulfinates with Grignard reagents)
- IT 677-22-5, tert-Butylmagnesium chloride 693-04-9, Butylmagnesium chloride
931-50-0, Cyclohexylmagnesium bromide 931-51-1, Cyclohexylmagnesium chloride 1068-55-9, Isopropylmagnesium chloride 1589-82-8, Benzylmagnesium bromide 4294-57-9, p-Tolylmagnesium bromide 35293-35-7, 2-Methyl-2-phenylpropylmagnesium chloride 82297-89-0, 4-Fluoro-3-methylphenylmagnesium bromide 216007-93-1 257276-58-7 257276-66-7 335591-44-1 335591-46-3 335591-47-4 335591-49-6 335591-50-9 646516-62-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(asym. synthesis of α,β -unsatd. sulfoxides via nucleophilic substitution of chiral cholesteryl alkenesulfinates with Grignard reagents)
- IT 34553-13-4P 41103-85-9P 54828-68-1P 91874-30-5P 122833-94-7P
148091-66-1P 257276-59-8P 257276-60-1P 257276-61-2P 257276-62-3P
257276-63-4P 257276-64-5P 257276-65-6P 646516-46-3P 646516-47-4P
646516-48-5P 646516-49-6P 646516-50-9P 646516-51-0P 646516-52-1P
646516-53-2P 646516-54-3P 646516-55-4P 646516-56-5P
646516-57-6P 646516-58-7P 646516-59-8P 646516-60-1P 646516-61-2P
646516-63-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis of α,β -unsatd. sulfoxides via nucleophilic substitution of chiral cholesteryl alkenesulfinates with Grignard reagents)
- IT 216007-75-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(mechanistic studies; asym. synthesis of α,β -unsatd. sulfoxides via nucleophilic substitution of chiral cholesteryl alkenesulfinates with Grignard reagents)
- IT 30749-71-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(mechanistic studies; asym. synthesis of α,β -unsatd. sulfoxides via nucleophilic substitution of chiral cholesteryl alkenesulfinates with Grignard reagents)
- IT 100-39-0, Benzyl bromide
RL: RCT (Reactant); RACT (Reactant or reagent)
(sulfenate trapping agent; asym. synthesis of α,β -unsatd. sulfoxides via nucleophilic substitution of chiral cholesteryl alkenesulfinates with Grignard reagents)
- IT 646516-55-4P
RL: SPN (Synthetic preparation); PREP (Preparation)


(asym. synthesis of α,β -unsatd. sulfoxides via nucleophilic substitution of chiral cholesteryl alkenesulfinates with Grignard reagents)

RN 646516-55-4 HCAPLUS

CN Benzene, [[(S)-[(1E)-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Double bond geometry as shown.



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib ed ab hitind hitstr 2-11

YOU HAVE REQUESTED DATA FROM FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' - CONTINUE? (Y)/N:y

L133 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2001:334964 HCAPLUS Full-text

DOCUMENT NUMBER: 135:122252

TITLE: Simple and stereoselective synthetic route to (E)-1-alkenyl sulfoxides via terminal alkynes

AUTHOR(S): Zhong, Ping; Guo, Meng-Ping; Huang, Xian

CORPORATE SOURCE: Department of Chemistry, Yichun Normal Institute, Yichun, 336000, Peop. Rep. China

SOURCE: Journal of Chemical Research, Synopses (2000), (12), 588-589

CODEN: JRPSDC; ISSN: 0308-2342

PUBLISHER: Science Reviews Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:122252

ED Entered STN: 11 May 2001

AB Terminal alkynes react with $\text{Cp}_2\text{Zr}(\text{H})\text{Cl}$ ($\text{Cp} = \eta^5\text{-C}_5\text{H}_5$) to give organozirconium(IV) complexes, which are trapped with sulfinyl chlorides to afford (E)-1-alkenyl sulfoxides.

CC 25-12 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

ST alkenyl sulfoxide stereoselective prepn; alkyne reaction zirconocene chloride sulfinyl chloride

IT Stereoselective synthesis (of (E)-1-alkenyl sulfoxides via terminal alkynes)

IT Alkynes


RL: RCT (Reactant); RACT (Reactant or reagent) (stereoselective preparation of (E)-1-alkenyl sulfoxides via terminal alkynes)

IT Sulfoxides

RL: SPN (Synthetic preparation); PREP (Preparation) (stereoselective preparation of (E)-1-alkenyl sulfoxides via terminal alkynes)

- IT 536-74-3, Phenylacetylene 628-71-7, 1-Heptyne 693-02-7, 1-Hexyne
 4972-29-6, Benzenesulfinyl chloride 10439-23-3, 4-Methylbenzenesulfinyl
 chloride 37342-97-5, Zirconocene chloride hydride 41719-05-5,
 Benzenemethanesulfinyl chloride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (stereoselective preparation of (E)-1-alkenyl sulfoxides via
 terminal alkynes)
- IT 40110-66-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (stereoselective preparation of (E)-1-alkenyl sulfoxides via
 terminal alkynes)
- IT 56246-14-1P 66967-41-7P 98750-73-3P 138286-20-1P
160426-22-2P 257904-70-4P 350826-92-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (stereoselective preparation of (E)-1-alkenyl sulfoxides via
 terminal alkynes)
- IT 160426-22-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (stereoselective preparation of (E)-1-alkenyl sulfoxides via
 terminal alkynes)
- RN 160426-22-2 HCAPLUS
 CN Benzene, [[[1E]-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L133 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 1998:651752 HCAPLUS Full-text

DOCUMENT NUMBER: 130:13631

TITLE: 1-Alkenesulfinyl Chlorides: Synthesis,
Characterization, and Some Substitution
Reactions

AUTHOR(S): Schwan, Adrian L.; Strickler, Rick R.; Lear, Yvonne;
Kalin, Mark L.; Rietveld, Tanya E.; Xiang, Ting-Jian;
Brillon, Denis

CORPORATE SOURCE: Guelph-Waterloo Centre for Graduate Work in Chemistry
and Biochemistry Department of Chemistry and
Biochemistry, University of Guelph, Guelph, ON, N1G
2W1, Can.

SOURCE: Journal of Organic Chemistry (1998), 63(22),
7825-7832

CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 130:13631

ED Entered STN: 15 Oct 1998

AB A number of 1-alkenyl sulfoxides bearing either a diphenylmethyl (DPM) or a p-methoxybenzyl (PMB) group have been prepared and exposed to the chlorine surrogate SO₂Cl₂. Through an oxidative fragmentation reactions, a new family of sulfur acid derivs., 1-alkenesulfinyl chlorides, is generated. They can be characterized by IR spectroscopy before chemical capture with an alc. Ethenesulfinyl chloride and 1-propenesulfinyl chloride, obtained from their corresponding DPM precursor, can be distilled at reduced pressure to afford ca. 90% pure material. NMR chemical shift comparison of various 1-alkenesulfinyl-containing compds. is made. 1-Alkenesulfinylmethyl phenyl(alkyl) ketones can be prepared directly from 1-alkenesulfinyl chlorides although decomposition and/or isomerization is sometimes extensive during purification

CC 21-2 (General Organic Chemistry)

ST alkenesulfinyl chloride prepn reaction; oxidative
fragmentation alkenyl sulfoxide; sulfinic ester prepn

IT Fragmentation reactions
(preparation of alkenesulfinyl chlorides by oxidative
fragmentation of alkenyl sulfoxides)

IT Sulfoxides

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of alkenesulfinyl chlorides by oxidative
fragmentation of alkenyl sulfoxides)

IT Halides

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(sulfinyl chlorides; preparation of alkenesulfinyl chlorides by
oxidative fragmentation of alkenyl sulfoxides)

IT 91-01-0, Benzhydrol 104-93-8, p-Methoxytoluene 105-13-5,
p-Methoxybenzyl alcohol 108-93-0, Cyclohexanol, reactions
122-97-4, 3-Phenylpropanol 536-74-3, Phenylacetylene 558-37-2,
3,3-Dimethyl-1-butene 776-74-9, Diphenylmethyl bromide 922-67-8,
Methyl propiolate 1833-53-0 6258-60-2 6651-36-1 7117-41-1
13735-81-4 24281-03-6 24281-04-7 24281-06-9 156598-22-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and reactions of alkenesulfinyl chlorides)

IT 2245-30-9P 2746-25-0P, p-Methoxybenzyl bromide 4237-48-3P,

Diphenylmethanethiol 35378-93-9P 45434-29-5P 77481-43-7P
 94001-59-9P 176907-85-0P 176907-89-4P 176907-90-7P 176907-91-8P
 176907-95-2P 176907-96-3P 216007-60-2P 216007-61-3P 216007-62-4P
 216007-63-5P 216007-64-6P 216007-65-7P 216007-66-8P
216007-67-9P 216007-69-1P 216007-70-4P 216007-71-5P
 216007-72-6P 216007-73-7P 216007-74-8P 216007-75-9P
 216007-76-0P, Ethenesulfinyl chloride 216007-77-1P 216007-78-2P
 216007-79-3P 216007-80-6P, 1-Cyclohexene-1-sulfinyl chloride
 216007-81-7P 216007-82-8P 216007-83-9P 216007-84-0P 216007-85-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation and reactions of alkenesulfinyl chlorides)

IT 176907-97-4P 176908-01-3P 176908-02-4P 216007-86-2P 216007-87-3P
 216007-88-4P 216007-89-5P 216007-90-8P 216007-91-9P 216007-92-0P
 216007-93-1P 216007-94-2P 216007-95-3P 216007-96-4P 216007-97-5P
 216007-98-6P 216007-99-7P 216008-00-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and reactions of alkenesulfinyl chlorides)

IT 216007-66-8P 216007-67-9P 216007-71-5P
216007-73-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation and reactions of alkenesulfinyl chlorides)

RN 216007-66-8 HCAPLUS

CN Benzene, 1,1'-[[[(1E)-2-phenylethenyl]sulfinyl]methylene]bis- (9CI) (CA
 INDEX NAME)


Double bond geometry as shown.



RN 216007-67-9 HCAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA
 INDEX NAME)


Double bond geometry as shown.



RN 216007-71-5 HCAPLUS

CN Benzene, 1,1'-[[[(1Z)-2-phenylethenyl]sulfinyl]methylene]bis- (9CI) (CA
 INDEX NAME)


Double bond geometry as shown.



RN 216007-73-7 HCAPLUS

CN Benzene, 1-methoxy-4-[[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L133 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 1996:213412 HCAPLUS Full-text

DOCUMENT NUMBER: 124:342597

TITLE: Oxidative fragmentations of selected 1-alkenyl sulfoxides. Chemical and spectroscopic evidence for 1-alkenesulfinyl chlorides

AUTHOR(S): Schwan, Adrian L.; Kalin, Mark L.; Vajda, Kristin E.; Xiang, Ting-Jian; Brillon, Denis

CORPORATE SOURCE: Guelph-Waterloo Cent. Grad. Work Chem., Univ. Guelph, Guelph, ON, N1G 2W1, Can.

SOURCE: Tetrahedron Letters (**1996**), 37(14), 2345-8

CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:342597

ED Entered STN: 13 Apr 1996

AB A collection of 1-alkenyl sulfoxides possessing diphenylmethyl, p-methoxybenzyl or 2-(trimethylsilyl)ethyl groups, e.g., $\text{RCH}_2\text{CCl:C}(\text{CH}_2\text{R})\text{S}(\text{O})(\text{CH}_2)_2\text{SiMe}_3$ (R = Me, OAc), can be converted to 1-alkenesulfinyl chlorides using SO_2Cl_2 . The 1-alkenesulfinyl chlorides were spectroscopically characterized by IR and were chemical captured as their cyclohexyl or 3-phenylpropyl 1-alkenesulfinate esters.

CC 23-11 (Aliphatic Compounds)

IT 108-93-0, Cyclohexanol, reactions 122-97-4, 3-Phenylpropanol
142-29-0, Cyclopentene 536-74-3, Phenylacetylene 754-05-2, Vinyl trimethylsilane 776-74-9 928-49-4, 3-Hexyne 1573-17-7,
1,4-Diacetoxy-2-butyne 2746-25-0 21466-62-6, Phenylthiirane S-oxide 156090-91-4, 2-(Trimethylsilyl)ethanesulfinyl chloride 176907-85-0
176907-86-1 176907-87-2 **176907-88-3** 176907-89-4
176907-90-7 176907-91-8 176907-92-9 176907-93-0 **176907-94-1**
176907-95-2 176907-96-3


RL: RCT (Reactant); RACT (Reactant or reagent)
(substitution of alkenyl sulfoxides via sulfinyl chlorides)

IT **176907-88-3 176907-94-1**

RL: RCT (Reactant); RACT (Reactant or reagent)
(substitution of alkenyl sulfoxides via sulfinyl chlorides)


RN 176907-88-3 HCAPLUS

CN Benzene, 1,1'-[[(2-phenylethenyl)sulfinyl]methylene]bis- (9CI) (CA INDEX NAME)



RN 176907-94-1 HCAPLUS

CN Benzene, 1-methoxy-4-[[(2-phenylethenyl)sulfinyl]methyl]- (9CI) (CA INDEX NAME)



L133 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 1990:631146 HCAPLUS Full-text

DOCUMENT NUMBER: 113:231146

TITLE: Synthesis and properties of substituted α' -lithiated $\alpha(Z),\gamma$ -dienyl sulfoxides. Part II. Stereochemical studies on products obtained by cyclization of α' -lithiated $\alpha(Z),\gamma$ -dienyl sulfide, sulfoxide, and sulfone

AUTHOR(S): Reglier, M.; Julia, S. A.

CORPORATE SOURCE: Fac. Sci. Saint-Jerome, Univ. Aix-Marseille III, Marseille, 13397, Fr.

SOURCE: Bulletin de la Societe Chimique de France (1990), (March-April), 236-44

CODEN: BSCFAS; ISSN: 0037-8968

DOCUMENT TYPE: Journal

LANGUAGE: French

OTHER SOURCE(S): CASREACT 113:231146

ED Entered STN: 22 Dec 1990

AB The lithio derivative of sulfide I was prepared and gave after protonation the two compds. trans-II (45%) and cis-III (15%). In the same way, the corresponding sulfoxide and sulfone were converted stereospecifically into the anti,cis (68%) and cis (61%) compds., resp. For each of the three lithio derivs., the possible transition states were examined

CC 27-13 (Heterocyclic Compounds (One Hetero Atom))

IT 99834-14-7P 99834-21-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and oxidn of)

IT 100483-88-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and oxidation of)

IT 100420-66-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reduction of)

IT 99834-11-4P 100420-61-9P 130629-39-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and sequential lithiation and cyclization of)

IT 99834-15-8P 100420-70-0P 100420-78-8P 130629-40-2P

130629-41-3P 130629-42-4P 130629-43-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

IT 100-53-8, Benzenemethanethiol

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, with cyclohexenylacetylene)

IT 931-49-7

RL: RCT (Reactant); RACT (Reactant or reagent)


(reaction of, with toluenethiol)

IT 100420-61-9PRL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and sequential lithiation and cyclization of)

RN 100420-61-9 HCAPLUS

CN Benzene, [[[2-(1-cyclohexen-1-yl)ethenyl]sulfinyl]methyl]-, (Z)- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.

IT 100420-70-0PRL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 100420-70-0 HCAPLUS

CN Benzene, [[[2-(1-cyclohexen-1-yl)ethenyl]sulfinyl]methyl]-, (E)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



L133 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 1986:88389 HCAPLUS Full-text

DOCUMENT NUMBER: 104:88389

TITLE: Stereospecific cyclizations of substituted
 α' -lithiated $\alpha(Z),\gamma$ -butadienyl
sulfoxides

AUTHOR(S): Reglier, Marius; Julia, Sylvestre A.

CORPORATE SOURCE: Lab. Chim., Ec. Norm. Super., Paris, 75231, Fr.

SOURCE: Tetrahedron Letters (1985), 26(22), 2655-8

CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 104:88389

ED Entered STN: 22 Mar 1986

AB The title compds. I [R = Ph, Me2C:CH, R1 = H, R2 = Me; R = Ph, R1R2 = (CH2)4]
were prepared and converted stereospecifically to the lithiated cyclic
sulfoxides I through a concerted disrotatory electrocyclization.

CC 27-15 (Heterocyclic Compounds (One Hetero Atom))


IT Cyclocondensation reaction(stereoselective, of lithiated butadienyl sulfoxides, lithiated
dihydrothiopyran oxides from)

IT 100420-58-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


- (preparation and lithiation of)
 IT 100420-59-5P 100420-60-8P **100420-61-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
- (preparation and lithiation-stereoselective cyclization of)
 IT 100420-65-3P 100420-66-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
- (preparation and oxidation and reduction of)
 IT 100420-64-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
- (preparation and oxidation of)
 IT 99834-14-7P 100420-62-0P 100420-63-1P 100420-67-5P 100420-68-6P
 100420-69-7P **100420-70-0P** 100420-71-1P 100420-72-2P
 100420-73-3P 100420-74-4P 100420-75-5P 100420-76-6P 100420-77-7P
 100420-78-8P 100440-52-6P 100440-53-7P 100483-86-1P 100483-87-2P
 100483-88-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
- (preparation of)
 IT **100420-61-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
- (preparation and lithiation-stereoselective cyclization of)
 RN 100420-61-9 HCAPLUS
 CN Benzene, [[[2-(1-cyclohexen-1-yl)ethenyl]sulfinyl]methyl]-, (Z)- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.



- IT **100420-70-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
- (preparation of)
 RN 100420-70-0 HCAPLUS
 CN Benzene, [[[2-(1-cyclohexen-1-yl)ethenyl]sulfinyl]methyl]-, (E)- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.



L133 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 8
 ACCESSION NUMBER: 1984:67936 HCAPLUS Full-text
 DOCUMENT NUMBER: 100:67936

TITLE: Sodium bromite: a new selective reagent for the oxidation of sulfides and alcohols

AUTHOR(S): Kageyama, Toshifumi; Ueno, Yoshio; Okawara, Makoto

CORPORATE SOURCE: Fac. Eng., Kanto Gakuin Univ., Yokohama, 236, Japan

SOURCE: Synthesis (1983), (10), 815-16
CODEN: SYNTBF; ISSN: 0039-7881

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 100:67936

ED Entered STN: 12 May 1984

AB Oxidation of 8 RS₁ (R = Ph, Bu, p-tolyl, styryl, 2-hydroxycyclohexanol, R₁ = Ph, Bu, PhCH₂, p-tolyl, allyl, morpholino) with NaBrO₂ in aqueous dioxane gave 78-97% RS(O)R₁. Similarly RCH(OH)R₁ [R = Me, R₁ = (CH₂)₄Me, HOCH₂CH₂; RR₁ = (CH₂)_n, n = 4-6] gave 82-100% RCOR₁.

CC 25-16 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

ST sodium bromite oxidizing agent; oxidn sulfide alc; ketone prepn oxidn alc; sulfoxide prepn oxidn sulfide

IT Alcohols, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of, with sodium bromite, ketones from)

IT Sulfides, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of, with sodium bromite, sulfoxides from)

IT Ketones, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by oxidation of alcs. with sodium bromite)

IT Sulfoxides
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by oxidation of sulfides with sodium bromite)

IT 71-41-0, reactions 96-41-3 107-88-0 108-93-0,
reactions 502-41-0 543-49-7 1490-04-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of, with sodium bromite, ketones from)

IT 109-52-4P, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by oxidation of pentanol with bromine)

IT 2173-56-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by oxidation of pentanol with sodium bromite)


IT 108-94-1P, preparation 110-43-0P 120-92-3P 502-42-1P
590-90-9P 10458-14-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by oxidation of the alc. with sodium bromite)

IT 833-82-9P 945-51-7P 1774-35-2P 2168-93-6P 16066-32-3P
19093-37-9P 65117-26-2P 88584-31-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by oxidation of the sulfide by sodium bromite)

IT 88584-31-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by oxidation of the sulfide by sodium bromite)

RN 88584-31-0 HCAPLUS

CN Benzene, [[(2-phenylethenyl)sulfinyl]methyl]- (9CI) (CA INDEX NAME)



L133 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 9

ACCESSION NUMBER: 1963:428075 HCAPLUS Full-text

DOCUMENT NUMBER: 59:28075

ORIGINAL REFERENCE NO.: 59:5004b-c

TITLE: Transfer reactions involving boron. III.
Hydroboration studies with enethiol ethers

AUTHOR(S): Pasto, D. J.; Miesel, J. L.

CORPORATE SOURCE: Univ. of Notre Dame, Notre Dame, IN

SOURCE: J. Am. Soc. Soc. (1963), 85(14), 2118-24

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

ED Entered STN: 22 Apr 2001

AB cf. CA 58, 12444a. A new rearrangement reaction of unstable substituted organoboranes is reported. Hydroboration of enethiol ethers gives both possible substituted organoboranes in which H and C undergo an intermol. transfer from B to C with the sulfur residue migrating from C to B. The reactions are proposed to proceed via fourcentered transition states.

CC 32 (Physical Organic Chemistry)

IT 32093-01-9P, Sulfone, benzyl styryl, trans- 32291-81-9P, Sulfone, benzyl styryl, cis- 93902-69-3P, 2-Hexanone, 3,4-diphenyl- 852284-93-6P, Sulfoxide, benzyl styryl, cis-

RL: PREP (Preparation)

(preparation of)

IT 852284-93-6P, Sulfoxide, benzyl styryl, cis-


RL: PREP (Preparation)

(preparation of)

RN 852284-93-6 HCAPLUS

CN Benzene, [[[1Z]-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L133 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 10

ACCESSION NUMBER: 1963:428074 HCAPLUS Full-text

DOCUMENT NUMBER: 59:28074

ORIGINAL REFERENCE NO.: 59:5003g-h, 5004a-b

TITLE: Intermolecular transfer of the 2,4,6-trinitrophenyl group bound to amino radicals

AUTHOR(S): Tanaka, Masaru; Tsuzukida, Yasuharu; Satake, Kazuo

CORPORATE SOURCE: Tokyo Metropolitan Univ.

SOURCE: Nippon Kagaku Zasshi (1962), (83), 895-901

CODEN: NPKZAZ; ISSN: 0369-5387

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

ED Entered STN: 22 Apr 2001

AB Transferability of the picryl (TNP) group in picramide (I) and its derivs. was studied especially with amino acids. Analyses of the starting material and the product were carried out by electronic absorption spectra or by paper chromatography followed by densitometry. TNP-amino acids (20 mol.) were treated with 20 ml. 15N NH₃; TNP-proline (II) was the most reactive. TNP-glycine and TNP-glycylpeptide also react rapidly but no I was detected. Other TNP-amino acids give almost quant. I, but the reaction velocity depends on the

steric effect of the α -substituent. TNP-peptides react similarly. TNP group at the α -position of lysine is more rapidly transferred than that at ϵ -position. When there is a primary CH, COa2H, or p-C6H4OH group β to the TNP-Ngroup, the reaction is slow, but the products are normal. Effect of concentration of NH3 on the transfer was studied with TNP-glutamic acid (III). If the concentration is »IN, the reaction rate is not much affected, although more concentrated solution gives faster reaction. The reaction rate also depends on pH, the critical pH being 11.7. The reaction is complete within several min. at 100° and is faster when EtOH is present. Reaction between alkylamines and III produces only alkylpicramide (IV) and glutamic acid. Reaction between I and Me2NH (V) gives no N,N-dimethylpicramide (VI). IV and NH3 give I easily but V gives unidentified material. VI and NH3 react smoothly but reaction between I and alkylamine is slow, especially when the alkyl chain is long. II and V do not react but proline and VI react to produce a little II. Thus it is concluded that, as TNP-donor, the ability is I «IV « VI and that, as acceptor, the ability is NH3 » primary amine » secondary amine.

CC 32 (Physical Organic Chemistry)

IT Reaction kinetics and(or) Velocity
(of ammonolysis of N-picryl amino acids)

IT Amines
(reactions of, with N-picryl amino acids)

IT 838-67-5P, Benzyl alcohol, α -[(benzylthio)methyl]- 2157-59-7P,
Sulfide, α -ethylbenzyl phenyl 32093-01-9P, Sulfone, benzyl styryl,
trans- 32291-81-9P, Sulfone, benzyl styryl, cis- 87413-33-0P, Sulfone,
 α -ethylbenzyl phenyl 93902-69-3P, 2-Hexanone, 3,4-diphenyl-
94264-79-6P, Phenethyl alcohol, β -(α -ethylbenzyl)- α -
methyl- 95126-90-2P, Sulfoxide, α -ethylbenzyl phenyl
852284-93-6P, Sulfoxide, benzyl styryl, cis-
RL: PREP (Preparation)

(preparation of)


IT 7664-41-7, Ammonia
(reaction with N-picryl amino acids)

IT 852284-93-6P, Sulfoxide, benzyl styryl, cis-
RL: PREP (Preparation)
(preparation of)

RN 852284-93-6 HCAPLUS

CN Benzene, [[[1Z]-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L133 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:414144 HCAPLUS Full-text

DOCUMENT NUMBER: 133:192741

TITLE: The reaction of thiirane S-oxides with
methyllithium lithium bromide complex. A surprising
preference for deprotonation over desulfurization

AUTHOR(S): Schwan, Adrian L.; Lear, Yvonne

CORPORATE SOURCE: Guelph-Waterloo Centre for Graduate Work in Chemistry
and Biochemistry, Department of Chemistry and
Biochemistry, University of Guelph, Guelph, ON, N1G


2W1, Can.
 SOURCE: Sulfur Letters (2000), 23(3), 111-119
 CODEN: SULED2; ISSN: 0278-6117
 PUBLISHER: Harwood Academic Publishers
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 22 Jun 2000
 AB Selected organolithium reagents demonstrate a surprising preference for deprotonation of thiirane S-oxides over other modes of attack including desulfurization. The MeLi·LiBr complex in particular was shown to generate (E)-1-alkenesulfenate anions in 50-75% yield via an initial deprotonation reaction of alkyl substituted thiirane S-oxides. These results are comparable to the established deprotonation reaction using disilazide bases, but lead to cleaner reaction mixts.
 CC 21-2 (General Organic Chemistry)
 ST thiirane oxide deprotonation lithium bromide methyllithium; alkenylsulfinylmethyl benzene prepn; sulfine alkenyl prepn
 IT Deprotonation
 (preparation of [(alkenylsulfinyl)methyl]benzene derivs. by deprotonation of thiirane oxides with methyllithium-lithium bromide complex)
 IT Organic compounds, preparation
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (sulfines; preparation of [(alkenylsulfinyl)methyl]benzene derivs. by deprotonation of thiirane oxides with methyllithium-lithium bromide complex)
 IT 100-42-5P, preparation
 RL: BYP (Byproduct); PREP (Preparation)
 (preparation of)
 IT 289507-41-1P 289507-43-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 IT 917-54-4, Methyllithium 7550-35-8, Lithium bromide
 RL: NUU (Other use, unclassified); USES (Uses)
 (preparation of [(alkenylsulfinyl)methyl]benzene derivs. by deprotonation of thiirane oxides with methyllithium-lithium bromide complex)
 IT 100-39-0, Benzyl bromide 7117-41-1, Thiirane 1-oxide. 21386-27-6, Methylthiirane 1-oxide 21386-28-7, 7-Thiabicyclo[4.1.0]heptane 7-oxide 21466-62-6, Phenylthiirane 1-oxide 202071-56-5 202071-67-8, Triethyl(1-oxidothiiranyl)silane 289507-40-0, (1,1-Dimethylethyl)thiirane 1-oxide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of [(alkenylsulfinyl)methyl]benzene derivs. by deprotonation of thiirane oxides with methyllithium-lithium bromide complex)
 IT 73927-19-2P, [(Ethenylsulfinyl)methyl]benzene 152459-50-2P, [(1-Cyclohexen-1-yl)sulfinyl]methyl]benzene 160426-22-2P, [(E)-(2-Phenylethenyl)sulfinyl]methyl]benzene 160426-23-3P, [(1-Phenylethenyl)sulfinyl]methyl]benzene 160426-29-9P, Triethyl[1-[(phenylmethyl)sulfinyl]ethenyl]silane 160426-30-2P 289507-42-2P, [(1E)-(1-Propenylsulfinyl)methyl]benzene 289507-44-4P 289507-45-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of [(alkenylsulfinyl)methyl]benzene derivs. by deprotonation of thiirane oxides with methyllithium-lithium bromide complex)
 IT 160426-22-2P, [(E)-(2-Phenylethenyl)sulfinyl]methyl]benzene
 RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of [(alkenylsulfinyl)methyl]benzene derivs. by deprotonation of thiirane oxides with methyllithium-lithium bromide complex)

RN 160426-22-2 HCAPLUS

CN Benzene, [[[(1E)-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L133 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:283696 HCAPLUS Full-text

DOCUMENT NUMBER: 122:80624

TITLE: Theoretical and Experimental Analyses of the Deprotonation of Thiirane S-Oxides: The Stereoselective Formation of trans-Alkyl- and gem-Silylethenesulfenate Anions

AUTHOR(S): Refvik, Mitchell D.; Froese, Robert D. J.; Goddard, John D.; Pham, Hung H.; Pippert, Mark F.; Schwan, Adrian L.

CORPORATE SOURCE: Guelph-Waterloo Centre for Graduate Work in Chemistry, University of Guelph, Guelph, ON, N1G 2W1, Can.

SOURCE: Journal of the American Chemical Society (1995), 117(1), 184-92

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 10 Jan 1995

AB Exptl. and theor. studies of the regioselective deprotonation of thiirane S-oxides are reported. Exptl. under the reaction conditions of LiHMDS/THF/-78° with anti-alkylthiirane S-oxides or anti-silylthiirane S-oxides as starting materials, the products of ring opening are (E)-2-alkylethenesulfenate and 1-silylethenesulfenate anions, resp. Expts. involving deuterium labeling clearly indicate that a regioselective deprotonation reaction was followed by a stereoselective ring opening. Ab initio methods at both the Hartree-Fock and Moeller-Plesset perturbation theory levels with the 6-31+G(d) basis set were used to exam. both lithiated methyl- and silylthiirane S-oxides. Of the possible anti-substituted species, the coordination of the lithium anti to the Me and gem to the silyl is predicted to be the most stable. These stable intermediates with the lithium syn to the sulfoxide could open to yield the exptl. observed products.

CC 22-12 (Physical Organic Chemistry)

Section cross-reference(s): 29


IT Protonation and Proton transfer reaction

(deprotonation, regioselective, exptl. and theor. study of deprotonation and ring cleavage of thiirane oxides)

IT	73927-19-2P	152459-44-4P	152459-46-6P	152459-47-7P	152459-48-8P
	152459-49-9P	152459-50-2P	152459-51-3P	152459-52-4P	160426-15-3P
	160426-17-5P	160426-18-6P	160426-19-7P	160426-20-0P	160426-21-1P
	<u>160426-22-2P</u>	160426-23-3P	160426-29-9P	160426-30-2P	
	160426-31-3P	160426-32-4P	160426-33-5P	160426-34-6P	160426-35-7P

160426-36-8P 160426-39-1P 160426-40-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 IT 160426-22-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 160426-22-2 HCAPLUS
 CN Benzene, [[[1E]-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> d ibib ab fhit 12

YOU HAVE REQUESTED DATA FROM FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' -
 CONTINUE? (Y)/N:y

L133 ANSWER 12 OF 21 CASREACT COPYRIGHT 2007 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 143:1247 CASREACT Full-text
 TITLE: α,β -Unsaturated sulfoxides for treating
 proliferative disorders and as radioprotective and
 chemoprotective agents
 INVENTOR(S): Reddy, Premkumar E.; Reddy, Ramana M. V.; Bell,
 Stanley C.
 PATENT ASSIGNEE(S): Temple University-of the Commonwealth System of Higher
 Education, USA; Onconova Therapeutics Inc.
 SOURCE: PCT Int. Appl., 120 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046599	A2	20050526	WO 2004-US37293	20041108
WO 2005046599	A3	20051006		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004289281	A1	20050526	AU 2004-289281	20041108

CA 2546495 A1 20050526 CA 2004-2546495 20041108
 EP 1689706 A2 20060816 EP 2004-816944 20041108
 R: AT, BE, CH, LI, CY, BG, CZ
 US 2006280746 A1 20061214 US 2006-574993 20060406
 PRIORITY APPLN. INFO.: US 2003-520523P 20031114
 WO 2004-US37293 20041108

OTHER SOURCE(S): MARPAT 143:1247

AB $\alpha\beta$ -Unsatd. sulfoxides Ar1[CH(R1)]nS(O)CH=CHAr2 [Ar1, Ar2 = (un)substituted (hetero)aryl (when Ar1 and Ar2 are both Ph, at least one of Ar1 and Ar2 is substituted); n = 0, 1; R1 = H, C1-8 hydrocarbyl, CN, etc.; conformation of substituents on carbon-carbon double bond is E or Z; conformation of substituents on sulfoxide S atom is R-, S- or any mixture of R- and S-; when R1 other than H, conformation of substituents on carbon atom to which R1 is attached is R-, S- or any mixture of R- and S-] are disclosed which are useful as antiproliferative agents including e.g. anticancer agents and as radioprotective and chemoprotective agents. Processes or prep. compds. of the invention are also disclosed.

RX(2) OF 15 ... F + G ==> H



RX(2) RCT F 852285-79-1, G 830-79-5
 PRO H 852283-22-8
 CAT 110-89-4 Piperidine, 65-85-0 BzOH
 SOL 108-88-3 PhMe
 CON SUBSTAGE(1) 25 deg C
 SUBSTAGE(2) 25 deg C -> reflux
 SUBSTAGE(3) 6 hours, reflux
 SUBSTAGE(4) reflux -> 25 deg C
 NTE stereoselective, Knoevenagel reaction

=> d ibib ab fhit 13-14

YOU HAVE REQUESTED DATA FROM FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' -
CONTINUE? (Y)/N:y

L133 ANSWER 13 OF 21 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 139:374247 CASREACT Full-text

TITLE: Structure-activity relationships of
2-(benzothiazolylthio)acetamide class of CCR3
selective antagonist

AUTHOR(S): Naya, Akira; Kobayashi, Kensuke; Ishikawa, Makoto;
Ohwaki, Kenji; Saeki, Toshihiko; Noguchi, Kazuhito;
Ohtake, Norikazu

CORPORATE SOURCE: Banyu Tsukuba Research Institute, Ibaraki, 300-2611,
Japan

SOURCE: Chemical & Pharmaceutical Bulletin (2003), 51(6),
697-701

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan


DOCUMENT TYPE: Journal

LANGUAGE: English


AB The structure activity relationships of novel selective CCR3 receptor antagonists, 2-(benzothiazolylthio)acetamide derivs. were described. A lead structure (1a) was discovered from the screening of the focused library that was based on the structure of our dual antagonists for the human CCR1 and CCR3 receptors. Derivatization of 1a including incorporation of substituent(s) into each benzene ring of the benzothiazole and piperidine side chain resulted in the identification of potent and selective compds. (1b,r,s) exhibiting nano-molar binding affinity (IC50s: 1.5-3.0 nM) and greater than 800-fold selectivity for the CCR3 receptor over the CCR1 receptor.


RX(93) OF 163 COMPOSED OF REACTION SEQUENCE RX(24), RX(6)
AND REACTION SEQUENCE RX(29), RX(21), RX(6)

...BF ==> R...


...BP + J + R ==> S

START NEXT REACTION SEQUENCE





3
STEPS
→



RX(24) RCT BF 6295-57-4
 RGT BG 37222-66-5 Oxone
 PRO R 625080-87-7
 SOL 109-99-9 THF, 7732-18-5 Water
 CON SUBSTAGE(1) 0 deg C
 SUBSTAGE(2) 4 hours, room temperature

RX(29) RCT BP 73874-95-0, J 6287-38-3
 RGT D 56553-60-7 Na. (AcO) 3BH
 PRO BC 328083-79-0
 SOL 67-66-3 CHCl₃
 CON SUBSTAGE(1) room temperature
 SUBSTAGE(2) 20 hours, room temperature

RX(21) RCT BC 328083-79-0

STAGE(1)
 RGT AY 7647-01-0 HCl
 SOL 67-56-1 MeOH
 CON 20 hours, room temperature

STAGE(2)
 RGT AZ 1310-73-2 NaOH
 SOL 7732-18-5 Water
 CON room temperature, pH >7

PRO M 92539-28-1

RX(6) RCT R 625080-87-7, M 92539-28-1
 RGT O 2592-95-2 1-Benzotriazolol, P 25952-53-8 EDAP

PRO S 625080-84-4
 SOL 67-66-3 CHCl3
 CON SUBSTAGE(1) room temperature
 SUBSTAGE(2) 20 hours, room temperature
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L133 ANSWER 14 OF 21 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 121:34787 CASREACT Full-text

TITLE: Ligand exchange reaction of sulfoxides in organic
 synthesis: a novel method for generation of magnesium
 enolates and its application to synthesis of
 α -halocarboxylic acid derivatives and
 α -haloaldehydes

AUTHOR(S): Satoh, Tsuyoshi; Kitoh, Yasushi; Ken-ichi Onda; Koji,
 Takano; Koji, Yamakawa

CORPORATE SOURCE: Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan

SOURCE: Tetrahedron (1994), 50(17), 4957-72


CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new method for synthesis of α -halo(Cl, F)carboxylic acid derivs. and α -haloaldehydes is described. α -Halo- α -sulfinyl carboxylic acids, esters, and α -halo- α -sulfinyl aldehydes were easily prepared from aryl 1-haloalkyl sulfoxides and alkyl chloroformate and Et formate, resp., in good yields. α -Chloro- α -sulfinyl amides were synthesized from (p-tolylthio)acetic acid. Ligand exchange reaction of the sulfonyl group of these acids, esters, amides, and aldehydes with EtMgBr gave the magnesium enolates, which were treated with water to give α -halocarboxylic acid derivs. and α -chloroaldehydes in good yields. The magnesium enolates from α -chloro- α -sulfinyl acid derivs. were trapped with carbonyl compds. to give α -halo- β -hydroxy adducts, which were cyclized to α,β -epoxy carboxylic acid derivs. Thermal elimination of the sulfinyl group in the α -halo- α -sulfinyl acid derivs. and the α -halo- α -sulfinyl aldehydes gave α -halo- α,β -unsatd. carboxylic acid derivs. and α -halo- α,β -unsatd. aldehydes in high yields.

RX(9) OF 148 ...H + Z ==> AA



RX(9) RCT H 148586-45-2

STAGE(1)

10/574,993

RGT D 925-90-6 EtMgBr
SOL 109-99-9 THF

STAGE(2)
RCT Z 100-52-7

STAGE(3)
RGT E 12125-02-9 NH4Cl, X 1310-73-2 NaOH
SOL 7732-18-5 Water

STAGE(4)
RGT Y 7647-01-0 HCl
SOL 7732-18-5 Water

PRO AA 25547-51-7

=> d bib ab fhit 15

YOU HAVE REQUESTED DATA FROM FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' -
CONTINUE? (Y)/N:y

L133 ANSWER 15 OF 21 CHEMINFORMRX COPYRIGHT 2007 FIZ CHEMIE on STN

AN 200647100 CHEMINFORMRX Full-text

TI Aryliododifluoromethylsulfides, Sulfoxides and Sulfones: The First
Optically Active Compounds with Polyfluoroalkyliodo Groups.

AU YAGUPOLSKII, L. M.; MATSNEV, A. V.

CS Inst. Org. Chem., Natl. Acad. Sci. Ukr., Kiev 02094, Ukraine

SO Mendeleev Commun.(3), 132-134 (2006)



CODEN: MENCEX ISSN: 0959-9436

LA English


AB A new method for the synthesis of compounds with the difluoromethyliodide
group directly connected to sulfide or sulfonyl groups is reported. Sulfoxides
(II) and (VII) with difluoriodomethyl and difluoromethyl groups bound to
sulfur, resp., and their optically active forms are synthesized for the first
time.

RX(18) OF 19 COMPOSED OF RX(3), RX(10)

RX(18) H + T ==> U



2
STEPS
→



F
R1

VI
YIELD 60.0%



RX(3) RCT I, **884923**
 RGT 1275 (21908-53-2), HgO
 109 (7553-56-2), I2
 SOL 55 (107-06-2), CH2Cl-CH2Cl
 PRO II, 1187783
 YDS 35.0 - 75.0 %
 T.KW REFLUX
 KW halogenation; C-halogenation; iodination; alkylation
 NTE reaction:I -> II, example: 3
 RX(10) RCT II, 1187783
 V, **10110** (104-87-0)
 RGT 1184653, (Et2N)2C=C(NEt2)2
 PRO VI, 1187787
 YDS 60.0 %
 T -15.0 - 25.0 Cel
 KW addition; alkylation; C-alkylation
 NTE reaction:IIc (V) -> VI

=> d bib ab fh1t 16-18

YOU HAVE REQUESTED DATA FROM FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' -
 CONTINUE? (Y)/N:y

L133 ANSWER 16 OF 21 CHEMINFORMRX COPYRIGHT 2007 FIZ CHEMIE on STN
 AN 200120073 CHEMINFORMRX Full-text
 TI Simple and Stereoselective Synthetic Route to (E)-1-Alkenyl Sulfoxides via
 Terminal Alkynes.
 AU ZHONG, P.; GUO, M.-P.; HUANG, X.
 CS Dep. Chem., Zhejiang Univ., Hangzhou 310028, Peop. Rep. China
 SO J. Chem. Res., Synop.(12), 588-589 (2000)
 CODEN: JRPSDC ISSN: 0308-2342
 LA English
 AB Hydrozirconation of terminal alkynes (I) and subsequent trapping of the
 organo-zirconium(IV) complexes formed with sulfonyl chlorides (II) results in
 the regio- and stereospecific formation of (E)-1- alkenyl sulfoxides (III) (7
 examples). Vinyl sulfoxides (III) are valuable reagents in organic synthesis,
 e.g. the preparation of α,β -dichlorosulfides such as (IV).

RX(2) OF 6 A + F ==> G



RX(2) RCT I, 8427 (536-74-3)
 II, 807508
 STAGE(1)
 RGT 2375, ZrHCl(Cp)₂
 SOL 206 (109-99-9), THF
 T 25.0 Cel
 TIM 0.3 hr
 STAGE(2)
 PRO III, 807509
 YDS 74.0 %
 KW addition; vinylation; alkylation; S-alkylation
 NTE reaction: I 2.(II) -> III, example: 2

L133 ANSWER 17 OF 21 CHEMINFORMRX COPYRIGHT 2007 FIZ CHEMIE on STN

AN 199912049 CHEMINFORMRX Full-text

TI 1-Alkenesulfinyl Chlorides: Synthesis, Characterization, and Some Substitution Reactions.

AU SCHWAN, A. L.; STRICKLER, R. R.; LEAR, Y.; KALIN, M. L.; RIETVELD, T. E.; XIANG, T.-J.; BRILLON, D.

CS Guelph-Waterloo Cent. Grad. Work Chem., Dep. Chem. Biochem., Univ. Guelph, Guelph, Ont. N1G 2W1, Can.


SO J. Org. Chem., 63(22), 7825-7832 (1998)

CODEN: JOCEAH ISSN: 0022-3263

LA English

AB Treatment of various alkenylsulfoxides bearing either a diphenylmethyl or a p-methoxybenzyl group with SO₂Cl₂ leads to the cleavage of the S-benzyl bond and generation of a new family of sulfur acid derivatives, alkenesulfinyl chlorides, which can be characterized by IR spectroscopy before chemical capture with alcohols (II) and (IX). Chlorides (XIIIa) and (XIIIb) are isolated after distillation at reduced pressure to afford ca. 90% pure material. The preparation of derivatives of type (XV) from sulfinyl chlorides is accompanied in some cases by decomposition and/or isomerization during purification.

RX(5) OF 15 M + B ==> N



RX(5) RCT I, 658062
 II, 9890 (122-97-4)
 STAGE(1)
 RGT 199 (7791-25-5), SO₂Cl₂
 SOL 60 (75-09-2), CH₂Cl₂
 T -78.0 - 25.0 Cel
 STAGE(2)
 RGT 768 (584-08-7), K₂CO₃
 SOL 60 (75-09-2), CH₂Cl₂
 T -78.0 - 25.0 Cel
 PRO III, 658063
 YDS 75.0 %
 NTE reaction: I 2.(II) -> III, example: 5

L133 ANSWER 18 OF 21 CHEMINFORMRX COPYRIGHT 2007 FIZ CHEMIE on STN

AN 199632098 CHEMINFORMRX Full-text

TI Oxidative Fragmentations of Selected 1-Alkenyl Sulfoxides. Chemical and Spectroscopic Evidence for 1-Alkenesulfinyl Chlorides.

AU SCHWAN, A. L.; KALIN, M. L.; VAJDA, K. E.; XIANG, T.-J.; BRILLON, D.

CS Dep. Chem. Biochem., Univ. Guelph, Guelph, Ont. N1G 2W1, Can.



SO Tetrahedron Lett., 37(14), 2345-2348 (1996)

CODEN: TELEAY ISSN: 0040-4039

LA English

AB Upon treatment with sulfonyl chloride, a series of 1-alkenyl sulfoxides undergo oxidative cleavage of the C-S bond to give 1- alkenesulfinyl chlorides (cf. (IV)). These intermediates are characterized by IR spectroscopy and by chemical conversion to alkenesulfinate esters. In contrast, similar treatment of the sulfoxides (I) does not afford sulfinyl chlorides but produces α, β-dichlorinated products (II).

RX(13) OF 15 AA + P ==> AB



XI
YIELD 65.0%

RX(13) RCT X, 478465
VIII, 9890 (122-97-4)
STAGE(1)
RGT 199 (7791-25-5), SO₂Cl₂
SOL 60 (75-09-2), CH₂Cl₂
T -78.0 - 25.0 Cel
STAGE(2)
RGT 768 (584-08-7), K₂CO₃
T -78.0 - 25.0 Cel
PRO XI, 478466
YDS 65.0 %
NTE reaction: X 2.(VIII) -> XI, example: 2

=> d ibib ab 19-20

YOU HAVE REQUESTED DATA FROM FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' -
CONTINUE? (Y)/N:y

L133 ANSWER 19 OF 21 BABS COPYRIGHT 2007 BEILSTEIN MDL on STN

ACCESSION NUMBER: 6282045 BABS Full-text

TITLE: Synthesis and characterization of homochiral
cholesteryl 1-alkenesulfinate esters

AUTHOR(S): Strickler, Rick R.; Schwan, Adrian L.

SOURCE: Tetrahedron: Asymmetry (2000), 11(24), 4843 - 4852
CODEN: TASYE3

DOCUMENT TYPE: Journal

LANGUAGE: English

SUMMARY LANGUAGE: English

AB A number of \$a\$, \$b\$-unsaturated sulfinyl chlorides 1 has been separately prepared and treated with (-)-cholesterol under various conditions some of which incorporated chiral amines quinine or quinidine. Some (R&s%) vinylic sulfonates could be isolated in enantiopure form following one or two recrystallizations of the resulting diastereomeric mixtures of (-)-cholesteryl 1-alkenesulfonates 2. Access to diastereomerically enriched (S&s%) vinylic sulfonates (66-75 percent de) was achieved in three instances. Absolute stereochemical assignments were made with the assistance of the chiral solvating agent (R)-2,2,2-trifluoro-1-(9-anthryl)ethanol.

L133 ANSWER 20 OF 21 BABS COPYRIGHT 2007 BEILSTEIN MDL on STN

ACCESSION NUMBER: **5521334** BABS Full-text
 TITLE: Synthesis and properties of substituted \$a'\$-lithiated \$a(Z)\$,\$g\$-butadienyl sulfoxides. Part II : Stereochemical studies on products obtained by cyclisation of \$a'\$-lithiated \$a(Z)\$,\$g\$-butadienyl sulfide, sulfoxide and sulfone.
 AUTHOR(S): Reglier, M.; Julia, S. A.
 SOURCE: Bull.Soc.Chim.Fr. (1990), (2), 236-244
 CODEN: BSCFAS
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 SUMMARY LANGUAGE: English

AB The lithio derivative of sulfide 1 was prepared and gave after protonation the two compounds trans 6 (45 percent) and cis 7 (15 percent). In the same way, the sulfoxide 2 and sulfone 3 were converted stereospecifically into the anti, cis 11 (68 percent) and cis 9 (61 percent) compounds respectively. The cis heterocyclic compounds 7, 9, and 11 have been chemically correlated and after a thorough survey of the NMR spectra, their stereochemistry has been established. For each of the three lithio derivatives, the possible transition states were examined.

=> d ide hitstr 21


YOU HAVE REQUESTED DATA FROM FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' -
 CONTINUE? (Y)/N:y

'IDE' IS NOT A VALID FORMAT


REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT): ibib hitstr

L133 ANSWER 21 OF 21 CAOLD COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: CA59:5004b CAOLD
 TITLE: transfer reactions involving B - (III) hydroboration studies with enethiol ethers
 AUTHOR NAME: Pasto, Daniel J.; Miesel, J. L.
 IT **88584-31-0**
 RN 88584-31-0 CAOLD
 CN Benzene, [[(2-phenylethenyl)sulfinyl]methyl]- (9CI) (CA INDEX NAME)



=> d que stat l112
L110 STR



NODE ATTRIBUTES:

CONNECT IS E3 RC AT 3
CONNECT IS E2 RC AT 4
CONNECT IS E2 RC AT 5
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 1 6
GGCAT IS UNS AT 1
GGCAT IS UNS AT 6
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L112 52 SEA FILE=MARPAT SSS FUL L110

100.0% PROCESSED 43635 ITERATIONS (6 INCOMPLETE) 52 ANSWERS
SEARCH TIME: 00.00.14

=> d his l112-l119

(FILE 'MARPAT' ENTERED AT 08:23:53 ON 13 APR 2007)

FILE 'STNGUIDE' ENTERED AT 08:24:37 ON 13 APR 2007

FILE 'MARPAT' ENTERED AT 08:27:50 ON 13 APR 2007

L112 52 S L110 FUL
SAVE TEMP L112 NWA993MARPA

FILE 'HCAPLUS' ENTERED AT 08:30:56 ON 13 APR 2007

L113 52 S L112
L114 6 S L113 AND L32-L37
L115 46 S L113 NOT L114
L116 34 S L115 AND L85
L117 34 S L116 AND (L39-L75 OR L79-L80)
L118 1 S L117 AND ATHEROSCLER?/TI

FILE 'STNGUIDE' ENTERED AT 08:33:56 ON 13 APR 2007

FILE 'HCAPLUS' ENTERED AT 08:34:03 ON 13 APR 2007

L119 34 S L117 NOT L88

=> d que nos l119

L6 STR
L7 STR
L9 547 SEA FILE=REGISTRY SSS FUL L7

L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
 L32 QUE ABB=ON PLU=ON REDDY, E?/AU
 L33 QUE ABB=ON PLU=ON REDDY, P?/AU
 L34 QUE ABB=ON PLU=ON REDDY, M?/AU
 L35 QUE ABB=ON PLU=ON REDDY, R?/AU
 L36 QUE ABB=ON PLU=ON BELL, S?/AU
 L37 QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
)/CS,SO,PA
 L39 QUE ABB=ON PLU=ON PROLIFER?
 L40 QUE ABB=ON PLU=ON DISEAS? OR DISORDER? OR SYNDROM? OR
 MALADY OR SICKNESS OR ILLNESS OR CONDITION
 L41 QUE ABB=ON PLU=ON HEMANGIOMAT?
 L42 QUE ABB=ON PLU=ON MULTIPLE (W) SCLERO?
 L43 QUE ABB=ON PLU=ON MS
 L44 QUE ABB=ON PLU=ON MYELODEGENER?
 L45 QUE ABB=ON PLU=ON ?DEGENER?(3A)?MYELO?
 L46 QUE ABB=ON PLU=ON GANGLIONEUROMATO?
 L47 QUE ABB=ON PLU=ON KELOID?
 L48 QUE ABB=ON PLU=ON PAGET?
 L49 QUE ABB=ON PLU=ON FIBROCYS?
 L50 QUE ABB=ON PLU=ON COLORECT?
 L51 QUE ABB=ON PLU=ON SKIN OR DERM? OR EPIDER?
 L52 QUE ABB=ON PLU=ON BRAIN?
 L53 QUE ABB=ON PLU=ON LEUKEM? OR LEUKAEM?
 L54 QUE ABB=ON PLU=ON IONIZ? OR IONIS?
 L55 QUE ABB=ON PLU=ON RADIATION
 L56 QUE ABB=ON PLU=ON OPTIC?
 L57 QUE ABB=ON PLU=ON ISOMER?
 L58 QUE ABB=ON PLU=ON THERAP? OR DRUG OR PHARM? OR MEDIC?
 L59 QUE ABB=ON PLU=ON SARCOID?
 L60 QUE ABB=ON PLU=ON PERONIES
 L61 QUE ABB=ON PLU=ON DUPUTREN
 L62 QUE ABB=ON PLU=ON FIBROSIS
 L63 QUE ABB=ON PLU=ON CIRRHOSIS
 L64 QUE ABB=ON PLU=ON ?ATHEROSCLERO? OR ANIATHEROSCLER?
 L65 QUE ABB=ON PLU=ON ?VASCULAR?
 L66 QUE ABB=ON PLU=ON RESTENO?
 L67 QUE ABB=ON PLU=ON ?CANCER? OR ?CARCIN? OR ?ONCO? OR ?S
 ARCOM? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLAS? OR ?MALIGN? OR
 ?DYPLAS?
 L68 QUE ABB=ON PLU=ON ANTICANCER? OR ANTICARCIN? OR ANTISA
 RCOM? OR ANTITUM? OR ANTINEOPLAS?
 L69 QUE ABB=ON PLU=ON OVARY OR OVARIAN
 L70 QUE ABB=ON PLU=ON BREAST OR MAMMAR?
 L71 QUE ABB=ON PLU=ON PROSTAT?
 L72 QUE ABB=ON PLU=ON TESTIS OR TESTIC?
 L73 QUE ABB=ON PLU=ON LUNG
 L74 QUE ABB=ON PLU=ON PULMONAR?
 L75 QUE ABB=ON PLU=ON KIDNEY OR RENAL?
 L77 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L12
 L78 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 AND (L39 OR L40 OR L41 OR
 L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
 L51 OR L52 OR L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR L59 OR
 L60 OR L61 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68 OR
 L69 OR L70 OR L71 OR L72 OR L73 OR L74 OR L75)
 L79 QUE ABB=ON PLU=ON SYNTHES? OR SYNTH OR PREP? OR REACT?
 L80 QUE ABB=ON PLU=ON MANUFACT?
 L81 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 AND (L79 OR L80)
 L82 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 OR L78 OR L81
 L83 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L82 AND (L32 OR L33 OR L34 OR

L84 L35 OR L36 OR L37)
 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY
 <2004 OR REVIEW/DT
 L85 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004
 L86 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L82 NOT L83
 L87 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L86 AND L84
 L88 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L86 OR L87
 L110 STR
 L112 52 SEA FILE=MARPAT SSS FUL L110
 L113 52 SEA FILE=HCAPLUS ABB=ON PLU=ON L112
 L114 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L113 AND (L32 OR L33 OR L34
 OR L35 OR L36 OR L37)
 L115 46 SEA FILE=HCAPLUS ABB=ON PLU=ON L113 NOT L114
 L116 34 SEA FILE=HCAPLUS ABB=ON PLU=ON L115 AND L85
 L117 34 SEA FILE=HCAPLUS ABB=ON PLU=ON L116 AND ((L39 OR L40 OR L41
 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50
 OR L51 OR L52 OR L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR L59
 OR L60 OR L61 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68
 OR L69 OR L70 OR L71 OR L72 OR L73 OR L74 OR L75) OR (L79 OR
 L80))
 L119 34 SEA FILE=HCAPLUS ABB=ON PLU=ON L117 NOT L88

=> d ibib ed ab hitind l119

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L119 ANSWER 1 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:451346 HCAPLUS Full-textDOCUMENT NUMBER: 142:481741TITLE: Preparation of sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses

INVENTOR(S): Dasseux, Jean-Louis; Oniciu, Carmen Daniela

PATENT ASSIGNEE(S): Esperion Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 251 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047236	A1	20050526	WO 2003-US41614	20031224 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004122091	A1	20040624	US 2003-702701	20031107 <--
AU 2003300440	A1	20040606	AU 2003-300440	20031224 <--
PRIORITY APPLN. INFO.:			US 2003-702701	A 20031107 <--
			US 2000-239105P	P 20001011 <--
			US 2001-976899	A3 20011011 <--
			WO 2003-US41614	W 20031224 <--

OTHER SOURCE(S): MARPAT 142:481741

ED Entered STN: 27 May 2005

AB Title compds. W1ZmSOGSOZmW2 (I) [wherein Z = independently CH₂, CH:CH, or C₆H₄; m = independently 1-9; when Z = C₆H₄, m = 1; G = (CH₂)_x, CH₂CH:CHCH₂, CH:CH, CH₂C₆H₄CH₂, or C₆H₄; x = 2-4; W1 and W2 = independently CR₁R₂(CH₂)_nY, tetrahydro(oxo)pyranyl(oxy), oxooxetanyl, tetrahydrooxofuranyl, etc.; CR₁R₂(CH₂)cCR₃R₄(CH₂)_nY, or CR₁R₂(CH₂)cV; n = 0-4; c = 1-2; R1 and R2 = independently alkyl, alkenyl, alkynyl, Ph, or benzyl; or when one or both of W1 and W2 = CR₁R₂(CH₂)cCR₃R₄Y, then R1 and R2 can both be H; R3 = H, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, NO₂, or CF₃; R4 = OH, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, CN, NO₂, or CF₃; Y = OH, CO₂H, CHO, CO₂R₅, SO₃H, mono-, di-, or triphosphate, dioxo- or dithioxohexahydrothieno[3,2-c]pyridinyl, sulfamoyl, tetrazolyl, hydroxyoxazolyl, hydroxypyranonyl, substituted imidazolidinedionyl, etc.; R5 = (un)substituted alkyl, alkenyl, alkynyl, Ph, or benzyl] were prepared as peroxisome proliferator activated receptor (PPAR) antagonists for treatment and prevention of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders. I are also useful for treating and preventing Alzheimer's Disease, Syndrome X, PPAR-related disorders, septicemia,

- thrombotic disorders , obesity, pancreatitis, hypertension, renal disease, cancer inflammation, and impotence. For example, 6-(5,5-dimethyl-6-hydroxyhexylsulfanyl)-2,2-dimethylhexan-1-ol was oxidized to 6-(5,5-dimethyl-6-hydroxyhexane-1-sulfinyl)-2,2-dimethylhexan-1-ol (quant.) using H₂O₂ in glacial AcOH. The latter increased reduced serum triglycerides in female obese Zucker rats by 48% and 42% after 1 and 2 wk of treatment. Although non-HDL cholesterol increased by 38% and 62%, a marked increase in HDL cholesterol of 2.2-fold and 3.1-fold after one and two weeks of treatment, resp., resulted in an unexpectedly beneficial increased ratio of HDL/non-HDL cholesterol from 2.70 (pretreatment) to 3.84 and 4.97. In certain embodiments, I may be administered in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
- IC ICM C07C317-18
ICS C07C317-24; C07C317-44; C07C317-14; C07C317-04; C07F009-09;
C07F009-24; C07F009-44; C07D335-02; C07D333-48; C07D305-12;
C07D307-32; C07D309-30; C07D309-38; A61K031-10
- CC 23-11 (Aliphatic Compounds)
Section cross-reference(s): 1, 63
- ST alkyl sulfoxide prepn anticholesterol hypolipidemic antidiabetic antiobesity; sulfoxide alkyl prepn peroxisome proliferator activated receptor antagonist
- IT Fats and Glyceridic oils, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(animal, reduction in livestock; preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Heart, disease
(cardiac syndrome X, treatment; preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Egg, poultry
(cholesterol reduction; preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Sexual disorders
(impotence, treatment; preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Metabolic disorders
(metabolic syndrome X, treatment; preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Inflammation
Pancreas, disease
(pancreatitis, treatment; preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Anti-Alzheimer's agents
Anti-inflammatory agents
Anticholesteremic agents
Anticoagulants
Antihypertensives
Antiobesity agents
Antitumor agents
Cardiovascular agents
Human
Hypolipemic agents
(preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Fatty acids, biological studies
Glycerides, biological studies
High-density lipoproteins
Low-density lipoproteins
Peroxisome proliferator-activated receptors

Very-low-density lipoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of sulfoxide and bis-sulfoxide compds. as for
cholesterol management and related uses)

IT Kidney, disease

Septicemia

(treatment; preparation of sulfoxide and bis-sulfoxide compds. as
for cholesterol management and related uses)

IT Dyslipidemia

Dyslipidemia

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(treatment; preparation of sulfoxide and bis-sulfoxide compds. as
for cholesterol management and related uses)

IT 50-99-7, Glucose, biological studies 57-88-5, Cholesterol, biological
studies 300-85-6 9004-10-8, Insulin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of sulfoxide and bis-sulfoxide compds. as for
cholesterol management and related uses)

IT	411213-93-9P	412951-56-5P	412951-57-6P	412951-58-7P	412951-59-8P
	412951-60-1P	412951-61-2P	412951-62-3P	412951-63-4P	412951-64-5P
	412951-65-6P	412951-66-7P	412951-67-8P	412951-68-9P	412951-69-0P
	412951-70-3P	412951-71-4P	412951-72-5P	412951-73-6P	412951-74-7P
	412951-75-8P	412951-76-9P	412951-77-0P	412951-78-1P	412951-79-2P
	412951-80-5P	412951-81-6P	412951-82-7P	412951-83-8P	412951-84-9P
	412951-85-0P	412951-86-1P	412951-87-2P	412951-88-3P	412951-89-4P
	412951-90-7P	412951-91-8P	412951-92-9P	412951-93-0P	412951-94-1P
	412951-95-2P	412951-96-3P	412951-97-4P	412951-98-5P	412951-99-6P
	412952-00-2P	412952-01-3P	412952-02-4P	412952-03-5P	412952-04-6P
	412952-05-7P	412952-06-8P	412952-07-9P	412952-08-0P	412952-09-1P
	412952-10-4P	412952-11-5P	412952-12-6P	412952-13-7P	412952-14-8P
	412952-15-9P	412952-16-0P	412952-17-1P	412952-18-2P	412952-19-3P
	412952-20-6P	412952-21-7P	412952-22-8P	412952-23-9P	412952-24-0P
	412952-25-1P	412952-26-2P	412952-27-3P	412952-28-4P	412952-29-5P
	412952-30-8P	412952-31-9P	412952-32-0P	412952-33-1P	412952-34-2P
	412952-35-3P	412952-36-4P	412952-37-5P	412952-38-6P	412952-39-7P
	412952-40-0P	412952-41-1P	412952-42-2P	412952-43-3P	412952-44-4P
	412952-45-5P	412952-47-7P	412952-49-9P	412952-51-3P	412952-52-4P
	412952-53-5P	412952-54-6P	412952-55-7P	412952-56-8P	412952-57-9P
	412952-58-0P	412952-59-1P	412952-60-4P	412952-61-5P	412952-62-6P
	412952-63-7P	412952-64-8P	412952-65-9P	412952-66-0P	412952-67-1P
	412952-68-2P	412952-69-3P	412952-70-6P	412952-71-7P	412952-72-8P
	412952-73-9P	412952-74-0P	412952-75-1P	412952-76-2P	412952-77-3P
	412952-78-4P	412952-79-5P	412952-80-8P	412952-81-9P	412952-82-0P
	412952-83-1P	412952-84-2P	412952-85-3P	412952-86-4P	412952-87-5P
	412952-88-6P	412952-89-7P	412952-90-0P	412952-91-1P	412952-92-2P
	412952-93-3P	412952-94-4P	412952-95-5P	412952-96-6P	412952-97-7P
	412952-98-8P	412952-99-9P	412953-00-5P	412953-01-6P	412953-02-7P
	412953-03-8P	412953-04-9P	412953-05-0P	412953-06-1P	412953-07-2P
	412953-08-3P	412953-09-4P	412953-10-7P	412953-11-8P	412953-12-9P
	412953-13-0P	412953-14-1P	412953-15-2P	412953-16-3P	412953-17-4P
	412953-18-5P	412953-19-6P	412953-20-9P	412953-21-0P	412953-22-1P
	412953-23-2P	412953-24-3P	412953-26-5P	412953-28-7P	412953-29-8P
	412953-30-1P	412953-31-2P	412953-32-3P	412953-33-4P	412953-34-5P
	412953-35-6P	412953-36-7P	412953-37-8P	412953-38-9P	412953-39-0P
	412953-40-3P	412953-41-4P	412953-42-5P	412953-43-6P	412953-44-7P
	412953-45-8P	412953-46-9P	412953-47-0P	412953-48-1P	412953-49-2P
	412953-50-5P	412953-51-6P	412953-52-7P	412953-53-8P	412953-54-9P
	412953-55-0P	412953-56-1P	412953-57-2P	412953-58-3P	412953-59-4P
	412953-60-7P	412953-61-8P	412953-62-9P	412953-63-0P	412953-64-1P
	412953-65-2P	412953-66-3P	412953-67-4P	412953-68-5P	412953-69-6P

412953-70-9P 412953-71-0P 412953-72-1P 412953-73-2P 412953-74-3P
 412953-75-4P 412953-76-5P 412953-77-6P 412953-78-7P 412953-79-8P
 412953-80-1P 412953-81-2P 412953-82-3P 412953-83-4P 412953-85-6P
 412953-86-7P 412953-87-8P 412953-88-9P 412953-89-0P 412953-90-3P
 412953-91-4P 412953-92-5P 412953-93-6P 412953-94-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of sulfoxide and bis-sulfoxide compds. as for
 cholesterol management and related uses)

IT 412953-95-8P 412953-96-9P 412953-97-0P 412953-98-1P 412953-99-2P
 412954-00-8P 412954-01-9P 412954-02-0P 412954-03-1P 412954-04-2P
 412954-05-3P 412954-06-4P 412954-07-5P 412954-08-6P 412954-09-7P
 412954-10-0P 412954-11-1P 412954-12-2P 412954-13-3P 412954-14-4P
 412954-15-5P 412954-16-6P 412954-17-7P 412954-18-8P 412954-19-9P
 412954-20-2P 412954-21-3P 412954-22-4P 412954-23-5P 412954-24-6P
 412954-25-7P 412954-26-8P 412954-27-9P 412954-28-0P 412954-29-1P
 412954-30-4P 412954-31-5P 412954-32-6P 412954-33-7P 412954-34-8P
 412954-35-9P 412954-36-0P 412954-37-1P 412954-38-2P 412954-39-3P
 412954-40-6P 412954-41-7P 412954-42-8P 412954-43-9P 412954-44-0P
 412954-45-1P 412954-46-2P 412954-47-3P 412954-48-4P 412954-49-5P
 412954-50-8P 412954-51-9P 412954-52-0P 412954-53-1P 412954-54-2P
 412954-55-3P 412954-56-4P 412954-57-5P 412954-58-6P 412954-59-7P
 412954-60-0P 412954-61-1P 412954-62-2P 412954-63-3P 412954-64-4P
 412954-65-5P 412954-66-6P 412954-67-7P 412954-68-8P 412954-69-9P
 412954-70-2P 412954-71-3P 412954-72-4P 412954-73-5P 412954-74-6P
 412954-75-7P 412954-76-8P 412954-77-9P 412954-78-0P 412954-79-1P
 412954-80-4P 412954-81-5P 412954-82-6P 412954-83-7P 412954-84-8P
 412954-85-9P 412954-86-0P 412954-87-1P 412954-88-2P 412954-89-3P
 412954-90-6P 412954-91-7P 412954-92-8P 412954-93-9P 412954-94-0P
 412954-95-1P 412954-96-2P 412954-97-3P 412954-98-4P 412954-99-5P
 412955-00-1P 412955-01-2P 412955-02-3P 412955-03-4P 412955-04-5P
 412955-05-6P 412955-06-7P 412955-07-8P 412955-08-9P 412955-09-0P
 412955-10-3P 412955-12-5P 412955-14-7P 412955-16-9P 412955-17-0P
 412955-18-1P 412955-19-2P 412955-20-5P 412955-21-6P 412955-22-7P
 412955-23-8P 412955-24-9P 412955-25-0P 412955-26-1P 412955-27-2P
 412955-28-3P 412955-29-4P 412955-30-7P 412955-31-8P 412955-32-9P
 412955-33-0P 412955-34-1P 412955-35-2P 412955-36-3P 412955-37-4P
 412955-38-5P 412955-39-6P 412955-40-9P 412955-41-0P 412955-42-1P
 412955-43-2P 412955-44-3P 412955-45-4P 412955-46-5P 412955-47-6P
 412955-48-7P 412955-49-8P 412955-50-1P 412955-51-2P 412955-52-3P
 412955-53-4P 412955-54-5P 412955-55-6P 412955-56-7P 412955-57-8P
 412955-58-9P 412955-59-0P 412955-60-3P 412955-61-4P 412955-62-5P
 412955-63-6P 412955-64-7P 412955-65-8P 412955-66-9P 412955-67-0P
 412955-68-1P 412955-69-2P 412955-70-5P 412955-71-6P 412955-72-7P
 412955-73-8P 412955-74-9P 412955-75-0P 412955-76-1P 412955-77-2P
 412955-78-3P 412955-79-4P 412955-80-7P 412955-81-8P 412955-82-9P
 412955-83-0P 412955-84-1P 412955-85-2P 412955-86-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of sulfoxide and bis-sulfoxide compds. as for
 cholesterol management and related uses)

IT 412934-88-4 412934-91-9 412935-66-1 412935-69-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of sulfoxide and bis-sulfoxide compds. as for
 cholesterol management and related uses)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib ed ab hitind l119 2-34

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L119 ANSWER 2 OF 34 HCAPLUS COPYRIGHT 2007 ACS. on STN

ACCESSION NUMBER: 2004:857199 HCAPLUS Full-textDOCUMENT NUMBER: 141:331803TITLE: Preparation of sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses

INVENTOR(S): Dasseux, Jean-Louis Henri; Oniciu, Daniela Carmen

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 142 pp., Cont.-in-part of U.S. Ser. No. 976,899.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004204502	A1	20041014	US 2003-744401	20031224 <--
US 2003022865	A1	20030130	US 2001-976899	20011011 <--
US 6673780	B2	20040106		
PRIORITY APPLN. INFO.:			US 2001-976899	A2 20011011 <--
			US 2000-239105P	P 20001011 <--

OTHER SOURCE(S): MARPAT 141:331803

ED Entered STN: 18 Oct 2004

AB Title compds. W1ZmSOGSOZmW2 (I) [wherein Z = independently CH₂, CH:CH, or C₆H₄; m = independently 1-9; when Z = C₆H₄, m = 1; G = (CH₂)_x, CH₂CH:CHCH₂, CH:CH, CH₂C₆H₄CH₂, or C₆H₄; x = 2-4; W1 and W2 = independently CR1R2(CH₂)_nY, tetrahydro(oxo)pyranyl(oxy), oxooxetanyl, tetrahydrooxofuranyl, etc.; CR1R2(CH₂)cCR3R4(CH₂)_nY, or CR1R2(CH₂)cV; n = 0-4; c = 1-2; R1 and R2 = independently alkyl, alkenyl, alkynyl, Ph, or benzyl; or when one or both of W1 and W2 = CR1R2(CH₂)cCR3R4Y, then R1 and R2 can both be H; R3 = H, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, NO₂, or CF₃; R4 = OH, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, CN, NO₂, or CF₃; Y = OH, CO₂H, CHO, CO₂R₅, SO₃H, mono-, di-, or triphosphate, dioxo- or dithioxohexahydrothieno[3,2-c]pyridinyl, sulfamoyl, tetrazolyl, hydroxyoxazolyl, hydroxypyranonyl, substituted imidazolidinedionyl, etc.; R5 = (un)substituted alkyl, alkenyl, alkynyl, Ph, or benzyl] were prepared as peroxisome proliferator activated receptor (PPAR) antagonists for treatment and prevention of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders. I are also useful for treating and preventing Alzheimer's Disease, Syndrome X, PPAR-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer inflammation, and impotence. For example, 6-(5,5-dimethyl-6-hydroxyhexylsulfanyl)-2,2-dimethylhexan-1-ol was oxidized to 6-(5,5-dimethyl-6-hydroxyhexane-1-sulfinyl)-2,2-dimethylhexan-1-ol (quant.) using H₂O₂ in glacial AcOH. The latter increased reduced serum triglycerides in female obese Zucker rats by 48% and 42% after 1 and 2 wk of treatment. Although non-HDL cholesterol increased by 38% and 62%, a marked increase in HDL cholesterol of 2.2-fold and 3.1-fold after one and two weeks of treatment, resp., resulted in an unexpectedly beneficial increased ratio of HDL/non-HDL cholesterol from 2.70 (pretreatment) to 3.84 and 4.97. In certain embodiments, I may be administered in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

IC ICM A61K031-10
 INCL 514708000; 568027000
 CC 23-11 (Aliphatic Compounds)
 Section cross-reference(s): 1, 63
 ST alkyl sulfoxide prepn anticholesterol hypolipidemic antidiabetic
 antiobesity; sulfoxide alkyl prepn peroxisome
proliferator activated receptor antagonist
 IT Fats and Glyceridic oils, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (animal, reduction in livestock; preparation of sulfoxide and
 bis-sulfoxide compds. as for cholesterol management and related uses)
 IT Heart, disease
 (cardiac syndrome X, treatment; preparation of sulfoxide
 and bis-sulfoxide compds. as for cholesterol management and related
 uses)
 IT Egg, poultry
 (cholesterol reduction; preparation of sulfoxide and bis-sulfoxide
 compds. as for cholesterol management and related uses)
 IT Sexual disorders
 (impotence, treatment; preparation of sulfoxide and bis-sulfoxide
 compds. as for cholesterol management and related uses)
 IT Metabolic disorders
 (metabolic syndrome X, treatment; preparation of
 sulfoxide and bis-sulfoxide compds. as for cholesterol management and
 related uses)
 IT Inflammation
 Pancreas, disease
 (pancreatitis, treatment; preparation of sulfoxide and
 bis-sulfoxide compds. as for cholesterol management and related uses)
 IT Anti-Alzheimer's agents
 Anti-inflammatory agents
 Anticholesteremic agents
 Anticoagulants
 Antihypertensives
 Antiobesity agents
Antitumor agents
Cardiovascular agents
 Human
 Hypolipemic agents
 (preparation of sulfoxide and bis-sulfoxide compds. as for
 cholesterol management and related uses)
 IT Fatty acids, biological studies
 Glycerides, biological studies
 High-density lipoproteins
 Low-density lipoproteins
 Peroxisome proliferator-activated receptors
 Very-low-density lipoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of sulfoxide and bis-sulfoxide compds. as for
 cholesterol management and related uses)
 IT Kidney, disease
 Septicemia
 (treatment; preparation of sulfoxide and bis-sulfoxide compds. as
 for cholesterol management and related uses)
 IT Dyslipidemia
 Dyslipidemia
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (treatment; preparation of sulfoxide and bis-sulfoxide compds. as
 for cholesterol management and related uses)
 IT 50-99-7, Glucose, biological studies 57-88-5, Cholesterol, biological

studies 300-85-6 9004-10-8, Insulin, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of sulfoxide and bis-sulfoxide compds. as for
 cholesterol management and related uses)

IT	411213-93-9P	412951-56-5P	412951-57-6P	412951-58-7P	412951-59-8P
	412951-60-1P	412951-61-2P	412951-62-3P	412951-63-4P	412951-64-5P
	412951-65-6P	412951-66-7P	412951-67-8P	412951-68-9P	412951-69-0P
	412951-70-3P	412951-71-4P	412951-72-5P	412951-73-6P	412951-74-7P
	412951-75-8P	412951-76-9P	412951-77-0P	412951-78-1P	412951-79-2P
	412951-80-5P	412951-81-6P	412951-82-7P	412951-83-8P	412951-84-9P
	412951-85-0P	412951-86-1P	412951-87-2P	412951-88-3P	412951-89-4P
	412951-90-7P	412951-91-8P	412951-92-9P	412951-93-0P	412951-94-1P
	412951-95-2P	412951-96-3P	412951-97-4P	412951-98-5P	412951-99-6P
	412952-00-2P	412952-01-3P	412952-02-4P	412952-03-5P	412952-04-6P
	412952-05-7P	412952-06-8P	412952-07-9P	412952-08-0P	412952-09-1P
	412952-10-4P	412952-11-5P	412952-12-6P	412952-13-7P	412952-14-8P
	412952-15-9P	412952-16-0P	412952-17-1P	412952-18-2P	412952-19-3P
	412952-20-6P	412952-21-7P	412952-22-8P	412952-23-9P	412952-24-0P
	412952-25-1P	412952-26-2P	412952-27-3P	412952-28-4P	412952-29-5P
	412952-30-8P	412952-31-9P	412952-32-0P	412952-33-1P	412952-34-2P
	412952-35-3P	412952-36-4P	412952-37-5P	412952-38-6P	412952-39-7P
	412952-40-0P	412952-41-1P	412952-42-2P	412952-43-3P	412952-44-4P
	412952-45-5P	412952-47-7P	412952-49-9P	412952-51-3P	412952-52-4P
	412952-53-5P	412952-54-6P	412952-55-7P	412952-56-8P	412952-57-9P
	412952-58-0P	412952-59-1P	412952-60-4P	412952-61-5P	412952-62-6P
	412952-63-7P	412952-64-8P	412952-65-9P	412952-66-0P	412952-67-1P
	412952-68-2P	412952-69-3P	412952-70-6P	412952-71-7P	412952-72-8P
	412952-73-9P	412952-74-0P	412952-75-1P	412952-76-2P	412952-77-3P
	412952-78-4P	412952-79-5P	412952-80-8P	412952-81-9P	412952-82-0P
	412952-83-1P	412952-84-2P	412952-85-3P	412952-86-4P	412952-87-5P
	412952-88-6P	412952-89-7P	412952-90-0P	412952-91-1P	412952-92-2P
	412952-93-3P	412952-94-4P	412952-95-5P	412952-96-6P	412952-97-7P
	412952-98-8P	412952-99-9P	412953-00-5P	412953-01-6P	412953-02-7P
	412953-03-8P	412953-04-9P	412953-05-0P	412953-06-1P	412953-07-2P
	412953-08-3P	412953-09-4P	412953-10-7P	412953-11-8P	412953-12-9P
	412953-13-0P	412953-14-1P	412953-15-2P	412953-16-3P	412953-17-4P
	412953-18-5P	412953-19-6P	412953-20-9P	412953-21-0P	412953-22-1P
	412953-23-2P	412953-24-3P	412953-26-5P	412953-28-7P	412953-29-8P
	412953-30-1P	412953-31-2P	412953-32-3P	412953-33-4P	412953-34-5P
	412953-35-6P	412953-36-7P	412953-37-8P	412953-38-9P	412953-39-0P
	412953-40-3P	412953-41-4P	412953-42-5P	412953-43-6P	412953-44-7P
	412953-45-8P	412953-46-9P	412953-47-0P	412953-48-1P	412953-49-2P
	412953-50-5P	412953-51-6P	412953-52-7P	412953-53-8P	412953-54-9P
	412953-55-0P	412953-56-1P	412953-57-2P	412953-58-3P	412953-59-4P
	412953-60-7P	412953-61-8P	412953-62-9P	412953-63-0P	412953-64-1P
	412953-65-2P	412953-66-3P	412953-67-4P	412953-68-5P	412953-69-6P
	412953-70-9P	412953-71-0P	412953-72-1P	412953-73-2P	412953-74-3P
	412953-75-4P	412953-76-5P	412953-77-6P	412953-78-7P	412953-79-8P
	412953-80-1P	412953-81-2P	412953-82-3P	412953-83-4P	412953-85-6P
	412953-86-7P	412953-87-8P	412953-88-9P	412953-89-0P	412953-90-3P
	412953-91-4P	412953-92-5P	412953-93-6P	412953-94-7P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of sulfoxide and bis-sulfoxide compds. as for
 cholesterol management and related uses)

IT	412953-95-8P	412953-96-9P	412953-97-0P	412953-98-1P	412953-99-2P
	412954-00-8P	412954-01-9P	412954-02-0P	412954-03-1P	412954-04-2P
	412954-05-3P	412954-06-4P	412954-07-5P	412954-08-6P	412954-09-7P
	412954-10-0P	412954-11-1P	412954-12-2P	412954-13-3P	412954-14-4P

412954-15-5P	412954-16-6P	412954-17-7P	412954-18-8P	412954-19-9P
412954-20-2P	412954-21-3P	412954-22-4P	412954-23-5P	412954-24-6P
412954-25-7P	412954-26-8P	412954-27-9P	412954-28-0P	412954-29-1P
412954-30-4P	412954-31-5P	412954-32-6P	412954-33-7P	412954-34-8P
412954-35-9P	412954-36-0P	412954-37-1P	412954-38-2P	412954-39-3P
412954-40-6P	412954-41-7P	412954-42-8P	412954-43-9P	412954-44-0P
412954-45-1P	412954-46-2P	412954-47-3P	412954-48-4P	412954-49-5P
412954-50-8P	412954-51-9P	412954-52-0P	412954-53-1P	412954-54-2P
412954-55-3P	412954-56-4P	412954-57-5P	412954-58-6P	412954-59-7P
412954-60-0P	412954-61-1P	412954-62-2P	412954-63-3P	412954-64-4P
412954-65-5P	412954-66-6P	412954-67-7P	412954-68-8P	412954-69-9P
412954-70-2P	412954-71-3P	412954-72-4P	412954-73-5P	412954-74-6P
412954-75-7P	412954-76-8P	412954-77-9P	412954-78-0P	412954-79-1P
412954-80-4P	412954-81-5P	412954-82-6P	412954-83-7P	412954-84-8P
412954-85-9P	412954-86-0P	412954-87-1P	412954-88-2P	412954-89-3P
412954-90-6P	412954-91-7P	412954-92-8P	412954-93-9P	412954-94-0P
412954-95-1P	412954-96-2P	412954-97-3P	412954-98-4P	412954-99-5P
412955-00-1P	412955-01-2P	412955-02-3P	412955-03-4P	412955-04-5P
412955-05-6P	412955-06-7P	412955-07-8P	412955-08-9P	412955-09-0P
412955-10-3P	412955-12-5P	412955-14-7P	412955-16-9P	412955-17-0P
412955-18-1P	412955-19-2P	412955-20-5P	412955-21-6P	412955-22-7P
412955-23-8P	412955-24-9P	412955-25-0P	412955-26-1P	412955-27-2P
412955-28-3P	412955-29-4P	412955-30-7P	412955-31-8P	412955-32-9P
412955-33-0P	412955-34-1P	412955-35-2P	412955-36-3P	412955-37-4P
412955-38-5P	412955-39-6P	412955-40-9P	412955-41-0P	412955-42-1P
412955-43-2P	412955-44-3P	412955-45-4P	412955-46-5P	412955-47-6P
412955-48-7P	412955-49-8P	412955-50-1P	412955-51-2P	412955-52-3P
412955-53-4P	412955-54-5P	412955-55-6P	412955-56-7P	412955-57-8P
412955-58-9P	412955-59-0P	412955-60-3P	412955-61-4P	412955-62-5P
412955-63-6P	412955-64-7P	412955-65-8P	412955-66-9P	412955-67-0P
412955-68-1P	412955-69-2P	412955-70-5P	412955-71-6P	412955-72-7P
412955-73-8P	412955-74-9P	412955-75-0P	412955-76-1P	412955-77-2P
412955-78-3P	412955-79-4P	412955-80-7P	412955-81-8P	412955-82-9P
412955-83-0P	412955-84-1P	412955-85-2P	412955-86-3P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)

IT 412934-88-4 412934-91-9 412935-66-1 412935-69-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)

L119 ANSWER 3 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:546510 HCAPLUS Full-text

DOCUMENT NUMBER: 141:106487

TITLE: Preparation of pyrrolopyrimidine derivatives as antiproliferative agents

INVENTOR(S): Arcari, Joel Thomas; Chen, Jinshan; Lagreca, Susan; Marx, Matthew Arnold; Wessel, Matthew David

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 157 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
WO 2004056830      A1      20040708      WO 2003-IB5841      20031208 <--
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
    CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
    GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
    LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
    OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
    TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW:  BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
    BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
    ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
    TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2510853          A1      20040708      CA 2003-2510853      20031208 <--
AU 2003286317       A1      20040714      AU 2003-286317       20031208 <--
EP 1578751          A1      20050928      EP 2003-777060       20031208 <--
R:   AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003017524       A       20051116      BR 2003-17524        20031208 <--
CN 1726218          A       20060125      CN 2003-80106451     20031208 <--
JP 2006512356       T       20060413      JP 2004-561818       20031208 <--
US 2005037999       A1      20050217      US 2003-732509       20031210 <--
NL 1025068          A1      20040622      NL 2003-1025068      20031218 <--
NL 1025068          C2      20041116
IN 2005DN02441      A       20070105      IN 2005-DN2441        20050607 <--
NO 2005002802       A       20050719      NO 2005-2802          20050609 <--
PRIORITY APPLN. INFO.:      US 2002-434568P      P 20021219 <--
                                WO 2003-IB5841      W 20031208 <--

```

OTHER SOURCE(S): MARPAT 141:106487

ED Entered STN: 08 Jul 2004

AB Pyrrolopyrimidines I (Q = CO, amino, S, sulfinyl, sulfonyl, etc.; A = bond, aryl, heteroarom. ring, alkyl, etc.; L = alkylene, O, S, sulfinyl, sulfonyl, amino, etc.; R1 = H, alkyl, cycloalkyl, substituted bicycloalkyl, etc.; R2 = H, halo, alkyl, cycloalkyl, heterocycloalkyl, amino, etc.; R3 = H, alkyl, cycloalkyl, heteroalkyl, etc.) and their pharmaceutically acceptable salts, useful for treatment of hyperproliferative disorders, are prepared Thus, reaction of 2,6-difluorophenyl isocyanate with (4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-(3-aminophenyl)-methanone in pyridine at 90° for 3 h gave 28% 1-[3-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-3-(2,6-difluorophenyl)-urea.

IC ICM C07D487-04

ICS A61K031-505; A61P035-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST pyrrolopyrimidine prepn antiproliferative agent

IT Cytotoxic agents

(antimetabolites, combination therapy; preparation of pyrrolopyrimidines as antiproliferative agents)

IT Alkylating agents, biological

Angiogenesis inhibitors

(combination therapy; preparation of pyrrolopyrimidines as antiproliferative agents)

IT Hormone antagonists

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(combination therapy; preparation of pyrrolopyrimidines as antiproliferative agents)

IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination therapy; preparation of pyrrolopyrimidines as antiproliferative agents)

- IT Antiandrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of pyrrolopyrimidines as antiproliferative agents)
- IT Cell proliferation
(inhibition, hyperproliferation, combination therapy; preparation of pyrrolopyrimidines as antiproliferative agents)
- IT Cell cycle
Mitosis
(inhibitor, combination therapy; preparation of pyrrolopyrimidines as antiproliferative agents)
- IT Growth factors, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor, combination therapy; preparation of pyrrolopyrimidines as antiproliferative agents)
- IT Antibiotics
(intercalating, combination therapy; preparation of pyrrolopyrimidines as antiproliferative agents)
- IT Antitumor agents
Neoplasm
(preparation of pyrrolopyrimidines as antiproliferative agents)
- IT Drug delivery systems
(prodrugs; preparation of pyrrolopyrimidines as antiproliferative agents)
- IT 80449-01-0, Topoisomerase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor, combination therapy; preparation of pyrrolopyrimidines as antiproliferative agents)
- IT 65-85-0, Benzoic acid, reactions 74-88-4, Iodomethane, reactions 75-07-0, Acetaldehyde, reactions 121-90-4, 3-Nitrobenzoyl chloride 122-04-3, 4-Nitrobenzoyl chloride 124-63-0, Methanesulfonyl chloride 137-43-9, Cyclopentyl bromide 610-14-0, 2-Nitrobenzoyl chloride 618-51-9, 3-Iodobenzoic acid 705-21-5, 3,5-Dichlorophenylsulfonyl chloride 765-30-0, Cyclopropylamine 1609-86-5, tert-Butyl isocyanate 1885-14-9, Phenyl chloroformate 1975-50-4, 2-Methyl-3-nitrobenzoic acid 2450-71-7, Propargylamine 2646-90-4, 2,5-Difluorobenzaldehyde 2905-23-9, 2-Chlorobenzenesulfonyl chloride 3680-69-1, 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine 6638-79-5, O,N-Dimethylhydroxylamine hydrochloride 7051-34-5, (Bromomethyl)cyclopropane 18063-02-0, 2,6-Difluorobenzoyl chloride 19654-32-1, 2,4-Dichlorobenzyl isocyanate 22948-02-3, 3-Aminobenzenethiol 24424-99-5, Di-tert-butyl dicarbonate 28611-39-4, 4-Dimethylaminophenylboronic acid 34893-92-0, 3,5-Dichlorophenyl isocyanate 65295-69-4, 2,6-Difluorophenyl isocyanate 85958-57-2, 2-Chloro-4-fluorobenzenesulfonyl chloride 109384-19-2, 4-Hydroxypiperidine-1-carboxylic acid tert-butyl ester 213745-17-6 717900-73-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolopyrimidines as antiproliferative agents)
- IT 7781-10-4P 92136-39-5P 170282-53-8P, 3-Iodo-N-methoxy-N-methylbenzamide 177963-15-4P 195622-56-1P 212268-44-5P 717900-59-9P 717900-60-2P 717900-61-3P 717900-62-4P 717900-64-6P 717900-65-7P 717900-66-8P 717900-67-9P 717900-68-0P 717900-70-4P 717900-71-5P 717900-72-6P 717900-74-8P 717900-76-0P 717900-77-1P 717900-78-2P 717900-79-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolopyrimidines as antiproliferative agents)
- IT 717894-28-5P 717897-97-7P 717898-28-7P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)

(preparation of pyrrolopyrimidines as antiproliferative agents)

IT	717894-30-9P	717894-32-1P	717894-34-3P	717894-36-5P	717894-38-7P
	717894-40-1P	717894-42-3P	717894-44-5P	717894-46-7P	717894-48-9P
	717894-49-0P	717894-50-3P	717894-51-4P	717894-53-6P	717894-55-8P
	717894-57-0P	717894-59-2P	717894-63-8P	717894-65-0P	717894-67-2P
	717894-69-4P	717894-71-8P	717894-72-9P	717894-74-1P	717894-76-3P
	717894-79-6P	717894-81-0P	717894-83-2P	717894-86-5P	717894-89-8P
	717894-90-1P	717894-92-3P	717894-94-5P	717894-96-7P	717894-97-8P
	717894-98-9P	717895-00-6P	717895-02-8P	717895-06-2P	717895-08-4P
	717895-10-8P	717895-12-0P	717895-13-1P	717895-15-3P	717895-17-5P
	717895-21-1P	717895-23-3P	717895-25-5P	717895-27-7P	717895-29-9P
	717895-32-4P	717895-34-6P	717895-36-8P	717895-38-0P	717895-40-4P
	717895-42-6P	717895-44-8P	717895-46-0P	717895-48-2P	717895-50-6P
	717895-52-8P	717895-54-0P	717895-57-3P	717895-59-5P	717895-61-9P
	717895-63-1P	717895-65-3P	717895-67-5P	717895-69-7P	717895-71-1P
	717895-74-4P	717895-75-5P	717895-77-7P	717895-79-9P	717895-81-3P
	717895-83-5P	717895-85-7P	717895-87-9P	717895-89-1P	717895-90-4P
	717895-92-6P	717895-94-8P	717895-96-0P	717895-99-3P	717896-01-0P
	717896-03-2P	717896-05-4P	717896-07-6P	717896-09-8P	717896-11-2P
	717896-14-5P	717896-16-7P	717896-17-8P	717896-19-0P	717896-21-4P
	717896-23-6P	717896-25-8P	717896-28-1P	717896-30-5P	717896-32-7P
	717896-34-9P	717896-36-1P	717896-38-3P	717896-40-7P	717896-42-9P
	717896-44-1P	717896-46-3P	717896-48-5P	717896-51-0P	717896-53-2P
	717896-55-4P	717896-56-5P	717896-58-7P	717896-60-1P	717896-63-4P
	717896-65-6P	717896-67-8P	717896-68-9P	717896-70-3P	717896-72-5P
	717896-74-7P	717896-77-0P	717896-79-2P	717896-81-6P	717896-83-8P
	717896-84-9P	717896-86-1P	717896-88-3P	717896-91-8P	717896-92-9P
	717896-94-1P	717896-95-2P	717896-96-3P	717896-97-4P	717896-99-6P
	717897-00-2P	717897-01-3P	717897-02-4P	717897-03-5P	717897-05-7P
	717897-06-8P	717897-07-9P	717897-08-0P	717897-09-1P	717897-10-4P
	717897-11-5P	717897-13-7P	717897-14-8P	717897-15-9P	717897-16-0P
	717897-17-1P	717897-18-2P	717897-19-3P	717897-21-7P	717897-22-8P
	717897-23-9P	717897-24-0P	717897-25-1P	717897-26-2P	717897-28-4P
	717897-29-5P	717897-30-8P	717897-31-9P	717897-32-0P	717897-33-1P
	717897-34-2P	717897-36-4P	717897-37-5P	717897-38-6P	717897-39-7P
	717897-40-0P	717897-41-1P	717897-43-3P	717897-44-4P	717897-45-5P
	717897-46-6P	717897-47-7P	717897-48-8P	717897-49-9P	717897-51-3P
	717897-52-4P	717897-53-5P	717897-54-6P	717897-55-7P	717897-56-8P
	717897-57-9P	717897-58-0P	717897-60-4P	717897-61-5P	717897-62-6P
	717897-63-7P	717897-64-8P	717897-65-9P	717897-67-1P	717897-68-2P
	717897-69-3P	717897-70-6P	717897-71-7P	717897-72-8P	717897-73-9P
	717897-75-1P	717897-76-2P	717897-77-3P	717897-78-4P	717897-79-5P
	717897-80-8P	717897-82-0P	717897-83-1P	717897-84-2P	717897-85-3P
	717897-86-4P	717897-87-5P	717897-88-6P	717897-90-0P	717897-91-1P
	717897-92-2P	717897-93-3P	717897-94-4P	717897-96-6P	717897-98-8P
	717897-99-9P	717898-00-5P	717898-01-6P	717898-02-7P	717898-03-8P
	717898-05-0P	717898-06-1P	717898-07-2P	717898-08-3P	717898-09-4P
	717898-10-7P	717898-12-9P	717898-13-0P	717898-14-1P	717898-15-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyrimidines as antiproliferative agents)

IT	717898-16-3P	717898-17-4P	717898-18-5P	717898-20-9P	717898-21-0P
	717898-22-1P	717898-23-2P	717898-24-3P	717898-25-4P	717898-26-5P
	717898-27-6P	717898-30-1P	717898-31-2P	717898-32-3P	717898-33-4P
	717898-34-5P	717898-35-6P	717898-36-7P	717898-37-8P	717898-39-0P
	717898-40-3P	717898-41-4P	717898-42-5P	717898-43-6P	717898-44-7P
	717898-45-8P	717898-46-9P	717898-48-1P	717898-49-2P	717898-50-5P
	717898-51-6P	717898-52-7P	717898-53-8P	717898-54-9P	717898-55-0P

717898-57-2P	717898-58-3P	717898-59-4P	717898-60-7P	717898-61-8P
717898-62-9P	717898-63-0P	717898-64-1P	717898-66-3P	717898-67-4P
717898-68-5P	717898-69-6P	717898-70-9P	717898-71-0P	717898-72-1P
717898-73-2P	717898-74-3P	717898-75-4P	717898-76-5P	717898-78-7P
717898-79-8P	717898-80-1P	717898-81-2P	717898-82-3P	717898-83-4P
717898-84-5P	717898-86-7P	717898-87-8P	717898-88-9P	717898-89-0P
717898-90-3P	717898-91-4P	717898-93-6P	717898-94-7P	717898-95-8P
717898-96-9P	717898-97-0P	717898-98-1P	717899-00-8P	717899-01-9P
717899-02-0P	717899-03-1P	717899-04-2P	717899-05-3P	717899-07-5P
717899-08-6P	717899-09-7P	717899-10-0P	717899-11-1P	717899-12-2P
717899-13-3P	717899-15-5P	717899-16-6P	717899-17-7P	717899-18-8P
717899-19-9P	717899-20-2P	717899-21-3P	717899-22-4P	717899-23-5P
717899-24-6P	717899-25-7P	717899-26-8P	717899-27-9P	717899-29-1P
717899-30-4P	717899-31-5P	717899-32-6P	717899-33-7P	717899-34-8P
717899-35-9P	717899-37-1P	717899-38-2P	717899-39-3P	717899-40-6P
717899-41-7P	717899-42-8P	717899-43-9P	717899-44-0P	717899-45-1P
717899-47-3P	717899-48-4P	717899-49-5P	717899-50-8P	717899-51-9P
717899-52-0P	717899-53-1P	717899-54-2P	717899-56-4P	717899-57-5P
717899-58-6P	717899-59-7P	717899-60-0P	717899-61-1P	717899-62-2P
717899-63-3P	717899-65-5P	717899-66-6P	717899-67-7P	717899-68-8P
717899-69-9P	717899-70-2P	717899-71-3P	717899-72-4P	717899-74-6P
717899-75-7P	717899-76-8P	717899-77-9P	717899-78-0P	717899-79-1P
717899-80-4P	717899-82-6P	717899-83-7P	717899-84-8P	717899-85-9P
717899-86-0P	717899-87-1P	717899-88-2P	717899-89-3P	717899-90-6P
717899-91-7P	717899-92-8P	717899-93-9P	717899-94-0P	717899-95-1P
717899-96-2P	717899-97-3P	717899-99-5P	717900-00-0P	717900-01-1P
717900-02-2P	717900-03-3P	717900-04-4P	717900-05-5P	717900-06-6P
717900-07-7P	717900-08-8P	717900-09-9P	717900-11-3P	717900-12-4P
717900-13-5P	717900-14-6P	717900-15-7P	717900-16-8P	717900-18-0P
717900-19-1P	717900-22-6P	717900-24-8P	717900-25-9P	717900-26-0P
717900-27-1P	717900-28-2P	717900-30-6P	717900-32-8P	717900-33-9P
717900-34-0P	717900-35-1P	717900-36-2P	717900-37-3P	717900-38-4P
717900-40-8P	717900-41-9P	717900-42-0P	717900-43-1P	717900-44-2P
717900-45-3P	717900-46-4P	717900-48-6P	717900-49-7P	717900-50-0P
717900-51-1P	717900-52-2P	717900-53-3P	717900-54-4P	717900-55-5P
717900-57-7P	717900-58-8P	717907-91-0P	717907-92-1P	717907-93-2P
717907-94-3P	717907-95-4P	717907-96-5P	717907-97-6P	

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyrimidines as antiproliferative agents)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 4 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:203659 HCAPLUS Full-text

DOCUMENT NUMBER: 140:247064

TITLE: Method using quinolinecarboxamides and other heterocyclic compounds for preventing or treating atherosclerosis or restenosis

INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 299 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2004019932 A1 20040311 WO 2003-US26962 20030828 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003262947 A1 20040319 AU 2003-262947 20030828 <--
US 2004186131 A1 20040923 US 2003-651309 20030828 <--
PRIORITY APPLN. INFO.: US 2002-407563P P 20020830 <--
US 2003-467497P P 20030502 <--
WO 2003-US26962 W 20030828 <--

OTHER SOURCE(S): MARPAT 140:247064

ED Entered STN: 14 Mar 2004

AB The invention provides a method for preventing or treating atherosclerosis or restenosis in mammals, which comprises administering an effective amount of a quinolinecarboxamide or other heterocyclic compound

IC ICM A61K031-33

CC 1-8 (Pharmacology)

ST quinolinecarboxamide atherosclerosis restenosis treatment; heterocyclic compd atherosclerosis restenosis treatment

IT Antiarteriosclerotics

(antiatherosclerotics; quinolinecarboxamides and other heterocyclic compds. for preventing or treating atherosclerosis or restenosis)

IT Drug delivery systems

(oral; quinolinecarboxamides and other heterocyclic compds. for preventing or treating atherosclerosis or restenosis)

IT Drug delivery systems

(parenterals; quinolinecarboxamides and other heterocyclic compds. for preventing or treating atherosclerosis or restenosis)

IT Atherosclerosis

Cardiovascular agents

Human

Livestock

Pet animal

(quinolinecarboxamides and other heterocyclic compds. for preventing or treating atherosclerosis or restenosis)

IT Drug delivery systems

(rectal; quinolinecarboxamides and other heterocyclic compds. for preventing or treating atherosclerosis or restenosis)

IT Artery, disease

(restenosis; quinolinecarboxamides and other heterocyclic compds. for preventing or treating atherosclerosis or restenosis)

IT Drug delivery systems

(topical; quinolinecarboxamides and other heterocyclic compds. for preventing or treating atherosclerosis or restenosis)

IT Drug delivery systems

(vaginal; quinolinecarboxamides and other heterocyclic compds. for preventing or treating atherosclerosis or restenosis)

IT Drugs

(veterinary; quinolinecarboxamides and other heterocyclic compds. for preventing or treating atherosclerosis or restenosis)

IT	228725-33-5	228725-34-6	228725-35-7	228725-36-8	228725-37-9
	228725-38-0	228725-39-1	228725-40-4	228725-41-5	228725-42-6
	228725-43-7	228725-44-8	228725-45-9	228725-46-0	228725-47-1
	228725-48-2	228725-50-6	228725-51-7	228725-52-8	228725-53-9
	228725-54-0	228725-55-1	228725-56-2	228725-57-3	228725-58-4
	228725-59-5	228725-60-8	228725-61-9	228725-62-0	228725-63-1
	228725-64-2	228725-65-3	228725-66-4	228725-67-5	228725-68-6
	228725-69-7	228725-70-0	228725-71-1	228725-72-2	228725-73-3
	228725-74-4	228725-75-5	228725-76-6	228725-77-7	228725-78-8
	228725-79-9	228725-80-2	228725-81-3	228725-82-4	228725-83-5
	228725-84-6	228725-85-7	228725-86-8	228725-87-9	228725-88-0
	228725-89-1	228725-90-4	228725-91-5	228725-92-6	228725-93-7
	228725-94-8	228725-95-9	228725-96-0	228725-97-1	228725-98-2
	228725-99-3	228726-00-9	228726-01-0	228726-02-1	228726-03-2
	228726-04-3	228726-05-4	228726-06-5	228726-07-6	228726-08-7
	228726-09-8	228726-10-1	228726-11-2	228726-12-3	228726-13-4
	228726-14-5	228726-15-6	228726-16-7	228726-17-8	228726-18-9
	228726-19-0	228726-20-3	228726-21-4	228726-22-5	228726-23-6
	228726-24-7	228726-25-8	228726-26-9	228726-27-0	228726-28-1
	228726-29-2	228726-30-5	228726-31-6	228726-32-7	228726-33-8
	228726-34-9	228726-35-0	228726-36-1	228726-37-2	228726-38-3
	228726-39-4	228726-40-7	228726-41-8	228726-42-9	228726-43-0
	228726-44-1	228726-45-2	228726-46-3	228726-47-4	228726-48-5
	228726-49-6	228726-50-9	228726-51-0	228726-52-1	228726-53-2
	228726-54-3	228726-55-4	228726-57-6	228726-58-7	228726-59-8
	228726-60-1	228726-61-2	228726-62-3	228726-63-4	228726-64-5
	228726-65-6	228726-66-7	228726-67-8	228726-68-9	228726-69-0
	228726-70-3	228726-71-4	228726-72-5	228726-73-6	228726-74-7
	228726-75-8	228726-76-9	228726-77-0	228726-78-1	228726-79-2
	228726-80-5	228726-83-8	228726-84-9	228726-85-0	228726-86-1
	228726-87-2	228726-90-7	228726-91-8	228726-92-9	228726-93-0
	228726-94-1	228726-95-2	228726-96-3	228726-97-4	228726-98-5
	228727-00-2	228727-01-3	228727-02-4	228727-03-5	228727-04-6
	228727-05-7	228727-06-8	228727-07-9	228727-08-0	228727-09-1
	228727-10-4	228727-11-5	228727-12-6	228727-13-7	228727-14-8
	228727-15-9	228727-16-0	228727-17-1	228727-18-2	228727-19-3
	228727-20-6	228727-21-7	228727-22-8	228727-23-9	228727-24-0
	228727-25-1	228727-26-2	228727-27-3	228727-28-4	228727-29-5
	228727-30-8	228727-31-9	228727-32-0	228727-33-1	228727-34-2
	228727-35-3	228727-36-4	228727-37-5	228727-38-6	228727-39-7
	228727-40-0	228727-41-1	228727-42-2	228727-43-3	228727-44-4
	228727-46-6	228727-47-7	228727-48-8	228727-49-9	228727-50-2
	228727-51-3	228727-52-4	228727-53-5	228727-54-6	228727-55-7
	228727-56-8	228727-57-9	228727-58-0	228727-59-1	228727-60-4
	228727-61-5	228727-62-6	228727-63-7	228727-64-8	228727-65-9
	228727-66-0	228727-67-1	228727-68-2	228727-69-3	228727-70-6
	228727-71-7	228727-72-8	228727-73-9	228727-74-0	228727-75-1

RL: AGR (Agricultural use); PAC (Pharmacological activity); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(quinolinecarboxamides and other heterocyclic compds. for preventing or treating atherosclerosis or restenosis)

IT	228727-76-2	228727-77-3	228727-78-4	228727-79-5	228727-80-8
	228727-81-9	228727-82-0	228727-83-1	228727-84-2	228727-85-3
	228727-86-4	228727-87-5	228727-89-7	228727-90-0	228727-91-1
	228727-92-2	228727-93-3	228727-94-4	228727-95-5	228727-96-6

228727-97-7	228727-98-8	228727-99-9	228728-00-5	228728-01-6
281650-66-6	281650-67-7	281650-68-8	281650-69-9	281650-71-3
281650-72-4	281650-73-5	281650-74-6	281650-75-7	281650-76-8
281650-77-9	281650-78-0	281650-79-1	281650-80-4	281650-81-5
281650-82-6	281650-83-7	281650-84-8	281650-85-9	281650-86-0
281650-87-1	281650-88-2	281650-89-3	281650-90-6	281650-91-7
281650-92-8	281650-93-9	281650-94-0	281650-95-1	281650-96-2
281650-97-3	281650-98-4	281650-99-5	281651-01-2	281651-02-3
281651-03-4	281651-04-5	281651-05-6	281651-06-7	281651-07-8
281651-08-9	281651-09-0	281651-10-3	281651-11-4	281651-12-5
281651-14-7	281651-15-8	281651-16-9	281651-17-0	281651-18-1
281651-19-2	281651-20-5	281651-21-6	281651-22-7	281651-23-8
281651-24-9	281651-25-0	281651-26-1	281651-27-2	281651-28-3
281651-29-4	281651-30-7	281651-31-8	281651-32-9	281651-33-0
281651-34-1	281651-35-2	281651-36-3	281651-37-4	281651-38-5
281651-39-6	281651-40-9	281651-41-0	281651-42-1	281651-43-2
281651-44-3	281651-45-4	281651-46-5	281651-47-6	281651-48-7
281651-48-7	281651-49-8	281651-49-8	281651-50-1	281651-51-2
281651-51-2	281651-52-3	281651-52-3	281651-53-4	281651-54-5
281651-54-5	281651-55-6	281651-55-6	281651-56-7	281651-56-7
281651-57-8	281651-58-9	281651-59-0	281651-60-3	281651-61-4
281651-62-5	281651-63-6	281651-64-7	281651-65-8	281651-66-9
281651-67-0	281651-68-1	281651-69-2	281651-70-5	281651-71-6
281651-72-7	281651-73-8	281651-74-9	281651-75-0	281651-76-1
281651-77-2	281651-78-3	281651-79-4	281651-80-7	281651-81-8
281651-82-9	281651-83-0	281651-84-1	281651-85-2	281651-86-3
281651-87-4	281651-88-5	281651-89-6	281652-04-8	281652-08-2
281652-16-2	281652-43-5	281652-43-5	281652-64-0	281652-65-1
281652-66-2	281652-67-3	281652-68-4	281652-69-5	282536-21-4
282536-25-8	282536-28-1	282536-38-3	282536-43-0	282536-47-4
333780-66-8	333780-67-9	333780-68-0	333780-69-1	382604-97-9
382604-98-0	382604-99-1	382605-01-8	382605-02-9	382605-03-0
382605-04-1	382605-05-2	382605-06-3	382605-07-4	382605-08-5
382605-09-6	382605-10-9	382605-11-0	382605-12-1	382605-13-2
382605-14-3	382605-15-4	382605-16-5	382605-17-6	382605-19-8
382605-20-1	382605-21-2	382605-22-3	382605-23-4	382605-24-5
382605-25-6	382605-26-7	382605-27-8	382605-28-9	389133-56-6
389133-57-7	389133-58-8	389133-59-9	389133-60-2	389133-61-3
389133-62-4	389133-63-5	389133-64-6	389133-65-7	389133-66-8
389133-67-9	389133-68-0	389133-69-1	389133-70-4	389133-71-5
389133-72-6	389133-73-7	389133-74-8	389133-79-3	389133-80-6
389133-81-7	389133-82-8	389133-83-9	389133-84-0	389133-85-1
389133-86-2	389133-88-4	389133-90-8	389133-91-9	389133-92-0

RL: AGR (Agricultural use); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(quinolinecarboxamides and other heterocyclic compds. for preventing or
treating atherosclerosis or restenosis)

IT	389133-93-1	389133-94-2	389133-95-3	389133-96-4	389133-97-5
	389133-98-6	389133-99-7	389134-00-3	389134-01-4	389134-02-5
	389134-03-6	389134-04-7	389134-05-8	389134-06-9	389134-07-0
	389134-08-1	389134-09-2	389134-10-5	389134-11-6	389134-12-7
	389134-13-8	389134-14-9	389134-15-0	389134-16-1	389134-17-2
	389134-18-3	389134-19-4	389134-20-7	389134-21-8	389134-22-9
	389134-23-0	389134-24-1	389134-25-2	389134-26-3	389134-27-4
	389134-28-5	389134-89-8	389134-90-1	389134-91-2	389134-92-3
	389134-93-4	389134-94-5	389134-95-6	389134-96-7	389134-97-8
	389134-98-9	389134-99-0	389135-00-6	389135-01-7	389135-02-8
	389135-03-9	389135-04-0	389135-05-1	389135-06-2	389135-07-3
	389135-08-4	389135-09-5	389135-10-8	389135-11-9	389135-12-0
	389135-13-1	389135-14-2	389135-16-4	389135-17-5	389135-18-6

389135-19-7	389135-20-0	389135-21-1	389135-22-2	389135-23-3
389135-24-4	389135-25-5	389135-26-6	389135-27-7	389135-28-8
389135-29-9	389135-30-2	389135-31-3	389135-32-4	389135-33-5
389135-34-6	389135-35-7	389135-36-8	389135-37-9	389135-38-0
389135-39-1	389135-40-4	389135-41-5	389135-42-6	389135-43-7
389135-44-8	389135-45-9	389135-46-0	389135-47-1	389135-48-2
389135-49-3	389135-50-6	389135-51-7	389135-52-8	669051-10-9
669051-11-0	669051-12-1	669051-13-2	669051-14-3	669051-15-4
669051-16-5	669051-17-6	669051-18-7	669051-24-5	669051-40-5
669051-42-7	669051-43-8	669051-44-9	669051-45-0	669051-46-1
669051-47-2	669051-48-3	669051-49-4	669051-50-7	669051-51-8
669051-52-9	669051-53-0	669051-54-1	669051-55-2	669051-56-3
669051-60-9	669051-61-0	669051-63-2	669051-64-3	669051-73-4
669051-74-5	669051-75-6	669051-76-7	669051-78-9	

RL: AGR (Agricultural use); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(quinolinecarboxamides and other heterocyclic compds. for preventing or
treating atherosclerosis or restenosis)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 5 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:182874 HCAPLUS Full-text

DOCUMENT NUMBER: 140:235742

TITLE: Preparation of quinazolinones as inosine
5'-monophosphate dehydrogenase (IMPDH) inhibitors.

INVENTOR(S): Haughan, Alan Findlay; Buckley, George Martin; Dyke,
Hazel Joan; Hannah, Duncan Robert; Richard, Marianna
Dilani; Sharpe, Andrew; Williams, Sophie Caroline

PATENT ASSIGNEE(S): Celltech R & D Limited, UK

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018462	A1	20040304	WO 2003-GB3600	20030818 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,			
	PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,			
	TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,			
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,			
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003255803	A1	20040311	AU 2003-255803	20030818 <--
PRIORITY APPLN. INFO.:			GB 2002-19638	A 20020823 <--
			GB 2003-3866	A 20030220 <--
			GB 2003-12773	A 20030604 <--
			WO 2003-GB3600	W 20030818 <--

OTHER SOURCE(S): MARPAT 140:235742

ED Entered STN: 05 Mar 2004

AB Title compds. [I; X = O, S; R1 = aliphatic, cycloaliph., cycloalkylalkyl; R2 =
(substituted) heteroaryl, cyano; R3 = (Alk1)mL1(Alk2)nR6; m, n, p, q = 0, 1;
Alk1-Alk4 = (substituted) aliphatic, heteroaliph. chain; L1, L2 = bond, linker

atom or group; R6 = H, (substituted) cycloaliph., heterocycloaliph., aryl, heteroaryl; R4 = (Alk3)pL2(Alk4)qR7; R7 = H, halo, cyano, (substituted) cycloaliph., heterocycloaliph., aryl, heteroaryl; R5 = H, (substituted) aliphatic; and the salts, solvates, hydrates, tautomers, isomers or N-oxides thereof], were prepared. Thus, 2-amino-4-methoxy-N-(2-morpholin-4-ylethyl)-5-oxazol-5-ylbenzamide (preparation given) was refluxed 6 h with MgSO₄ and p-TsOH in acetone to give 16% 7-methoxy-2,2-dimethyl-3-(2-morpholin-4-ylethyl)-6-oxazol-5-yl-2,3-dihydro-1H-quinazolin-4-one. I inhibited IMPDH with IC₅₀ ≤ 5 μM.

IC ICM C07D413-04
ICS C07D413-14; A61K031-517

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST quinazolinone prepn inosine monophosphate dehydrogenase IMPDH inhibitor; cancer inflammation autoimmune disorder psoriasis viral disorder treatment quinazolinone

IT Immune system
(agents; preparation of quinazolinones as IMP dehydrogenase (IMPDH) inhibitors)

IT Anti-inflammatory agents
Antitumor agents
Antiviral agents
Human
(preparation of quinazolinones as IMP dehydrogenase (IMPDH) inhibitors)

IT Autoimmune disease
Inflammation
Neoplasm
Psoriasis
(treatment; preparation of quinazolinones as IMP dehydrogenase (IMPDH) inhibitors)

IT Infection
(viral, treatment; preparation of quinazolinones as IMP dehydrogenase (IMPDH) inhibitors)

IT 9028-93-7, Inosine 5'-monophosphate dehydrogenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of quinazolinones as IMP dehydrogenase (IMPDH) inhibitors)

IT 667939-11-9P 667939-12-0P 667939-13-1P 667939-14-2P 667939-15-3P
667939-16-4P 667939-17-5P 667939-18-6P 667939-19-7P 667939-20-0P
667939-21-1P 667939-22-2P 667939-23-3P 667939-24-4P 667939-25-5P
667939-26-6P 667939-27-7P 667939-28-8P 667939-29-9P 667939-30-2P
667939-31-3P 667939-32-4P 667939-33-5P 667939-34-6P 667939-35-7P
667939-36-8P 667939-37-9P 667939-38-0P 667939-39-1P 667939-40-4P
667939-41-5P 667939-42-6P 667939-43-7P 667939-44-8P 667939-45-9P
667939-46-0P 667939-47-1P 667939-48-2P 667939-49-3P 667939-50-6P
667939-51-7P 667939-52-8P 667939-53-9P 667939-54-0P 667939-55-1P
667939-56-2P 667939-57-3P 667939-58-4P 667939-59-5P 667939-60-8P
667939-61-9P 667939-62-0P 667939-63-1P 667939-64-2P 667939-65-3P
667939-66-4P 667939-67-5P 667939-68-6P 667939-69-7P 667939-70-0P
667939-71-1P 667939-72-2P 667939-73-3P 667939-74-4P 667939-75-5P
667939-76-6P 667939-77-7P 667939-78-8P 667939-79-9P 667939-80-2P
667939-81-3P 667939-82-4P 667939-83-5P 667939-84-6P 667939-85-7P
668486-10-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolinones as IMP dehydrogenase (IMPDH) inhibitors)

IT 65-85-0, Benzoic acid, reactions 67-64-1, Acetone,

reactions 75-07-0, Acetaldehyde, reactions 98-01-1,
 2-Furaldehyde, reactions 98-89-5, Cyclohexanecarboxylic acid
 100-52-7, Benzaldehyde, reactions 100-61-8, N-Methylaniline,
reactions 105-45-3, Methyl acetoacetate 110-89-4, Piperidine,
reactions 127-17-3, Pyruvic acid, reactions
 421-50-1, 1,1,1-Trifluoroacetone 563-96-2, Glyoxylic acid monohydrate
 593-51-1, Methylamine hydrochloride 617-35-6, Ethyl pyruvate 621-87-4,
 Phenoxyacetone 623-15-4, 4-(2-Furyl)-3-buten-2-one 924-44-7, Ethyl
 glyoxylate 943-88-4 1011-47-8 1071-73-4, 3-Acetyl-1-propanol
 1121-60-4, 2-Pyridinecarboxaldehyde 1439-36-7, 1-
 Triphenylphosphoranylidene-2-propanone 1611-38-7 1646-26-0,
 Benzofuran-2-yl methyl ketone 1646-32-8, 2-Acetyl-5-chlorobenzofuran
 1817-57-8, 4-Phenyl-3-buten-2-one 1896-62-4 2038-03-1,
 4-Morpholineethanamine 2833-24-1 2987-16-8 3160-40-5 3783-77-5,
 N-(3-Oxobutyl)phthalimide 4244-84-2, β -Alanine ethyl ester
 hydrochloride 4265-16-1, 2-Benzofurancarboxaldehyde 4436-81-1
 5813-64-9, Neopentylamine 5878-19-3, Methoxyacetone 5930-98-3,
 4-Trimethylsilyl-3-buten-2-one 7152-32-1 7797-83-3,
 1,3-Benzodioxole-4-carboxaldehyde 10412-98-3, 5-Oxohexanenitrile
 10601-80-6, Ethyl (3,3-diethoxy)propionate 13258-63-4,
 4-(2-Aminoethyl)pyridine 13750-81-7, 1-Methyl-2-imidazolecarboxaldehyde
 13803-39-9, 5-Phenylfuran-2-carboxaldehyde 13939-69-0,
 1-Piperidinecarbonyl chloride 14063-86-6 20306-75-6,
 N-Methylacetoacetamide 22539-93-1, Benzylloxyacetone 23100-12-1,
 2-Chloropyridine-5-carboxaldehyde 25784-83-2 27421-51-8,
 1-Methylindole-2-carboxaldehyde 27861-32-1 28447-16-7 33016-47-6,
 1-Tritylimidazole-4-carboxaldehyde 33603-63-3 34047-39-7,
 4-Methylthio-2-butanone 43071-52-9, 2-Acetyl-7-methoxybenzofuran
 54614-95-8 55728-58-0 65308-89-6 67808-66-6, Methyl
 5-formyl-3-thiophenecarboxylate 70661-09-5 75277-96-2 81559-89-9
 93668-43-0 107624-85-1 371251-38-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinazolinones as IMP dehydrogenase (IMPDH)
 inhibitors)

IT	553677-82-0P	667939-86-8P	667939-87-9P	667939-88-0P	667939-89-1P
	667939-90-4P	667939-91-5P	667939-92-6P	667939-93-7P	667939-94-8P
	667939-95-9P	667939-96-0P	667939-97-1P		

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of quinazolinones as IMP dehydrogenase (IMPDH)
 inhibitors)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 6 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:60309 HCAPLUS Full-text

DOCUMENT NUMBER: 140:105273

TITLE: Topical treatment of skin diseases

INVENTOR(S): Rundfeldt, Chris; Kietzmann, Manfred; Hoppmann,
 Joachim; Baeumer, Wolfgang; Kuss, Hildegard; Hoefgen,
 Norbert

PATENT ASSIGNEE(S): Elbion AG, Germany

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
WO 2004006920      A1      20040122      WO 2003-EP7514      20030710 <--
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
    CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
    GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
    LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
    PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
    TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
    KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
    FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
    BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2004038958      A1      20040226      US 2003-611649      20030701 <--
CA 2492093         A1      20040122      CA 2003-2492093     20030710 <--
AU 2003254332      A1      20040202      AU 2003-254332     20030710 <--
BR 2003012696      A       20050426      BR 2003-12696      20030710 <--
EP 1531818         A1      20050525      EP 2003-763810     20030710 <--
R:   AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1681500         A       20051012      CN 2003-821520     20030710 <--
JP 2005537262      T       20051208      JP 2004-520586     20030710 <--
NZ 537482          A       20060929      NZ 2003-537482     20030710 <--
ZA 2005000108      A       20050223      ZA 2005-108        20050106 <--
NO 2005000718      A       20050401      NO 2005-718        20050210 <--
PRIORITY APPLN. INFO.:      US 2002-395221P      P 20020711 <--
                                WO 2003-EP7514      W 20030710 <--

```

OTHER SOURCE(S): MARPAT 140:105273

ED Entered STN: 26 Jan 2004

AB The present invention relates to a method for the treatment of an inflammatory and/or allergic skin disease comprising topically administering a substituted hydroxy indole which is a phosphodiesterase 4 inhibitor. Examples are provided of the topical effectiveness of AWD 12-281 and cilomilast in dermal immunol. inflammation.

IC ICM A61K031-4439

ICS A61P017-00

CC 1-7 (Pharmacology)

ST phosphodiesterase inhibitor topical hydroxy indole skin inflammation

IT Allergy

(allergic dermatitis; phosphodiesterase inhibitors for treatment of skin inflammatory and/or allergic reactions)

IT Dermatitis

(allergic; phosphodiesterase inhibitors for treatment of skin inflammatory and/or allergic reactions)

IT Dermatitis

(phosphodiesterase inhibitors for treatment of skin inflammatory and/or allergic reactions)

IT Interleukin 4

Interleukin 6

Macrophage inflammatory protein 2

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(phosphodiesterase inhibitors for treatment of skin inflammatory and/or allergic reactions)

IT Corticosteroids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phosphodiesterase inhibitors for treatment of skin inflammatory and/or allergic reactions)

IT Drug delivery systems

(topical; phosphodiesterase inhibitors for treatment of skin

inflammatory and/or allergic reactions)
 IT 60-92-4, Camp 9036-21-9, Phosphodiesterase IV
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (phosphodiesterase inhibitors for treatment of skin
 inflammatory and/or allergic reactions)
 IT 153259-65-5, Cilomilast 257892-33-4, AWD 12-281
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phosphodiesterase inhibitors for treatment of skin
 inflammatory and/or allergic reactions)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 7 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:60255 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:105258
 TITLE: Benzimidazole compound-pentamidine compound
 combinations for the treatment of neoplasms
 INVENTOR(S): Borisy, Alexis; Keith, Curtis; Foley, Michael A.;
 Stockwell, Brent R.; Gaw, Debra A.
 PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
 SOURCE: PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006849	A2	20040122	WO 2003-US21984	20030715 <--
WO 2004006849	A3	20040603		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003251904	A1	20040202	AU 2003-251904	20030715 <--
PRIORITY APPLN. INFO.:			US 2002-396151P	P 20020715 <--
			WO 2003-US21984	W 20030715 <--

OTHER SOURCE(S): MARPAT 140:105258

ED Entered STN: 26 Jan 2004

AB The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) a benzimidazole or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amts. sufficient to inhibit the growth of the neoplasm.

IC ICM A61K

CC 1-6 (Pharmacology)

ST benzimidazole compd pentamidine compd combination neoplasm treatment; antitumor benzimidazole compd pentamidine compd combination

IT Bone, neoplasm
 (Ewing's sarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)

- IT Sarcoma
(Ewing's; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Sarcoma
(Kaposi's; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Lymphoproliferative disorders
(Waldenstrom's macroglobulinemia; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Kidney, neoplasm
(Wilms'; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Nerve, neoplasm
(acoustic neuroma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Acute myeloid leukemia
(acute erythroblastic leukemia, acute; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
Lung, neoplasm
(adenocarcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Neuroglia, neoplasm
(astrocytoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Skin, neoplasm
(basal cell carcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(basal cell; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Acute lymphocytic leukemia
Acute monocytic leukemia
Acute myeloid leukemia
Acute myelomonocytic leukemia
Acute promyelocytic leukemia
Antitumor agents
Carcinoma
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Drug delivery systems
Drug interactions
Drug screening
Hodgkin's disease
Human
Leukemia
Leukemia
Mammary gland, neoplasm
Melanoma
Neoplasm
Neuroglia, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Polycythemia vera
Prostate gland, neoplasm
Testis, neoplasm
Uterus, neoplasm
(benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)

- IT Biliary tract, neoplasm
(bile duct, carcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(bladder; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(bronchial; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Bladder, neoplasm
Bronchi, neoplasm
Lung, neoplasm
Sebaceous gland
Sweat gland
(carcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Sarcoma
(cartilage chondrosarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Uterus, neoplasm
(cervix; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(choledochal; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Cartilage, neoplasm
(chondrosarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Neoplasm
(chordoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
Chorion, neoplasm
(choriocarcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Intestine, neoplasm
(colon, carcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(colon; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Neoplasm
(craniopharyngioma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Ovary, neoplasm
(cystadenocarcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(embryonal; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Brain, neoplasm
(ependymoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Sarcoma
(fibrosarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Disease, animal
(heavy chain disease; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Blood vessel, neoplasm

- (hemangioblastoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Blood vessel, neoplasm
Sarcoma
 (hemangiosarcoma, lymphangiosarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Blood vessel, neoplasm
Sarcoma
 (hemangiosarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
 (hepatocellular; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Liver, neoplasm
 (hepatoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Drug delivery systems
 (inhalants; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Drug delivery systems
 (injections, i.m.; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Drug delivery systems
 (injections, i.v.; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
 (large cell; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Myoma
Sarcoma
 (leiomyosarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Adipose tissue, neoplasm
Sarcoma
 (liposarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Sarcoma
 (lymphangioendotheliosarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
 (medullary; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Brain, neoplasm
 (medulloblastoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Nervous system, neoplasm
 (meningioma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Mesothelium, neoplasm
 (mesothelioma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Sarcoma
 (myxosarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Astrocyte
 (neoplasm, astrocytoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Notochord

- (neoplasm, chordoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Meninges
(neoplasm, meningioma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Oligodendrocyte
(neoplasm, oligodendroglioma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Schwann cell
(neoplasm, schwannoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Nerve, neoplasm
(neuroblastoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Lymphoma
(non-Hodgkin's; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Neuroglia, neoplasm
(oligodendroglioma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Drug delivery systems
(oral; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Bone, neoplasm
Sarcoma
(osteosarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(ovarian cystadenocarcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Thyroid gland, neoplasm
(papillary carcinoma, adenocarcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Thyroid gland, neoplasm
(papillary carcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Pineal gland
(pinealoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(pulmonary adenocarcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(pulmonary small-cell; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(pulmonary; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Drug delivery systems
(rectal; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Kidney, neoplasm
(renal cell carcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma

- (renal cell; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Eye, neoplasm
(retinoblastoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Sarcoma
(rhabdomyosarcoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Nervous system, neoplasm
(schwannoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Testis, neoplasm
(seminoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Lung, neoplasm
(small-cell carcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(squamous cell; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Neoplasm
(synovioma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(thyroid papillary, adenocarcinoma; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT Carcinoma
(thyroid papillary; benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
- IT 51-17-2D, Benzimidazole, derivs. 60-56-0, Mercazole 100-33-4, Pentamidine 100-33-4D, Pentamidine, derivs. 101-62-2, Phenamidine 104-32-5, Propamidine 122-06-5, Stilbamidine 140-64-7, Pentamidine isethionate 148-79-8, Thiabendazole 495-99-8, Hydroxystilbamidine 496-00-4, Dibrompropamidine 536-71-0, Diminazene 548-73-2, Droperidol 618-39-3, Benzamidine 1402-38-6, Actinomycin 1438-30-8, Netropsin 1929-88-0, Benzthiazuron 2062-78-4, Pimozide 3459-96-9, Amicarbalide 6306-71-4, Lobendazole 11056-06-7, Bleomycin 14255-87-9, Parbendazole 17804-35-2, Benomyl 18691-97-9, Methabenzthiazuron 20559-55-1, Oxibendazole 20830-81-3, Daunorubicin 24370-25-0, 2-Benzimidazolylurea 26097-80-3, Cambendazole 26130-02-9, Frentizole 31430-15-6, Flubendazole 31430-18-9, Nocodazole 31431-39-7, Mebendazole 31431-39-7D, Mebendazole, derivs. 31431-43-3, Cyclobendazole 33016-12-5, TN-16 33763-36-9, 3,7-Dibenzofurandicarbonitrile 39389-47-4, Distamycin 41738-62-9, 3,7-Dibenzothiophenedicarbonitrile 41738-64-1, 3,7-Dibenzothiophenediamine 43210-67-9, Fenbendazole 53716-50-0, Oxfendazole 54029-12-8, Albendazole sulfoxide 54965-21-8, Albendazole 54965-21-8D, Albendazole, derivs. 57808-66-9, Domperidone 61570-90-9, Tioxidazole 66639-24-5 67019-91-4 68844-77-9, Astemizole 73590-58-6, Omeprazole 73819-26-8 74733-75-8 75184-71-3, Albendazole sulfone 75846-15-0 75846-16-1 80434-77-1, NSC 181928 80498-71-1 80498-74-4 83834-10-0 90509-02-7, Luxabendazole 91371-12-9 94345-47-8, Heptamidine 100562-53-6 101689-95-6 116644-53-2, Mibefradil 124076-61-5, Butamidine 124076-65-9 148344-21-2 157168-41-7 157168-42-8 157168-43-9 157168-44-0 157168-45-1 157168-46-2 157168-47-3 157168-48-4 157168-49-5 157168-50-8 157168-51-9 160522-89-4 161374-52-3, Nonamidine 165596-46-3 166601-05-4 166601-10-1 166601-11-2 168637-58-9 173420-56-9 173420-58-1 173420-61-6 173420-63-8 179118-03-7 179118-04-8 179118-05-9 179118-08-2 179118-10-6 179118-22-0 186395-09-5

186395-18-6	186395-20-0	186395-22-2	186395-24-4	186395-25-5
186395-26-6	186395-28-8	186395-29-9	186395-30-2	190958-06-6
190958-12-4	190958-16-8	200878-34-8	212829-50-0	213972-16-8
216308-12-2	216308-13-3	216308-14-4	216308-16-6	216308-18-8
216502-98-6	216502-99-7	216503-00-3	216503-01-4	216503-02-5
216503-05-8	216503-06-9	216503-07-0	216503-08-1	216503-09-2
219483-82-6	232940-82-8,	2,8-Dibenzofurandicarbonitrile		232940-83-9
232940-84-0	247032-11-7	247032-13-9	247032-15-1	247032-16-2
247032-17-3	247032-18-4	338945-24-7, 2,8-Dibenzofurandicarboximidamide		
415718-14-8	415718-17-1	415718-20-6	415718-26-2	415718-29-5
415718-32-0,	2,8-Dibenzothiophenedicarboximidamide			415718-35-3
415718-41-1,	3,7-Dibenzothiophenedicarboximidamide			415718-44-4
415718-47-7	415718-50-2	442842-45-7	648415-30-9	648415-31-0
648415-32-1	648415-33-2	648415-34-3	648415-36-5	648415-37-6
648415-38-7	648415-39-8	648415-40-1	648415-41-2	648415-42-3
648415-43-4	648415-44-5	648415-45-6	648415-46-7	648415-47-8
648415-48-9	648415-49-0	648415-50-3	648415-51-4	648415-52-5
648415-53-6	648415-54-7	648415-55-8	648415-56-9	648415-58-1
648415-59-2				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(benzimidazole compound-pentamidine compound combinations for the treatment
of neoplasms)

L119 ANSWER 8 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:736248 HCAPLUS Full-text

DOCUMENT NUMBER: 137:262954

TITLE: Process for producing sulfone derivative

INVENTOR(S): Mizufune, Hideya; Yamamoto, Hiroaki; Miki, Shokyo

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074762	A1	20020926	WO 2002-JP2323	20020313 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002238857	A1	20021003	AU 2002-238857	20020313 <--
JP 2002338565	A	20021127	JP 2002-70442	20020314 <--
PRIORITY APPLN. INFO.:			JP 2001-74010	A 20010315 <--
			WO 2002-JP2323	W 20020313 <--

OTHER SOURCE(S): MARPAT 137:262954

ED Entered STN: 27 Sep 2002

AB This document discloses a process for producing a sulfone derivative represented by the general formula R-W-S(O)₂-X-Y-L₂ (R represents an optionally substituted cyclic hydrocarbon group, etc.; W represents a bond or an optionally substituted divalent chain hydrocarbon group; X represents an optionally substituted divalent chain hydrocarbon group; Y represents CO,

S(O), S(O)₂, CH₂, etc.; and L₂ represents hydrogen, hydroxy, or optionally substituted alkoxy) or a salt thereof, characterized by reacting a sulfinic acid derivative represented by the general formula R-W-S(O)₂-M (R and W are the same as defined above; and M represents hydrogen, an alkali metal, or an alkaline earth metal) or a salt thereof with a compound represented by the general formula L₁-X-Y-L₂ (wherein X, Y, and L₂ are the same as defined above; L₁ represents a leaving group; and R₅ represents hydrogen, etc.) or a salt thereof. The title process is used in the preparation of antithrombotic agents. For example, 3-[(6-chloro-2-naphthyl)sulfonyl]propionic acid Me ester was prepared in 88% yield by the title process.

IC ICM C07D401-04
ICS C07C315-00; C07C317-44
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
ST naphthylsulfonylpropionic acid prepn; methyl acrylate
reaction naphthylsulfinic acid deriv; sulfone deriv prepn
antithrombotic
IT Addition reaction
(addition reaction of naphthylsulfinic acid derivative with Me
acrylate or with acrylamide derivative)
IT Amines, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of amines with piperidone derivs. in presence of
reducing agents)
IT 74-89-5, Methylamine, reactions 96-33-3, Methyl acrylate
814-68-6, Acryloyl chloride 3678-63-5, 4-Chloro-2-methylpyridine
41979-39-9, 4-Piperidinone hydrochloride 102153-63-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for producing sulfone derivative)
IT 64-18-6, Formic acid, reactions 56553-60-7, Sodium
triacetoxyborohydride
RL: RGT (Reagent); RACT (Reactant or reagent)
(process for producing sulfone derivative)

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 9 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:610316 HCAPLUS Full-text

DOCUMENT NUMBER: 137:163829

TITLE: Use of a composition comprising a retinoid and an Erb
inhibitor in the preparation of a
medicament for the treatment of retinoid
skin damage

INVENTOR(S): Elder, James Tilford; Varani, James

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: Eur. Pat. Appl., 43 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1230919	A2	20020814	EP 2002-2611	20020205 <--
EP 1230919	A3	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 516873	A	20031128	NZ 2002-516873	20020128 <--
CA 2370236	A1	20020812	CA 2002-2370236	20020131 <--

10/574,993

AU 2002015470	A5	20020815	AU 2002-15470	20020207 <--
CN 1370535	A	20020925	CN 2002-104570	20020208 <--
US 2002169176	A1	20021114	US 2002-73569	20020211 <--
HU 200200492	A2	20021228	HU 2002-492	20020211 <--
ZA 2002001157	A	20030811	ZA 2002-1157	20020211 <--
JP 2002275095	A	20020925	JP 2002-33608	20020212 <--
HK 1048271	A1	20050902	HK 2003-100597	20030123 <--
US 2004198752	A1	20041007	US 2004-824182	20040414 <--
PRIORITY APPLN. INFO.:			US 2001-268220P	P 20010212 <--
			US 2002-73569	A1 20020211 <--

OTHER SOURCE(S): MARPAT 137:163829

ED Entered STN: 15 Aug 2002

AB Erb inhibitors used in combination with retinoids are effective to prevent skin injury otherwise caused by retinoids alone. A method of treating skin aging and similar skin disorders comprises administering retinoids in combination with erb inhibitors I (E1-E3 include halo; R is alkylcarbonyl or alkenylcarbonyl; R' is lower alkoxy optionally substituted with amino groups).

IC ICM A61K031-07
ICS A61K031-517; A61K031-519; A61P017-00

CC 1-12 (Pharmacology)

ST Erb inhibitor retinoid combination therapeutic skin disorder; aging skin Erb inhibitor retinoid combination; quinazoline deriv retinoid combination therapeutic skin disorder

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Erb; retinoid and Erb inhibitor for treatment of retinoid skin damage)

IT Skin, disease
(aging; retinoid and Erb inhibitor for treatment of retinoid skin damage)

IT Skin, neoplasm
(and precancerous lesions; retinoid and Erb inhibitor for treatment of retinoid skin damage)

IT Hyperplasia
(cutaneous; retinoid and Erb inhibitor for treatment of retinoid skin damage)

IT Pituitary gland
(extract; retinoid and Erb inhibitor for treatment of retinoid skin damage)

IT Skin, disease
(hyperplasia; retinoid and Erb inhibitor for treatment of retinoid skin damage)

IT Skin
(keratinocyte; retinoid and Erb inhibitor for treatment of retinoid skin damage)

IT Skin, disease
(photoaging; retinoid and Erb inhibitor for treatment of retinoid skin damage)

IT Drug delivery systems
(prodrugs; retinoid and Erb inhibitor for treatment of retinoid skin damage)

IT Acne
Antitumor agents
Drug delivery systems
Drug interactions
Drug toxicity
Fibroblast
Human
Psoriasis

Skin, disease(retinoid and Erb inhibitor for treatment of retinoid skin damage)

IT Retinoids

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(retinoid and Erb inhibitor for treatment of retinoid skin damage)IT 68-26-8, all-trans-Retinol 116-31-4, all-trans-Retinal 302-79-4, all-trans-Retinoic acid 472-86-6, 13-cis-Retinal 514-85-2, 9-cis-Retinal 2052-63-3, 13-cis-Retinol 4759-48-2, 13-cis-Retinoic acid 5300-03-8, 9-cis-Retinoic acid 22737-97-9, 9-cis-Retinol
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(retinoid and Erb inhibitor for treatment of retinoid skin damage)IT 7440-70-2, Calcium, biological studies 9004-10-8, Insulin, biological studies 62229-50-9, Epidermal growth factor 79079-06-4, EGF receptor tyrosine kinase 154531-34-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(retinoid and Erb inhibitor for treatment of retinoid skin damage)IT 253-82-7D, Quinazoline, derivs. 171179-06-9, PD 158780 198959-99-8 198960-77-9 267243-28-7 289499-45-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(retinoid and Erb inhibitor for treatment of retinoid skin damage)

L119 ANSWER 10 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:574927 HCAPLUS Full-textDOCUMENT NUMBER: 137:119655TITLE: Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

INVENTOR(S): Borisy, Alexis; Keith, Curtis; Foley, Michael A.; Stockwell, Brent R.

PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058697	A1	20020801	WO 2002-US1707	20020122 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002165261	A1	20021107	US 2001-768870	20010124 <--
US 6693125	B2	20040217		
AU 2002243618	A1	20020806	AU 2002-243618	20020122 <--

EP 1363625 A1 20031126 EP 2002-709117 20020122 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2004063769 A1 20040401 US 2003-677664 20031002 <--
 PRIORITY APPLN. INFO.: US 2001-768870 A1 20010124 <--
 WO 2002-US1707 W 20020122 <--

OTHER SOURCE(S): MARPAT 137:119655

ED Entered STN: 02 Aug 2002

AB The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) a benzimidazole or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amts. sufficient to inhibit the growth of the neoplasm.

IC ICM A61K031-415

CC 1-6 (Pharmacology)

Section cross-reference(s): 63

ST antitumor agent benzimidazole pentamidine analog combination

IT Uterus, neoplasm

(cervix; drug combinations for treatment of neoplastic disorders)

IT Intestine, neoplasm

(colon; drug combinations for treatment of neoplastic disorders)

IT Intestine, neoplasm

(colorectal; drug combinations for treatment of neoplastic disorders)

IT Antitumor agents

Brain, neoplasm

Kidney, neoplasm

Leukemia

Liver, neoplasm

Lung, neoplasm

Lymphoma

Mammary gland, neoplasm

Ovary, neoplasm

Pancreas, neoplasm

Prostate gland, neoplasm

Sarcoma

Skin, neoplasm

Stomach, neoplasm

Testis, neoplasm

Uterus, neoplasm

(drug combinations for treatment of neoplastic disorders)

IT Drug delivery systems

(inhalants; drug combinations for treatment of neoplastic disorders)

IT Drug delivery systems

(injections, i.m.; drug combinations for treatment of neoplastic disorders)

IT Drug delivery systems

(injections, i.v.; drug combinations for treatment of neoplastic disorders)

IT Drug delivery systems

(oral; drug combinations for treatment of neoplastic disorders)

IT Drug delivery systems

(rectal; drug combinations for treatment of neoplastic disorders)

IT 60-56-0, Mercazole 100-33-4, Pentamidine 101-62-2, Phenamidine

104-32-5, Propamidine 122-06-5, Stilbamidine 140-64-7, Pentamidine isethionate 495-99-8, Hydroxystilbamidine 496-00-4, Dibrompropamidine 536-71-0, Diminazene 548-73-2, Droperidol 618-39-3, Benzamidine 1402-38-6, Actinomycin 1438-30-8, Netropsin 1929-88-0, Benzthiazuron 2062-78-4, Pimozide 3459-96-9, Amicarbalide 6306-71-4, Lobendazole 11056-06-7, Bleomycin 14255-87-9, Parbendazole 17804-35-2, Benomyl 18691-97-9, Methabenzthiazuron 20559-55-1, Oxibendazole 20830-81-3, Daunorubicin 22769-68-2 24370-25-0, 2-Benzimidazolylurea 26097-80-3, Cambendazole 26130-02-9, Frentizole 31430-15-6, Flubendazole 31430-18-9, Nocodazole 31431-39-7, Mebendazole 31431-43-3, Cyclobendazole 33016-12-5, TN-16 39389-47-4, Distamycin 43210-67-9, Fenbendazole 53716-50-0, Oxfendazole 54029-12-8, Albendazole sulfoxide 54965-21-8, Albendazole 57808-66-9, Domperidone 61570-90-9, Tioxidazole 68844-77-9, Astemizole 73590-58-6, Omeprazole 75184-71-3, Albendazole sulfone 80434-77-1, NSC 181928 90509-02-7, Luxabendazole 94345-47-8, Heptamidine 116644-53-2, Mibefradil 124076-61-5, Butamidine 124076-65-9 161374-52-3, Nonamidine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(drug combinations for treatment of neoplastic disorders)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 11 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:293607 HCAPLUS Full-text

DOCUMENT NUMBER: 136:325232

TITLE: Preparation of sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses

INVENTOR(S): Dasseux, Jean-Louis H.; Oniciu, Carmen Daniela

PATENT ASSIGNEE(S): Esperion Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 262 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030882	A2	20020418	WO 2001-US31871	20011011 <--
WO 2002030882	A9	20030220		
WO 2002030882	A3	20030925		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2425678	A1	20020418	CA 2001-2425678	20011011 <--
AU 2002011667	A5	20020422	AU 2002-11667	20011011 <--
EP 1366024	A2	20031203	EP 2001-979735	20011011 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004531459	T	20041014	JP 2002-534270	20011011 <--

BR 2001014623 A 20051213 BR 2001-14623 20011011 <--
 PRIORITY APPLN. INFO.: US 2000-239105P P 20001011 <--
 WO 2001-US31871 W 20011011 <--

OTHER SOURCE(S): MARPAT 136:325232

ED Entered STN: 19 Apr 2002

AB Title compds. W1ZmSOGSOZmW2 (I) [wherein Z = independently CH₂, CH:CH, or C₆H₄; m = independently 1-9; when Z = C₆H₄, m = 1; G = (CH₂)_x, CH₂CH:CHCH₂, CH:CH, CH₂C₆H₄CH₂, or C₆H₄; x = 2-4; W1 and W2 = independently CR1R2(CH₂)_nY, tetrahydro(oxo)pyranyl(oxy), oxooxetanyl, tetrahydrooxofuranyl, etc.; CR1R2(CH₂)cCR3R4(CH₂)_nY, or CR1R2(CH₂)cV; n = 0-4; c = 1-2; R1 and R2 = independently alkyl, alkenyl, alkynyl, Ph, or benzyl; or when one or both of W1 and W2 = CR1R2(CH₂)cCR3R4Y, then R1 and R2 can both be H; R3 = H, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, NO₂, or CF₃; R4 = OH, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, CN, NO₂, or CF₃; Y = OH, CO₂H, CHO, CO₂R₅, SO₃H, mono-, di-, or triphosphate, dioxo- or dithioxohexahydrothieno[3,2-c]pyridinyl, sulfamoyl, tetrazolyl, hydroxyoxazolyl, hydroxypyranonyl, substituted imidazolidinedionyl, etc.; R5 = (un)substituted alkyl, alkenyl, alkynyl, Ph, or benzyl] were prepared as peroxisome proliferator activated receptor (PPAR) antagonists for treatment and prevention of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders. I are also useful for treating and preventing Alzheimer's Disease, Syndrome X, PPAR-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer inflammation, and impotence. For example, 6-(5,5-dimethyl-6-hydroxyhexylsulfanyl)-2,2-dimethylhexan-1-ol was oxidized to 6-(5,5-dimethyl-6-hydroxyhexane-1-sulfinyl)-2,2-dimethylhexan-1-ol (quant.) using H₂O₂ in glacial AcOH. The latter increased reduced serum triglycerides in female obese Zucker rats by 48% and 42% after 1 and 2 wk of treatment. Although non-HDL cholesterol increased by 38% and 62%, a marked increase in HDL cholesterol of 2.2-fold and 3.1-fold after one and two weeks of treatment, resp., resulted in an unexpectedly beneficial increased ratio of HDL/non-HDL cholesterol from 2.70 (pretreatment) to 3.84 and 4.97. In certain embodiments, I may be administered in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

IC ICM C07C317-18

ICS A61K031-10; A61P009-00; C07C317-10; C07C317-22; C07C317-44;
 C07D233-40; C07D233-42; C07D249-04; C07D257-04; C07D261-12;
 C07D305-12; C07D307-32; C07D309-12; C07D309-30; C07D309-40;
 C07D333-48; C07D335-02; C07D495-04; C07F009-09

CC 23-11 (Aliphatic Compounds)

Section cross-reference(s): 1

ST alkyl sulfoxide prepn anticholesterol hypolipidemic antidiabetic
 antiobesity; sulfoxide alkyl prepn peroxisome
proliferator activated receptor antagonist

IT Fats and Glyceridic oils, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (animal, reduction in livestock; preparation of sulfoxide and
 bis-sulfoxide compds. as for cholesterol management and related uses)

IT Heart, disease

(cardiac syndrome X, treatment; preparation of sulfoxide
 and bis-sulfoxide compds. as for cholesterol management and related
 uses)

IT Egg, poultry

(cholesterol reduction; preparation of sulfoxide and bis-sulfoxide
 compds. as for cholesterol management and related uses)

IT Sexual disorders

(impotence, treatment; preparation of sulfoxide and bis-sulfoxide
 compds. as for cholesterol management and related uses)

IT Metabolic disorders

(metabolic syndrome X, treatment; preparation of

- sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Inflammation
Pancreas, disease
(pancreatitis, treatment; preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Anti-Alzheimer's agents
Anti-inflammatory agents
Anticholesteremic agents
Anticoagulants
Antihypertensives
Antiobesity agents
Antitumor agents
Cardiovascular agents
Human
Hypolipemic agents
(preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Fatty acids, biological studies
Glycerides, biological studies
High-density lipoproteins
Low-density lipoproteins
Peroxisome proliferator-activated receptors
Very-low-density lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Kidney, disease
Septicemia
(treatment; preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT Dyslipidemia
Dyslipidemia
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment; preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT 50-99-7, Glucose, biological studies 57-88-5, Cholesterol, biological studies 300-85-6 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)
- IT 411213-93-9P 412951-56-5P 412951-57-6P 412951-58-7P 412951-59-8P
412951-60-1P 412951-61-2P 412951-62-3P 412951-63-4P 412951-64-5P
412951-65-6P 412951-66-7P 412951-67-8P 412951-68-9P 412951-69-0P
412951-70-3P 412951-71-4P 412951-72-5P 412951-73-6P 412951-74-7P
412951-75-8P 412951-76-9P 412951-77-0P 412951-78-1P 412951-79-2P
412951-80-5P 412951-81-6P 412951-82-7P 412951-83-8P 412951-84-9P
412951-85-0P 412951-86-1P 412951-87-2P 412951-88-3P 412951-89-4P
412951-90-7P 412951-91-8P 412951-92-9P 412951-93-0P 412951-94-1P
412951-95-2P 412951-96-3P 412951-97-4P 412951-98-5P 412951-99-6P
412952-00-2P 412952-01-3P 412952-02-4P 412952-03-5P 412952-04-6P
412952-05-7P 412952-06-8P 412952-07-9P 412952-08-0P 412952-09-1P
412952-10-4P 412952-11-5P 412952-12-6P 412952-13-7P 412952-14-8P
412952-15-9P 412952-16-0P 412952-17-1P 412952-18-2P 412952-19-3P
412952-20-6P 412952-21-7P 412952-22-8P 412952-23-9P 412952-24-0P
412952-25-1P 412952-26-2P 412952-27-3P 412952-28-4P 412952-29-5P
412952-30-8P 412952-31-9P 412952-32-0P 412952-33-1P 412952-34-2P
412952-35-3P 412952-36-4P 412952-37-5P 412952-38-6P 412952-39-7P
412952-40-0P 412952-41-1P 412952-42-2P 412952-43-3P 412952-44-4P
412952-45-5P 412952-47-7P 412952-49-9P 412952-51-3P 412952-52-4P

412952-53-5P	412952-54-6P	412952-55-7P	412952-56-8P	412952-57-9P
412952-58-0P	412952-59-1P	412952-60-4P	412952-61-5P	412952-62-6P
412952-63-7P	412952-64-8P	412952-65-9P	412952-66-0P	412952-67-1P
412952-68-2P	412952-69-3P	412952-70-6P	412952-71-7P	412952-72-8P
412952-73-9P	412952-74-0P	412952-75-1P	412952-76-2P	412952-77-3P
412952-78-4P	412952-79-5P	412952-80-8P	412952-81-9P	412952-82-0P
412952-83-1P	412952-84-2P	412952-85-3P	412952-86-4P	412952-87-5P
412952-88-6P	412952-89-7P	412952-90-0P	412952-91-1P	412952-92-2P
412952-93-3P	412952-94-4P	412952-95-5P	412952-96-6P	412952-97-7P
412952-98-8P	412952-99-9P	412953-00-5P	412953-01-6P	412953-02-7P
412953-03-8P	412953-04-9P	412953-05-0P	412953-06-1P	412953-07-2P
412953-08-3P	412953-09-4P	412953-10-7P	412953-11-8P	412953-12-9P
412953-13-0P	412953-14-1P	412953-15-2P	412953-16-3P	412953-17-4P
412953-18-5P	412953-19-6P	412953-20-9P	412953-21-0P	412953-22-1P
412953-23-2P	412953-24-3P	412953-26-5P	412953-28-7P	412953-29-8P
412953-30-1P	412953-31-2P	412953-32-3P	412953-33-4P	412953-34-5P
412953-35-6P	412953-36-7P	412953-37-8P	412953-38-9P	412953-39-0P
412953-40-3P	412953-41-4P	412953-42-5P	412953-43-6P	412953-44-7P
412953-45-8P	412953-46-9P	412953-47-0P	412953-48-1P	412953-49-2P
412953-50-5P	412953-51-6P	412953-52-7P	412953-53-8P	412953-54-9P
412953-55-0P	412953-56-1P	412953-57-2P	412953-58-3P	412953-59-4P
412953-60-7P	412953-61-8P	412953-62-9P	412953-63-0P	412953-64-1P
412953-65-2P	412953-66-3P	412953-67-4P	412953-68-5P	412953-69-6P
412953-70-9P	412953-71-0P	412953-72-1P	412953-73-2P	412953-74-3P
412953-75-4P	412953-76-5P	412953-77-6P	412953-78-7P	412953-79-8P
412953-80-1P	412953-81-2P	412953-82-3P	412953-83-4P	412953-85-6P
412953-86-7P	412953-87-8P	412953-88-9P	412953-89-0P	412953-90-3P
412953-91-4P	412953-92-5P	412953-93-6P	412953-94-7P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)

IT	412953-95-8P	412953-96-9P	412953-97-0P	412953-98-1P	412953-99-2P
	412954-00-8P	412954-01-9P	412954-02-0P	412954-03-1P	412954-04-2P
	412954-05-3P	412954-06-4P	412954-07-5P	412954-08-6P	412954-09-7P
	412954-10-0P	412954-11-1P	412954-12-2P	412954-13-3P	412954-14-4P
	412954-15-5P	412954-16-6P	412954-17-7P	412954-18-8P	412954-19-9P
	412954-20-2P	412954-21-3P	412954-22-4P	412954-23-5P	412954-24-6P
	412954-25-7P	412954-26-8P	412954-27-9P	412954-28-0P	412954-29-1P
	412954-30-4P	412954-31-5P	412954-32-6P	412954-33-7P	412954-34-8P
	412954-35-9P	412954-36-0P	412954-37-1P	412954-38-2P	412954-39-3P
	412954-40-6P	412954-41-7P	412954-42-8P	412954-43-9P	412954-44-0P
	412954-45-1P	412954-46-2P	412954-47-3P	412954-48-4P	412954-49-5P
	412954-50-8P	412954-51-9P	412954-52-0P	412954-53-1P	412954-54-2P
	412954-55-3P	412954-56-4P	412954-57-5P	412954-58-6P	412954-59-7P
	412954-60-0P	412954-61-1P	412954-62-2P	412954-63-3P	412954-64-4P
	412954-65-5P	412954-66-6P	412954-67-7P	412954-68-8P	412954-69-9P
	412954-70-2P	412954-71-3P	412954-72-4P	412954-73-5P	412954-74-6P
	412954-75-7P	412954-76-8P	412954-77-9P	412954-78-0P	412954-79-1P
	412954-80-4P	412954-81-5P	412954-82-6P	412954-83-7P	412954-84-8P
	412954-85-9P	412954-86-0P	412954-87-1P	412954-88-2P	412954-89-3P
	412954-90-6P	412954-91-7P	412954-92-8P	412954-93-9P	412954-94-0P
	412954-95-1P	412954-96-2P	412954-97-3P	412954-98-4P	412954-99-5P
	412955-00-1P	412955-01-2P	412955-02-3P	412955-03-4P	412955-04-5P
	412955-05-6P	412955-06-7P	412955-07-8P	412955-08-9P	412955-09-0P
	412955-10-3P	412955-12-5P	412955-14-7P	412955-16-9P	412955-17-0P
	412955-18-1P	412955-19-2P	412955-20-5P	412955-21-6P	412955-22-7P
	412955-23-8P	412955-24-9P	412955-25-0P	412955-26-1P	412955-27-2P
	412955-28-3P	412955-29-4P	412955-30-7P	412955-31-8P	412955-32-9P

412955-33-0P 412955-34-1P 412955-35-2P 412955-36-3P 412955-37-4P
 412955-38-5P 412955-39-6P 412955-40-9P 412955-41-0P 412955-42-1P
 412955-43-2P 412955-44-3P 412955-45-4P 412955-46-5P 412955-47-6P
 412955-48-7P 412955-49-8P 412955-50-1P 412955-51-2P 412955-52-3P
 412955-53-4P 412955-54-5P 412955-55-6P 412955-56-7P 412955-57-8P
 412955-58-9P 412955-59-0P 412955-60-3P 412955-61-4P 412955-62-5P
 412955-63-6P 412955-64-7P 412955-65-8P 412955-66-9P 412955-67-0P
 412955-68-1P 412955-69-2P 412955-70-5P 412955-71-6P 412955-72-7P
 412955-73-8P 412955-74-9P 412955-75-0P 412955-76-1P 412955-77-2P
 412955-78-3P 412955-79-4P 412955-80-7P 412955-81-8P 412955-82-9P
 412955-83-0P 412955-84-1P 412955-85-2P 412955-86-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of sulfoxide and bis-sulfoxide compds. as for
 cholesterol management and related uses)

IT 412934-88-4 412934-91-9 412935-66-1 412935-69-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of sulfoxide and bis-sulfoxide compds. as for
 cholesterol management and related uses)

L119 ANSWER 12 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:72048 HCAPLUS Full-text

DOCUMENT NUMBER: 136:118386

TITLE: Preparation of 1-aryl-4-haloalkyl-2(1H)-
 pyridones as herbicides

INVENTOR(S): Sagasser, Ingo; Menke, Olaf; Hamprecht, Gerhard; Puhl,
 Michael; Reinhard, Robert; Witschel, Matthias; Zagar,
 Cyrill; Walter, Helmut

PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 119 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006233	A1	20020124	WO 2001-EP8251	20010717 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2416192	A1	20030115	CA 2001-2416192	20010717 <--
EP 1301483	A1	20030416	EP 2001-956538	20010717 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004504300	T	20040212	JP 2002-512137	20010717 <--
US 2003216257	A1	20031120	US 2003-332860	20030114 <--
PRIORITY APPLN. INFO.:			DE 2000-10034838	A 20000718 <--
			WO 2001-EP8251	W 20010717 <--

OTHER SOURCE(S): MARPAT 136:118386

ED Entered STN: 25 Jan 2002

AB Title compds. [I; R1 = H, halo; R2, R7 = H, amino, alkyl; R3 = haloalkyl; R4 = H, halo; R5 = H, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy; A = O, S; X = bond, (substituted) CH2, OCH2, SCH2, CH2CH2, CH:CH, C.tplbond.C, CH:CHCH:CH; R6 = H, NO2, cyano, halo, halosulfonyl, OYR8, OCOYR8, N(YR8)(ZR9), N(YR8)SO2ZR9, etc.; Y, Z = bond, (substituted) CH2, CH2CH2; R8, R9 = H, haloalkyl, alkoxyalkyl, alkenyl, etc.; Q = N, CR10; R10 = H, OH, SH, NH2; XR6R10 = (substituted) (O-, S-, N-interrupted) (CH2)3, (CH2)4], were prepared. Thus, i-Pr 2-chloro-5-[2,6-dioxo-4-trifluoromethyl-3,6-dihydro-1(2H)-pyridinyl]-4-fluorobenzoate (preparation given) was refluxed with POCl3 to give 46% i-Pr 2-chloro-5-[2-chloro-6-oxo-4-trifluoromethyl-1(6H)-pyridinyl]-4-fluorobenzoate. I at 1000 ppm were said to show very good pre- and postemergent herbicidal activity for Callosobruchus chinensis, etc.

IC ICM C07D213-64

ICS C07D213-69; C07D413-04; C07D417-04; A01N043-76; A01N043-78; A01N043-40

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 5

ST arylhaloalkylpyridone prepn herbicide; defoliant

arylhaloalkylpyridone prepn; pyridone aryl haloalkyl

prepn herbicide

IT Defoliant

Herbicides

(preparation of (aryl)(haloalkyl)pyridones as herbicides)

IT 390412-38-1P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of (aryl)(haloalkyl)pyridones as herbicides)

IT 390412-37-0P 390412-39-2P 390412-40-5P 390412-41-6P 390412-42-7P
390412-43-8P 390412-44-9P 390412-45-0P 390412-46-1P 390412-47-2P
390412-48-3P 390412-49-4P 390412-50-7P 390412-51-8P 390412-52-9P
390412-53-0P 390412-54-1P 390412-55-2P 390412-56-3P 390412-57-4P
390412-58-5P 390412-59-6P 390412-60-9P 390412-61-0P 390412-62-1P
390412-63-2P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (aryl)(haloalkyl)pyridones as herbicides)

IT 107-19-7, 2-Propyn-1-ol 383-63-1, Ethyl trifluoroacetate 50650-59-4,
4-(Trifluoromethyl)-2-pyridone 86819-51-4 98349-22-5,
2,4,5-Trifluorobenzonitrile

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (aryl)(haloalkyl)pyridones as herbicides)

IT 390412-30-3P 390412-31-4P 390412-32-5P 390412-33-6P 390412-34-7P
390412-35-8P 390412-36-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (aryl)(haloalkyl)pyridones as herbicides)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 13 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:851140 HCAPLUS Full-text

DOCUMENT NUMBER: 136:5978

TITLE: Preparation of 3-arylisothiazoles as herbicides, desiccants, and defoliants.

INVENTOR(S): Sagasser, Ingo; Menke, Olaf; Rack, Michael; Hamprecht, Gerhard; Puhl, Michael; Reinhard, Robert; Witschel, Matthias; Zagar, Cyrill; Walter, Helmut; Westphalen, Karl-Otto

PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 141 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087863	A1	20011122	WO 2001-EP5457	20010514 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2408686	A1	20021112	CA 2001-2408686	20010514 <--
EP 1289970	A1	20030312	EP 2001-940469	20010514 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003533517	T	20031111	JP 2001-584259	20010514 <--
US 2004023807	A1	20040205	US 2002-276226	20021114 <--
PRIORITY APPLN. INFO.:			DE 2000-10023770	A 20000515 <--
			WO 2001-EP5457	W 20010514 <--

OTHER SOURCE(S): MARPAT 136:5978

ED Entered STN: 23 Nov 2001

AB Title compds. [I; X = bond, (substituted) CH₂, CH₂CH₂, CH:CH, C.tplbond.C, OCH₂, etc.; R₁ = haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, alkylsulfinyl, alkylsulfonyl, alkylsulfonyloxy, etc.; R₂ = H, halo, amino, cyano, NO₂, alkyl, haloalkyl; R₃ = H, halo; R₄ = H, cyano, NO₂, halo, alkyl, haloalkyl, alkoxy, haloalkoxy; R₅ = H, NO₂, cyano, halo, halosulfonyl, etc.; Q = N, CR₆; R₆ = H; R₄R₅X, R₆R₅X = (substituted) 3-4 membered chains containing C and 1-3 heteroatoms], were prepared Thus, 3-(4-chloro-2-fluoro-5-hydroxyphenyl)-4-chloro-5-trifluoromethylthiazole (preparation given) reacted with Me (S)-2-chloropropionate to give Me (R)-2-[2-chloro-4-fluoro-5-(4-chloro-5-trifluoromethylisothiazol-3-yl)phenoxy]propionate. The latter at 15.6 g/ha showed very good herbicidal activity against weeds, including velvetleaf.

IC ICM C07D275-02

ICS C07D417-04; A01N043-80

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 5

ST arylisothiazole prepn herbicide desiccant defoliant; thiazole

aryl prepn herbicide desiccant defoliant

IT Defoliant

Desiccants, plant

Herbicides

(preparation of arylisothiazoles as herbicides)

IT 374780-00-4P 374780-01-5P 374780-02-6P 374780-03-7P 374780-04-8P

374780-05-9P 374780-06-0P 374780-07-1P 374780-08-2P 374780-09-3P

374780-10-6P 374780-11-7P 374780-12-8P 374780-13-9P 374780-14-0P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN

(Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of arylisothiazoles as herbicides)

IT 96-32-2, Methyl bromoacetate 106-96-7, Propargyl bromide 123-62-6,

Propionic anhydride 2365-48-2, Methyl thioglycolate 4023-34-1,
Cyclopropanecarbonyl chloride 5445-17-0, Methyl 2-bromopropionate
6306-60-1, 2,4-Dichlorobenzeneacetonitrile 73246-45-4, Methyl
(S)-2-chloropropionate 82424-97-3 146447-10-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of arylisothiazoles as herbicides)

IT 374780-15-1P 374780-16-2P 374780-17-3P 374780-18-4P 374780-19-5P
374780-20-8P 374780-21-9P 374780-22-0P 374780-23-1P 374780-24-2P
374780-25-3P 374780-26-4P 374780-27-5P 374780-28-6P 374780-29-7P
374780-31-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of arylisothiazoles as herbicides)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 14 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:851133 HCAPLUS Full-text

DOCUMENT NUMBER: 135:371736

TITLE: Preparation of 3-(4,5-dihydroisoxazol-5-
yl)benzoylcyclohexenones as herbicides

INVENTOR(S): Baumann; Ernst; Von Deyn, Wolfgang; Kudis, Steffen;
Langemann, Klaus; Mayer, Guido; Misslitz, Ulf;
Neidlein, Ulf; Walter, Helmut; Zagar, Cyrill;
Witschel, Matthias

PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087856	A1	20011122	WO 2001-EP5390	20010511 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2408680	A1	20021112	CA 2001-2408680	20010511 <--
EP 1284969	A1	20030226	EP 2001-936353	20010511 <--
EP 1284969	B1	20040818		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003533516	T	20031111	JP 2001-584252	20010511 <--
AT 273965	T	20040915	AT 2001-936353	20010511 <--
US 2003199699	A1	20031023	US 2002-276225	20021114 <--
US 6645919	B2	20031111		

PRIORITY APPLN. INFO.: DE 2000-10024107 A 20000518 <--
WO 2001-EP5390 W 20010511 <--

OTHER SOURCE(S): MARPAT 135:371736

ED Entered STN: 23 Nov 2001

AB Title compds. [I; R1, R2 = H, NO2, halo, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, etc.; R3 = H, halo, alkyl; R4 = H,

alkyl; R5, R6 = H, halo, cyano, NO₂, alkyl, alkoxyalkyl, dialkoxyalkyl, etc.; R5R6 = (substituted) (O-, N-interrupted) alkylene; R7 = halo, cyano, OH, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, etc.; R12 = OH, SH, halo, etc.; R13, R17 = H, alkyl, alkylthio, alkoxycarbonyl, etc.; R14, R16, R18 = H, alkyl, etc.; R15 = H, OH, halo, alkyl, haloalkyl, etc.], were prepared Thus, a solution of 1-hydroxycyclohex-1-en-3-one and Et₃N in MeCN at 0-5° was treated dropwise with 2-methyl-3-(3-methyl-4,5-dihydroisoxazol-5-yl)-4-methylsulfonylbenzoyl chloride in MeCN followed by stirring for 3 h at room temperature and addition of Et₃N and Me₃SiCN to give after 12 h stirring 43% 2-[2-methyl-3-(3-methyl-4,5-dihydroisoxazol-5-yl)-4-methylsulfonylbenzoyl]-3-hydroxycyclohex-2-en-1-one. Several I at 125 or at 62.5 ppm were said to show very good pre- and postemergent herbicidal activity on *Chenopodium album*, etc.

IC ICM C07D261-04

ICS A01N043-80

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 5

ST isoxazolybenzoylcyclohexenone prepn herbicide; cyclohexenone benzoyl dihydroisoxazolyl prepn herbicide

IT Herbicides

(preparation of dihydroisoxazolybenzoylcyclohexenones as herbicides)

IT	374076-76-3P	374076-77-4P	374076-78-5P	374076-79-6P	374076-80-9P
	374076-81-0P	374076-82-1P	374076-83-2P	374076-84-3P	374076-85-4P
	374076-86-5P	374076-87-6P	374076-88-7P	374076-89-8P	374076-90-1P
	374076-91-2P	374076-92-3P	374076-93-4P	374076-94-5P	374076-95-6P
	374076-96-7P	374076-97-8P	374076-98-9P	374076-99-0P	374077-00-6P
	374077-01-7P	374077-02-8P	374077-03-9P	374077-04-0P	

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dihydroisoxazolybenzoylcyclohexenones as herbicides)

IT 79-24-3, Nitroethane 637-91-2 14337-43-0 30182-67-3, 3-Hydroxycyclohex-2-en-1-one 345907-77-9 345907-79-1 345907-84-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of dihydroisoxazolybenzoylcyclohexenones as herbicides)

IT	345907-76-8P	345907-78-0P	345907-80-4P	345907-81-5P	345907-82-6P
	345907-85-9P	345907-86-0P	345907-87-1P	345907-88-2P	345907-89-3P
	353237-66-8P				

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dihydroisoxazolybenzoylcyclohexenones as herbicides)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 15 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:228868 HCAPLUS Full-text

DOCUMENT NUMBER: 134:252356

TITLE: Preparation of 2-(arylamino)-4-quinazolinols as inhibitors of cleavage of protein substrates by caspase-3

INVENTOR(S): Jacobs, Robert Toms; Folmer, James; Simpson, Thomas Richard; Chaudhari, Bipinchandra; Frazee, William Jackson; Davenport, Timothy Wayne

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021598	A1	20010329	WO 2000-GB3555	20000918 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1218358	A1	20020703	EP 2000-958907	20000918 <--
EP 1218358	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509501	T	20030311	JP 2001-524977	20000918 <--
AT 339406	T	20061015	AT 2000-958907	20000918 <--
US 6399603	B1	20020604	US 2000-668322	20000922 <--
PRIORITY APPLN. INFO.:			US 1999-155623P	P 19990923 <--
			WO 2000-GB3555	W 20000918 <--

OTHER SOURCE(S): MARPAT 134:252356

ED Entered STN: 30 Mar 2001

AB I (e.g. [2-[(3,4-dichlorophenyl)amino]-4-hydroxy-6-nitroquinazolin-8-yl]-N-[(4-fluorophenyl)methyl]carboxamide) or a pharmaceutically -acceptable salt thereof and methods of using such compds. for the treatment of various diseases and pharmaceutical compns. comprising such compds. are claimed. In I, R2 is H, acetyl or (C1-C5)alkyl. R4 is H, acetyl or (C1-C5)alkyl. R5, R6 and R7 are independently H, halogen, (C1-C2)alkyl, halo(C1-C2)alkyl, nitro and cyano. R8 is H, Ph, (C1-C6)alkyl, Ri, heterocycle, substituted heterocycle, - (CH2)mC(O)N-[(CH2)pRg]Rb, -(CH2)mN[(CH2)pRg]Rb, -CH:CHRC, halogen, - (CH2)mC(O)(CH2)mRo, -C(O)Rp, -(CH2)mC(O)O[(CH2)pRg], -(CH2)mN[(CH2)pRg]C(O)Rb, -(CH2)mOC(O)[(CH2)pRg], -CHORDRe, -CH2XRf, -S(O)2N[(CH2)pRg]Rb, -N[(CH2)pRg]S(O)2Rb, -S(O)2N[(CH2)pRg]Rb, -C(O)H, allyl and 4-hydroxybut-1-en-4-yl. R3', R4' and R5' are independently H, halogen, (C1-C4)alkyl, (C1-C4)alkoxy and halo(C1-C4)alkyl; wherein at least one of R5, R6, R7, R8, R3' and R5' is not H; and R4' is not equal to R7. Rb is H, (C1-C4)alkyl or substituted (C1-C4)alkyl. Rc is H, Ph, Ri, heterocycle, substituted heterocycle, -CO2Rb, -C(O)NRbRb, -S(O)n-Rf, 2-hydroxyisopropyl and cyano. Rd and Re are independently (C1-C4)alkyl; or Rd and Re together are -CH2CH2- or -CH2CH2CH2-. Rf is (C1-C4)alkyl, vinyl, -CH2CO2Rb, Ph or benzyl. Rg is (C1-C10)alkyl, substituted (C1-C10)alkyl, Ph, Ri, heterocycle, substituted heterocycle, -ORb, -NRbRb, -NRjRo, -N(Rj)SO2Rj, -CO2Rb, -C(O)NRjRj, -SO2phenyl and 2-oxopyrrolid-1-yl; or Rg and Rb together form -CH2CH2N(Rj)CH2CH2-, -(CH2)4-, -CH(Rh)CH2CH2CH2-, or -CH2CH2OCH2CH2-. Rh is -CO2Rf or -CH2O-Ph. Ri is Ph, containing 1-3 substituents selected from halogen, (C1-C6)alkyl, -ORj, -O(substituted phenyl)-NRjRj, halo(C1-C6)alkyl, halo(C1-C4)alkoxy, nitro, -C(O)Rj, -C(O)(substituted phenyl), -(CH2)mC(O)NRjRk, -(CH2)mC(O)N(Rj)SO2[(C1-C6)alkyl], -(CH2)mC(O)NRj(substituted phenyl), -(CH2)nCO2Rj, -OC(O)Rj, -N(Rj)C(O)Rj, -NRjC(O)halo(C1-C4)alkoxy, -C(O)NRjRj, -NRjS(O)2(C1-C4)alkyl, -SON(C1-C6)alkyl, -SON(halogen), -Som(CH2)nphenyl, -SO2NRjRj, -SO2NRjRk, -SO2NRj(substituted (C1-C6)alkyl), -SO2(CH2)nRo, -SO2N(Rj)(CH2)nRo, -SON(halo(C1-C3)alkyl), -SON(pyrrolidin-1-yl substituted in the 2 position by Rn), -CN, -SCN, Ph, heterocycle and benzyl. Rj is H or (C1-C6)alkyl. Rk is -(CH2)nCH2OCH2Rb, -

C(O)NRjRj or -C(O)Rj. Rm is heterocycle, containing one or two substituents selected from halogen, (C1-C6)alkyl, -ORj, -O(substituted phenyl)-NRjRj, halo(C1-C6)alkyl, halo(C1-C4)alkoxy, nitro, -C(O)Rj, -C(O)(substituted phenyl), -(CH2)mC(O)NRjRk, -(CH2)mC(O)N(Rj)SO2[(C1-C6)alkyl], -(CH2)mC(O)NRj(substituted phenyl), -(CH2)nCO2Rj, -OC(O)Rj, -N(Ri)C(O)Rj, -NRjC(O)-halo(C1-C4)alkoxy, -C(O)NRjRj, -NRjS(O)2(C1-C4)alkyl, -SOn(C1-C6)alkyl, -SOn(halogen), -SOn(CH2)nphenyl, -SO2NRjRj, -SO2NRjRk, -SO2NRj(substituted (C1-C6)alkyl), -SO2(CH2)nRo, -SO2N(Rj)(CH2)nRo, -SOn(halo(C1-C3)alkyl), -SOn(pyrrolidin-1-yl substituted in the 2 position by Rn), -CN, -SCN, Ph, heterocycle and benzyl. Rn is -C(O)Rj, -CH2ORj or -C(O)NRjRj. Ro is Ph, substituted Ph, heterocycle or substituted heterocycle. Rp is a heterocycle containing one or two substituents selected from substituted Ph, heterocycle, Ph, benzyl, -SOnRo or SO2NRjRj. M is 0-3; n is 0-2; p is 0-7; X is S, O or N. A method is claimed of treating a mammalian disease selected from cell apoptosis, immune deficiency syndromes, autoimmune diseases, pathogenic infections, cardiovascular and neurol. injury, alopecia, aging, cancer, Parkinson's disease, Alzheimer's disease, Huntington's disease, acute and chronic neurodegenerative disorders, stroke, vascular dementia, head trauma, ALS, neuromuscular disease, myocardial ischemia, cardiomyopathy, macular degeneration, osteoarthritis, diabetes, acute liver failure and spinal cord injury. Although caspase-3 inhibition and apoptosis assay methods are described, quant. assay results are not given. Although the methods of preparation are not claimed, 17 example prepn. are included.

- IC ICM C07D239-95
- ICS C07D405-06; C07D401-06; C07D403-06; A61K031-517; A61P035-00;
C07D401-12; C07D403-12; C07D417-06; C07D405-04
- CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
- ST quinazolinol arylamino deriv prepn caspase 3 inhibitor;
apoptosis treatment arylaminoquinazolinol deriv
- IT Nervous system
(Huntington's chorea; preparation of 2-(arylamino)-4-quinazolinols
for treatment of)
- IT Nervous system
(amyotrophic lateral sclerosis; preparation of
2-(arylamino)-4-quinazolinols for treatment of)
- IT Heart, disease
(cardiomyopathy; preparation of 2-(arylamino)-4-quinazolinols for
treatment of)
- IT Nervous system
(degeneration; preparation of 2-(arylamino)-4-quinazolinols for
treatment of)
- IT Mental disorder
(dementia, vascular; preparation of 2-(arylamino)-4-
quinazolinols for treatment of)
- IT Nervous system
(disease; preparation of 2-(arylamino)-4-quinazolinols
for treatment of)
- IT Liver, disease
(failure; preparation of 2-(arylamino)-4-quinazolinols for
treatment of)
- IT Drug delivery systems
(for 2-(arylamino)-4-quinazolinols as caspase-3 inhibitors)
- IT Spinal cord
(injury; preparation of 2-(arylamino)-4-quinazolinols for
treatment of)
- IT Heart, disease
(ischemia; preparation of 2-(arylamino)-4-quinazolinols for
treatment of)
- IT Eye, disease

- (macula, degeneration; preparation of 2-(arylamino)-4-quinazolinols for treatment of)
- IT Anti-Alzheimer's agents
 Anti-infective agents
 Antiarthritics
 Antidiabetic agents
 Antiparkinsonian agents
Antitumor agents
Cardiovascular agents
 Nervous system agents
 (preparation of 2-(arylamino)-4-quinazolinols as)
- IT Aging, animal
 Alopecia
 Apoptosis
 Autoimmune disease
 Immunodeficiency
 Neuromuscular diseases
 (preparation of 2-(arylamino)-4-quinazolinols for treatment of)
- IT Brain, disease
 (stroke; preparation of 2-(arylamino)-4-quinazolinols for treatment of)
- IT Head
 (trauma; preparation of 2-(arylamino)-4-quinazolinols for treatment of)
- IT 1640-60-4P, 6-Chloro-2,4-dihydroxyquinazoline 17459-03-9P,
 N,N-Dimethyl-4-nitrobenzenesulfonamide 20780-74-9P, 7-Bromoindoline-2,3-
 dione 39576-83-5P, 2,4-Dichloro-8-methylquinazoline 67449-23-4P,
 2,4-Dihydroxy-8-methylquinazoline 101080-38-0P, N-(2-Bromophenyl)-2-
 (hydroxyimino)acetamide 104670-74-8P, Methyl 2-amino-3-bromobenzoate
 192218-38-5P, 8-(Bromomethyl)-2,4-dichloroquinazoline 309295-31-6P,
 8-Bromo-6-nitroquinazoline-2,4-diol 331646-87-8P, 2-[(3,4-
 Dichlorophenyl)amino]-4-hydroxy-6-nitroquinazoline-8-carboxylic acid
 331646-89-0P, 2,4-Dihydroxy-6-nitroquinazoline-8-carboxylic acid
 331646-91-4P, Methyl 2,4-dihydroxy-6-nitroquinazoline-8-carboxylate
 331646-93-6P, Methyl 2,4-dichloro-6-nitroquinazoline-8-carboxylate
 331646-94-7P, Methyl 2-chloro-4-hydroxy-6-nitroquinazoline-8-carboxylate
 331646-98-1P 331646-99-2P, 8-Bromoquinazoline-2,4-diol 331647-00-8P,
 8-Bromo-2,4-dichloro-6-nitroquinazoline 331647-05-3P,
 8-Bromo-2,4-dichloroquinazoline 331647-09-7P, 8-Bromo-2-chloro-6-
 methylquinazolin-4-ol 331647-10-0P, 8-Bromo-6-methylquinazoline-2,4-diol
 331647-14-4P, 2-Amino-5-fluoro-3-iodobenzoic acid 331647-15-5P,
 2,4-Dihydroxy-6-fluoro-8-iodoquinazoline 331647-16-6P,
 2,4-Dichloro-6-fluoro-8-iodoquinazoline 331647-17-7P,
 2-Chloro-6-fluoro-8-iodoquinazolin-4-ol 331647-21-3P,
 2-Chloro-8-(1,3-dioxolan-2-yl)-4-hydroxy-6-nitroquinazoline
 331647-22-4P, 2,4-Dichloro-6-nitroquinazoline-8-carboxaldehyde
 331647-23-5P, 8-(1,3-Dioxolan-2-yl)-6-nitroquinazoline-2,4-diol
 331647-26-8P, 2,6-Dichloro-8-[(N-benzyl-N-methylamino)sulfonyl]quinazolin-
 4-ol 331647-27-9P, 6-Chloro-8-chlorosulfonyl-2,4-dihydroxyquinazoline
 331647-28-0P, 6-Chloro-8-[(N-methyl-N-benzylamino)sulfonyl]quinazoline-2,4-
 diol 331647-29-1P, N-Methyl-N-benzyl(2,4,6-trichloroquinazolin-8-
 yl)sulfonamide 331647-32-6P, 3-[2-(3,4-Dichlorophenylamino)-4-hydroxy-6-
 nitroquinazolin-8-yl]propionic acid 331647-33-7P, 3-(2,4-
 Dihydroxyquinazolin-8-yl)acrylic acid methyl ester 331647-34-8P,
 3-(2,4-Dihydroxyquinazolin-8-yl)propionic acid methyl ester
 331647-35-9P, 3-(2,4-Dihydroxy-6-nitroquinazolin-8-yl)propionic acid
 methyl ester 331647-36-0P, 3-(2-Chloro-4-hydroxy-6-nitroquinazolin-8-
 yl)propionic acid methyl ester 331647-37-1P, N-(4-Fluorophenyl)-2-chloro-
 4-hydroxy-6-nitroquinazoline-8-carboxamide 331647-38-2P,
 2,4-Dihydroxyquinazoline-8-carboxylic acid methyl ester 331647-41-7P,

N-(4-Fluorophenyl)-2,4-dihydroxy-6-nitroquinazoline-8-carboxamide
 331647-45-1P, 2-(4-Fluorophenyl)amino-4-hydroxy-6-nitroquinazoline-8-carboxylic acid 331647-46-2P, Methyl 2-(4-fluorophenyl)amino-4-hydroxy-6-nitroquinazoline-8-carboxylate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 2-(arylamino)-4-quinazolinols as inhibitors of cleavage of protein substrates by caspase-3)

IT 331642-39-8P 331642-40-1P 331646-83-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 2-(arylamino)-4-quinazolinols as inhibitors of cleavage of protein substrates by caspase-3)

IT 331640-99-4P, 6-Bromo-2-(3-chloro-4-methylphenylamino)-4-quinazolinol
 331641-00-0P, 8-Bromo-2-(3,4-dichlorophenylamino)-6-methyl-5-nitro-4-quinazolinol 331641-01-1P, 2-(3,4-Dichlorophenylamino)-8-(2-(1H-imidazol-2-yl)vinyl)-6-methyl-5-nitro-4-quinazolinol 331641-02-2P, 2-(3,4-Dichlorophenylamino)-6-methyl-8-(2-(4-methylthiazol-5-yl)vinyl)-5-nitro-4-quinazolinol 331641-03-3P, 2-(3,4-Dichlorophenylamino)-6-methyl-5-nitro-8-(2-(4-pyridinyl)vinyl)-4-quinazolinol 331641-04-4P, 8-Bromo-2-(3,4-dichlorophenylamino)-6-methyl-4-quinazolinol 331641-05-5P, 8-(2-(3-Chlorophenyl)vinyl)-2-(3,4-dichlorophenylamino)-6-methyl-4-quinazolinol 331641-06-6P, 2-(3,4-Dichlorophenylamino)-6-methyl-8-(2-(4-pyridinyl)vinyl)-4-quinazolinol 331641-07-7P, N-Benzyl-N-methyl-6-chloro-2-(3,4-dichlorophenylamino)-4-hydroxy-8-quinazolinecarboxamide 331641-08-8P, N-(4-(Fluorosulfonyl)phenyl)-6-chloro-2-(3,4-dichlorophenylamino)-4-hydroxy-8-quinazolinecarboxamide 331641-09-9P, N-(3-Phenylpropyl)-6-chloro-2-(3,4-dichlorophenylamino)-4-hydroxy-8-quinazolinecarboxamide 331641-10-2P, N-(4-Phenylbutyl)-6-chloro-2-(3,4-dichlorophenylamino)-4-hydroxy-8-quinazolinecarboxamide 331641-11-3P, N-(3-Carboxycyclohexyl)-6-chloro-2-(3,4-dichlorophenylamino)-4-hydroxy-8-quinazolinecarboxamide 331641-12-4P, N-Isopropyl-6-chloro-2-(3,4-dichlorophenylamino)-4-hydroxy-8-quinazolinecarboxamide 331641-13-5P, N-(2,4-Dichlorobenzyl)-6-chloro-2-(3,4-dichlorophenylamino)-4-hydroxy-8-quinazolinecarboxamide 331641-14-6P, N-(2-(Trifluoromethyl)benzyl)-6-chloro-2-(3,4-dichlorophenylamino)-4-hydroxy-8-quinazolinecarboxamide 331641-15-7P, N-(2-Methylbenzyl)-6-chloro-2-(3,4-dichlorophenylamino)-4-hydroxy-8-quinazolinecarboxamide 331641-16-8P, N-(2-Chlorobenzyl)-6-chloro-2-(3,4-dichlorophenylamino)-4-hydroxy-8-quinazolinecarboxamide 331641-17-9P, N-(2-Fluorobenzyl)-6-chloro-2-(3,4-dichlorophenylamino)-4-hydroxy-8-quinazolinecarboxamide 331641-18-0P
 331641-19-1P 331641-20-4P 331641-21-5P 331641-22-6P 331641-23-7P
 331641-24-8P 331641-25-9P 331641-26-0P 331641-27-1P 331641-28-2P
 331641-29-3P 331641-30-6P 331641-31-7P 331641-32-8P 331641-33-9P
 331641-34-0P 331641-36-2P 331641-38-4P 331641-40-8P 331641-42-0P
 331641-44-2P 331641-46-4P 331641-48-6P 331641-50-0P 331641-52-2P
 331641-54-4P 331641-56-6P 331641-58-8P 331641-60-2P 331641-62-4P
 331641-65-7P 331641-67-9P 331641-69-1P 331641-71-5P 331641-73-7P
 331641-75-9P 331641-77-1P 331641-79-3P 331641-81-7P 331641-83-9P
 331641-85-1P 331641-87-3P 331641-89-5P 331641-91-9P 331641-93-1P
 331641-95-3P 331641-97-5P 331641-98-6P 331642-00-3P 331642-02-5P
 331642-04-7P 331642-06-9P 331642-08-1P 331642-10-5P 331642-12-7P
 331642-14-9P 331642-16-1P 331642-18-3P 331642-20-7P 331642-22-9P
 331642-24-1P 331642-26-3P 331642-28-5P 331642-30-9P 331642-32-1P
 331642-34-3P 331642-35-4P 331642-36-5P 331642-37-6P 331642-38-7P
 331642-41-2P 331642-42-3P 331642-43-4P 331642-44-5P 331642-45-6P
 331642-46-7P 331642-47-8P 331642-48-9P 331642-49-0P 331642-50-3P
 331642-51-4P 331642-52-5P 331642-53-6P 331642-54-7P 331642-55-8P

331642-56-9P	331642-57-0P	331642-58-1P	331642-59-2P	331642-60-5P
331642-61-6P	331642-62-7P	331642-63-8P	331642-64-9P	331642-65-0P
331642-66-1P	331642-67-2P	331642-68-3P	331642-69-4P	331642-70-7P
331642-71-8P	331642-72-9P	331642-73-0P	331642-74-1P	331642-75-2P
331642-76-3P	331642-77-4P	331642-78-5P	331642-80-9P	331642-82-1P
331642-86-5P	331642-87-6P	331642-90-1P	331642-93-4P	331642-96-7P
331642-99-0P	331643-02-8P	331643-05-1P	331643-07-3P	331643-09-5P
331643-10-8P	331643-12-0P	331643-14-2P	331643-15-3P	331643-17-5P
331643-19-7P	331643-20-0P	331643-21-1P	331643-22-2P	331643-23-3P
331643-24-4P	331643-25-5P	331643-26-6P	331643-27-7P	331643-28-8P
331643-29-9P	331643-30-2P	331643-31-3P	331643-32-4P	331643-33-5P
331643-34-6P	331643-35-7P	331643-36-8P	331643-37-9P	331643-38-0P
331643-39-1P	331643-40-4P	331643-41-5P	331643-42-6P	331643-43-7P
331643-44-8P	331643-45-9P	331643-46-0P	331643-47-1P	331643-48-2P
331643-49-3P	331643-50-6P	331643-51-7P	331643-52-8P	331643-53-9P
331643-54-0P	331643-55-1P	331643-56-2P	331643-57-3P	331643-58-4P
331643-59-5P	331643-60-8P	331643-61-9P	331643-62-0P	331643-63-1P
331643-64-2P	331643-65-3P	331643-66-4P	331643-67-5P	331643-68-6P
331643-69-7P	331643-70-0P	331643-71-1P	331643-72-2P	331643-73-3P
331643-74-4P	331643-75-5P	331643-76-6P	331643-77-7P	331643-78-8P
331643-79-9P	331643-80-2P	331643-81-3P	331643-82-4P	331643-83-5P
331643-84-6P	331643-85-7P	331643-86-8P	331643-87-9P	331643-88-0P
331643-89-1P	331643-90-4P	331643-91-5P	331643-92-6P	331643-93-7P
331643-94-8P	331643-95-9P	331643-96-0P	331643-97-1P	331643-98-2P
331643-99-3P	331644-01-0P	331644-03-2P	331644-06-5P	331644-08-7P
331644-10-1P	331644-12-3P	331644-14-5P		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(arylamino)-4-quinazolinols as inhibitors of cleavage of protein substrates by caspase-3)

IT	331644-15-6P	331644-16-7P	331644-17-8P	331644-18-9P	331644-19-0P
	331644-20-3P	331644-21-4P	331644-22-5P	331644-23-6P	331644-24-7P
	331644-25-8P	331644-26-9P	331644-27-0P	331644-28-1P	331644-29-2P
	331644-30-5P	331644-31-6P	331644-32-7P	331644-33-8P	331644-34-9P
	331644-35-0P	331644-36-1P	331644-37-2P	331644-38-3P	331644-39-4P
	331644-40-7P	331644-41-8P	331644-42-9P	331644-43-0P	331644-44-1P
	331644-45-2P	331644-46-3P	331644-47-4P	331644-48-5P	331644-49-6P
	331644-50-9P	331644-51-0P	331644-52-1P	331644-53-2P	331644-54-3P
	331644-55-4P	331644-56-5P	331644-57-6P	331644-58-7P	331644-59-8P
	331644-60-1P	331644-61-2P	331644-62-3P	331644-63-4P	331644-64-5P
	331644-65-6P	331644-67-8P	331644-69-0P	331644-71-4P	331644-72-5P
	331644-74-7P	331644-77-0P	331644-79-2P	331644-82-7P	331644-84-9P
	331644-86-1P	331644-89-4P	331644-90-7P	331644-92-9P	331644-94-1P
	331644-96-3P	331644-97-4P	331644-98-5P	331645-01-3P	331645-02-4P
	331645-03-5P	331645-04-6P	331645-05-7P	331645-06-8P	331645-07-9P
	331645-08-0P	331645-09-1P	331645-10-4P	331645-11-5P	331645-12-6P
	331645-13-7P	331645-14-8P	331645-15-9P	331645-16-0P	331645-17-1P
	331645-18-2P	331645-19-3P	331645-20-6P	331645-21-7P	331645-22-8P
	331645-23-9P	331645-24-0P	331645-25-1P	331645-26-2P	331645-27-3P
	331645-28-4P	331645-29-5P	331645-30-8P	331645-31-9P	331645-32-0P
	331645-33-1P	331645-34-2P	331645-35-3P	331645-36-4P	331645-37-5P
	331645-38-6P	331645-39-7P	331645-40-0P	331645-41-1P	331645-42-2P
	331645-43-3P	331645-44-4P	331645-45-5P	331645-46-6P	331645-47-7P
	331645-48-8P	331645-49-9P	331645-50-2P	331645-51-3P	331645-52-4P
	331645-53-5P	331645-54-6P	331645-55-7P	331645-56-8P	331645-57-9P
	331645-58-0P	331645-59-1P	331645-60-4P	331645-61-5P	331645-62-6P
	331645-63-7P	331645-64-8P	331645-65-9P	331645-66-0P	331645-67-1P
	331645-68-2P	331645-69-3P	331645-70-6P	331645-71-7P	331645-72-8P
	331645-73-9P	331645-74-0P	331645-75-1P	331645-76-2P	331645-77-3P

331645-78-4P	331645-79-5P	331645-80-8P	331645-81-9P	331645-82-0P
331645-83-1P	331645-84-2P	331645-85-3P	331645-86-4P	331645-87-5P
331645-88-6P	331645-89-7P	331645-90-0P	331645-91-1P	331645-92-2P
331645-93-3P	331645-94-4P	331645-95-5P	331645-96-6P	331645-97-7P
331645-98-8P	331645-99-9P	331646-00-5P	331646-01-6P	331646-02-7P
331646-03-8P	331646-04-9P	331646-05-0P	331646-06-1P	331646-07-2P
331646-08-3P	331646-09-4P	331646-10-7P	331646-11-8P	331646-12-9P
331646-13-0P	331646-14-1P	331646-15-2P	331646-16-3P	331646-17-4P
331646-18-5P	331646-19-6P	331646-20-9P	331646-21-0P	331646-22-1P
331646-23-2P	331646-24-3P	331646-25-4P	331646-26-5P	331646-27-6P
331646-28-7P	331646-29-8P	331646-30-1P	331646-31-2P	331646-32-3P
331646-33-4P	331646-34-5P	331646-35-6P	331646-36-7P	331646-37-8P
331646-38-9P	331646-39-0P	331646-40-3P	331646-41-4P	331646-42-5P
331646-43-6P	331646-44-7P	331646-45-8P	331646-46-9P	331646-47-0P
331646-48-1P	331646-49-2P	331646-50-5P	331646-51-6P	331646-52-7P
331646-53-8P	331646-54-9P	331646-55-0P	331646-56-1P	331646-57-2P
331646-58-3P	331646-59-4P	331646-60-7P	331646-61-8P	331646-62-9P
331646-63-0P	331646-64-1P	331646-65-2P		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(arylamino)-4-quinazolinols as inhibitors of cleavage of protein substrates by caspase-3)

IT 331646-66-3P 331646-67-4P 331646-68-5P 331646-69-6P 331646-70-9P
 331646-71-0P 331646-72-1P 331646-73-2P 331646-74-3P 331646-75-4P
 331646-76-5P 331646-78-7P 331646-80-1P 331646-81-2P 331646-85-6P
 331647-01-9P, 4-[(1E)-2-[2-[(3,4-Dichlorophenyl)amino]-4-hydroxy-6-nitroquinazolin-8-yl]vinyl]benzoic acid 331647-02-0P,
 8-[(1E)-2-(2-Pyridyl)vinyl]-2-[(3,4-dichlorophenyl)amino]-6-nitroquinazolin-4-ol 331647-06-4P, 4-[(1E)-2-[2-[(3,4-Dichlorophenyl)amino]-4-hydroxyquinazolin-8-yl]vinyl]phenyl acetate
 331647-11-1P, 8-[(1E)-2-(3-Chlorophenyl)vinyl]-2-[(3,4-dichlorophenyl)amino]-6-methylquinazolin-4-ol 331647-12-2P,
 8-[(1E)-2-(4-Pyridyl)vinyl]-2-[(3,4-dichlorophenyl)amino]-6-methyl-5-nitroquinazolin-4-ol 331647-13-3P, 8-[(1E)-2-(4-Methylphenyl)vinyl]-2-[(3,4-dichlorophenyl)amino]-6-fluoroquinazolin-4-ol 331647-18-8P,
 8-[(1E)-2-(2-Methylphenyl)vinyl]-2-[(3,4-dichlorophenyl)amino]-6-fluoroquinazolin-4-ol 331647-19-9P, 8-[(1E)-2-(Pyrid-4-yl)vinyl]-2-[(3,4-dichlorophenyl)amino]-6-fluoroquinazolin-4-ol 331647-20-2P,
 4-[(1E)-2-[2-[(3,4-Dichlorophenyl)amino]-6-fluoro-4-hydroxyquinazolin-8-yl]vinyl]phenyl acetate 331647-24-6P, N,N-Dimethyl-(2E)-3-[2-[(3,4-dichlorophenyl)amino]-4-hydroxy-6-nitroquinazolin-8-yl]prop-2-enamide
 331647-30-4P, N-(4-Chlorophenyl)-3-[2-[(3,4-dichlorophenyl)amino]-4-hydroxy-6-nitroquinazolin-8-yl]propionamide 331647-39-3P 331647-42-8P,
 N-(4-Fluorophenyl)-2-[(3,4-dichlorophenyl)-N-methylamino]-4-hydroxy-6-nitroquinazolin-8-carboxamide 331647-48-4P 331647-50-8P
 331647-51-9P 331647-53-1P 331664-95-0P 331681-70-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(arylamino)-4-quinazolinols as inhibitors of cleavage of protein substrates by caspase-3)

IT 169592-56-7, Caspase-3
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(preparation of 2-(arylamino)-4-quinazolinols as inhibitors of cleavage of protein substrates by caspase-3)

IT 77-48-5, 1,3-Dibromo-5,5-dimethylhydantoin 95-76-1, 3,4-Dichloroaniline
 96-33-3, Methyl acrylate 98-74-8, 4-Nitrobenzenesulfonyl chloride
 100-43-6, 4-Vinylpyridine 103-67-3, N-Benzylmethylamine 104-86-9,

4-Chlorobenzylamine 140-75-0, 4-Fluorobenzylamine 371-40-4,
 4-Fluoroaniline 446-08-2, 2-Amino-5-fluorobenzoic acid 455-14-1,
 4-Trifluoromethylaniline 615-36-1, 2-Bromoaniline 622-97-9,
 4-Methylstyrene 635-21-2, 2-Amino-5-chlorobenzoic acid 1075-49-6,
 4-Vinylbenzoic acid 1709-59-7, 4-(N,N-Dimethylsulfamoyl)aniline
 2039-85-2, 3-Chlorostyrene 2357-47-3, 4-Fluoro-3-
 (trifluoromethyl)aniline 2628-16-2, 4-Acetoxystyrene 4389-45-1,
 2-Amino-3-methylbenzoic acid 20173-24-4, 3-(2-Aminoethyl)pyridine
 40750-59-2, N-Methyl-3,4-dichloroaniline 206551-32-8, Methyl
 2-amino-3-bromo-5-methylbenzoate 331646-97-0, 8-Bromo-2-chloro-6-
 nitroquinazolin-4-ol 331647-04-2, 8-Bromo-2-chloroquinazolin-4-ol
 RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of 2-(arylamino)-4-quinazolinols

as inhibitors of cleavage of protein substrates by caspase-3)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 16 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:573773 HCAPLUS Full-text

DOCUMENT NUMBER: 133:177025

TITLE: Preparation of arylacrylamides and related
 compounds as inhibitors of Factor Xa.

INVENTOR(S): Song, Yonghong; Zhu, Bing-yan; Scarborough, Robert M.;
 Clizbe, Lane; Jia, Zhaozhong Jon; Su, Ting; Teng,
 Willy

PATENT ASSIGNEE(S): Cor Therapeutics Inc., USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047554	A2	20000817	WO 2000-US3405	20000211 <--
WO 2000047554	A3	20010809		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2361428	A1	20000817	CA 2000-2361428	20000211 <--
EP 1159264	A2	20011205	EP 2000-917623	20000211 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6399627	B1	20020604	US 2000-501371	20000211 <--
JP 2002536432	T	20021029	JP 2000-598475	20000211 <--
US 6545054	B1	20030408	US 2000-501370	20000211 <--
PRIORITY APPLN. INFO.:			US 1999-119640P	P 19990211 <--
			WO 2000-US3405	W 20000211 <--

OTHER SOURCE(S): MARPAT 133:177025

ED Entered STN: 18 Aug 2000

AB ABDECG1:CG2KL [A = (substituted) Ph, naphthyl, (aromatic) heterocyclyl; B = bond, CO, NR3, CR3aR3b, CONR3, SO2, O, SO2NR, NR3SO2, etc.; R3, R3a, R3b = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylphenyl, etc.; D = (substituted) Ph,

- heteroaryl; E = bond, CO, CONR5, SO2NR5, CH2SO2, etc.; R5 = H, OH, alkoxy, alkyl, alkenyl, alkynyl, cycloalkyl, alkylphenyl, etc.; K = (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; L = H, cyano, CONR12R13, (CH2)nNR12R13, etc.; n = 0-2; R12, R13 = H, OR14, NR14R15, alkyl, (substituted) alkylphenyl, alkylphenyl, etc.; R14, R15 = H, alkyl, alkoxy, carbonyl, CONH2, alkyl, etc.; G1, G2 = H, halo, alkyl, haloalkyl, cyano, NO2, alkenyl, alkynyl, cycloalkyl, cyanoalkyl, etc.], were prepared as inhibitors of Factor Xa (no data). Thus, [[2-(4-aminophenyl)phenyl]sulfonyl]tert-butylamine (preparation given) in CH2Cl2 was treated with Me3Al in hexane and then with Me 3-(3-cyanophenyl)acrylate to give 19% N-[4-[(2-tert-butylaminosulfonyl)phenyl]phenyl]-3-(3-cyanophenyl)acrylamide. The latter in MeOH was treated with HCl to give a residue which was refluxed with NH4OAc in MeOH to give 35% (2E)-N-[4-[(2-aminosulfonyl)phenyl]phenyl]-3-(3-amidinophenyl)-3-acrylamide.
- IC ICM C07C311-46
ICS C07D213-58; C07C257-18; C07D231-56; C07D239-94; C07D217-22; C07D401-12; C07D231-12; C07D307-54; A61K031-16; A61K031-18; A61K031-33; A61P007-02
- CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 27, 28
- ST arylacrylamide prepn Factor Xa inhibitor;
aminosulfonylphenylphenylamidinophenylacrylamide prepn Factor Xa inhibitor; antithrombotic amidinophenylacrylamide prepn
- IT Anticoagulants
(preparation of arylacrylamides and related compds. as inhibitors of Factor Xa)
- IT 9002-05-5, Factor Xa
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(inhibitors; preparation of arylacrylamides and related compds. as inhibitors of Factor Xa)
- IT 288309-80-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of arylacrylamides and related compds. as inhibitors of Factor Xa)
- IT 288307-81-3DP, derivs. 288307-81-3P 288307-83-5DP, derivs.
288307-83-5P 288307-84-6DP, derivs. 288307-84-6P 288307-85-7DP, derivs. 288307-85-7P 288307-86-8P 288307-87-9P 288307-88-0P
288307-89-1P 288307-90-4P 288307-91-5P 288307-92-6P 288307-93-7P
288307-94-8P 288307-95-9P 288307-96-0P 288307-97-1P 288307-98-2P
288307-99-3P 288308-00-9P 288308-01-0P 288308-02-1P 288308-03-2P
288308-04-3P 288308-05-4P 288308-06-5P 288308-07-6P 288308-08-7P
288308-09-8P 288308-10-1P 288308-11-2P 288308-12-3P 288308-13-4P
288308-14-5P 288308-15-6P 288308-16-7DP, derivs. 288308-16-7P
288308-17-8P 288308-18-9P 288308-19-0P 288308-20-3P 288308-21-4P
288308-22-5DP, derivs. 288308-22-5P 288308-23-6DP, derivs.
288308-23-6P 288308-24-7DP, derivs. 288308-24-7P 288308-25-8DP, derivs. 288308-25-8P 288308-26-9P 288308-27-0P 288308-28-1P
288308-29-2P 288308-30-5P 288308-31-6P 288308-32-7P 288308-33-8P
288308-34-9P 288308-35-0P 288308-36-1P 288308-37-2P 288308-38-3P
288308-39-4P 288308-40-7P 288308-41-8P 288308-42-9P 288308-43-0P
288308-44-1P 288308-45-2P 288308-46-3P 288308-47-4P 288308-48-5P
288308-49-6P 288308-50-9P 288308-51-0P 288308-52-1P 288308-53-2P
288308-54-3P 288308-55-4P 288308-56-5P 288308-57-6P 288308-58-7P
288308-59-8P 288308-60-1P 288308-61-2P 288308-62-3P 288308-63-4P
288308-64-5P 288308-65-6P 288308-66-7P 288308-67-8P 288308-68-9P
288308-69-0P 288308-70-3P 288308-71-4P 288308-72-5DP, derivs.

288308-72-5P 288308-73-6P 288308-74-7P 288308-75-8P 288308-76-9P
 288308-77-0P 288308-78-1P 288308-79-2P 288308-80-5P 288308-81-6P
 288308-82-7P 288308-83-8P 288308-84-9P 288308-85-0P 288308-86-1P
 288308-87-2P 288308-88-3P 288308-89-4P 288308-90-7P 288308-91-8P
 288308-92-9P 288308-93-0P 288308-94-1P 288308-95-2P 288308-96-3P
 288309-42-2P 288309-54-6P 288309-55-7P 288309-56-8P 288309-57-9P
 288309-58-0P 288309-59-1P 288309-60-4P 288309-61-5P 288309-62-6P
 288309-63-7P 288309-64-8P 288309-65-9P 288309-66-0P 288309-67-1P
 288309-68-2P 288309-69-3P 288309-70-6P 288309-71-7P 288309-72-8P
 288309-73-9P 288309-74-0P 288309-75-1P 288309-76-2P 288309-77-3P
 288309-78-4P 288309-79-5P 288309-81-9P 288309-82-0P 288309-83-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylacrylamides and related compds. as inhibitors of Factor Xa)

IT 79-30-1, Isobutyryl chloride 98-09-9, Benzenesulfonyl chloride
 106-40-1, 4-Bromoaniline 141-97-9, Ethyl acetoacetate 288-13-1,
 Pyrazole 372-31-6, Ethyl trifluoroacetate 590-97-6, Bromomethyl
 acetate 611-10-9, Ethyl 2-oxocyclopentanecarboxylate 615-36-1,
 2-Bromoaniline 1007-15-4, 3-Bromo-4-fluoroacetophenone 2356-16-3
 2605-67-6, Methoxycarbonylmethylenetriphenylphosphorane 3473-63-0,
 Formamidine acetate 3699-66-9, Triethyl 2-phosphonopropionate
 6136-68-1, 3-Acetylbenzotrile 7664-66-6, 4-Isopropoxyaniline
 24964-64-5, 3-Cyanobenzaldehyde 41051-15-4, Methyl 4-methoxy-3-
 oxobutanoate 42726-73-8, tert-Butyl methyl malonate 54401-85-3, Ethyl
 4-pyridylacetate 58794-09-5, 7-Bromoisoquinoline 88738-78-7
 97674-02-7 107905-52-2 134209-02-2 150255-96-2, 3-Cyanophenylboronic
 acid 203512-83-8 209919-51-7 288309-49-9 288309-51-3 288309-52-4
 288309-53-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of arylacrylamides and related compds. as inhibitors of Factor Xa)

IT 2512-24-5P 29632-73-3P, 2-Bromo-4-iodoaniline 50916-55-7P,
 3-(2-Bromoacetyl)benzotrile 52116-81-1P 122539-74-6P 125873-00-9P
 150691-04-6P 161801-48-5P 193006-34-7P 197792-47-5P 203512-82-7P
 209917-94-2P 215453-50-2P 215453-51-3P, 7-Bromo-1-chloroisoquinoline
 215453-52-4P, 7-Bromo-1-phenoxyisoquinoline 215453-53-5P,
 1-Amino-7-bromoisoquinoline 258333-33-4P 288308-97-4P 288308-98-5P
 288308-99-6P 288309-00-2P 288309-01-3P 288309-02-4P 288309-03-5P
 288309-04-6P 288309-05-7P 288309-06-8P 288309-07-9P,
 3-Cyano-4-fluoroacetophenone 288309-08-0P 288309-09-1P 288309-10-4P,
 7-Acetylisoquinoline 288309-11-5P 288309-12-6P 288309-13-7P
 288309-14-8P 288309-15-9P 288309-16-0P 288309-18-2P 288309-19-3P
 288309-20-6P 288309-21-7P 288309-22-8P 288309-23-9P 288309-24-0P
 288309-25-1P 288309-26-2P 288309-27-3P 288309-28-4P 288309-29-5P
 288309-30-8P 288309-31-9P 288309-32-0P 288309-33-1P 288309-34-2P
 288309-35-3P 288309-36-4P 288309-37-5P 288309-38-6P 288309-39-7P
 288309-40-0P 288309-41-1P 288309-43-3P 288309-44-4P 288309-45-5P
 288309-46-6P 288309-47-7P 288309-48-8P 288309-50-2P 288309-84-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylacrylamides and related compds. as inhibitors of Factor Xa)

L119 ANSWER 17 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:475644 HCAPLUS Full-text

DOCUMENT NUMBER: 133:89443

TITLE: Quinolinecarboxamides as antiviral agents, especially against viruses of the herpes family

INVENTOR(S): Turner, Steven Ronald; Strohbach, Joseph Walter;
 Thaisrivongs, Suvit; Vaillancourt, Valerie A.;
 Schnute, Mark E.; Tucker, John Alan
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 219 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040561	A1	20000713	WO 1999-US27960	19991222 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248739	B1	20010619	US 1999-466712	19991217 <--
CA 2353636	A1	20000713	CA 1999-2353636	19991222 <--
EP 1140850	A1	20011010	EP 1999-967145	19991222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101906	T2	20011221	TR 2001-200101906	19991222 <--
HU 200200308	A2	20020629	HU 2002-308	19991222 <--
HU 200200308	A3	20030328		
JP 2002534416	T	20021015	JP 2000-592270	19991222 <--
AU 760207	B2	20030508	AU 2000-23486	19991222 <--
NZ 512824	A	20030926	NZ 1999-512824	19991222 <--
BR 9916772	A	20040615	BR 1999-16772	19991222 <--
ZA 2001004711	A	20020610	ZA 2001-4711	20010608 <--
NO 2001003383	A	20010907	NO 2001-3383	20010706 <--
PRIORITY APPLN. INFO.:			US 1999-115301P	P 19990108 <--
			US 1999-140610P	P 19990623 <--
			WO 1999-US27960	W 19991222 <--

OTHER SOURCE(S): MARPAT 133:89443

ED Entered STN: 14 Jul 2000

AB The invention provides quinolinecarboxamides I (X = O, S; W = R², etc., where R¹-R⁶ = a wide variety of defined groups, with 125 examples), e.g., hydroxypropynyl derivative II, and their pharmaceutically acceptable salts which are useful as antiviral agents, in particular, as agents against viruses of the herpes family. Activities of the compds. against HCMV, HSV, and VZV polymerase are presented. Pharmaceutical compns. comprising compds. I are claimed (no examples).

IC ICM C07D215-16

ICS C07D215-18; C07D215-22; C07D215-36; C07D215-38; C07D215-58; C07D215-233; A61K031-47; A61P031-12

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
 Section cross-reference(s): 1, 63

ST quinolinecarboxamide prepn antiviral agent; herpes virus
 quinolinecarboxamide antiviral agent

IT Amides, preparation

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(quinolinecarboxamides; preparation of quinolinecarboxamides as antiviral agents)

- IT 29943-42-8, Tetrahydro-4H-pyran-4-one
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (conversion to oxazepanone and for preparation of
 quinolinecarboxamide derivs.)
- IT 57-14-7, 1,1-Dimethylhydrazine 75-26-3, 2-Bromopropane 87-13-8,
 Diethyl ethoxymethylenemalonate 100-11-8, 4-Nitrobenzyl bromide
 102-71-6, reactions 104-63-2, N-Benzylethanolamine 104-86-9,
 4-Chlorobenzylamine 106-93-4, 1,2-Dibromoethane 107-08-4,
 1-Iodopropane 107-19-7, Propargyl alcohol 110-65-6, 1,4-Butynediol
 110-73-6 110-77-0, Ethyl 2-hydroxyethyl sulfide 110-91-8, Morpholine,
reactions 111-46-6, reactions 111-90-0,
 2-Ethoxy-(2-ethoxy)ethanol 112-35-6, Triethyleneglycol monomethyl ether
 140-75-0, 4-Fluorobenzylamine 350-46-9, 1-Fluoro-4-nitrobenzene
 352-34-1, 4-Fluoriodobenzene 505-10-2, 3-Methylthiopropanol 513-48-4,
 2-Iodobutane 540-37-4, 4-Iodoaniline 615-43-0, 2-Iodoaniline
 622-08-2, 2-Benzyloxyethanol 628-89-7, 2-(2-Chloroethoxy)ethanol
 699-12-7, 2-Hydroxyethyl phenyl sulfide 881-95-8, dl-Metanephrene
 hydrochloride 927-74-2, 3-Butyn-1-ol 1069-72-3 1445-73-4,
 N-Methyl-4-piperidone 1479-24-9, Ethyl 3-(2-fluorophenyl)-3-
 oxopropanoate 2008-75-5, 1-(2-Chloroethyl)piperidine hydrochloride
 2213-43-6, 1-Aminopiperidine 2373-51-5, Chloromethyl methyl sulfide
 3647-69-6, N-(2-Chloroethyl)morpholine hydrochloride 3970-21-6,
 2-Methoxyethoxymethyl chloride 4261-68-1, 2-(Diisopropylamino)ethyl
 chloride hydrochloride 4319-49-7, 4-Aminomorpholine 4584-46-7,
 Dimethylaminoethyl chloride hydrochloride 5188-07-8, Sodium
 thiomethoxide 5292-43-3, tert-Butyl bromoacetate 5407-04-5,
 3-Dimethylaminopropyl chloride hydrochloride 5466-88-6,
 (2H)1,4-Benzoxazin-3(4H)-one 5472-49-1, N-(3-Chloropropyl)piperidine
 hydrochloride 6148-64-7, Potassium ethyl malonate 6542-54-7
 6589-55-5, α -(Methylaminomethyl)benzyl alcohol 6928-85-4,
 1-Amino-4-methylpiperazine 6972-79-8, 1,3-Dibenzyloxy-2-propanol
 7205-90-5, Chloromethyl 4-chlorophenyl sulfide 7205-91-6, Chloromethyl
 phenyl sulfide 7250-67-1, 1-(2-Chloroethyl)pyrrolidine hydrochloride
 10595-09-2, 3,3'-Thiodipropanol 16589-24-5, Synephrine 16596-41-1,
 1-Aminopyrrolidine 17201-43-3, 4-(Bromomethyl)benzonitrile 18621-18-6,
 3-Azetidinol hydrochloride 21151-56-4, α ,4-Dichloroanisole
 26177-44-6, 4-Bromobenzylamine hydrochloride 27374-25-0,
 [(1-Ethoxycyclopropyl)oxy]trimethylsilane 29632-74-4,
 2-Fluoro-4-iodoaniline 31560-06-2 33821-94-2, 2-(3-
 Bromopropoxy)tetrahydro-2H-pyran 50586-80-6, 2-(2-Methoxyethoxy)ethyl
 p-toluenesulfonate 54288-69-6, 2-Chloromethyl-1-methylpyrrolidine
 hydrochloride 58305-05-8 72748-99-3, (R)-1-Amino-2-
 (methoxymethyl)pyrrolidine 79099-07-3, 1-(tert-Butoxycarbonyl)-4-
 piperidone 84466-87-5, 4-(Azidomethyl)benzonitrile 117924-33-1
 121838-84-4 132091-42-0 281652-58-2, 2-Chloro-5-iodobenzoyl chloride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (for preparation of quinolinecarboxamide derivs.)
- IT 2767-70-6P, 4-Nitrobenzyltriphenylphosphonium bromide 5638-60-8P
 6425-46-3P, 4-(4-Nitrobenzyl)morpholine 10406-25-4P,
 4-(Aminomethyl)benzonitrile 21987-29-1P, 4,4-Difluoropiperidine
 51013-67-3P, 4-(4-Aminobenzyl)morpholine 101184-85-4P 124700-41-0P,
 2-Fluoro-5-iodobenzoic acid 281651-96-5P, N-Cyclopropyl-4-iodoaniline
 281652-00-4P 281652-01-5P 281652-05-9P 281652-10-6P, tert-Butyl
 4,4-difluoro-1-piperidinecarboxylate 281652-11-7P, 4-Fluoro-1,2,3,6-
 tetrahydropyridine hydrochloride 281652-25-3P, 4-(3-Bromo-4-
 fluorobenzyl)morpholine 281652-26-4P 281652-27-5P 281652-40-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (for preparation of quinolinecarboxamide derivs.)
- IT 49713-42-0P, Ethyl 4-hydroxy-8-iodo-3-quinolinecarboxylate 58287-31-3P

103318-52-1P 188752-88-7P 228725-37-9P 228725-72-2P 228725-85-7P
 228726-33-8P 228726-41-8P 228726-42-9P 228726-59-8P 228726-66-7P
 228726-92-9P 228726-93-0P 228728-08-3P 228728-23-2P, Ethyl
 4-hydroxy-6-iodoquinoline-3-carboxylate 228728-41-4P 228728-42-5P
 281651-90-9P 281651-91-0P 281651-92-1P 281651-93-2P 281651-94-3P
 281651-95-4P 281651-97-6P 281651-98-7P 281651-99-8P 281652-02-6P
 281652-03-7P 281652-04-8P 281652-06-0P 281652-07-1P 281652-08-2P
 281652-09-3P 281652-12-8P 281652-13-9P 281652-14-0P 281652-15-1P
 281652-21-9P 281652-22-0P, 4-(4-Nitrobenzylidene)tetrahydro-2H-pyran
 281652-23-1P 281652-24-2P 281652-28-6P 281652-29-7P 281652-30-0P
 281652-31-1P 281652-32-2P 281652-33-3P 281652-34-4P 281652-35-5P
 281652-36-6P 281652-37-7P 281652-38-8P 281652-39-9P 281652-41-3P
 281652-42-4P 281652-44-6P 281652-45-7P 281652-46-8P 281652-47-9P
 281652-48-0P 281652-49-1P 281652-50-4P 281652-51-5P 281652-52-6P
 281652-53-7P 281652-54-8P 281652-55-9P 281652-56-0P 281652-57-1P
 281652-59-3P 281652-60-6P 281652-61-7P 281652-62-8P 281652-63-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate, for preparation of quinolinecarboxamide derivs. as
 antiviral agents)
 IT 281652-16-2P 281652-17-3P 281652-18-4P 281652-19-5P 281652-20-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate, for preparation of quinolinethiocarboxamide derivs.
 as antiviral agents)
 IT 10341-26-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydride reduction to oxazepane)
 IT 2896-98-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydride reduction to thiazepane)
 IT 281650-73-5P 281650-90-6P 281650-91-7P 281650-93-9P 281650-96-2P
 281650-97-3P 281651-04-5P 281651-07-8P 281651-22-7P 281651-25-0P
 281651-26-1P 281651-31-8P 281651-38-5P 281651-40-9P 281651-41-0P
 281651-48-7P 281651-65-8P 281651-70-5P 281651-76-1P 281651-82-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
 (Reactant or reagent); USES (Uses)
 (preparation of quinolinecarboxamides as antiviral agents, especially
 against herpes virus)
 IT 281650-66-6P 281650-67-7P 281650-68-8P 281650-69-9P 281650-70-2P
 281650-71-3P 281650-72-4P 281650-74-6P 281650-75-7P 281650-76-8P
 281650-77-9P 281650-78-0P 281650-79-1P 281650-80-4P 281650-81-5P
 281650-82-6P 281650-83-7P 281650-84-8P 281650-85-9P 281650-86-0P
 281650-87-1P 281650-88-2P 281650-89-3P 281650-92-8P 281650-94-0P
 281650-95-1P 281650-98-4P 281650-99-5P 281651-01-2P 281651-02-3P
 281651-08-9P 281651-09-0P 281651-10-3P 281651-11-4P 281651-12-5P
 281651-13-6P 281651-14-7P 281651-15-8P 281651-16-9P 281651-17-0P
 281651-18-1P 281651-19-2P 281651-20-5P 281651-21-6P 281651-23-8P
 281651-24-9P 281651-27-2P 281651-28-3P 281651-29-4P 281651-30-7P
 281651-32-9P 281651-33-0P 281651-34-1P 281651-35-2P 281651-36-3P
 281651-37-4P 281651-39-6P 281651-42-1P 281651-43-2P 281651-44-3P
 281651-45-4P 281651-46-5P 281651-47-6P 281651-49-8P 281651-50-1P
 281651-51-2P 281651-52-3P 281651-53-4P 281651-54-5P 281651-55-6P
 281651-57-8P 281651-58-9P 281651-59-0P 281651-60-3P 281651-61-4P
 281651-62-5P 281651-63-6P 281651-64-7P 281651-66-9P 281651-67-0P
 281651-68-1P 281651-69-2P 281651-71-6P 281651-72-7P 281651-73-8P

281651-74-9P 281651-75-0P 281651-77-2P 281651-78-3P 281651-79-4P
 281651-80-7P 281651-81-8P 281651-83-0P 281651-84-1P 281651-85-2P
 281651-86-3P 281651-87-4P 281651-88-5P 281651-89-6P 281652-43-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolinecarboxamides as antiviral agents, especially against herpes virus)

IT 281651-00-1P 281651-03-4P 281651-05-6P 281651-06-7P 281651-56-7P
 281652-64-0P 281652-65-1P 281652-66-2P 281652-67-3P 281652-68-4P
 281652-69-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolinecarboxamides as antiviral agents, especially against herpes virus)

IT 603-35-0, Triphenylphosphine, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)
 (quaternization with nitrobenzyl bromide)

IT 78191-00-1, N-Methyl-N-methoxyacetamide

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction with bromofluorobenzylmorpholine)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 18 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:194129 HCAPLUS Full-text

DOCUMENT NUMBER: 130:237562

TITLE: Preparation of pyrazole compounds and plant disease control agent

INVENTOR(S): Akiyama, Shigeaki; Niki, Toshio; Utsunomiya, Tomohisa; Watanabe, Junichi; Nishioka, Masanori; Suzuki, Hiroyuki; Hayasaka, Fumio; Yamagishi, Kazuhiro

PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912910	A1	19990318	WO 1998-JP3997	19980907 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9889985	A	19990329	AU 1998-89985	19980907 <--
EP 1020447	A1	20000719	EP 1998-941740	19980907 <--
R:	CH, DE, FR, GB, IT, LI			
TW 499295	B	20020821	TW 1998-87115006	19980909 <--
PRIORITY APPLN. INFO.:			JP 1997-246529	A 19970911 <--
			JP 1998-138325	A 19980520 <--
			WO 1998-JP3997	W 19980907 <--

OTHER SOURCE(S): MARPAT 130:237562

ED Entered STN: 25 Mar 1999

- AB Claimed are pyrazole compds. represented by general formula [I; wherein R is Cl-4 alkyl; X1 is halogeno; X2 is H or halogeno; A is a direct bond, (un)substituted CH2, CH2CH2, CH:CH, etc.; B is N3, OH, NH2, C(R23):NR24, C(R23):NOR24, etc.; wherein R23 is H, Cl-4 alkyl, etc.; and R24 is H, Cl-6 alkyl, C2-6 alkenyl, etc.] or salts of the compds. and a plant disease control agent containing at least one of the compds. and salts as the active ingredient. The compds. are highly effective against plant diseases, e.g. fungi, and are safe for crops. Thus, Et 3-chloro-1-methylpyrazole-5-carboxylate was reduced by NaBH4 in MeOH under reflux for 1 h to give 3-chloro-1-methyl-5-hydroxymethylpyrazole which was acetylated by acetyl chloride in the presence of Et3N in THF at room temperature for 12 h to give I (R = Me, X1 = Cl, X2 = H, A-B = CH2OH) (II). II at 500 ppm spray completely prevented rice seedling from being infected with Pyricularia oryzae.
- IC ICM C07D231-16
ICS C07D401-06; C07D403-06; A01N043-56; A01N043-34; A01N043-72
- CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 5
- ST pyrazole prepn plant disease control agent; fungicide
plant pyrazole prepn
- IT Fungicides
(agrochem.; preparation of pyrazole compds. and plant disease control agent)
- IT 221274-48-2P 221274-49-3P 221274-50-6P 221274-51-7P 221274-52-8P
221274-53-9P 221274-54-0P 221274-55-1P 221274-56-2P 221274-57-3P
221274-58-4P 221274-59-5P 221274-60-8P 221274-61-9P 221274-62-0P
221274-63-1P 221274-64-2P 221274-65-3P 221274-67-5P 221274-68-6P
221274-69-7P 221274-70-0P 221274-71-1P 221274-72-2P 221274-73-3P
221274-74-4P 221274-76-6P 221274-78-8P 221274-80-2P 221274-83-5P
221274-84-6P 221274-85-7P 221274-86-8P 221274-87-9P 221274-88-0P
221274-89-1P 221274-90-4P 221274-91-5P 221274-92-6P 221274-94-8P
221274-95-9P 221274-96-0P 221274-97-1P 221274-98-2P 221274-99-3P
221275-00-9P 221275-01-0P 221275-02-1P 221275-03-2P 221275-04-3P
221275-05-4P 221275-06-5P 221275-07-6P 221275-08-7P 221275-09-8P
221275-10-1P 221275-11-2P 221275-12-3P 221275-13-4P 221275-14-5P
221275-15-6P 221275-16-7P 221275-17-8P 221275-18-9P 221275-19-0P
221275-20-3P 221275-21-4P 221275-22-5P 221275-23-6P 221275-24-7P
221275-25-8P 221275-26-9P 221275-27-0P 221275-28-1P 221275-29-2P
221275-30-5P 221275-31-6P 221275-32-7P 221275-33-8P 221275-34-9P
221275-35-0P 221275-36-1P 221275-37-2P 221275-39-4P 221275-40-7P
221275-41-8P 221275-42-9P 221275-43-0P 221275-44-1P 221275-45-2P
221275-46-3P 221275-47-4P 221275-48-5P 221275-49-6P 221275-50-9P
221275-51-0P 221275-52-1P 221275-54-3P 221275-55-4P 221275-56-5P
221275-57-6P 221275-58-7P 221275-59-8P 221275-60-1P 221275-61-2P
221275-62-3P 221275-63-4P 221275-64-5P 221275-65-6P 221275-66-7P
221275-67-8P 221275-68-9P 221275-69-0P 221275-70-3P 221275-71-4P
221275-73-6P 221275-75-8P 221275-77-0P 221275-80-5P 221275-81-6P
221275-84-9P 221275-86-1P 221275-88-3P 221275-90-7P 221275-92-9P
221275-94-1P 221275-96-3P 221275-98-5P 221276-02-4P 221276-04-6P
221276-06-8P 221276-07-9P 221276-08-0P 221276-09-1P 221276-10-4P
221276-11-5P 221276-12-6P 221276-13-7P 221276-14-8P
- RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole compds. and plant disease control agent)
- IT 62-53-3, Aniline, reactions 74-88-4, Methyl iodide, reactions
reactions 75-15-0, Carbon disulfide, reactions
75-36-5, Acetyl chloride 98-88-4, Benzoyl chloride 103-71-9, Phenyl
isocyanate, reactions 407-25-0, Trifluoroacetic anhydride
1074-82-4 2136-75-6, Triphenylphosphoranylideneacetaldehyde 2687-43-6,

O-Benzylhydroxylamine hydrochloride 173841-07-1 221276-16-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazole compds. and plant disease
control agent)

IT 221276-15-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(preparation of pyrazole compds. and plant disease
control agent)REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 19 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:113672 HCAPLUS Full-textDOCUMENT NUMBER: 130:182476TITLE: Preparation of heterocyclic compounds as
irreversible bicyclic inhibitors of tyrosine kinases

INVENTOR(S): Bridges, Alexander James

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906396	A1	19990211	WO 1998-US15592	19980729 <--
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9886659	A	19990222	AU 1998-86659	19980729 <--
US 6153617	A	20001128	US 1999-269647	19990325 <--
US 2003087881	A1	20030508	US 2002-272651	20021017 <--
PRIORITY APPLN. INFO.:			US 1997-54061P	P 19970729 <--
			WO 1998-US15592	W 19980729 <--
			US 1999-269647	A3 19990325 <--
			US 2000-656331	B1 20000906 <--

OTHER SOURCE(S): MARPAT 130:182476

ED Entered STN: 19 Feb 1999

AB The title compds., e.g. I [X = DEF, Y = SR4, etc. ; or X = SR4, etc., and Y = DEF; D = O, etc.; E = CO, etc.; F = CR1(:C):C(R5)H, etc.; a proviso is given; R1 = H, halo, etc.; R5 = H, halo, perfluoroalkyl, etc.; Z = indoline moiety (generic structure given), etc.; R4 = H, alkyl, etc.], are prepared This invention also provides a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases. N-[4-(6-bromo-2,3-dihydroindol-1-yl)quinazolin-6-yl]acrylamide in vitro showed IC50 of 0.4 nM against epidermal growth factor receptor tyrosine kinase.

IC ICM C07D403-04

ICS A61K031-505; C07D401-04; C07D413-14

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1ST heterocycle prepn tyrosine kinase inhibitor; quinazoline

	<u>prepn</u> tyrosine kinase inhibitor; <u>antitumor</u> heterocycle				
	<u>prepn</u> tyrosine kinase inhibitor				
IT	Artery, <u>disease</u>				
	(coronary, <u>restenosis</u> ; <u>preparation</u> and <u>therapeutic</u> effect of heterocyclic compds. as irreversible bicyclic inhibitors of tyrosine kinases)				
IT	Uterus, <u>disease</u>				
	(endometriosis; <u>preparation</u> and <u>therapeutic</u> effect of heterocyclic compds. as irreversible bicyclic inhibitors of tyrosine kinases)				
IT	<u>Antitumor</u> agents				
	<u>Atherosclerosis</u>				
	Psoriasis				
	(preparation and therapeutic effect of heterocyclic compds. as irreversible bicyclic inhibitors of tyrosine kinases)				
IT	220488-73-3P	220575-55-3P	220575-56-4P	220575-57-5P	220575-58-6P
	220575-59-7P	220575-60-0P	220575-61-1P	220575-62-2P	220575-63-3P
	220575-64-4P	220575-66-6P	220575-69-9P	220575-70-2P	220575-71-3P
	220575-72-4P	220575-73-5P	220575-74-6P	220575-76-8P	220575-77-9P
	220575-78-0P	220575-79-1P	220575-80-4P	220575-81-5P	220575-82-6P
	220575-83-7P	220575-84-8P	220575-85-9P	220575-86-0P	220575-87-1P
	220575-88-2P	220575-89-3P	220575-90-6P	220575-91-7P	220575-92-8P
	220575-93-9P	220575-94-0P	220575-95-1P	220575-96-2P	220575-97-3P
	220575-98-4P	220575-99-5P	220576-00-1P	220576-01-2P	220576-02-3P
	220576-03-4P	220576-04-5P	220576-05-6P	220576-06-7P	220576-07-8P
	220576-08-9P	220576-09-0P	220576-10-3P	220576-11-4P	220576-12-5P
	220576-13-6P	220576-14-7P	220576-15-8P	220576-16-9P	220576-17-0P
	220576-18-1P	220576-19-2P	220576-20-5P	220576-21-6P	220576-22-7P
	220576-23-8P	220576-24-9P	220576-25-0P	220576-26-1P	220576-27-2P
	220576-28-3P	220576-29-4P	220576-30-7P	220576-31-8P	220576-32-9P
	220576-33-0P	220576-34-1P	220576-35-2P	220576-36-3P	220576-37-4P
	220576-38-5P	220576-39-6P	220576-40-9P	220576-41-0P	220576-42-1P
	220576-43-2P	220576-44-3P	220576-45-4P	220576-46-5P	220576-47-6P
	220576-48-7P	220576-49-8P	220576-50-1P	220576-51-2P	220576-52-3P
	220576-53-4P	220576-54-5P	220576-55-6P	220576-56-7P	220576-57-8P
	220576-58-9P	220576-59-0P	220576-60-3P	220576-61-4P	220576-62-5P
	220576-63-6P	220576-64-7P	220576-65-8P	220576-66-9P	220576-67-0P
	220576-68-1P	220576-69-2P	220576-70-5P	220576-71-6P	220576-72-7P
	220576-73-8P	220576-74-9P	220576-75-0P	220576-76-1P	220576-77-2P
	220576-78-3P	220576-79-4P	220576-80-7P	220576-81-8P	220576-82-9P
	220576-83-0P	220576-84-1P	220576-85-2P	220576-86-3P	220576-87-4P
	220576-88-5P	220576-89-6P	220576-90-9P	220576-91-0P	220576-92-1P
	220576-93-2P	220576-94-3P	220576-95-4P	220576-96-5P	220576-97-6P
	220576-98-7P	220576-99-8P	220577-00-4P	220577-01-5P	220577-02-6P
	220577-03-7P	220577-04-8P	220577-05-9P	220577-06-0P	220577-07-1P
	220577-08-2P	220577-09-3P	220577-10-6P	220577-11-7P	220577-12-8P
	220577-13-9P	220577-14-0P	220577-15-1P	220577-16-2P	220577-18-4P
	220577-19-5P	220577-20-8P	220577-21-9P	220577-22-0P	220577-23-1P
	220577-24-2P	220577-25-3P	220577-26-4P	220577-27-5P	220577-28-6P
	220577-29-7P	220577-30-0P	220577-31-1P	220577-32-2P	220577-33-3P
	220577-34-4P	220577-35-5P	220577-36-6P	220577-37-7P	220577-38-8P
	220577-39-9P	220577-40-2P	220577-41-3P	220577-43-5P	220577-44-6P
	220577-45-7P	220577-46-8P	220577-47-9P	220577-48-0P	220577-49-1P
	220577-50-4P	220577-51-5P	220577-52-6P	220577-53-7P	220577-54-8P
	220577-55-9P	220577-56-0P	220577-57-1P	220577-58-2P	220577-59-3P
	220577-60-6P	220577-61-7P	220577-62-8P	220577-63-9P	220577-64-0P
	220577-65-1P	220577-66-2P	220577-67-3P	220577-68-4P	220577-69-5P
	220577-70-8P	220577-71-9P	220577-72-0P	220577-73-1P	220577-74-2P
	220577-75-3P	220577-76-4P	220577-77-5P	220577-78-6P	220577-79-7P
	220577-80-0P	220577-81-1P	220577-82-2P	220577-83-3P	220577-84-4P

10/574,993

220577-85-5P 220577-86-6P 220577-88-8P 220577-90-2P 220577-92-4P
220577-94-6P 220577-96-8P 220577-98-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as irreversible bicyclic inhibitors of tyrosine kinases)

IT 220578-00-7P 220578-01-8P 220578-02-9P 220578-03-0P 220578-04-1P
220578-05-2P 220578-06-3P 220578-07-4P 220578-08-5P 220578-09-6P
220578-10-9P 220578-11-0P 220578-12-1P 220578-13-2P 220578-14-3P
220578-15-4P 220578-16-5P 220578-17-6P 220578-18-7P 220578-19-8P
220578-20-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as irreversible bicyclic inhibitors of tyrosine kinases)

IT 80449-02-1, Tyrosine kinase

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(preparation of heterocyclic compds. as irreversible bicyclic inhibitors of tyrosine kinases)

IT 79-10-7, 2-Propenoic acid, reactions 19815-16-8,
4-Chloro-6-nitroquinazoline 63839-24-7, 6-Bromoindoline

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as irreversible bicyclic inhibitors of tyrosine kinases)

IT 220578-21-2P 220578-22-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as irreversible bicyclic inhibitors of tyrosine kinases)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 20 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:113656 HCAPLUS Full-text

DOCUMENT NUMBER: 130:168387

TITLE: Irreversible inhibitors of tyrosine kinases

INVENTOR(S): Bridges, Alexander James

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906378	A1	19990211	WO 1998-US15784	19980729 <--
W:	AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9887607	A	19990222	AU 1998-87607	19980729 <--
US 6127374	A	20001003	US 1999-269545	19990325 <--

ED Entered STN: 19 Feb 1999

AB Pyrimidine derivs. that are irreversible inhibitors of tyrosine kinases are reported. Thus, PhCH₂OH was treated with 4-FC₆H₄NO₂ to give 4-PhCH₂OC₆H₄NO₂, which was reduced to the amine and used to aminate 4-chloro-6-nitroquinazoline hydrochloride. The resulting 6-nitro-4-(4-benzyloxyanilino)quinazoline hydrochloride was reduced to the amine and acylated to give N-[4-(4-benzyloxyanilino)quinazolin-6-yl]acrylamide (I). I had an IC₅₀ for inhibition of **epidermal** growth factor receptor tyrosine kinase of 3.6 nM.

IC ICM C07D239-74

ICS C07D239-88; C07D239-93; C07D239-94; C07D471-04; C07D487-04;
C07D495-04; A61K031-505; C07D471-04; C07D239-00; C07D221-00;
C07D487-04; C07D239-00; C07D239-00; C07D487-04; C07D239-00;
C07D209-00; C07D495-04; C07D333-00; C07D239-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 7

ST pyrimidine **prepn** tyrosine kinase inhibitor;

quinazolinylacrylamide **prepn** tyrosine kinase inhibitor

IT 220488-25-5P 220488-27-7P 220490-90-4P 220490-91-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of anilinoquinazolinylacrylamides and related compds.
as tyrosine kinase inhibitors)

IT 80449-02-1, Tyrosine kinase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(preparation of anilinoquinazolinylacrylamides and related compds.
as tyrosine kinase inhibitors)

IT 79-10-7, 2-Propenoic acid, **reactions** 100-51-6, Benzyl alcohol,

reactions 108-95-2, Phenol, reactions 350-46-9,
1-Fluoro-4-nitrobenzene 220488-24-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of anilinoquinazolinylacrylamides and related compds. as tyrosine kinase inhibitors)

IT	101-63-3P	139-59-3P, 4-Phenoxyaniline	1145-76-2P	6373-46-2P,
----	-----------	-----------------------------	------------	-------------

4-Benzyloxyaniline	179247-03-1P	179247-04-2P	179247-07-5P
179247-08-6P			

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of anilinoquinazolinylacrylamides and related compds.
as tyrosine kinase inhibitors)

IT	220488-28-8P	220488-29-9P	220488-30-2P	220488-31-3P	220488-32-4P
	220488-33-5P	220488-34-6P	220488-35-7P	220488-36-8P	220488-37-9P
	220488-38-0P	220488-39-1P	220488-40-4P	220488-41-5P	220488-42-6P
	220488-43-7P	220488-44-8P	220488-45-9P	220488-46-0P	220488-47-1P
	220488-48-2P	220488-49-3P	220488-50-6P	220488-51-7P	220488-52-8P
	220488-53-9P	220488-54-0P	220488-55-1P	220488-56-2P	220488-57-3P
	220488-58-4P	220488-59-5P	220488-60-8P	220488-61-9P	220488-62-0P
	220488-63-1P	220488-64-2P	220488-65-3P	220488-66-4P	220488-67-5P
	220488-68-6P	220488-69-7P	220488-70-0P	220488-71-1P	220488-72-2P
	220488-73-3P	220488-74-4P	220488-75-5P	220488-76-6P	220488-77-7P
	220488-78-8P	220488-79-9P	220488-80-2P	220488-81-3P	220488-82-4P
	220488-84-6P	220488-86-8P	220488-87-9P	220488-89-1P	220488-90-4P
	220488-91-5P	220488-92-6P	220488-93-7P	220488-94-8P	220488-95-9P
	220488-96-0P	220488-97-1P	220488-98-2P	220488-99-3P	220489-00-9P

10/574,993

220489-01-0P	220489-02-1P	220489-03-2P	220489-04-3P	220489-05-4P
220489-06-5P	220489-08-7P	220489-09-8P	220489-10-1P	220489-11-2P
220489-12-3P	220489-13-4P	220489-15-6P	220489-16-7P	220489-19-0P
220489-21-4P	220489-23-6P	220489-25-8P	220489-27-0P	220489-29-2P
220489-31-6P	220489-33-8P	220489-34-9P	220489-35-0P	220489-36-1P
220489-37-2P	220489-38-3P	220489-39-4P	220489-40-7P	220489-42-9P
220489-43-0P	220489-44-1P	220489-45-2P	220489-46-3P	220489-47-4P
220489-48-5P	220489-49-6P	220489-50-9P	220489-51-0P	220489-52-1P
220489-53-2P	220489-54-3P	220489-55-4P	220489-56-5P	220489-57-6P
220489-58-7P	220489-59-8P	220489-60-1P	220489-61-2P	220489-63-4P
220489-65-6P	220489-67-8P	220489-69-0P	220489-72-5P	220489-75-8P
220489-78-1P	220489-81-6P	220489-83-8P	220489-84-9P	220489-85-0P
220489-86-1P	220489-87-2P	220489-88-3P	220489-89-4P	220489-90-7P
220489-91-8P	220489-92-9P	220489-93-0P	220489-94-1P	220489-95-2P
220489-96-3P	220489-97-4P	220489-98-5P	220489-99-6P	220490-00-6P
220490-01-7P	220490-02-8P	220490-03-9P	220490-04-0P	220490-05-1P
220490-06-2P	220490-07-3P	220490-08-4P	220490-09-5P	220490-10-8P
220490-11-9P	220490-13-1P	220490-14-2P	220490-15-3P	220490-16-4P
220490-17-5P	220490-18-6P	220490-19-7P	220490-20-0P	220490-21-1P
220490-22-2P	220490-23-3P	220490-24-4P	220490-25-5P	220490-26-6P
220490-27-7P	220490-28-8P	220490-30-2P	220490-31-3P	220490-32-4P
220490-33-5P	220490-34-6P	220490-35-7P	220490-36-8P	220490-37-9P
220490-38-0P	220490-39-1P	220490-40-4P	220490-41-5P	220490-42-6P
220490-43-7P	220490-44-8P	220490-46-0P	220490-47-1P	220490-48-2P
220490-49-3P	220490-50-6P	220490-51-7P	220490-52-8P	220490-53-9P
220490-54-0P	220490-55-1P	220490-56-2P	220490-58-4P	220490-59-5P
220490-60-8P	220490-61-9P	220490-62-0P	220490-63-1P	220490-65-3P
220490-66-4P	220490-67-5P	220490-68-6P	220490-69-7P	220490-70-0P
220490-72-2P	220490-74-4P	220490-76-6P	220490-78-8P	220490-79-9P
220490-80-2P	220490-81-3P	220490-82-4P	220490-83-5P	220490-84-6P
220490-86-8P	220490-87-9P	220490-88-0P	220490-89-1P	220491-03-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of anilinoquinazolinylacrylamides and related compds. as tyrosine kinase inhibitors)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 21 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:621194 HCAPLUS Full-text

DOCUMENT NUMBER: 129:260454

TITLE: Process for preparing pyrazoles

INVENTOR(S): Newsome, Peter Wyatt

PATENT ASSIGNEE(S): Rhone-Poulenc Agro, Fr.

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9840358	A1	19980917	WO 1998-EP1226	19980305 <--
W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,			

GA, GN, ML, MR, NE, SN, TD, TG

US 5907041	A	19990525	US 1997-815848	19970312 <--
ZA 9801875	A	19980909	ZA 1998-1875	19980305 <--
CA 2283507	A1	19980917	CA 1998-2283507	19980305 <--
AU 9868270	A	19980929	AU 1998-68270	19980305 <--
AU 750836	B2	20020801		
EP 966444	A1	19991229	EP 1998-913641	19980305 <--
EP 966444	B1	20020904		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI

BR 9808854	A	20000725	BR 1998-8854	19980305 <--
HU 200002931	A2	20001228	HU 2000-2931	19980305 <--
NZ 337766	A	20010330	NZ 1998-337766	19980305 <--
JP 2001514642	T	20010911	JP 1998-539172	19980305 <--
AT 223382	T	20020915	AT 1998-913641	19980305 <--
ES 2179476	T3	20030116	ES 1998-913641	19980305 <--
CN 1107672	B	20030507	CN 1998-803283	19980305 <--
SK 284800	B6	20051103	SK 1999-1231	19980305 <--
CZ 296302	B6	20060215	CZ 1999-3197	19980305 <--
US 6090927	A	20000718	US 1999-249798	19990216 <--
MX 9908353	A	20000228	MX 1999-8353	19990910 <--
BG 103778	A	20010531	BG 1999-103778	19991004 <--
BG 64648	B1	20051031		
CN 1432569	A	20030730	CN 2002-143826	20020925 <--

PRIORITY APPLN. INFO.: US 1997-815848 A 19970312 <--
WO 1998-EP1226 W 19980305 <--

OTHER SOURCE(S): CASREACT 129:260454; MARPAT 129:260454

ED Entered STN: 01 Oct 1998

AB The title compds. [I; Ar = (un)substituted Ph, pyridyl; R3 = CN, CO2H, CHO, etc.; R4 = as R3 excluding CN and halo; R6 = NH2, OH, Me], useful as pesticides (no data), were prepared by reaction of ArN.tplbond.N+X- [X = a compatible anion] with R3CH(R4)CH2R5 [R5 = CN, CO2R8, C(O)C1-6 alkyl; R8 = C1-6 alkyl, C1-6 haloalkyl] followed by rearrangement of the intermediate R3C(R4)(CH2R5)N:NAr.

IC ICM C07D231-10
ICS C07D231-44; C07D231-38; C07C317-48; C07C317-44; C07C255-65

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))

ST pyrazole prepn manufg

IT 189338-31-6P 195372-79-3P 213457-40-0P 213457-41-1P 213457-42-2P
213457-43-3P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparing pyrazoles)

IT 213457-37-5P 213457-38-6P 213457-39-7P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparing pyrazoles)

IT 590-17-0, Bromoacetonitrile 1851-09-8, 4-Chlorophenylsulfonyl acetonitrile 5000-48-6 24279-39-8, 2,6-Dichloro-4-trifluoromethylaniline 40497-11-8, Ethyl 2,3-dicyanopropionate
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for preparing pyrazoles)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 22 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:76286 HCAPLUS Full-text

DOCUMENT NUMBER: 128:128783

TITLE: Polycarbonate compositions with less physical deterioration and yellowing by ionizing

radiation at sterilization
 INVENTOR(S): Miya, Shinya; Kanayama, Satoshi
 PATENT ASSIGNEE(S): Mitsubishi Engineering Plastic K. K., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10030055	A	19980203	JP 1996-185816	19960716 <--
PRIORITY APPLN. INFO.:			JP 1996-185816	19960716 <--

OTHER SOURCE(S): MARPAT 128:128783
 ED Entered STN: 09 Feb 1998
 AB Title compns., useful for medical goods, comprise (A) 100 parts polycarbonates, (B) 0.01-5 parts cinnamyl compds., and (C) 0.01-5 parts sulfides, sulfoxides, or sulfones. Thus, a composition containing Iupilon S 2000 100, cinnamyl acetate 0.5, and di-Ph sulfoxide 0.5 part, was mixed, pelletized, and injection-molded to give a test piece, which showed less yellowing at irradiation of 60Co γ -ray.
 IC ICM C08L069-00
 ICS C08K005-04; C08K005-37; C08K005-41; C08K005-42
 CC 37-6 (Plastics Manufacture and Processing)
 Section cross-reference(s): 63
 ST yellowing discoloration prevention polycarbonate blend; phys deterioration prevention polycarbonate blend; cinnamyl compd polycarbonate blend; sulfide polycarbonate blend medical goods; sulfoxide polycarbonate blend sterilization ionization radiation; sulfone polycarbonate blend yellowing prevention
 IT Gamma ray sterilization
Medical goods
 Yellowing prevention
 Yellowing prevention
 (polycarbonate compns. with less phys. deterioration and yellowing by ionizing radiation at sterilization for medical goods)
 IT Sulfides, properties
 Sulfones
 Sulfoxides
 RL: MOA (Modifier or additive use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polycarbonate compns. with less phys. deterioration and yellowing by ionizing radiation at sterilization for medical goods)
 IT Polycarbonates, properties
 RL: POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polycarbonate compns. with less phys. deterioration and yellowing by ionizing radiation at sterilization for medical goods)
 IT 103-41-3, Benzyl cinnamate 103-54-8, Cinnamyl acetate 104-54-1, Cinnamyl alcohol 127-63-9, Diphenyl sulfone 538-74-9, Dibenzyl sulfide 877-94-1, Cinnamyl methyl ketone 945-51-7, Diphenyl sulfoxide 2550-40-5, Dicyclohexyl disulfide
 RL: MOA (Modifier or additive use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polycarbonate compns. with less phys. deterioration and yellowing by ionizing radiation at sterilization for

medical goods)
 IT 24936-68-3, Iupilon S 2000, properties 25037-45-0
 RL: POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use);
 BIOL (Biological study); USES (Uses)
 (polycarbonate comps. with less phys. deterioration and yellowing by
ionizing radiation at sterilization for
medical goods)

L119 ANSWER 23 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:51521 HCAPLUS Full-text

DOCUMENT NUMBER: 128:75297

TITLE: Indole compounds and their use in treating
diseases of the central nervous system

INVENTOR(S): Lundbeck, Jane Marie; Kanstrup, Anders

PATENT ASSIGNEE(S)': Novo Nordisk A/S, Den.

SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 509,471.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5696148	A	19971209	US 1996-749520	19961118 <--
US 5536721	A	19960716	US 1995-403357	19950314 <--
US 5783575	A	19980721	US 1995-509471	19950731 <--
PRIORITY APPLN. INFO.:			DK 1994-295	A 19940314 <--
			US 1995-403357	A2 19950314 <--
			DK 1995-870	A 19950731 <--
			US 1995-509471	A2 19950731 <--

OTHER SOURCE(S): MARPAT 128:75297

ED Entered STN: 29 Jan 1998

AB Indole compds. I (R1 = alkyl, haloalkyl, alkenyl, cycloalkyl, etc.; R2 = halo, cycloalkylalkyl, cycloalkyl, alkenyl, alkynyl, benzyl, etc.; R3, R4 = H, CN, acyl, carbalkoxy, alkylsulfonyl, etc.; R5 = H, alkyl; R6-9 = H, nitro, amino, halo, trifluoromethyl, etc.) were prepared for treating diseases of the central nervous system related to the metabotropic glutamate receptor system. Thus, Et 2-cyano-3-(1-benzyl-2-chloro-3-indolyl)acrylate was prepared by condensation of 1-benzyl-2-chloro-3-indolecarboxaldehyde in EtOH containing Et3N. The product showed IC50 of 2.2 μ M against PI-hydrolysis in BHK 570 cells expressing mGluR1 α receptors.

IC A61K031-40; C07D209-22; C07D209-24; C07D209-30

INCL 514419000

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 63

ST indoleacrylate prepn treatment central nervous system

IT Nervous system
 (Huntington's chorea; preparation of indole compds. for treating
 central nervous system diseases)

IT Nervous system
 (central, disease; preparation of indole compds. for
 treating central nervous system diseases)

IT Brain, disease
 (ischemia; preparation of indole compds. for treating central
 nervous system diseases)

IT Glutamate receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (metabotropic; preparation of indole compds. for treating central
 nervous system diseases)

IT Epilepsy
Parkinson's disease
(preparation of indole compds. for treating central nervous system
diseases)

IT Mental disorder
(senile psychosis; preparation of indole compds. for treating
central nervous system diseases)

IT 188034-08-4P 188034-09-5P 188034-10-8P 188034-11-9P 188034-12-0P
188034-13-1P 188034-15-3P 188034-16-4P 188034-17-5P 188034-18-6P
188034-19-7P 188034-20-0P 188034-21-1P 188034-22-2P 188034-23-3P
188034-28-8P 188034-29-9P 188034-30-2P 188034-31-3P 188034-32-4P
188034-34-6P 188034-35-7P 188034-36-8P 188034-37-9P 188034-38-0P
188034-39-1P 200641-26-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole compds. for treating central nervous system
diseases)

IT 74-93-1, Methyl mercaptan, reactions 105-53-3, Diethyl
malonate 105-56-6 2274-42-2, Methylsulfonylacetonitrile 24279-74-1
75621-49-7 75621-50-0 75621-51-1 77655-46-0 77655-47-1
77655-86-8, 1H-Indole-3-carboxaldehyde, 2-chloro-1-(cyclopropylmethyl)-
120069-21-8 188034-40-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indole compds. for treating central nervous system
diseases)

IT 188034-14-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of indole compds. for treating central nervous system
diseases)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L119 ANSWER 24 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:28734 HCAPLUS Full-text
DOCUMENT NUMBER: 128:75394
TITLE: Preparation of 3-aryl-5-haloalkylpyrazoles
INVENTOR(S): Hamper, Bruce C.; Mao, Michael K.
PATENT ASSIGNEE(S): Monsanto Co., USA
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9748668	A2	19971224	WO 1997-US10525	19970616 <--
WO 9748668	A3	19980402		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
IN 177859	A1	19970222	IN 1993-MA778	19931103 <--
IN 177858	A1	19970222	IN 1993-MA784	19931103 <--

IN 182467	A1	19990417	IN 1996-MA62	19960112 <--
US 5698708	A	19971216	US 1996-667103	19960620 <--
US 5869688	A	19990209	US 1996-667135	19960620 <--
US 5880290	A	19990309	US 1996-667256	19960620 <--
AU 9734919	A	19980107	AU 1997-34919	19970616 <--
AU 720882	B2	20000615		
EP 923520	A2	19990623	EP 1997-931231	19970616 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9710711	A	19990817	BR 1997-10711	19970616 <--
NZ 333414	A	20000526	NZ 1997-333414	19970616 <--
JP 2000512656	T	20000926	JP 1998-503274	19970616 <--
HU 200104324	A2	20020228	HU 2001-4324	19970616 <--
HU 200104324	A3	20020429		

PRIORITY APPLN. INFO.:

US 1996-667103	A	19960620 <--
US 1996-667135	A	19960620 <--
US 1996-667256	A	19960620 <--
IN 1992-MA173	A1	19920318 <--
IN 1993-MA784	A1	19931103 <--
US 1994-189337	A2	19940131 <--
US 1994-277726	B3	19940720 <--
US 1995-407352	A2	19950320 <--
WO 1997-US10525	W	19970616 <--

OTHER SOURCE(S): CASREACT 128:75394; MARPAT 128:75394

ED Entered STN: 17 Jan 1998

AB Title compds. (I; R1, R10 = alkyl; R2 = haloalkyl; R3, R5, R6 = halo) were prepared Thus, 4-chloro-2-fluoro-5-methylacetophenone was condensed with ClCOCF₃ and the product cyclocondensed with MeNHNH₂ to give, after oxidation, bromination, and esterification steps, I (R1 = Me, R2 = CF₃, R3 = Br, R5 = F, R6 = Cl, R10 = CHMe₂).

IC ICM C07C045-45

ICS C07D231-16

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))

ST arylhaloalkylpyrazole prepn

IT 142623-48-1P 142623-56-1P 142623-96-9P 174514-08-0P 177211-21-1P
177489-17-7P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-aryl-5-haloalkylpyrazoles)

IT 174514-07-9P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of 3-aryl-5-haloalkylpyrazoles)

IT 67-63-0, Isopropanol, reactions 4447-60-3, Triisopropyl orthoformate 142623-87-8 177211-26-6, 1-(4-Chloro-2-fluoro-5-methylphenyl)ethanone

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-aryl-5-haloalkylpyrazoles)

L119 ANSWER 25 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:696745 HCAPLUS Full-textDOCUMENT NUMBER: 128:3695

TITLE: Preparation of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors

INVENTOR(S): Bridges, Alexander James; Denny, William Alexander; Dobrusin, Ellen Myra; Doherty, Annette Marian; Fry, David W.; Mcnamara, Dennis Joseph; Showalter, Howard Daniel Hollis; Smaill, Jeffrey B.; Zhou, Hairong; et al.

PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Bridges, Alexander James;

Denny, William Alexander; Dobrusin, Ellen Myra;
 Doherty, Annette Marian; Fry, David W.; Mcnamara,
 Dennis Joseph; Showalter, Howard Daniel Hollis;
 Smaill, Jeffrey B.; Zhou, Hairong
 PCT Int. Appl., 193 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9738983	A1	19971023	WO 1997-US5778	19970408 <--
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2249446	A1	19971023	CA 1997-2249446	19970408 <--
AU 9724463	A	19971107	AU 1997-24463	19970408 <--
AU 725533	B2	20001012		
EP 892789	A1	19990127	EP 1997-920213	19970408 <--
EP 892789	B1	20020227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1218456	A	19990602	CN 1997-194458	19970408 <--
CN 1145614	B	20040414		
HU 9901207	A2	19990728	HU 1999-1207	19970408 <--
BR 9708640	A	19990803	BR 1997-8640	19970408 <--
JP 2000508657	T	20000711	JP 1997-537173	19970408 <--
JP 3370340	B2	20030127		
AT 213730	T	20020315	AT 1997-920213	19970408 <--
PT 892789	T	20020731	PT 1997-920213	19970408 <--
ES 2174250	T3	20021101	ES 1997-920213	19970408 <--
CN 1495172	A	20040512	CN 2003-10114126	19970408 <--
SK 284073	B6	20040908	SK 1998-1417	19970408 <--
CZ 295468	B6	20050817	CZ 1998-3244	19970408 <--
PL 190489	B1	20051230	PL 1997-329391	19970408 <--
CN 1923818	A	20070307	CN 2006-10101827	19970408 <--
ZA 9703060	A	19971104	ZA 1997-3060	19970410 <--
BG 63160	B1	20010531	BG 1998-102811	19981001 <--
NO 9804718	A	19981209	NO 1998-4718	19981009 <--
NO 312588	B1	20020603		
KR 2000005364	A	20000125	KR 1998-708086	19981010 <--
US 6344459	B1	20020205	US 1999-155501	19990608 <--
HK 1019739	A1	20050218	HK 1999-104872	19991028 <--
US 6602863	B1	20030805	US 2000-671559	20000927 <--
US 2003229051	A1	20031211	US 2003-441450	20030520 <--
PRIORITY APPLN. INFO.:			US 1996-15351P	P 19960412 <--
			CN 2003-10114126	A3 19970408 <--
			WO 1997-US5778	W 19970408 <--
			US 1999-155501	A3 19990608 <--
			US 2000-671559	A3 20000927 <--

OTHER SOURCE(S): MARPAT 128:3695

ED Entered STN: 05 Nov 1997

AB Title compds. [I; R = (CHR6)pR9; R1R2 = CH:CR7CR8:CH, CH:CR7CR8:N, CH:CR7N:CH, etc.; R6 = H or alkyl; 1 of R7,R8 = Z1Z2R10 and the other = OR4, SR4, NHR3; R3,R4 = (un)substituted alkyl, heterocyclalkyl, etc.; R9 = (un)substituted

Ph; R10 = CR11:CHR5, C.tplbond.CR5, CR11:C:CHR5; R5 = H, halo, alkyl, Ph, etc.; R11 = H, halo, alkyl; Z1 = bond, O, (alkyl)imino, CH2, etc.; Z2 = CO, SO, P(O)(OH), etc.; p = 0 or 1] were prepared Thus, I (R = C6H4Br-3, R1R2 = CH:NCR8:CH, R8 = F) was condensed with 3-morpholinopropylamine and the product acylated by CH2:CHCOCl to give title compound II. Data for biol. activity of I were given.

IC ICM C07D239-94

ICS C07D487-04; C07D471-04; C07D495-04

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

ST quinazolinylacrylamide prepn tyrosine kinase inhibitor

IT Growth factor receptors

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(mediated disorders; treatment; preparation of

N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors)

IT Antitumor agents

(preparation of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors)

IT	194423-07-9P	194423-11-5P	194423-13-7P	194423-15-9P	198959-82-9P
	198959-83-0P	198959-84-1P	198959-86-3P	198959-87-4P	198959-88-5P
	198959-89-6P	198959-91-0P	198959-92-1P	198959-93-2P	198959-94-3P
	198959-95-4P	198959-96-5P	198959-97-6P	198959-98-7P	198959-99-8P
	198960-00-8P	198960-01-9P	198960-02-0P	198960-04-2P	198960-05-3P
	198960-06-4P	198960-07-5P	198960-08-6P	198960-09-7P	198960-10-0P
	198960-11-1P	198960-12-2P	198960-13-3P	198960-14-4P	198960-15-5P
	198960-16-6P	198960-17-7P	198960-18-8P	198960-19-9P	198960-20-2P
	198960-21-3P	198960-22-4P	198960-23-5P	198960-24-6P	198960-25-7P
	198960-26-8P	198960-27-9P	198960-28-0P	198960-29-1P	198960-30-4P
	198960-32-6P	198960-34-8P	198960-35-9P	198960-36-0P	198960-37-1P
	198960-38-2P	198960-39-3P	198960-40-6P	198960-41-7P	198960-42-8P
	198960-43-9P	198960-44-0P	198960-45-1P	198960-46-2P	198960-47-3P
	198960-49-5P	198960-51-9P	198960-52-0P	198960-53-1P	198960-54-2P
	198960-55-3P	198960-56-4P	198960-57-5P	198960-58-6P	198960-59-7P
	198960-60-0P	198960-61-1P	198960-62-2P	198960-63-3P	198960-64-4P
	198960-65-5P	198960-66-6P	198960-67-7P	198960-68-8P	198960-69-9P
	198960-70-2P	198960-71-3P	198960-72-4P	198960-73-5P	198960-74-6P
	198960-75-7P	198960-76-8P	198960-77-9P	198960-78-0P	198960-79-1P
	198960-80-4P	198960-81-5P	198960-82-6P	198960-83-7P	198960-84-8P
	198960-85-9P	198960-86-0P	198960-87-1P	198960-88-2P	198960-89-3P
	198960-90-6P	198960-91-7P	198960-92-8P	198960-93-9P	198960-94-0P
	198960-95-1P	198960-96-2P	198960-97-3P	198960-98-4P	198960-99-5P
	198961-00-1P	198961-01-2P	198961-02-3P	198961-03-4P	198961-04-5P
	198961-06-7P	198961-08-9P	198961-09-0P	198961-11-4P	198961-13-6P
	198961-15-8P	198961-16-9P	198961-17-0P	198961-18-1P	198961-19-2P
	198961-20-5P	198961-21-6P	198961-22-7P	198961-23-8P	198961-24-9P
	198961-25-0P	198961-26-1P	198961-27-2P	198961-28-3P	198961-29-4P
	198961-30-7P	198961-31-8P	198961-33-0P	198961-34-1P	198961-35-2P
	198961-36-3P	198961-37-4P	198961-38-5P	198961-39-6P	198961-40-9P
	198961-41-0P	198961-42-1P	198961-43-2P	198961-44-3P	198961-45-4P
	198961-46-5P	198961-47-6P	198961-48-7P	198961-50-1P	198961-52-3P
	198961-54-5P	198961-55-6P	198961-56-7P	198961-57-8P	198961-58-9P
	198961-59-0P	198961-60-3P	198961-61-4P	198961-62-5P	198961-63-6P
	198961-64-7P	198961-65-8P	198961-66-9P	198961-67-0P	198961-68-1P
	198961-69-2P	198961-70-5P	198961-71-6P	198961-72-7P	198961-73-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors)

- IT 80449-02-1, Tyrosine kinase
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (preparation of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors)
- IT 198961-98-7P
 RL: BYP (Byproduct); PREP (Preparation)
 (preparation of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors)
- IT 79-03-8, Propanoyl chloride 79-10-7, 2-Propenoic acid, reactions
 79-41-4, reactions 108-31-6, 2,5-Furandione, reactions
 108-44-1, m-Toluidine, reactions 110-91-8, Morpholine, reactions
 123-00-2, 3-(4-Morpholinyl)propanamine 140-10-3, trans-Cinnamic acid, reactions
 471-25-0, Propiolic acid 590-93-2, 2-Butynoic acid 591-19-5, 3-Bromoaniline 625-35-4, trans-Crotonyl chloride 627-63-4 814-68-6, Acryloyl chloride 920-46-7, Methacryloyl chloride 1427-07-2, 2-Fluoro-4-nitrotoluene 1609-93-4, cis-3-Chloroacrylic acid 2345-51-9, 3-Butynoic acid 2393-23-9, 4-Methoxybenzylamine 2459-05-4, Monoethyl fumarate 2833-28-5 3970-35-2, 2-Chloro-3-nitrobenzoic acid 4441-30-9, 3-(4-Morpholinyl)-1-propanol 5317-33-9, 3-(4-Methyl-1-piperazinyl)-1-propanol 6943-17-5, 6-Nitro-4-quinazolinone 10487-71-5, Crotonoyl chloride 13330-96-6, 4-Dimethylamino-1-butanol 21651-12-7, trans-2,4-Pentadienoic acid 51390-23-9, 3-(1-Imidazolyl)-1-propanol 71027-02-6, 4,4,4-Trifluoro-2-butenic acid 153436-69-2 153436-70-5 162012-69-3, 4(1H)-Quinazolinone, 7-fluoro-6-nitro- 169205-78-1 169205-81-6 171178-26-0 171178-44-2, 6-Fluoropyrido[3,4-d]pyrimidin-4(3H)-one 171179-02-5 171179-06-9 171179-43-4 171744-81-3 174709-17-2 175357-98-9 198961-95-4 198961-96-5 198961-97-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors)
- IT 350-32-3P, 2-Fluoro-4-nitrobenzamide 403-24-7P, 2-Fluoro-4-nitrobenzoic acid 34662-24-3P, 2-Chloro-3-nitrobenzonitrile 34667-88-4P, 2-Fluoro-4-nitrobenzonitrile 35212-90-9P, Methyl 3-amino-6-nitrobenzothiothiophene-2-carboxylate 76878-02-9P 76878-17-6P 117054-76-9P, 2-Chloro-3-nitrobenzamide 162012-66-0P 171179-03-6P 175357-96-7P 175357-97-8P 198204-59-0P 198961-74-9P 198961-75-0P 198961-76-1P 198961-77-2P, 6-Amino-4-dimethylaminoquinazoline 198961-78-3P 198961-79-4P 198961-80-7P 198961-81-8P 198961-82-9P 198961-83-0P 198961-84-1P 198961-85-2P 198961-86-3P 198961-87-4P 198961-88-5P 198961-89-6P 198961-90-9P 198961-91-0P 198961-92-1P 198961-93-2P 198961-94-3P 198962-01-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors)
- IT 198961-99-8P 198962-00-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors)

L119 ANSWER 26 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:350496 HCAPLUS Full-text

DOCUMENT NUMBER: 127:18472

TITLE: Polycarbonate resin compositions resistant to discoloration by ionizing radiation

INVENTOR(S): Miya, Shinya; Kanayama, Satoshi

PATENT ASSIGNEE(S): Mitsubishi Engineering Plastic K. K., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09087507	A	19970331	JP 1995-247676	19950926 <--
PRIORITY APPLN. INFO.:			JP 1995-247676	19950926 <--
OTHER SOURCE(S): MARPAT 127:18472				
ED Entered STN: 04 Jun 1997				
AB	The title compns. contain polycarbonates 100, aromatic hydrocarbon-aldehyde resins 0.01-5, and sulfoxides or sulfones 0.01-5 parts. Thus, a test piece containing Iupilon S 2000 100, Nikanol Y 50 0.25, and di-Ph sulfoxide 0.5 part showed low yellowing by γ ray.			
IC	ICM C08L069-00			
	ICS C08K005-41; C08L069-00; C08L061-06			
CC	37-6 (Plastics Manufacture and Processing)			
ST	<u>radiation</u> yellowing resistant polycarbonate; aldehyde resin sulfone polycarbonate molding; gamma <u>radiation</u> yellowing resistant polycarbonate			
IT	Gamma ray			
	Yellowing prevention			
	(polycarbonate resin compns. containing aromatic hydrocarbon-aldehyde resins			
	and sulfoxides and sulfones resistant to discoloration by <u>ionizing radiation</u>)			
IT	Sulfones			
	Sulfoxides			
	RL: MOA (Modifier or additive use); PRP (Properties); USES (Uses)			
	(polycarbonate resin compns. containing aromatic hydrocarbon-aldehyde resins			
	and sulfoxides and sulfones resistant to discoloration by <u>ionizing radiation</u>)			
IT	Aromatic hydrocarbons, properties			
	RL: MOA (Modifier or additive use); PRP (Properties); USES (Uses)			
	(polymers with aldehydes; polycarbonate resin compns. containing aromatic hydrocarbon-aldehyde resins and sulfoxides and sulfones resistant to discoloration by <u>ionizing radiation</u>)			
IT	Aldehydes, properties			
	RL: MOA (Modifier or additive use); PRP (Properties); USES (Uses)			
	(polymers with aromatic hydrocarbons; polycarbonate resin compns. containing			
	aromatic hydrocarbon-aldehyde resins and sulfoxides and sulfones resistant to discoloration by <u>ionizing radiation</u>)			
IT	24936-68-3, Iupilon S 2000, properties			
	RL: POF (Polymer in formulation); PRP (Properties); USES (Uses)			
	(Iupilon S 2000; polycarbonate resin compns. containing aromatic hydrocarbon-aldehyde resins and sulfoxides and sulfones resistant to discoloration by <u>ionizing radiation</u>)			
IT	26139-75-3			
	RL: MOA (Modifier or additive use); PRP (Properties); USES (Uses)			
	(Nikanol Y 50; polycarbonate resin compns. containing aromatic hydrocarbon-aldehyde resins and sulfoxides and sulfones resistant to discoloration by <u>ionizing radiation</u>)			
IT	107-61-9, 1,4-Thioxane-1,1-dioxide 621-08-9, Dibenzyl sulfoxide 945-51-7, Diphenyl sulfoxide 151183-90-3, Nikanol DS			
	RL: MOA (Modifier or additive use); PRP (Properties); USES (Uses)			
	(polycarbonate resin compns. containing aromatic hydrocarbon-aldehyde			

resins

and sulfoxides and sulfones resistant to discoloration by
ionizing radiation)

IT 25037-45-0

RL: POF (Polymer in formulation); PRP (Properties); USES (Uses)
 (polycarbonate resin compns. containing aromatic hydrocarbon-aldehyde

resins

and sulfoxides and sulfones resistant to discoloration by
ionizing radiation)

L119 ANSWER 27 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:224107 HCAPLUS Full-textDOCUMENT NUMBER: 126:212041

TITLE: Preparation of indolyl compounds for
 treatment of diseases in the central nervous
 system related to the metabotropic glutamate receptor
 system

INVENTOR(S): Lundbeck, Jane Marie; Kanstrup, Anders

PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.; Lundbeck, Jane Marie;
 Kanstrup, Anders

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705109	A1	19970213	WO 1996-DK332	19960731 <--
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CF, CG, CI, CM			
AU 9665142	A	19970226	AU 1996-65142	19960731 <--
EP 843660	A1	19980527	EP 1996-924801	19960731 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
JP 11509847	T	19990831	JP 1996-507124	19960731 <--
PRIORITY APPLN. INFO.:			DK 1995-870	A 19950731 <--
			WO 1996-DK332	W 19960731 <--

OTHER SOURCE(S): MARPAT 126:212041

ED Entered STN: 07 Apr 1997

AB The title compds. [I; R1 = C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R2 = halo, C1-6 alkyl, PhCH2, etc.; R3, R4 = H, CN, COOPh, etc.; R5 = H, C1-6 alkyl; R6-R9 = H, NO2, NH2, etc.], useful in treating epilepsy, senile dementia, Parkinson's disease, Huntington's Chorea, pain or deficiency of mental and motoric performance seen after conditions of brain ischemia, were prepared and formulated. Thus, reaction of 1-benzyl-2-chloroindole-3-carbaldehyde with Et 2-cyanoacetate in the presence of Et3N in EtOH afforded II which showed IC50 of 2.2 μ M against PI-hydrolysis in BHK 570 cells expressing mGluR1 α receptors.

IC ICM C07D209-18

ICS C07D209-30; A61K031-40

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 63

ST indolyl compd prepn formulation CNS agent; metabotropic
 glutamate receptor indolyl compd prepn; phosphoinositide
 hydrolysis inhibitor indolyl compd prepn; antiepileptic indolyl
 compd prepn formulation; senile dementia indolyl compd

- prepn formulation; Parkinson's disease indolyl compd
prepn formulation; Huntington's disease indolyl compd
prepn formulation; analgesic indolyl compd prepn
formulation; deficiency disease indolyl compd prepn
formulation
- IT Nervous system
(Huntington's chorea, treatment of; preparation of indolyl compds.
for treatment of diseases in the central nervous system
related to the metabotropic glutamate receptor system)
- IT Phosphoinositides
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(PI-hydrolysis inhibitors; preparation of indolyl compds. for
treatment of diseases in the central nervous system related
to the metabotropic glutamate receptor system)
- IT Disease, animal
(deficiency, deficiency of mental and motoric performance seen after
conditions of brain ischemia; preparation of
indolyl compds. for treatment of diseases in the central
nervous system related to the metabotropic glutamate receptor system)
- IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(metabotropic, mGluR1; preparation of indolyl compds. for
treatment of diseases in the central nervous system related
to the metabotropic glutamate receptor system)
- IT Analgesics
Anticonvulsants
Glutamate antagonists
Nervous system agents
(preparation of indolyl compds. for treatment of diseases
in the central nervous system related to the metabotropic glutamate
receptor system)
- IT Mental disorder
(senile psychosis, treatment of; preparation of indolyl compds.
for treatment of diseases in the central nervous system
related to the metabotropic glutamate receptor system)
- IT Parkinson's disease
(treatment of; preparation of indolyl compds. for treatment of
diseases in the central nervous system related to the
metabotropic glutamate receptor system)
- IT 188034-08-4P 188034-09-5P 188034-10-8P 188034-11-9P 188034-12-0P
188034-13-1P 188034-14-2P 188034-15-3P 188034-16-4P 188034-17-5P
188034-18-6P 188034-19-7P 188034-20-0P 188034-21-1P 188034-22-2P
188034-23-3P 188034-24-4P 188034-25-5P 188034-26-6P 188034-27-7P
188034-28-8P 188034-29-9P 188034-30-2P 188034-31-3P 188034-32-4P
188034-33-5P 188034-34-6P 188034-35-7P 188034-36-8P 188034-37-9P
188034-38-0P 188034-39-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolyl compds. for treatment of diseases
in the central nervous system related to the metabotropic glutamate
receptor system)
- IT 105-53-3, Diethyl malonate 105-56-6 2274-42-2 24279-74-1
75621-49-7 75621-50-0 75621-51-1 77655-46-0 77655-47-1
77655-86-8 120069-21-8 175137-63-0 188034-40-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indolyl compds. for treatment of diseases
in the central nervous system related to the metabotropic glutamate

receptor system)

L119 ANSWER 28 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:220659 HCAPLUS Full-textDOCUMENT NUMBER: 126:211923TITLE: Preparation of naphthyloxyacetic acid derivatives with binding activity to prostaglandin E2 receptor and drugs comprising the same as active ingredients

INVENTOR(S): Nagao, Yuuki; Torisu, Kazuhiko; Hamanaka, Nobuyuki

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 162 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705091	A1	19970213	WO 1996-JP1833	19960702 <--
W: JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 845451	A1	19980603	EP 1996-921146	19960702 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 6018068	A	20000125	US 1998-102	19980126 <--
US 6197993	B1	20010306	US 1999-440674	19991116 <--
US 2001005760	A1	20010628	US 2001-765676	20010122 <--
US 6335366	B2	20020101		
US 2003023096	A1	20030130	US 2001-21060	20011219 <--
PRIORITY APPLN. INFO.:			JP 1995-209279	A 19950726 <--
			WO 1996-JP1833	W 19960702 <--
			US 1998-102	A3 19980126 <--
			US 1999-440674	XX 19991116 <--
			US 2001-765676	A3 20010122 <--

OTHER SOURCE(S): MARPAT 126:211923

ED Entered STN: 05 Apr 1997

AB Naphthyloxyacetate acid derivs. represented by general formula [I; A = H, C1-4 alkylene-CO2R1, C1-4 alkylene-CONR2R3, C1-4 hydroxyalkyl, tetrazolyl-C1-4 alkyl, cyano-C1-4 alkyl; wherein R1 - R3 = H, C1-4 alkyl; E = a single bond or C1-6 alkylene; G = S, SO, SO2, O or NR4; L = C1-6 alkylene, (CH2)mCH:CH(CH2)n or (CH2)xCH(OH)(CH2)y; wherein m, n, y = 0, 1-3; x = 1-3; M = Ph, PhS, PhO, PhNH, Ph2CH, Ph2CHS, Ph2CHO, or Ph2CHNH, each Ph group being optionally substituted by 1-3 of C1-4 alkyl, C1-4 alkoxy, halo, NO2, or CF3; provisos are given] or nontoxic salt, acid addition salts, or hydrates thereof are prepared. These compds. bind to PGE2 receptors and exhibit an antagonistic or agonistic effect thereon and are useful as hypolipidemics, medicines for preventing miscarriage, analgesics, antidiarrhea agents, drugs for sleep induction and abortion, diuretics, antidiabetics, purgatives, antiulcer agents, drugs for gastritis, antihypertensives, etc. Thus, TsOCH2CH(OTHP)CH2OPh (preparation given) was condensed with 1-(2-acetylthioethyl)-6-(methoxymethoxy)naphthalene (preparation given) in the presence of NaOEt in EtOH at room temperature for 1 h followed by treatment with a mixture of 4 N aqueous HCl, EtOAc, and MeOH to give the title compound (II). II in vitro inhibited the binding of [3H]PGE2 to CHO cells expressing prostanoid receptor subtype (mouse EP3 α) with Ki value of 0.0086 μ M. A tablet formulation containing II was prepared.

IC ICM C07C043-178

ICS C07C043-196; C07C043-23; C07C217-30; C07C217-48; C07C317-18;
C07C317-20; C07C317-22; C07C323-16; C07C323-17; C07C323-18;
C07D257-04; A61K031-075; A61K031-085; A61K031-095; A61K031-10;

- A61K031-135; A61K031-40
- CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1
- ST naphthylxyacetic acid prepn PGE antagonist agonist;
prostaglandin E2 receptor antagonist agonist; hypolipidemic
naphthylxyacetic acid; miscarriage prevention naphthylxyacetic acid;
analgesic naphthylxyacetic acid; antidiarrhea agent naphthylxyacetic
acid; sleep induction naphthylxyacetic acid; abortion naphthylxyacetic
acid; diuretic naphthylxyacetic acid; antidiabetic naphthylxyacetic
acid; purgative naphthylxyacetic acid; antiulcer agent naphthylxyacetic
acid; gastritis naphthylxyacetic acid; antihypertensive naphthylxyacetic
acid
- IT Prostanoid receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(antagonists and agonists; preparation of naphthylxyacetic acid
derivs. with binding activity to prostaglandin E2 receptor as
drugs)
- IT Stomach, disease
(gastritis; preparation of naphthylxyacetic acid derivs. with
binding activity to prostaglandin E2 receptor as drugs)
- IT Abortion
(induced; preparation of naphthylxyacetic acid derivs. with
binding activity to prostaglandin E2 receptor as drugs)
- IT Analgesics
Antidiabetic agents
Antihypertensives
Antiulcer agents
Diarrhea
Diuretics
Hypnotics and Sedatives
Hypolipemic agents
Laxatives
(preparation of naphthylxyacetic acid derivs. with binding
activity to prostaglandin E2 receptor as drugs)
- IT Abortion
(spontaneous, prevention; preparation of naphthylxyacetic acid
derivs. with binding activity to prostaglandin E2 receptor as
drugs)
- IT 363-24-6, Prostaglandin E2
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL
(Biological study); PROC (Process)
(preparation of naphthylxyacetic acid derivs. with binding
activity to prostaglandin E2 receptor as drugs)
- IT 187981-08-4P 187981-09-5P 187981-10-8P 187981-11-9P 187981-12-0P
187981-13-1P 187981-14-2P 187981-15-3P 187981-16-4P 187981-17-5P
187981-18-6P 187981-19-7P 187981-20-0P 187981-21-1P 187981-22-2P
187981-23-3P 187981-24-4P 187981-25-5P 187981-26-6P 187981-27-7P
187981-28-8P 187981-29-9P 187981-30-2P 187981-31-3P 187981-32-4P
187981-33-5P 187981-34-6P 187981-35-7P 187981-36-8P 187981-37-9P
187981-38-0P 187981-39-1P 187981-40-4P 187981-41-5P 187981-42-6P
187981-43-7P 187981-44-8P 187981-45-9P 187981-46-0P 187981-47-1P
187981-48-2P 187981-50-6P 187981-52-8P 187981-54-0P 187981-56-2P
187981-58-4P 187981-60-8P 187981-62-0P 187981-64-2P 187981-65-3P
187981-66-4P 187981-67-5P 187981-69-7P 187981-70-0P 187981-72-2P
187981-73-3P 187981-74-4P 187981-75-5P 187981-76-6P 187981-77-7P
187981-78-8P 187981-79-9P 187981-80-2P 187981-81-3P 187981-82-4P
187981-83-5P 187981-84-6P 187981-85-7P 187981-86-8P 187981-87-9P

187981-88-0P 187981-89-1P 187981-90-4P 187981-91-5P 187981-92-6P
 187981-93-7P 187981-94-8P 187981-95-9P 187981-96-0P 187981-97-1P
 187981-99-3P 187982-00-9P 187982-02-1P 187982-04-3P 187982-06-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of naphthyloxyacetic acid derivs. with binding activity to prostaglandin E2 receptor as drugs)

IT 74-89-5, Methylamine, reactions 84-58-2, 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 91-01-0, Diphenylmethanol 93-56-1, 1-Phenyl-1,2-ethanediol 96-32-2, Methyl bromoacetate 98-59-9, p-Toluenesulfonyl chloride 100-79-8, 2,2-Dimethyl-1,3-dioxolane-4-methanol 106-44-5, 4-Methylphenol, reactions 106-48-9, 4-Chlorophenol 107-30-2, Methoxymethyl chloride 108-95-2, Phenol, reactions 108-98-5, Thiophenol, reactions 110-87-2, Dihydropyran 119-56-2, 4-Chlorobenzhydrol 122-60-1 135-76-2, Sodium 6-hydroxy-2-naphthalenesulfonate 150-76-5, 4-Methoxyphenol 383-63-1, Ethyl trifluoroacetate 540-51-2, 2-Bromoethanol 541-41-3, Ethyl chloroformate 590-17-0, Bromoacetonitrile 1779-49-3, Methyltriphenylphosphonium bromide 3422-02-4, Benzyl phenylcarbamate 7677-24-9, Trimethylsilyl cyanide 10387-40-3, Potassium thioacetate 14347-78-5, (R)-2,2-Dimethyl-1,3-dioxolane-4-methanol 15677-02-8, Carboxymethylenetriphenylphosphorane 22323-82-6, (S)-2,2-Dimethyl-1,3-dioxolane-4-methanol 26628-22-8, Sodium azide 33892-75-0, 5-Methoxy-1-tetralone

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of naphthyloxyacetic acid derivs. with binding activity to prostaglandin E2 receptor as drugs)

IT 538-43-2P 3813-01-2P 7305-59-1P 20816-78-8P 40348-74-1P
 53379-98-9P 68938-62-5P 69269-77-8P 77204-19-4P 98218-37-2P
 187982-10-1P 187982-12-3P 187982-14-5P 187982-19-0P 187982-21-4P
 187982-23-6P 187982-25-8P 187982-27-0P 187982-29-2P 187982-31-6P
 187982-32-7P 187982-33-8P 187982-34-9P 187982-35-0P 187982-36-1P
 187982-37-2P 187982-38-3P 187982-39-4P 187982-40-7P 187982-41-8P
 187982-42-9P 187982-43-0P 187982-44-1P 187982-45-2P 187982-46-3P
 187982-47-4P 187982-48-5P 187982-49-6P 187982-50-9P 187982-51-0P
 187982-52-1P 187982-53-2P 187982-54-3P 187982-55-4P 187982-56-5P
 187982-57-6P 187982-58-7P 187982-59-8P 187982-60-1P 187982-61-2P
 187982-62-3P 187982-63-4P 187982-64-5P 187982-65-6P 188004-53-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of naphthyloxyacetic acid derivs. with binding activity to prostaglandin E2 receptor as drugs)

L119 ANSWER 29 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:120865 HCAPLUS Full-text

DOCUMENT NUMBER: 126:132228

TITLE: Polycarbonate compositions containing sulfoxides

INVENTOR(S): Mya, Shinya; Kanayama, Satoshi

PATENT ASSIGNEE(S): Mitsubishi Enjiniaringu Purasuchikkusu, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08311322	A	19961126	JP 1995-142417	19950518 <--

JP 3373330 B2 20030204
 PRIORITY APPLN. INFO.: JP 1995-142417 19950518 <--
 OTHER SOURCE(S): MARPAT 126:132228
 ED Entered STN: 21 Feb 1997
 AB The compns. contain 100 parts polycarbonates and 0.01-5 parts sulfoxides R1S(O)R2, R3S(O)(R4S(O))nR5, or I (R1-3, R5 = C1-30 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, arylalkenyl, acylalkyl, alkoxyalkyl, aryloxyalkyl, alkoxy, alkoxy carbonyl, pyridyl; where the aryl, arylalkyl, arylalkenyl, and aryloxyalkyl are mononuclear groups and may be substituted with C1-4 alkyl, halo, NO2, NH2, CO2H, CO2Me, OH, and/or OMe at the nuclei and the acylalkyl, alkoxyalkyl, and aryloxyalkyl may have ≥ 2 of acyl, alkoxy, or aryloxy groups at the alkyl chains; R1-3, R5 may be bonded through covalent bonds; R4, R6, R7 = C1-15 alkylene, alkenylene, arylene; where the arylene is a mononuclear group that may be substituted with C1-4 alkyl, halo, NO2, NH2, CO2H, CO2Me, OH, and/or OMe at the nucleus; n = 1-100). The compns. are resistant to discoloration by ionizing radiation and are useful for medical devices. Iupilon S 2000 (100 parts) was mixed with 1 part Ph2S(O), pelletized, and injection molded to give test pieces, which showed yellowness index 12.3 after 25 kGy 60Co γ ray irradiation
 IC ICM C08L069-00
 ICS C08K005-41
 CC 37-6 (Plastics Manufacture and Processing)
 Section cross-reference(s): 38, 63
 ST polycarbonate discoloration prevention sulfoxide; radiation
 discoloration prevention polycarbonate sulfoxide
 IT Sulfoxides
 RL: MOA (Modifier or additive use); PRP (Properties); TEM (Technical or engineered material use); USES (Uses)
 (discoloration prevention agents; polycarbonate compns. containing sulfoxides with low discoloration by ionizing radiation)
 IT Ionizing radiation
 (polycarbonate compns. containing sulfoxides with low discoloration by ionizing radiation)
 IT Polycarbonates, properties
 RL: POF (Polymer in formulation); PRP (Properties); TEM (Technical or engineered material use); USES (Uses)
 (polycarbonate compns. containing sulfoxides with low discoloration by ionizing radiation)
 IT Medical goods
 (polycarbonate compns. containing sulfoxides with low discoloration by ionizing radiation for)
 IT Discoloration prevention agents
 (sulfoxides; polycarbonate compns. containing sulfoxides with low discoloration by ionizing radiation)
 IT 621-08-9, Dibenzyl sulfoxide 945-51-7, Diphenyl sulfoxide 1193-82-4, Phenyl methyl sulfoxide 1600-44-8, Tetramethylene sulfoxide 2168-93-6, Dibutyl sulfoxide
 RL: MOA (Modifier or additive use); PRP (Properties); TEM (Technical or engineered material use); USES (Uses)
 (discoloration prevention agent; polycarbonate compns. containing sulfoxides with low discoloration by ionizing radiation)
 IT 24936-68-3, Iupilon S 2000, properties 25037-45-0, Bisphenol A-carbonic acid copolymer
 RL: POF (Polymer in formulation); PRP (Properties); TEM (Technical or engineered material use); USES (Uses)
 (polycarbonate compns. containing sulfoxides with low discoloration by ionizing radiation)

L119 ANSWER 30 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:605797 HCAPLUS Full-textDOCUMENT NUMBER: 121:205797TITLE: Preparation and formulation of
17-acylandrosta-3,5-diene-3-carboxylates as steroid
5 α -reductase inhibitors

INVENTOR(S): Holt, Dennis Alan; Levy, Mark Alan

PATENT ASSIGNEE(S): SmithKline Beckman Corp., USA

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9411386	A1	19940526	WO 1993-US11241	19931118 <--
W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9308538	A	19940913	ZA 1993-8538	19931116 <--
ZA 9308540	A	19940913	ZA 1993-8540	19931116 <--
CA 2149427	A1	19940526	CA 1993-2149427	19931118 <--
AU 9456717	A	19940608	AU 1994-56717	19931118 <--
CN 1101914	A	19950426	CN 1993-114775	19931118 <--
CN 1101916	A	19950426	CN 1993-121434	19931118 <--
EP 669932	A1	19950906	EP 1994-902307	19931118 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08503474	T	19960416	JP 1993-512507	19931118 <--
US 5641765	A	19970624	US 1995-436240	19950517 <--
US 5641877	A	19970624	US 1995-453865	19950530 <--
PRIORITY APPLN. INFO.:				
			GB 1992-24213	A 19921118 <--
			GB 1993-16954	A 19930814 <--
			WO 1993-US11241	W 19931118 <--
			US 1995-436240	A1 19950517 <--

OTHER SOURCE(S): MARPAT 121:205797

ED Entered STN: 29 Oct 1994

AB Title compds. [I; A = (saturated) hydrocarbylene; R = substituted alkyl, (un)substituted cycloalkyl, -heterocyclyl, -(hetero)aryl] were prepared. Thus, androst-4-en-3-one-17 β -carboxylic acid was converted in 4 steps to 17 β -(phenethylcarbonyl)androsta-3,5-diene-3-carboxylic acid. I had Ki of 2-85 and 0.2-7nM against isoenzyme 1 and 2 of steroid 5 α -reductase, resp.

IC ICM C07J003-00

ICS C07J005-00; C07J007-00; C07J009-00; C07J015-00; C07J017-00;

C07J033-00; C07J041-00; C07J043-00; C07J075-00

CC 32-4 (Steroids)

Section cross-reference(s): 1, 63

ST acylandrostadienecarboxylate prepn steroid reductase inhibitorIT Prostate gland(disease, prostatitis, treatment of,
acylandrostadienecarboxylates for)IT Prostate gland(neoplasm, adenocarcinoma, treatment of,
acylandrostadienecarboxylates for)

IT	139755-35-4P	139755-36-5P	146175-29-3P	156699-24-0P	156699-29-5P
	156699-30-8P	156699-33-1P	157977-50-9P	157977-51-0P	157977-52-1P
	157977-53-2P	157977-54-3P			

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of steroid 5 α -reductase inhibitor)

IT 156699-35-3P 157977-40-7P 157977-41-8P 157977-42-9P 157977-43-0P
157977-44-1P 157977-45-2P 157977-46-3P 157977-47-4P 157977-48-5P
157977-49-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of, as steroid 5 α -reductase inhibitor)

IT 302-97-6, Androst-4-en-3-one-17 β -carboxylic acid 1462-75-5,
3-Phenylpropylmagnesium bromide 2127-03-9, 2,2'-Dipyridyl disulfide
3277-89-2, Phenethylmagnesium bromide 6921-34-2, Benzylmagnesium
chloride 35166-78-0, Cyclohexylmethylmagnesium bromide 36278-54-3,
2-(4-Methoxyphenyl)ethylmagnesium bromide 55766-17-1,
2-Cyclohexylethylmagnesium bromide 119169-78-7 126201-52-3
157977-55-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of steroid 5 α -reductase inhibitor)

L119 ANSWER 31 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:604953 HCAPLUS Full-text

DOCUMENT NUMBER: 121:204953

TITLE: Preparation of benzophenone hydrazones as pesticides

INVENTOR(S): Hall, Roger Graham; Pascual, Alfons; Kristiansen, Odd

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 31 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 581725	A1	19940202	EP 1993-810461	19930629 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5340837	A	19940823	US 1993-83245	19930625 <--
CA 2099820	A1	19940108	CA 1993-2099820	19930705 <--
HU 65079	A2	19940428	HU 1993-1955	19930705 <--
AU 9341775	A	19940113	AU 1993-41775	19930706 <--
ZA 9304833	A	19940202	ZA 1993-4833	19930706 <--
BR 9302770	A	19940208	BR 1993-2770	19930706 <--
CN 1084510	A	19940330	CN 1993-108008	19930706 <--
MX 9304052	A	20000430	MX 1993-4052	19930706 <--
JP 06184079	A	19940705	JP 1993-192916	19930707 <--
US 5405871	A	19950411	US 1994-223795	19940406 <--
PRIORITY APPLN. INFO.:			CH 1992-2147	A 19920707 <--
			US 1993-83245	A3 19930625 <--

OTHER SOURCE(S): MARPAT 121:204953

ED Entered STN: 29 Oct 1994

AB Title compds. [I; o, p = 0-5; R1, R2 = alkyl, haloalkyl, halo, NO2, OH, alkoxy, haloalkoxy, alkylthio, haloalkylthio, PhO, sulfonylamino, etc.; R1R1, R2R2 = atoms to form rings; R3 = H, alkyl, haloalkyl; R4 = R3, (substituted) Ph, naphthyl; R5 = SR7, SOR7, SO2R7, NO2, cyano, COR8, CO2R8; R7 = alkyl, cycloalkyl, haloalkyl, (substituted) Ph, etc.; R8 = alkyl, haloalkyl,

(substituted) Ph; X = N, CR9; R9 = H, alkyl, haloalkyl, cyano, acyl], were prepared Thus, 4-chloro-4'-trifluoromethylsulfonyloxybenzophenone hydrazone in dioxane was treated with 1-aza-1-ethanesulfonyl-3-oxapent-1-ene and Et3N followed by 17 h reflux to give title compound II and 1,3-diene tautomer. Numerous I as 400 ppm emulsions gave > 80% control of Spodoptera littoralis on soybean plants.

IC ICM C07C311-51
ICS C07C309-65; C07D317-46; C07C251-86; A01N041-04; A01N041-06;
A01N043-30; A01N035-10

CC 25-16 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 5

ST benzophenone hydrazone prepn pesticide; insecticide benzophenone
hydrazone

IT 158063-73-1P 158063-74-2P 158063-75-3P 158063-76-4P 158063-77-5P
158063-78-6P 158063-79-7P 158063-80-0P 158063-81-1P 158063-82-2P
158063-83-3P 158063-84-4P 158063-85-5P 158063-86-6P 158063-87-7P
158063-88-8P 158063-89-9P 158063-90-2P 158063-91-3P 158063-92-4P
158063-93-5P 158063-94-6P 158063-95-7P 158063-96-8P 158063-97-9P
158063-98-0P 158063-99-1P 158064-00-7P 158064-01-8P 158064-02-9P
158064-03-0P 158064-04-1P 158064-05-2P 158064-06-3P 158064-07-4P
158064-08-5P 158064-09-6P 158064-10-9P 158064-11-0P 158064-12-1P
158064-13-2P 158064-14-3P 158064-15-4P 158064-16-5P 158064-17-6P
158064-18-7P 158064-19-8P 158064-20-1P 158064-21-2P 158064-22-3P
158064-23-4P 158064-24-5P 158064-25-6P 158064-26-7P 158064-27-8P
158064-28-9P 158064-29-0P 158064-30-3P 158064-31-4P 158064-32-5P
158064-33-6P 158064-34-7P 158064-35-8P 158064-36-9P 158064-37-0P
158064-38-1P 158064-39-2P 158064-40-5P 158064-41-6P 158064-42-7P
158064-43-8P 158064-44-9P 158064-45-0P 158064-46-1P 158064-47-2P
158064-48-3P 158064-49-4P 158064-50-7P 158064-51-8P 158064-52-9P
158064-53-0P 158064-54-1P 158064-55-2P 158064-56-3P 158064-57-4P
158064-58-5P 158064-59-6P 158064-60-9P 158064-61-0P 158064-62-1P
158064-63-2P 158064-64-3P 158064-65-4P 158064-66-5P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except
adverse); BSU (Biological study, unclassified); SPN (Synthetic
preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as pesticide)

IT 123-54-6, Pentane-2,4-dione, reactions 65672-02-8 78930-87-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of pesticide)

L119 ANSWER 32 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:107004 HCAPLUS Full-text

DOCUMENT NUMBER: 120:107004

TITLE: Imidazole histamin H3 receptors antagonists

INVENTOR(S): Schwartz, Jean Charles; Arrang, Jean Michel; Garbarg,
Monique; Lecomte, Jeanne Marie; Ganellin, Charon
Robin; Fkyerat, Abdellatif; Tertiuk, Wasyl; Schunack,
Walter; Lipp, Ralph; et al.

PATENT ASSIGNEE(S): Institut National de la Sante et de la Recherche
Medicale (INSERM), Fr.; Societe Civile Bioprojet

SOURCE: PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9314070	A2	19930722	WO 1993-FR15	19930108 <--

WO 9314070 A3 19930819
W: CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
FR 2686084 A1 19930716 FR 1992-189 19920110 <--
FR 2686084 B1 19951222
CA 2105867 A1 19930711 CA 1993-2105867 19930108 <--
CA 2105867 C 19930722
EP 597088 A1 19940518 EP 1993-914482 19930108 <--
EP 597088 B1 20001206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
JP 06506003 T 19940707 JP 1993-512191 19930108 <--
JP 3829259 B2 20061004
AT 197951 T 20001215 AT 1993-914482 19930108 <--
ES 2154270 T3 20010401 ES 1993-914482 19930108 <--
PT 597088 T 20010430 PT 1993-914482 19930108 <--
US 5559113 A 19960924 US 1994-117161 19940128 <--
US 5708171 A 19980113 US 1996-663679 19960614 <--
US 37303 E1 20010731 US 2000-544755 20000406 <--
GR 3035414 T3 20010531 GR 2001-400244 20010214 <--
PRIORITY APPLN. INFO.: FR 1992-189 A 19920110 <--
WO 1993-FR15 W 19930108 <--
US 1994-117161 A3 19940128 <--

OTHER SOURCE(S): MARPAT 120:107004

ED Entered STN: 05 Mar 1994

AB The title compds. I and II [A = (un)saturated (un)branched (un)substituted hydrocarbon chain; B = (CH₂)_n, (CH₂)_mO, (CH₂)ms; m = 1,2; n = 0-5; C2-8 alkylene; X = O, S, (un)substituted NH, NHCO, NHCONH, NHCSNH, NHCS, O₂C, CO₂, etc.; Y = (un)branched C1-8 alkyl, C3-6 cycloalkyl, bicycloalkyl, cycloalkenyl, (un)substituted aryl, 5- or 6-membered heterocyclic group, etc.] which are histamine H₃ receptor antagonists and useful as sedatives, anticonvulsants, psychostimulants, antiallergics, antiulcer drugs (no data), etc., are prepared Thus, 3-cyclopentylpropanoyl chloride was esterified with 3-(1H-imidazol-4-yl)propanol hydrochloride and the intermediate ester was neutralized with maleic acid to give 3-(1H-imidazol-4-yl)propyl 3-cyclopentylpropanoate maleic acid salt (III). III had an apparent inhibition constant for rat brain H₃ histamine receptors of 3 nM.

IC ICM C07D233-64

ICS C07D233-84; C07D403-12; C07D401-12; C07D417-12; A61K031-415

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

ST imidazole prepn histamine receptor antagonist; antiulcer imidazole prepn; sedative imidazole prepn; anticonvulsant imidazole prepn; psychostimulant imidazole prepn; antiallergic imidazole prepn

IT 7728-79-2P 152028-19-8P 152028-20-1P 152028-21-2P 152028-23-4P
152028-25-6P 152028-27-8P 152028-29-0P 152028-31-4P 152028-33-6P
152028-35-8P 152028-37-0P 152028-39-2P 152028-41-6P 152028-43-8P
152028-45-0P 152028-47-2P 152028-49-4P 152028-51-8P 152028-53-0P
152028-55-2P 152028-56-3P 152028-59-6P 152028-61-0P 152028-62-1P
152028-64-3P 152028-66-5P 152028-68-7P 152028-70-1P 152028-72-3P
152028-74-5P 152028-76-7P 152028-78-9P 152028-80-3P 152028-83-6P
152028-85-8P 152028-88-1P 152028-91-6P 152028-93-8P 152028-95-0P
152028-97-2P 152028-99-4P 152029-01-1P 152029-03-3P 152029-05-5P
152029-08-8P 152029-10-2P 152029-15-7P 152029-17-9P 152029-18-0P
152029-19-1P 152029-20-4P 152029-22-6P 152029-25-9P 152029-27-1P
152029-29-3P 152029-31-7P 152029-33-9P 152029-35-1P 152029-36-2P
152029-38-4P 152029-42-0P 152029-44-2P 152029-46-4P 152029-48-6P
152029-50-0P 152029-52-2P 152029-53-3P 152029-54-4P 152029-55-5P
152029-57-7P 152029-59-9P 152029-61-3P 152029-63-5P 152029-65-7P
152029-67-9P 152029-69-1P 152029-71-5P 152029-73-7P 152029-75-9P

152029-77-1P 152029-79-3P 152029-81-7P 152029-83-9P 152029-84-0P
 152029-86-2P 152029-88-4P 152029-89-5P 152029-91-9P 152029-93-1P
 152029-94-2P 152029-95-3P 152029-97-5P 152029-98-6P 152030-00-7P
 152030-02-9P 152030-04-1P 152030-05-2P 152030-07-4P 152030-09-6P
 152030-11-0P 152030-12-1P 152030-14-3P 152030-15-4P 152030-16-5P
 152030-17-6P 152030-18-7P 152030-19-8P 152030-21-2P 152030-22-3P
 152030-24-5P 152030-26-7P 152030-28-9P 152030-30-3P 152030-31-4P
 152030-33-6P 152030-35-8P 152030-36-9P 152030-38-1P 152030-39-2P
 152030-41-6P 152030-43-8P 152030-45-0P 152030-46-1P 152030-47-2P
 152030-48-3P 152030-51-8P 152030-56-3P 152645-93-7P 152645-94-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and histamine H3 receptor antagonists activity of)
 IT 152029-07-7P 152029-12-4P 152029-16-8P 152029-40-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and histamine H3 receptor antagonists activity of,
reaction of)
 IT 38603-70-2P 152028-57-4P 152030-49-4P 152030-50-7P 152030-52-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, in preparation of
 histamine H3 receptor antagonists)
 IT 51-45-6, Histamine, reactions 60-23-1, 2-Aminoethanethiol
 76-83-5, Triphenylmethyl chloride 86-52-2 90-15-3, 1-Naphthol
 95-89-6, 2-Chloro-3,6-dimethylpyrazine 99-76-3, Methyl 4-hydroxybenzoate
 100-00-5, 1-Chloro-4-nitrobenzene 100-02-7, 4-Nitrophenol,
reactions 100-14-1, 4-Nitrobenzyl chloride 103-71-9,
 Phenylisocyanate, reactions 104-12-1, 4-Chlorophenylisocyanate
 104-83-6 106-41-2, 4-Bromophenol 109-04-6, 2-Bromopyridine 118-93-4,
 2-Hydroxyacetophenone 120-47-8 123-07-9, 4-Ethylphenol 135-19-3,
 2-Naphthol, reactions 150-76-5, 4-Methoxyphenol 329-01-1,
 3-Trifluoromethylphenylisocyanate 371-41-5, 4-Fluorophenol 402-45-9,
 4-Trifluoromethylphenol 554-84-7, 3-Nitrophenol 591-35-5,
 3,5-Dichlorophenol 615-20-3, 2-Chlorobenzothiazole 622-58-2,
 4-Methylphenylisocyanate 637-59-2 645-56-7, 4-Propylphenol 673-50-7
 767-00-0, 4-Cyanophenol 771-61-9, Pentafluorophenol 872-35-5,
 2-Mercaptoimidazole 872-82-2, 1H-Imidazole-4-ethanol 873-62-1,
 3-Hydroxybenzonitrile 1072-95-3 1124-62-5 1195-45-5,
 4-Fluorophenylisocyanate 1462-75-5, 3-Phenylpropylmagnesium bromide
 1548-13-6, 4-Trifluoromethylphenylisocyanate 1722-12-9,
 2-Chloropyrimidine 1849-36-1, 4-Nitrothiophenol 1943-82-4,
 2-Phenylethylisocyanate 2285-12-3, 2-Trifluoromethylphenylisocyanate
 2637-34-5, 2-Mercaptopyridine 3034-53-5, 2-Bromothiazole 3173-53-3,
 Cyclohexylisocyanate 3173-56-6, Benzylisocyanate 3218-02-8,
 Cyclohexylmethanamine 3320-86-3, 2-Nitrophenylisocyanate 3465-72-3,
 trans-Urocanic acid 4461-33-0, Benzoylisocyanate 4548-45-2,
 2-Chloro-5-nitropyridine 4830-93-7 5470-18-8, 2-Chloro-3-nitropyridine
 6429-10-3 13198-73-7 13400-46-9, 1H-Imidazole-4-methanamine
 14432-16-7, 2-Chloro-4-nitropyridine N-oxide 14508-49-7,
 2-Chloropyrazine 14649-03-7 15845-62-2, 4-Iodophenylisocyanate
 23138-56-9 23785-22-0, 4-Chloromethylimidazole 24734-68-7,
 3-Phenylpropylmercaptan 25694-89-7, Cyclopropylmethylisocyanate
 30280-44-5, 4-Chlorobenzylisocyanate 32366-02-2, N-Benzyl-N-
 methylcarbamoyl chloride 32385-58-3 32673-41-9 33375-06-3
 38585-61-4 40546-33-6, 1H-Imidazole-4-propanamine 49549-75-9,
 1H-Imidazole-4-propanol 52334-81-3, 2-Chloro-5-trifluoromethylpyridine
 54589-53-6 55245-73-3 63289-53-2, 4-Nitrobenzylisocyanate 64473-34-3
 64747-82-6 68664-23-3 73781-91-6 74003-34-2 79463-77-7
 82258-76-2 84157-77-7 99935-67-8 102422-55-9 104091-57-8
 111016-57-0 122394-21-2 127607-62-9 128255-31-2,
 2-Iodophenylisocyanate 132740-43-3 141400-29-5 152028-81-4

152028-86-9 152028-89-2 152029-13-5 152029-23-7 152029-85-1
152029-95-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of histamine H3 receptor
antagonists)

L119 ANSWER 33 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:105966 HCAPLUS Full-text
DOCUMENT NUMBER: 116:105966
TITLE: Preparation of Δ^2 -cephem sulfones as
elastase inhibitors
INVENTOR(S): Bissolino, Pier Luigi; Alpegiani, Marco; Perrone,
Ettore; Cassinelli, Giuseppe
PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.r.l., Italy
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 457381	A2	19911121	EP 1991-200943	19910419 <--
EP 457381	A3	19920708		
EP 457381	B1	19960306		
R: DE, GB, IT				
JP 04226995	A	19920817	JP 1991-139708	19910515 <--
PRIORITY APPLN. INFO.:			GB 1990-10941	A 19900516 <--
OTHER SOURCE(S): MARPAT 116:105966				
ED Entered STN: 20 Mar 1992				
AB Title compds. I [R7 = halo, C1-4 alkoxy; R4 = CHR5CHR6Y, CR5:CHY; R5,R6 = H, (substituted) C1-7 alkyl, Ph, CH2Ph; R5R6 = (carboxy)propylene, (carboxy)butylene; Y = electron-withdrawing group; R = H, C1-7 alkyl, (substituted) CH2Ph, Ph2CH; R3 = Me, C1-4 alkoxyethyl; R2 = H, R4] were <u>prepared</u> as elastase inhibitors useful for the treatment of inflammatory and degenerative <u>diseases</u> . Thus, benzhydryl 7 α -chloro-3-methyl-3-cephem-4-carboxylate-1,1-dioxide was dissolved in MeCOCH:CH2, the solution was cooled to 0°, and Et3N was added. The mixture was stirred 1 h at 0° to give title compound I (R7 = Cl, R4 = CH2CH2COMe, R = Ph2CH, R3 = Me, R2 = H). Kinetic parameters for inhibition of human leukocyte elastase by other I were determined				
IC ICM C07D501-00				
ICS A61K031-545				
CC 26-5 (Biomolecules and Their Synthetic Analogs)				
Section cross-reference(s): 1				
ST cephem sulfone <u>prepn</u> antiinflammatory; elastase inhibitor cephem sulfone; degenerative <u>disease</u> treatment cephem sulfone				
IT Respiratory distress <u>syndrome</u>				
(adult, treatment of, Δ^2 -cephem sulfones for)				
IT <u>Disease</u>				
(degenerative, treatment of, Δ^2 -cephem sulfones for)				
IT 138831-30-8P 138831-31-9P 138831-32-0P 138831-33-1P 138831-34-2P				
138831-35-3P 138831-36-4P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of, as elastase inhibitor)				
IT 13831-03-3, tert-Butyl propiolate				
RL: RCT (Reactant); RACT (Reactant or reagent)				
(reaction of)				

IT 137115-97-0 138831-29-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with Me vinyl ketone, in preparation of elastase inhibitors)

IT 78-94-4, Methyl vinyl ketone, reactions
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with cephem sulfone derivative, in preparation of elastase inhibitors)

IT 138831-28-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with tert-Bu propiolate, in preparation of elastase inhibitors)

L119 ANSWER 34 OF 34 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:126134 HCAPLUS Full-text

DOCUMENT NUMBER: 98:126134

TITLE: 1,4-Thiazanecarboxylic acid derivatives and their use

PATENT ASSIGNEE(S): MUDIT Societe Fiduciaire Enregistree, Liechtenstein

SOURCE: Belg., 68 pp.

CODEN: BEXXAL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 893025	A1	19821029	BE 1982-207967	19820429 <--
WO 8203860	A1	19821111	WO 1982-BE9	19820421 <--
W: AT, AU, CH, DE, DK, FI, GB, JP, NL, NO, SE, US				
AU 8283941	A	19821207	AU 1982-83941	19820421 <--
NL 8220153	A	19830301	NL 1982-20153	19820421 <--
DE 3242665	T0	19830407	DE 1982-3242665	19820421 <--
JP 58500713	T	19830506	JP 1982-501451	19820421 <--
JP 03030592	B	19910430		
GB 2111056	A	19830629	GB 1982-35353	19820421 <--
GB 2111056	B	19850306		
FR 2509303	A1	19830114	FR 1982-7461	19820429 <--
ZA 8202926	A	19830330	ZA 1982-2926	19820429 <--
DK 8205543	A	19821214	DK 1982-5543	19821214 <--
FI 8204279	A	19821214	FI 1982-4279	19821214 <--
FI 66366	B	19840629		
SE 8207294	A	19821221	SE 1982-7294	19821221 <--
NO 8204398	A	19821228	NO 1982-4398	19821228 <--
PRIORITY APPLN. INFO.:			LU 1981-83327	A 19810429 <--
			BE 1981-83327	A 19810429 <--
			WO 1982-BE9	A 19820421 <--

OTHER SOURCE(S): CASREACT 98:126134; MARPAT 98:126134

ED Entered STN: 12 May 1984

AB Title compds. I [n = 0, 1, 2; R = H, alkyl, acyl, CONH2; R1 and R2 (same or different) are H, alkyl, Ph, halo-, alkyl-, or alkoxyphenyl, or R1 and R2 form a spiro ring which can contain hetero atoms; R3 = OH, (un)substituted alkyl, (un) substituted amino, 3-phthalidyloxy, 1-succinimidoethoxy, or R and R3 form a fused hydantoin ring; R4 and R5 (same or different) are H, alkyl, Ph, halo-, alkyl-, or alkoxyphenyl, (un)esterified CH2CO2H; R6 = H, alkyl, Ph, halo-, alkyl-, or alkoxyphenyl] were prepared, and they exhibited antithrombotic activity. Penicillamine was converted to S-(2-hydroxyethyl)penicillamine and S-(2-chloroethyl)penicillamine hydrochloride (II), and II was heated with Et3N in DMF to give I (R = R4 = R5 = R6 = H, R1 = R2 = Me, R3 = OH, n = 0).

ICI A61

CC 28-14 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63

ST thiazanecarboxylic acid prepn antithrombotic

IT 106-95-6, reactions 540-51-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (etherification by, of penicillamine)

IT 83573-53-9P 84915-43-5P 84915-46-8P 84915-48-0P 84915-49-1P
 84915-52-6P 84915-54-8P 84915-55-9P 84915-56-0P 84915-57-1P
 84915-58-2P 84915-59-3P 84915-60-6P 84915-61-7P 84915-62-8P
 84915-63-9P 84915-64-0P 84915-65-1P 84915-66-2P 84915-67-3P
 84915-68-4P 84915-69-5P 84915-70-8P 84915-71-9P 84915-72-0P
 84915-73-1P 84915-74-2P 84915-76-4P 84915-78-6P 84915-79-7P
 84915-80-0P 84915-81-1P 84915-82-2P 84915-83-3P 84915-84-4P
 84915-85-5P 84915-86-6P 84915-87-7P 84915-88-8P 84935-17-1P
 84935-20-6P 84985-33-1P 84985-34-2P 84985-35-3P 84985-36-4P
 84985-39-7P 84985-40-0P 84985-41-1P 84985-42-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antithrombotic activity of)

IT 84915-45-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclization of)

IT 84915-50-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclocondensation of)

IT 84915-47-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrobromination of)

IT 84915-44-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, with hydrogen chloride)

IT 84915-89-9P 84915-90-2P 84915-91-3P 84915-92-4P 84915-94-6P
 84915-95-7P 84915-96-8P 84915-97-9P 84915-98-0P 84915-99-1P
 84916-00-7P 84916-01-8P 84916-02-9P 84916-03-0P 84916-04-1P
 84916-05-2P 84916-06-3P 84916-07-4P 84916-08-5P 84935-16-0P
 84935-18-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

IT 74-88-4, reactions
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (N-alkylation by, of thiazanecarboxylic acid derivative)

=> d que nos 183

```

L6          STR
L7          STR
L9          547 SEA FILE=REGISTRY SSS FUL L7
L12         339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
L32         QUE ABB=ON PLU=ON REDDY, E?/AU
L33         QUE ABB=ON PLU=ON REDDY, P?/AU
L34         QUE ABB=ON PLU=ON REDDY, M?/AU
L35         QUE ABB=ON PLU=ON REDDY, R?/AU
L36         QUE ABB=ON PLU=ON BELL, S?/AU
L37         QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
           )/CS,SO,PA
L39         QUE ABB=ON PLU=ON PROLIFER?
L40         QUE ABB=ON PLU=ON DISEAS? OR DISORDER? OR SYNDROM? OR
           MALADY OR SICKNESS OR ILLNESS OR CONDITION
L41         QUE ABB=ON PLU=ON HEMANGIOMAT?
L42         QUE ABB=ON PLU=ON MULTIPLE (W) SCLERO?
L43         QUE ABB=ON PLU=ON MS
L44         QUE ABB=ON PLU=ON MYELODEGENER?
L45         QUE ABB=ON PLU=ON ?DEGENER?(3A)?MYELO?
L46         QUE ABB=ON PLU=ON GANGLIONEUROMATO?
L47         QUE ABB=ON PLU=ON KELOID?
L48         QUE ABB=ON PLU=ON PAGET?
L49         QUE ABB=ON PLU=ON FIBROCYS?
L50         QUE ABB=ON PLU=ON COLORECT?
L51         QUE ABB=ON PLU=ON SKIN OR DERM? OR EPIDER?
L52         QUE ABB=ON PLU=ON BRAIN?
L53         QUE ABB=ON PLU=ON LEUKEM? OR LEUKAEM?
L54         QUE ABB=ON PLU=ON IONIZ? OR IONIS?
L55         QUE ABB=ON PLU=ON RADIATION
L56         QUE ABB=ON PLU=ON OPTIC?
L57         QUE ABB=ON PLU=ON ISOMER?
L58         QUE ABB=ON PLU=ON THERAP? OR DRUG OR PHARM? OR MEDIC?
L59         QUE ABB=ON PLU=ON SARCOID?
L60         QUE ABB=ON PLU=ON PERONIES
L61         QUE ABB=ON PLU=ON DUPUTREN
L62         QUE ABB=ON PLU=ON FIBROSIS
L63         QUE ABB=ON PLU=ON CIRRH?
L64         QUE ABB=ON PLU=ON ?ATHEROSCLERO? OR ANIATHEROSCLER?
L65         QUE ABB=ON PLU=ON ?VASCULAR?
L66         QUE ABB=ON PLU=ON RESTENO?
L67         QUE ABB=ON PLU=ON ?CANCER? OR ?CARCIN? OR ?ONCO? OR ?S
           ARCOM? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLAS? OR ?MALIGN? OR
           ?DYPLAS?
L68         QUE ABB=ON PLU=ON ANTICANCER? OR ANTICARCIN? OR ANTISA
           RCOM? OR ANTITUM? OR ANTINEOPLAS?
L69         QUE ABB=ON PLU=ON OVARY OR OVARIAN
L70         QUE ABB=ON PLU=ON BREAST OR MAMMAR?
L71         QUE ABB=ON PLU=ON PROSTAT?
L72         QUE ABB=ON PLU=ON TESTIS OR TESTIC?
L73         QUE ABB=ON PLU=ON LUNG
L74         QUE ABB=ON PLU=ON PULMONAR?
L75         QUE ABB=ON PLU=ON KIDNEY OR RENAL?
L77         15 SEA FILE=HCAPLUS ABB=ON PLU=ON L12
L78         6 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 AND (L39 OR L40 OR L41 OR
           L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
           L51 OR L52 OR L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR L59 OR
           L60 OR L61 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68 OR
           L69 OR L70 OR L71 OR L72 OR L73 OR L74 OR L75)

```

L79 QUE ABB=ON PLU=ON SYNTHES? OR SYNTH OR PREP? OR REACT?
 L80 QUE ABB=ON PLU=ON MANUFACT?
 L81 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 AND (L79 OR L80)
 L82 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 OR L78 OR L81
 L83 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L82 AND (L32 OR L33 OR L34 OR
 L35 OR L36 OR L37)

=> d que nos 192

L6 STR
 L7 STR
 L9 547 SEA FILE=REGISTRY SSS FUL L7
 L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
 L32 QUE ABB=ON PLU=ON REDDY, E?/AU
 L33 QUE ABB=ON PLU=ON REDDY, P?/AU
 L34 QUE ABB=ON PLU=ON REDDY, M?/AU
 L35 QUE ABB=ON PLU=ON REDDY, R?/AU
 L36 QUE ABB=ON PLU=ON BELL, S?/AU
 L37 QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
)/CS,SO,PA
 L90 264 SEA FILE=REGISTRY ABB=ON PLU=ON L12 AND USPATFULL/LC
 L91 1 SEA FILE=USPATFULL ABB=ON PLU=ON L90
 L92 1 SEA FILE=USPATFULL ABB=ON PLU=ON L91 AND (L32 OR L33 OR L34
 OR L35 OR L36 OR L37)

=> d que nos 196

L6 STR
 L7 STR
 L9 547 SEA FILE=REGISTRY SSS FUL L7
 L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
 L32 QUE ABB=ON PLU=ON REDDY, E?/AU
 L33 QUE ABB=ON PLU=ON REDDY, P?/AU
 L34 QUE ABB=ON PLU=ON REDDY, M?/AU
 L35 QUE ABB=ON PLU=ON REDDY, R?/AU
 L36 QUE ABB=ON PLU=ON BELL, S?/AU
 L37 QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
)/CS,SO,PA
 L94 323 SEA FILE=REGISTRY ABB=ON PLU=ON L12 AND TOXCENTER/LC
 L95 3 SEA FILE=TOXCENTER ABB=ON PLU=ON L94
 L96 3 SEA FILE=TOXCENTER ABB=ON PLU=ON L95 AND (L32 OR L33 OR L34
 OR L35 OR L36 OR L37)

=> d que nos 1108

L6 STR
 L32 QUE ABB=ON PLU=ON REDDY, E?/AU
 L33 QUE ABB=ON PLU=ON REDDY, P?/AU
 L34 QUE ABB=ON PLU=ON REDDY, M?/AU
 L35 QUE ABB=ON PLU=ON REDDY, R?/AU
 L36 QUE ABB=ON PLU=ON BELL, S?/AU
 L37 QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
)/CS,SO,PA
 L104 112 SEA FILE=WPIX SSS FUL L6
 L105 4 SEA FILE=WPIX ABB=ON PLU=ON L104/DCR
 L106 4 SEA FILE=WPIX ABB=ON PLU=ON (RAI11O/DCN OR RAI11Q/DCN OR
 RAI11R/DCN OR RAI11S/DCN OR RAI11T/DCN OR RAI11U/DCN OR
 RAI12A/DCN OR RAI12B/DCN OR RAI12C/DCN OR RAI12D/DCN OR
 RAI12E/DCN OR RAI12F/DCN OR RAI12G/DCN OR RAI12H/DCN OR
 RAI2CA/DCN OR RAI2CB/DCN OR RAI2CC/DCN OR RAI2CD/DCN OR

RAI2CE/DCN OR RAI2CF/DCN OR RAI2CG/DCN OR RAI2CH/DCN OR
 RAI2CJ/DCN OR RAI2CK/DCN OR RAI2CL/DCN OR RAI2CM/DCN OR
 RAI2CN/DCN OR RAI2CO/DCN OR RAI2CP/DCN OR RAI2CQ/DCN OR
 RAI2CR/DCN OR RAI2CS/DCN OR RAI2CT/DCN OR RAI2CU/DCN OR
 RAI2CV/DCN OR RAI2CW/DCN OR RAI2CX/DCN OR RAI2CY/DCN OR
 RAI2CZ/DCN OR RAI2C5/DCN OR RAI2C6/DCN OR RAI2C7/DCN OR
 RAI2C8/DCN OR RAI2C9/DCN OR RAI2DA/DCN OR RAI2DB/DCN OR
 RAI2DC/DCN OR RAI2DD/DCN OR RAI2DE/DCN OR RAI2DF/DCN OR
 RAI2DG/DCN OR RAI2DH/DCN OR RAI2DI/DCN OR RAI2DJ/DCN OR
 RAI2DK/DCN OR RAI2DL/DCN OR RAI2DM/DCN OR RAI2DN/DCN OR
 RAI2DO/DCN OR RAI2DP/DCN OR RAI2DQ/DCN OR RAI2DR/DCN OR
 RAI2DS/DCN OR RAI2DT/DCN OR RAI2DU/DCN OR RAI2DV/DCN OR
 RAI2DX/DCN OR RAI2DY/DCN OR RAI2DZ/DCN OR RAI2D0/DCN OR
 RAI2D1/DCN OR RAI2D2/DCN OR RAI2D3/DCN OR RAI2D4/DCN OR
 RAI2D5/DCN OR RAI2D6/DCN OR RAI2D7/DCN OR RAI2D8/DCN OR
 RAI2D9/DCN OR RAI2EA/DCN OR RAI2E0/DCN OR RAI2E1/DCN OR
 RAI2E2/DCN OR RAI2E3/DCN OR RAI2E4/DCN OR RAI2E5/DCN OR
 RAI2E6/DCN OR RAI2E7/DCN OR RAI2E8/DCN OR RAI2E9/DCN OR
 RAJKMO/DCN OR RAJKMP/DCN OR RAJKN1/DCN OR RAJKN2/DCN OR
 RAJKN3/DCN OR RAJKOB/DCN OR RAJKOC/DCN OR RAJKOD/DCN OR
 RAJKOE/DCN OR RAJKOF/DCN OR RAJKOG/DCN OR RAJKOH/DCN OR
 RAJKOI/DCN OR RAJKOO/DCN OR RANXKV/DCN OR RANXKW/DCN OR
 RANXKX/DCN OR RANXKY/DCN OR RANXKZ/DCN OR RANXL0/DCN OR
 RANXL1/DCN OR RANXL2/DCN)

L107 4 SEA FILE=WPIX ABB=ON PLU=ON L105 OR L106
 L108 4 SEA FILE=WPIX ABB=ON PLU=ON L107 AND (L32 OR L33 OR L34 OR
 L35 OR L36 OR L37)

=> d que nos 1126

L37 QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
)/CS,SO,PA
 L38 QUE ABB=ON PLU=ON (REDDY OR BELL)/AU
 L123 QUE ABB=ON PLU=ON UNSAT? OR ?ALKENYL?
 L124 QUE ABB=ON PLU=ON ?SULFOXID?
 L125 16 SEA FILE=JAPIO ABB=ON PLU=ON L123(7A)L124
 L126 0 SEA FILE=JAPIO ABB=ON PLU=ON L125 AND (L37 OR L38)

=> d que nos 1120

L6 STR
 L7 STR
 L9 547 SEA FILE=REGISTRY SSS FUL L7
 L12 339 SEA FILE=REGISTRY SUB=L9 SSS FUL L6
 L32 QUE ABB=ON PLU=ON REDDY, E?/AU
 L33 QUE ABB=ON PLU=ON REDDY, P?/AU
 L34 QUE ABB=ON PLU=ON REDDY, M?/AU
 L35 QUE ABB=ON PLU=ON REDDY, R?/AU
 L36 QUE ABB=ON PLU=ON BELL, S?/AU
 L37 QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
)/CS,SO,PA
 L39 QUE ABB=ON PLU=ON PROLIFER?
 L40 QUE ABB=ON PLU=ON DISEAS? OR DISORDER? OR SYNDROM? OR
 MALADY OR SICKNESS OR ILLNESS OR CONDITION
 L41 QUE ABB=ON PLU=ON HEMANGIOMAT?
 L42 QUE ABB=ON PLU=ON MULTIPLE (W) SCLERO?
 L43 QUE ABB=ON PLU=ON MS
 L44 QUE ABB=ON PLU=ON MYELODEGENER?
 L45 QUE ABB=ON PLU=ON ?DEGENER?(3A)?MYELO?
 L46 QUE ABB=ON PLU=ON GANGLIONEUROMATO?

L47 QUE ABB=ON PLU=ON KELOID?
 L48 QUE ABB=ON PLU=ON PAGET?
 L49 QUE ABB=ON PLU=ON FIBROCYS?
 L50 QUE ABB=ON PLU=ON COLORECT?
 L51 QUE ABB=ON PLU=ON SKIN OR DERM? OR EPIDER?
 L52 QUE ABB=ON PLU=ON BRAIN?
 L53 QUE ABB=ON PLU=ON LEUKEM? OR LEUKAEM?
 L54 QUE ABB=ON PLU=ON IONIZ? OR IONIS?
 L55 QUE ABB=ON PLU=ON RADIATION
 L56 QUE ABB=ON PLU=ON OPTIC?
 L57 QUE ABB=ON PLU=ON ISOMER?
 L58 QUE ABB=ON PLU=ON THERAP? OR DRUG OR PHARM? OR MEDIC?
 L59 QUE ABB=ON PLU=ON SARCOID?
 L60 QUE ABB=ON PLU=ON PERONIES
 L61 QUE ABB=ON PLU=ON DUPUTREN
 L62 QUE ABB=ON PLU=ON FIBROSIS
 L63 QUE ABB=ON PLU=ON CIRRHOSIS?
 L64 QUE ABB=ON PLU=ON ?ATHEROSCLERO? OR ANIATHEROSCLER?
 L65 QUE ABB=ON PLU=ON ?VASCULAR?
 L66 QUE ABB=ON PLU=ON RESTENO?
 L67 QUE ABB=ON PLU=ON ?CANCER? OR ?CARCIN? OR ?ONCO? OR ?S
 ARCOM? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLAS? OR ?MALIGN? OR
 ?DYPLAS?
 L68 QUE ABB=ON PLU=ON ANTICANCER? OR ANTICARCIN? OR ANTISA
 RCOM? OR ANTITUM? OR ANTINEOPLAS?
 L69 QUE ABB=ON PLU=ON OVARY OR OVARIAN
 L70 QUE ABB=ON PLU=ON BREAST OR MAMMAR?
 L71 QUE ABB=ON PLU=ON PROSTAT?
 L72 QUE ABB=ON PLU=ON TESTIS OR TESTIC?
 L73 QUE ABB=ON PLU=ON LUNG
 L74 QUE ABB=ON PLU=ON PULMONAR?
 L75 QUE ABB=ON PLU=ON KIDNEY OR RENAL?
 L77 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L12
 L78 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 AND (L39 OR L40 OR L41 OR
 L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
 L51 OR L52 OR L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR L59 OR
 L60 OR L61 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68 OR
 L69 OR L70 OR L71 OR L72 OR L73 OR L74 OR L75)
 L79 QUE ABB=ON PLU=ON SYNTHES? OR SYNTH OR PREP? OR REACT?
 L80 QUE ABB=ON PLU=ON MANUFACT?
 L81 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 AND (L79 OR L80)
 L82 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 OR L78 OR L81
 L83 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L82 AND (L32 OR L33 OR L34 OR
 L35 OR L36 OR L37)
 L110 STR
 L112 52 SEA FILE=MARPAT SSS FUL L110
 L113 52 SEA FILE=HCAPLUS ABB=ON PLU=ON L112
 L114 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L113 AND (L32 OR L33 OR L34
 OR L35 OR L36 OR L37)
 L120 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L114 NOT L83

=> d his 1130

(FILE 'MEDLINE, BIOSIS, EMBASE, PASCAL, CABA, AGRICOLA, LIFESCI, BIOENG,
 BIOTECHNO, BIOTECHDS, DRUGU, DRUGB, VETU, VETB, SCISEARCH, CONFSCI,
 DISSABS, WPIX' ENTERED AT 08:53:12 ON 13 APR 2007)

L130 4 S L129 AND L32-L37

=> d que 1130

10/574,993

L32 QUE ABB=ON PLU=ON REDDY, E?/AU
L33 QUE ABB=ON PLU=ON REDDY, P?/AU
L34 QUE ABB=ON PLU=ON REDDY, M?/AU
L35 QUE ABB=ON PLU=ON REDDY, R?/AU
L36 QUE ABB=ON PLU=ON BELL, S?/AU
L37 QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
)/CS, SO, PA
L123 QUE ABB=ON PLU=ON UNSAT? OR ?ALKENYL?
L124 QUE ABB=ON PLU=ON ?SULFOXID?
L129 438 SEA L123 (5A) L124
L130 4 SEA L129 AND (L32 OR L33 OR L34 OR L35 OR L36 OR L37)

=> dup rem 183 192 196 1108 1120 1126 1130

L126 HAS NO ANSWERS

FILE 'HCAPLUS' ENTERED AT 09:19:16 ON 13 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:19:16 ON 13 APR 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 09:19:16 ON 13 APR 2007

COPYRIGHT (C) 2007 ACS

FILE 'WPIX' ENTERED AT 09:19:16 ON 13 APR 2007

COPYRIGHT (C) 2007 THE THOMSON CORPORATION

PROCESSING COMPLETED FOR L83

PROCESSING COMPLETED FOR L92

PROCESSING COMPLETED FOR L96

PROCESSING COMPLETED FOR L108

PROCESSING COMPLETED FOR L120

PROCESSING COMPLETED FOR L126

PROCESSING COMPLETED FOR L130

L134 8 DUP REM L83 L92 L96 L108 L120 L126 L130 (10 DUPLICATES REMOVED)

ANSWERS '1-6' FROM FILE HCAPLUS

ANSWER '7' FROM FILE USPATFULL

ANSWER '8' FROM FILE WPIX

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 09:19:28 ON 13 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Apr 6, 2007 (20070406/UP).

=> d ibib ed ab hitind hitstr

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, WPIX' - CONTINUE? (Y)/N:y

L134 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2006:884824 HCAPLUS Full-text

DOCUMENT NUMBER: 145:292708

TITLE: Synthesis of (E)- α,β -unsaturated
sulfides, sulfones, sulfoxides and sulfonamidesINVENTOR(S): Reddy, M. V. Ramana; Reddy, E.
Premkumar; Bell, Stanley C.PATENT ASSIGNEE(S): Temple University- Of the Commonwealth
System of Higher Education, USA; Onconova
Therapeutics Inc.

SOURCE: PCT Int. Appl., 61pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006091870	A2	20060831	WO 2006-US6698	20060224
WO 2006091870	A3	20070118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-656204P P 20050225

OTHER SOURCE(S): CASREACT 145:292708; MARPAT 145:292708

ED Entered STN: 31 Aug 2006

AB α,β -Unsatd. sulfides, sulfones, sulfoxides and sulfonamides (E)-
Ar1X(R)SONCH:CHAr2 (Ar1, Ar2 = aryl, heteroaryl; X = N, CH; n = 0, 1, 2; R =
H, C1-C8 hydrocarbonyl) are prepared by dehydration of β -hydroxy sulfides,
sulfones, sulfoxides or sulfonamides.

CC 25-12 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

ST sulfide unsatd prepn; sulfone unsatd prepn; sulfoxide
unsatd prepn; sulfonamide unsatd prepnIT Sulfides, preparation

Sulfonamides

Sulfones

Sulfoxides

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
(Preparation)(unsatd.; preparation of (E)- α,β -unsatd. sulfides,
sulfones, sulfoxides, and sulfonamides)IT 908343-81-7P 908343-83-9P 908343-84-0P 908343-86-2P 908344-19-4P,
2-[(4-Methoxy-3-nitrobenzyl)sulfonyl]-1-(2,4,6-trimethoxyphenyl)ethanone

908344-20-7P, 2-[(3-Amino-4-methoxybenzyl)sulfonyl]-1-(2,4,6-trimethoxyphenyl)ethanol 908344-22-9P, 2-[(4-Methoxy-3-nitrobenzyl)thio]-1-(2,4,6-trimethoxyphenyl)ethanol 908344-23-0P 908344-24-1P
 908344-25-2P 908344-26-3P, 2-(Benzylsulfonyl)-1-(4-fluorophenyl)ethanol
 908344-27-4P, 2-(Benzylsulfonyl)-1-(4-chlorophenyl)ethanol 908344-28-5P,
 2-(Benzylsulfonyl)-1-(4-iodophenyl)ethanol 908344-29-6P 908344-30-9P
 908344-31-0P 908344-32-1P 908344-33-2P 908344-34-3P,
 2-(Benzylsulfinyl)-1-(4-fluorophenyl)ethanol 908344-35-4P,
 2-(Benzylsulfinyl)-1-(4-chlorophenyl)ethanol 908344-36-5P,
 2-(Benzylsulfinyl)-1-(4-iodophenyl)ethanol 908344-37-6P,
 2-[(4-Methoxybenzyl)sulfinyl]-1-(4-chlorophenyl)ethanol 908344-38-7P,
 2-[(4-Methoxybenzyl)sulfinyl]-1-phenylethanol 908344-39-8P,
 2-[(4-Methoxybenzyl)sulfinyl]-1-(4-methoxyphenyl)ethanol 908344-40-1P,
 2-[(4-Chlorobenzyl)sulfinyl]-1-(4-chlorophenyl)ethanol 908344-41-2P,
 2-[(4-Chlorobenzyl)sulfinyl]-1-(4-fluorophenyl)ethanol 908344-42-3P,
 2-[(4-Chlorobenzyl)sulfinyl]-1-(4-bromophenyl)ethanol 908344-43-4P
 908344-44-5P 908344-45-6P 908344-46-7P, 2-[(3-Amino-4-methoxybenzyl)thio]-1-(2,4,6-trimethoxyphenyl)ethanol 908344-47-8P,
 2-[[5-[[[2-Hydroxy-2-(2,4,6-trimethoxyphenyl)ethyl]thio]methyl]-2-methoxyphenyl]amino]acetic acid 908344-48-9P, 2-(Benzylthio)-1-(4-fluorophenyl)ethanol 908344-49-0P, 2-(Benzylthio)-1-(4-chlorophenyl)ethanol 908344-50-3P, 2-(Benzylthio)-1-(4-iodophenyl)ethanol 908344-51-4P, 2-[(4-Methoxybenzyl)thio]-1-(4-chlorophenyl)ethanol 908344-52-5P, 2-[(4-Methoxybenzyl)thio]-1-phenylethanol 908344-53-6P, 2-[(4-Methoxybenzyl)thio]-1-(4-methoxyphenyl)ethanol 908344-54-7P, 2-[(4-Chlorobenzyl)thio]-1-(4-chlorophenyl)ethanol 908344-55-8P, 2-[(4-Chlorobenzyl)thio]-1-(4-fluorophenyl)ethanol 908344-56-9P, 2-[(4-Chlorobenzyl)thio]-1-(4-bromophenyl)ethanol 908344-57-0P 908344-58-1P, 5-[[[2-Hydroxy-2-(2,4,6-trimethoxyphenyl)ethyl]sulfonyl]amino]-2-methoxyphenol
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (E)- α,β -unsatd. sulfides, sulfones, sulfoxides, and sulfonamides)

IT 93468-07-6P 118672-28-9P 118672-29-0P 155784-75-1P,
 (E)-(4-Methoxybenzyl)(styryl)sulfide 180524-31-6P 216007-67-9P
 , (E)-1-Methoxy-4-[(styrylsulfinyl)methyl]benzene 222639-33-0P
 300699-95-0P 454479-26-6P 592542-50-2P 592542-59-1P 592542-82-0P
 595582-49-3P 595582-55-1P 851799-51-4P 852283-21-7P,
 (E)-5-[[[2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxybenzenamine
852283-22-8P, (E)-5-[[[2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenol 852283-27-3P, (E)-2-[[[5-[[[2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl]amino]ethanoic acid
852283-45-5P 852284-78-7P, (E)-1-[[[4-Chlorostyryl)sulfinyl]methyl]-4-methoxybenzene 852284-85-6P,
 1-[(E)-2-(Benzylsulfinyl)ethenyl]-4-chlorobenzene 852284-86-7P,
 (E)-1-[[[4-Fluorostyryl)sulfinyl]methyl]-4-chlorobenzene
852284-87-8P, (E)-1-[[[4-Chlorostyryl)sulfinyl]methyl]-4-chlorobenzene 865783-95-5P, (E)-5-[[[2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenol 865784-07-2P, (E)-5-[[[2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenol 889862-10-6P
 908343-82-8P 908343-87-3P 908343-88-4P 908343-89-5P 908343-90-8P
 908343-91-9P 908343-92-0P 908343-93-1P 908343-94-2P 908343-95-3P
 908343-96-4P 908343-98-6P, 1-[(E)-2-(Benzylsulfinyl)ethenyl]-4-fluorobenzene 908344-00-3P, 1-[(E)-2-(Benzylsulfinyl)ethenyl]-4-iodobenzene 908344-03-6P, (E)-1-[[[4-Methoxystyryl)sulfinyl]methyl]-4-methoxybenzene 908344-04-7P,
 (E)-1-[[[4-Bromostyryl)sulfinyl]methyl]-4-chlorobenzene
908344-05-8P 908344-06-9P, (E)-5-[[[2,4,6-Trimethoxystyryl)thio]methyl]-2-methoxyphenol 908344-07-0P,

(E)-2-[[5-[[2,4,6-Trimethoxystyryl)thio)methyl]-2-methoxyphenyl]amino]propanoic acid 908344-08-1P, (E)-5-[[2,4,6-Trimethoxystyryl)thio)methyl]-2-methoxybenzenamine 908344-09-2P, (E)-2-[[5-[[2,4,6-Trimethoxystyryl)thio)methyl]-2-methoxyphenyl]amino]ethanoic acid 908344-10-5P, (E)-(4-Fluorostyryl)(benzyl)sulfide 908344-11-6P, (E)-(4-Iodostyryl)(benzyl)sulfide 908344-12-7P, (E)-(4-Chlorostyryl)(benzyl)sulfide 908344-13-8P, (E)-(4-Chlorostyryl)(4-methoxybenzyl)sulfide 908344-14-9P, (E)-(4-Methoxybenzyl)(4-methoxystyryl)sulfide 908344-15-0P, (E)-(4-Chlorobenzyl)(4-chlorostyryl)sulfide 908344-16-1P, (E)-(4-Chlorobenzyl)(4-fluorostyryl)sulfide 908344-17-2P, (E)-(4-Bromostyryl)(4-chlorobenzyl)sulfide 908344-18-3P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of (E)- α,β -unsatd. sulfides, sulfones, sulfoxides, and sulfonamides)

IT 71-43-2, Benzene, reactions 462-06-6, Fluorobenzene 35543-30-7, 2-Chloro-1-(2,4,6-trimethoxyphenyl)ethanone 54109-15-8, 2-Bromo-1-(2,4,6-trimethoxyphenyl)ethanone 118672-20-1 222639-41-0 300700-06-5 675576-48-4 908343-76-0 908343-77-1 908343-78-2 908343-79-3 908343-80-6 908344-21-8, (4-Methoxy-3-nitrophenyl)methanethiol

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (E)- α,β -unsatd. sulfides, sulfones, sulfoxides, and sulfonamides)

IT 754999-72-9P 908343-71-5P 908343-72-6P 908343-73-7P 908343-74-8P 908343-75-9P 908343-85-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (E)- α,β -unsatd. sulfides, sulfones, sulfoxides, and sulfonamides)

IT 300699-94-9P 754999-68-3P 754999-69-4P 754999-70-7P 754999-71-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of (E)- α,β -unsatd. sulfides, sulfones, sulfoxides, and sulfonamides)

IT 216007-67-9P, (E)-1-Methoxy-4-[(styrylsulfinyl)methyl]benzene 852283-21-7P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxybenzenamine 852283-22-8P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenol 852283-27-3P, (E)-2-[[5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl]amino]ethanoic acid 852283-45-5P 852284-78-7P, (E)-1-[[4-Chlorostyryl)sulfinyl)methyl]-4-methoxybenzene 852284-85-6P, 1-[(E)-2-(Benzylsulfinyl)ethenyl]-4-chlorobenzene 852284-86-7P, (E)-1-[[4-Fluorostyryl)sulfinyl)methyl]-4-chlorobenzene 852284-87-8P, (E)-1-[[4-Chlorostyryl)sulfinyl)methyl]-4-chlorobenzene 908343-98-6P, 1-[(E)-2-(Benzylsulfinyl)ethenyl]-4-fluorobenzene 908344-00-3P, 1-[(E)-2-(Benzylsulfinyl)ethenyl]-4-iodobenzene 908344-03-6P, (E)-1-[[4-Methoxystyryl)sulfinyl)methyl]-4-methoxybenzene 908344-04-7P, (E)-1-[[4-Bromostyryl)sulfinyl)methyl]-4-chlorobenzene 908344-05-8P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of (E)- α,β -unsatd. sulfides, sulfones, sulfoxides, and sulfonamides)

RN 216007-67-9 HCAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-phenylethenyl)sulfinyl)methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-21-7 HCAPLUS

CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinylmethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-22-8 HCAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinylmethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-27-3 HCAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinylmethyl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852283-45-5 HCAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 852284-78-7 HCAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-85-6 HCAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-86-7 HCAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-87-8 HCAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 908343-98-6 HCAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[(phenylmethyl)sulfinyl]ethenyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.




RN 908344-00-3 HCAPLUS

CN Benzene, 1-iodo-4-[(1E)-2-[(phenylmethyl)sulfinyl]ethenyl]- (9CI) (CA

INDEX NAME)


Double bond geometry as shown.



RN 908344-03-6 HCAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-methoxyphenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 908344-04-7 HCAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-chlorophenyl]methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 908344-05-8 HCAPLUS

CN Benzeneacetic acid, α-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> d ibib ed ab hitind hitstr 2-6

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, WPIX' - CONTINUE? (Y)/N:y

L134 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2006:678223 HCAPLUS Full-text

DOCUMENT NUMBER: 145:137820

TITLE: Treatment of drug-resistant proliferative disorders

INVENTOR(S): Reddy, Ramana M. V.; Reddy, Premkumar E.; Cosenza, Stephen C.; Baker, Stacey J.

PATENT ASSIGNEE(S): Temple University-Of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074149	A2	20060713	WO 2006-US59	20060104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-641378P P 20050105

OTHER SOURCE(S): MARPAT 145:137820

ED Entered STN: 13 Jul 2006

AB The invention discloses a method of treating a protein kinase-dependent proliferative disorder, particularly cancer, in an individual, which disorder is resistant to treatment with an ATP-competitive protein kinase inhibitor, said method comprising administering to the individual in need of such treatment an effective amount of at least one compound according to the

formula Ar1XRSONCH=CHAr2 where Ar1 and Ar2 are independently selected from substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl; X = N or CH; n = 1 or 2; and R = H or (C1-C8)hydrocarbyl.

CC 1-6 (Pharmacology)

ST drug resistant proliferative disorders
treatment

IT Drug resistance

(antitumor; treatment of drug-resistant
proliferative disorders resistant to ATP-competitive
protein kinase inhibitors)

IT Neuroglia, neoplasm

(astrocytoma; treatment of drug-resistant
proliferative disorders resistant to ATP-competitive
protein kinase inhibitors)

IT Uterus, neoplasm

(carcinoma, papillary serous; treatment of drug-
resistant proliferative disorders resistant to
ATP-competitive protein kinase inhibitors)

IT Neoplasm

(chordoma; treatment of drug-resistant proliferative
disorders resistant to ATP-competitive protein kinase
inhibitors)

IT Eosinophil

(disease, hypereosinophilic syndrome; treatment of
drug-resistant proliferative disorders
resistant to ATP-competitive protein kinase inhibitors)

IT Carcinoma

(endometrial; treatment of drug-resistant
proliferative disorders resistant to ATP-competitive
protein kinase inhibitors)

IT Uterus, neoplasm

(endometrium, carcinoma; treatment of drug-
resistant proliferative disorders resistant to
ATP-competitive protein kinase inhibitors)

IT Lung, disease

(fibrosis; treatment of drug-resistant
proliferative disorders resistant to ATP-competitive
protein kinase inhibitors)

IT Neoplasm

(fibrous histiocytoma; treatment of drug-resistant
proliferative disorders resistant to ATP-competitive
protein kinase inhibitors)

IT Neuroglia, neoplasm

(glioblastoma; treatment of drug-resistant
proliferative disorders resistant to ATP-competitive
protein kinase inhibitors)

IT Blood, disease

(hypereosinophilic syndrome; treatment of drug-
resistant proliferative disorders resistant to
ATP-competitive protein kinase inhibitors)

IT Uterus, neoplasm

(leiomyosarcoma; treatment of drug-resistant
proliferative disorders resistant to ATP-competitive
protein kinase inhibitors)

IT Lymphoma

(lymphoblastic, acute; treatment of drug-resistant
proliferative disorders resistant to ATP-competitive
protein kinase inhibitors)


IT Brain, neoplasm

(medulloblastoma; treatment of drug-resistant

- proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Astrocyte
(neoplasm, astrocytoma; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Notochord
(neoplasm, chordoma; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Histiocyte
(neoplasm, fibrous histiocytoma; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Lung, neoplasm
(non-small-cell carcinoma; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Mutation
(of protein kinases; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Carcinoma
(papillary, uterus; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Disease, animal
(proliferative; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Carcinoma
(pulmonary non-small-cell; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Fibrosis
(pulmonary; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Antitumor agents
(resistance to; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Digestive tract, neoplasm
(stroma; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Mutation
(substitution, of protein kinases; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Antitumor agents
Chronic myeloid leukemia
Chronic myelomonocytic leukemia
Combination chemotherapy
Drug interactions
Human
Neoplasm
Neuroglia, neoplasm
Prostate gland, neoplasm
(treatment of drug-resistant proliferative

- disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Myoma
Sarcoma
 (uterine leiomyosarcoma; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT Carcinoma
 (uterine, papillary serous; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT 372092-80-3, Protein kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protein kinase; treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT 152459-95-5, Imatinib 592542-82-0
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT 79079-06-4, Epidermal growth factor receptor kinase.
 136396-12-8, Platelet-derived growth factor receptor β tyrosine kinase 138238-67-2, BCR-ABL kinase 138359-29-2, KIT tyrosine kinase 150027-21-7, Platelet-derived growth factor receptor α tyrosine kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT 152121-47-6, SB203580 153436-54-5, PD153035 183321-74-6, Erlotinib 184475-35-2, Gefitinib 204005-46-9, SU5416 252916-29-3, SU6668 287204-45-9, PD180970 302962-49-8, BMS-354825 341031-54-7, SU11248 592542-59-1 592543-23-2 592543-24-3 595582-55-1, (E)-2,4,6-Trimethoxystyryl-N-(3-carboxymethylamino-4-methoxyphenyl)sulfonamide 845895-51-4, AP23464 851799-47-8 851799-49-0 851799-50-3 851799-51-4 852283-27-3 852283-45-5 897013-49-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- IT 898570-53-1 898570-54-2 898570-55-3 898570-56-4 898570-57-5
 RL: PRP (Properties)
 (unclaimed protein sequence; treatment of drug-resistant proliferative disorders)
- IT 852283-27-3 852283-45-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)
- RN 852283-27-3 HCAPLUS ,
 CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852283-45-5 HCAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L134 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2005:1049789 HCAPLUS Full-text

DOCUMENT NUMBER: 143:346909

TITLE: Preparation of substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders and as radioprotectants and chemoprotectants

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana; Bell, Stanley C.

PATENT ASSIGNEE(S): Temple University-of the Commonwealth System of Higher Education, USA; Onconova Therapeutics Inc.

SOURCE: PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089269	A2	20050929	WO 2005-US8429	20050315
WO 2005089269	A3	20061214		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

AU 2005222947 A1 20050929 AU 2005-222947 20050315
 CA 2559187 A1 20050929 CA 2005-2559187 20050315
 EP 1740530 A2 20070110 EP 2005-736001 20050315

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
 HR, LV, MK, YU

PRIORITY APPLN. INFO.:

US 2004-554008P P 20040316
 WO 2005-US8429 W 20050315

OTHER SOURCE(S): MARPAT 143:346909

ED Entered STN: 30 Sep 2005

AB Title compds. I [A = S, O; R1 = H, haloalkyl, (un)substituted hetero/aryl,
 etc.; Q = hetero/aryl; R2, R3 = independently halo, hydrocarbyl, NO2, CN, OH
 and derivs., P(:O)(OH)2 and derivs., etc.; X = -NRx-Z-, -CH(Rx)Y-; Y = SO,
 SO2; Z = CO, SO2; Rx = H, alkyl, -CO-alkyl; with provisos; and their
 geometrical isomers] were prepared as antiproliferative agents including, for
 example, anticancer agents and as radioprotective and chemoprotective agents.
 For example, reacting 2-[(3-hydroxy-4-methoxybenzyl)sulfonyl]acetic acid with
 2,4,6-Trimethoxybenzaldehyde in the presence of PhCO2H/piperidine/toluene for
 2-3 h at reflux gave II in 62.5% yield.. I displayed antiproliferative
 activity; for II GI50 values = 0.004 μ M, 0.001 μ M, and 0.005 μ M towards Sk-OV-
 3, RF-48, and CEM tumor cell lines, resp.

IC ICM A61K

CC 25-10 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1, 63

ST phenoxy phenylthio deriv prepn proliferative
disorder radioprotectant chemoprotectant; unsatd sulfoxide sulfone
 amide prepn neoplasm

IT Neoplasm

(bone marrow; preparation of substituted phenoxy- and phenylthio-
 derivs. for treating proliferative disorders and as
 radioprotectants and chemoprotectants)

IT Intestine, neoplasm

(colon; preparation of substituted phenoxy- and phenylthio-
 derivs. for treating proliferative disorders and as
 radioprotectants and chemoprotectants)

IT Skin, neoplasm

(epidermis; preparation of substituted phenoxy- and
 phenylthio- derivs. for treating proliferative
disorders and as radioprotectants and chemoprotectants)

IT Neuroglia, neoplasm

(glioblastoma; preparation of substituted phenoxy- and phenylthio-
 derivs. for treating proliferative disorders and as
 radioprotectants and chemoprotectants)

IT Antibodies and Immunoglobulins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(monoclonal, conjugates, with phenoxy- and phenylthio- derivs.;
preparation of substituted phenoxy- and phenylthio- derivs. for
 treating proliferative disorders and as
 radioprotectants and chemoprotectants)

IT Antitumor agents

Bone marrow, disease

- Bone marrow, neoplasm
Brain, neoplasm
 Cytoprotective agents
 Cytotoxic agents
Drug delivery systems
Drug toxicity
 Fibroblast
 Human
Ionizing radiation
Kidney, neoplasm
Leukemia
Lung, neoplasm
 Lymphoma
Mammary gland, neoplasm
 Melanoma
Neoplasm
Ovary, neoplasm
 Pancreas, neoplasm
Prostate gland, neoplasm
 Radioprotectants
 Radiotherapy
Sarcoma
 Stomach, neoplasm
 (preparation of substituted phenoxy- and phenylthio- derivs. for
 treating proliferative disorders and as
 radioprotectants and chemoprotectants)
- IT Antibodies and Immunoglobulins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (preparation of substituted phenoxy- and phenylthio- derivs. for
 treating proliferative disorders and as
 radioprotectants and chemoprotectants)
- IT Intestine, neoplasm
 (rectum, colorectal; preparation of substituted phenoxy-
 and phenylthio- derivs. for treating proliferative
 disorders and as radioprotectants and chemoprotectants)
- IT 865783-96-6P 865783-97-7P, 2-[(3-Hydroxy-4-methoxybenzyl)sulfonyl]acetic
 acid 865783-98-8P, 2-[(3-Hydroxy-4-methoxybenzyl)sulfonyl]acetic acid
 865783-99-9P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-
 methoxyphenyl dihydrogen phosphate 865784-00-5P, (E)-5-[[[(2,4,6-
 Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl dibenzyl phosphate
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of substituted phenoxy- and
 phenylthio- derivs. for treating proliferative
 disorders and as radioprotectants and chemoprotectants)
- IT 684275-42-1P, (E)-N-(3-Hydroxy-4-methoxyphenyl)-3-(2,4,6-trimethoxyphenyl)-
 2-propenamide 852283-22-8P, (E)-5-[[[(2,4,6-
 Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenol 852285-79-1P,
 2-[(3-Hydroxy-4-methoxybenzyl)sulfinyl]acetic acid 865783-95-5P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenol
 865784-01-6P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-
 methoxyphenyl dihydrogen phosphate disodium salt 865784-02-7P,
 (E)-4-[3-[5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-
 methoxyphenoxy]propyl]morpholine 865784-03-8P, (E)-5-[[[(2,4,6-
 Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl 2-(dimethylamino)acetate
 865784-04-9P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-
 methoxyphenyl 4-methylbenzenesulfonate 865784-05-0P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxybenzenethiol

865784-06-1P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxybenzenethiol **865784-07-2P**, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenol **865784-08-3P**, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxybenzenethiol
865784-09-4P, (E)-N-(3-Mercapto-4-methoxyphenyl)-3-(2,4,6-trimethoxyphenyl)-2-propenamide **865784-10-7P**, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl dimethyl phosphate
865784-11-8P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl diethyl phosphate **865784-12-9P**, (E)-S-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl-O,O-dihydrogen phosphorothioate
865784-13-0P, (E)-S-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl-O,O-dimethyl phosphorothioate **865784-14-1P**, (E)-(S)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl-O,O-diethyl phosphorothioate
865784-15-2P, (E)-(S)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl-O,O-dibenzyl phosphorothioate **865784-16-3P**, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl dihydrogen phosphate
865784-17-4P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl dimethyl phosphate **865784-18-5P**, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl diethyl phosphate
865784-19-6P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl dibenzyl phosphate
865784-20-9P, (E)-(S)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl-O,O-dihydrogen phosphorothioate **865784-21-0P**, (E)-(S)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl-O,O-dimethyl phosphorothioate
865784-22-1P, (E)-(S)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl-O,O-diethyl phosphorothioate **865784-23-2P**, (E)-(S)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl-O,O-dibenzyl phosphorothioate
865784-24-3P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenyl dihydrogen phosphate
865784-25-4P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenyl dimethyl phosphate **865784-26-5P**, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenyl diethyl phosphate
865784-27-6P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenyl dibenzyl phosphate **865784-28-7P**, (E)-(S)-[5-[[(2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenyl]-O,O-dihydrogen phosphorothioate
865784-29-8P, (E)-(S)-[5-[[(2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenyl]-O,O-dimethyl phosphorothioate
865784-30-1P, (E)-S-[5-[[(2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenyl]-O,O-diethyl phosphorothioate
865784-31-2P, (E)-(S)-[5-[[(2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenyl]-O,O-dibenzyl phosphorothioate
865784-32-3P, 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl dihydrogen phosphate
865784-33-4P, 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl dimethyl phosphate **865784-34-5P**, 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl diethyl phosphate
865784-35-6P, 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl dibenzyl phosphate
865784-36-7P, S-5-[(E)-3-(2,4,6-Trimethoxyphenyl)acrylamido]-2-methoxyphenyl-O,O-dihydrogen phosphorothioate **865784-37-8P**, S-5-[(E)-3-(2,4,6-Trimethoxyphenyl)acrylamido]-2-methoxyphenyl-O,O-dimethyl phosphorothioate
865784-38-9P, S-5-[(E)-3-(2,4,6-Trimethoxyphenyl)acrylamido]-2-methoxyphenyl-O,O-diethyl phosphorothioate
865784-39-0P, S-5-[(E)-3-(2,4,6-Trimethoxyphenyl)acrylamido]-2-methoxyphenyl-O,O-dibenzyl phosphorothioate **865784-40-3P**, (E)-2-[[5-[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenoxy]carbonyl]ethanoic acid
865784-41-4P, (E)-5-[[(2,4,6-

Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 3,5-dinitrobenzoate
 865784-42-5P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 3,5-diaminobenzoate 865784-43-6P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-chloroacetate
 865784-44-7P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-(4-methylpiperazin-1-yl)acetate 865784-45-8P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl benzoate
 865784-46-9P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 4-nitrobenzoate 865784-47-0P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 4-aminobenzoate
 865784-48-1P, (E)-(R)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2,6-diaminohexanoate 865784-49-2P, (E)-(R)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-amino-3-hydroxypropanoate
 865784-50-5P, (E)-(S)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-amino-3-hydroxypropanoate 865784-51-6P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl carbamate
 865784-52-7P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 4-(4-methylpiperazin-1-yl)benzoate 865784-53-8P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-hydroxyacetate
 865784-54-9P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-(pyridinium-1-yl)acetate
 865784-55-0P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-acetoxyacetate 865784-56-1P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-hydroxypropanoate
 865784-57-2P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-(triethylammonium)acetate 865784-58-3P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-[tris(2-hydroxyethyl)ammonium]acetate
 865784-59-4P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-hydroxy-2-methylpropanoate 865784-60-7P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-acetoxy-2-methylpropanoate
 865784-61-8P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2,2,2-trifluoroacetate 865784-62-9P, (E)-3-[[5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenoxy]carbonyl]propanoic acid
 865784-63-0P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 3-(chlorocarbonyl)propanoate 865784-64-1P 865784-65-2P, (E)-4-[[5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenoxy]carbonyl]butanoic acid
 865784-66-3P, (E)-[[5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenoxy]carbonyl]methyl dihydrogen phosphate 865784-67-4P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl methyl carbonate
 865784-68-5P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-acetoxypropanoate 865784-69-6P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl methyl succinate
 865784-70-9P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl ethyl malonate 865784-71-0P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2,2,3,3,3-pentafluoropropanoate
 865784-72-1P, (E)-1-[5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl] 3-methyl 2,2-difluoromalonate 865784-73-2P, (E)-3-[[5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenoxy]carbonyl]-2,2,3,3-tetrafluoropropanoic acid
 865784-75-4P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-aminoacetate 865784-76-5P, (E)-2-[[5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenoxy]carbonyl]-2,2-difluoroethanoic acid
 865784-78-7P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-(dimethylamino)-2,2-difluoroacetate 865784-80-1P, 5-[[(2,4,6-Trimethoxystyryl)sulfonyl)methyl]-2-methoxyphenyl 2-(dimethylamino)acetate

865784-81-2P, (E)-2-[[5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenoxy]carbonyl]ethanoic acid 865784-82-3P,
 (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl
 3,5-dinitrobenzoate 865784-84-5P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 3,5-diaminobenzoate
865784-85-6P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-chloroacetate 865784-86-7P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-(4-methylpiperazin-1-yl)acetate 865784-87-8P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl benzoate
865784-88-9P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 4-nitrobenzoate 865784-89-0P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 4-aminobenzoate
865784-90-3P, (E)-(R)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2,6-diaminohexanoate 865784-91-4P,
 (E)-(R)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-amino-3-hydroxypropanoate 865784-92-5P 865784-93-6P,
 (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl carbamate
865784-94-7P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-(dimethylamino)acetate 865784-95-8P,
 (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 4-(4-methylpiperazin-1-yl)benzoate 865784-96-9P,
 (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-hydroxyacetate 865784-97-0P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-(pyridinium-1-yl)acetate 865784-98-1P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-acetoxyacetate
865784-99-2P 865785-00-8P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-(triethylammonium)acetate 865785-01-9P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-[tris(2-hydroxyethyl)ammonium]acetate 865785-02-0P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-hydroxy-2-methylpropanoate 865785-03-1P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-acetoxy-2-methylpropanoate 865785-04-2P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2,2,2-trifluoroacetate
865785-05-3P, (E)-3-[[5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenoxy]carbonyl]propanoic acid 865785-06-4P,
 (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 3-(chlorocarbonyl)propanoate 865785-07-5P 865785-08-6P,
 (E)-4-[[5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenoxy]carbonyl]butanoic acid 865785-09-7P,
 (E)-[[5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenoxy]carbonyl]methyl dihydrogen phosphate 865785-10-0P,
 (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl methyl carbonate 865785-11-1P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-acetoxypropanoate
865785-12-2P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl methyl succinate 865785-13-3P,
 (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl ethyl malonate 865785-14-4P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2,2,3,3,3-pentafluoropropanoate 865785-15-5P, (E)-1-[5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl] 3-methyl 2,2-difluoromalonate 865785-16-6P, (E)-3-[[5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenoxy]carbonyl]-2,2,3,3-tetrafluoropropanoic acid 865785-17-7P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-aminoacetate
865785-18-8P, (E)-2-[[5-[[2,4,6-Trimethoxystyryl)sulfinyl)methyl]-

2-methoxyphenoxy]carbonyl]-2,2-difluoroethanoic acid **865785-19-9P**,
 (E)-5-[[[2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl
 2-(dimethylamino)-2,2-difluoroacetate **865785-20-2P**,
 5-[[[2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl
 2-(dimethylamino)acetate **865785-21-3P**, 2-[[[5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl]oxy]carbonyl]acet
 ic acid **865785-22-4P**, 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl 3,5-dinitrobenzoate **865785-23-5P**,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl 3,5-diaminobenzoate **865785-24-6P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl 2-chloroacetate
865785-25-7P, 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-
 2-methoxyphenyl 2-(4-methylpiperazin-1-yl)acetate **865785-26-8P**,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl benzoate **865785-27-9P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl 4-nitrobenzoate
865785-28-0P, 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-
 2-methoxyphenyl 4-aminobenzoate **865785-29-1P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl
 (2R)-2,6-diaminohexanoate **865785-30-4P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl
 (2R)-2-amino-3-hydroxypropanoate **865785-31-5P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl
 (2S)-2-amino-3-hydroxypropanoate **865785-32-6P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl carbamate
865785-33-7P, 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-
 2-methoxyphenyl 2-(dimethylamino)acetate **865785-34-8P**,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl 4-(4-methylpiperazin-1-yl)benzoate **865785-35-9P**,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl 2-hydroxyacetate **865785-36-0P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl
 2-(pyridinium-1-yl)acetate **865785-37-1P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl
 2-acetyloxyacetate **865785-38-2P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl
 2-hydroxypropanoate **865785-39-3P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl
 2-(triethylammonium)acetate **865785-40-6P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl
 2-[tris(2-hydroxyethyl)ammonium]acetate **865785-41-7P**,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl 2-hydroxy-2-methylpropanoate **865785-42-8P**,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl 2-acetyloxy-2-methylpropanoate **865785-43-9P**,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl 2,2,2-trifluoroacetate **865785-44-0P**, 3-[[[5-[[[(1E)-2-
 (2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl]oxy]carbonyl]propanoic acid **865785-45-1P**,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl 3-(chlorocarbonyl)propanoate **865785-46-2P**,
 3-[[[5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl]oxy]carbonyl]methyl]oxy]carbonyl]propanoic acid
865785-47-3P, 4-[[[5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]am
 ino]-2-methoxyphenyl]oxy]carbonyl]butanoic acid **865785-48-4P**,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl 2-(phosphonoxy)acetate **865785-49-5P**, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl methoxyformate
865785-50-8P, 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-
 2-methoxyphenyl 2-acetyloxypropanoate **865785-51-9P**, 5-[[[(1E)-2-(2,4,6-

Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl methyl
 butane-1,4-dioate 865785-52-0P, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl ethyl
 propane-1,3-dioate 865785-53-1P, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl
 2,2,3,3,3-pentafluoropropanoate 865785-54-2P, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl methyl
 2,2-difluoropropane-1,3-dioate 865785-55-3P, 3-[[[5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl]oxy]carbonyl]-
 2,2,3,3-tetrafluoropropanoic acid 865785-56-4P, 5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-methoxyphenyl 2-aminoacetate
 865785-57-5P
 , 2-[[[5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl]oxy]carbonyl]-2,2-difluoroacetic acid 865785-58-6P,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl)sulfonyl]amino]-2-
 methoxyphenyl 2-(dimethylamino)-2,2-difluoroacetate 865785-59-7P,
 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2-(carboxy)acetate 865785-60-0P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 3,5-dinitrobenzoate 865785-61-1P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl 2-chloroacetate
 865785-62-2P, 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-
 methoxyphenyl 2-(4-methylpiperazin-1-yl)acetate 865785-63-3P,
 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 benzoate 865785-64-4P, 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]
 amino]-2-methoxyphenyl 4-nitrobenzoate 865785-65-5P,
 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 4-aminobenzoate 865785-66-6P 865785-67-7P, (R)-5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2-amino-3-hydroxypropanoate 865785-68-8P, (S)-5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2-amino-3-hydroxypropanoate 865785-69-9P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl carbamate
 865785-70-2P, 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-
 methoxyphenyl 2-(dimethylamino)acetate 865785-71-3P,
 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 4-(4-methylpiperazin-1-yl)benzoate 865785-72-4P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl 2-hydroxyacetate
 865785-73-5P, 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-
 methoxyphenyl 2-(pyridinium-1-yl)acetate 865785-74-6P,
 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2-acetyloxyacetate 865785-75-7P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2-hydroxypropanoate 865785-76-8P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2-(N,N,N-triethylamino)acetate 865785-77-9P 865785-78-0P,
 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2-hydroxy-2-methylpropanoate 865785-79-1P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2-acetoxy-2-methylpropanoate 865785-80-4P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2,2,2-trifluoroacetate 865785-81-5P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 3-carboxypropanoate 865785-82-6P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 3-(chlorocarbonyl)propanoate 865785-83-7P 865785-84-8P,
 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 4-carboxybutanoate 865785-85-9P, 5-[[[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenoxy]carbonyl]methyl
 dihydrogen phosphate 865785-86-0P, 5-[[[(E)-2-(2,4,6-

Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl methyl carbonate
 865785-87-1P, 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-
 methoxyphenyl 2-acetoxypropanoate 865785-88-2P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl methyl succinate
 865785-89-3P, 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-
 methoxyphenyl ethyl malonate 865785-90-6P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2,2,3,3,3-pentafluoropropanoate 865785-91-7P, 1-[5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl] 3-methyl
 2,2-difluoromalonate 865785-92-8P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 4-carboxy-2,2,3,3-tetrafluorobutanoate 865785-93-9P,
 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2-aminoacetate 865785-94-0P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2-carboxy-2,2-difluoroacetate 865785-95-1P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2-(dimethylamino)-2,2-difluoroacetate 865785-96-2P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl acetate
 865785-97-3P, 5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenyl
 2-(dimethylamino)acetate 865785-98-4P, (E)-5-[[[(2,4,6-
 Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl carboxymethanesulfonate
 865785-99-5P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-
 methoxyphenyl 2,4-dinitrobenzenesulfonate 865786-00-1P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl
 2,4-diaminobenzenesulfonate 865786-01-2P, (E)-5-[[[(2,4,6-
 Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl
 trifluoromethanesulfonate 865786-02-3P, (E)-5-[[[(2,4,6-
 Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl 4-
 methoxybenzenesulfonate 865786-03-4P, (E)-5-[[[(2,4,6-
 Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl carboxymethanesulfonate
865786-04-5P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-
 methoxyphenyl 2,4-dinitrobenzenesulfonate 865786-05-6P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl
 2,4-diaminobenzenesulfonate 865786-06-7P, (E)-5-[[[(2,4,6-
 Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl
 trifluoromethanesulfonate 865786-07-8P, (E)-5-[[[(2,4,6-
 Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl 4-
 methoxybenzenesulfonate 865786-08-9P, (E)-5-[[[(2,4,6-
 Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl 4-methylbenzenesulfonate
 865786-09-0P, 2-[[[5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl]am-
 ino]-2-methoxyphenyl]oxy]sulfonyl]acetic acid 865786-10-3P,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl]amino]-2-
 methoxyphenyl 2,4-dinitrobenzenesulfonate 865786-11-4P,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl]amino]-2-
 methoxyphenyl 2,4-diaminobenzenesulfonate 865786-12-5P,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl]amino]-2-
 methoxyphenyl trifluoromethanesulfonate 865786-13-6P,
 5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl]amino]-2-
 methoxyphenyl 4-methoxybenzenesulfonate 865786-14-7P,
 5-[[[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 carboxymethanesulfonate 865786-15-8P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 trifluoromethanesulfonate 865786-16-9P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2,4-dinitrobenzenesulfonate 865786-17-0P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 2,4-diaminobenzenesulfonate 865786-18-1P, 5-[[[(E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 4-methoxybenzenesulfonate 865786-19-2P, 5-[[[(E)-2-(2,4,6-

Trimethoxyphenyl)ethenyl]carbonyl]amino]-2-methoxyphenyl
 4-methylbenzenesulfonate 865786-20-5P, (E)-5-[[[2,4,6-
 Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenyl 4-methylbenzenesulfonate
 865786-21-6P, (E)-2-[5-[[[2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-
 methoxyphenoxy]ethanoic acid 865786-22-7P, (E)-2-[5-[[[2,4,6-
 Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenoxy]propanoic acid
 865786-23-8P, (E)-4-[5-[[[2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-
 methoxyphenoxy]butanoic acid 865786-24-9P, (E)-3-[5-[[[2,4,6-
 Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenoxy]propanoic acid
865786-25-0P, (E)-2-[5-[[[2,4,6-Trimethoxystyryl)sulfinyl]methyl]-
 2-methoxyphenoxy]ethanoic acid 865786-26-1P,
 (E)-2-[5-[[[2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-
 methoxyphenoxy]propanoic acid 865786-27-2P, (E)-4-[5-[[[2,4,6-
 Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenoxy]butanoic acid
865786-28-3P, (E)-3-[5-[[[2,4,6-Trimethoxystyryl)sulfinyl]methyl]-
 2-methoxyphenoxy]propanoic acid 865786-29-4P, (E)-4-[2-[5-[[[2,4,6-
 Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenoxy]ethyl]morpholine
865786-30-7P, (E)-4-[2-[5-[[[2,4,6-Trimethoxystyryl)sulfinyl]methy
 l]-2-methoxyphenoxy]ethyl]morpholine 865786-31-8P, 2-[5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]sulfonyl]amino]-2-methoxyphenoxy]acetic acid
 865786-32-9P, 2-[5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl]amin
 o]-2-methoxyphenoxy]propanoic acid 865786-33-0P, 4-[5-[[[(1E)-2-(2,4,6-
 Trimethoxyphenyl)ethenyl]sulfonyl]amino]-2-methoxyphenoxy]butanoic acid
 865786-34-1P, 3-[5-[[[(1E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl]amin
 o]-2-methoxyphenoxy]propanoic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of substituted phenoxy- and
 phenylthio- derivs. for treating proliferative
disorders and as radioprotectants and chemoprotectants)

IT 865786-35-2P, (E)-N-[3-(Carboxymethoxy)-4-methoxyphenyl]-3-(2,4,6-
 trimethoxyphenyl)-2-propenamide 865786-36-3P, (E)-N-[3-(1-Carboxyethoxy)-
 4-methoxyphenyl]-3-(2,4,6-trimethoxyphenyl)-2-propenamide 865786-37-4P,
 (E)-N-[3-(3-Carboxypropoxy)-4-methoxyphenyl]-3-(2,4,6-trimethoxyphenyl)-2-
 propenamide 865786-38-5P, (E)-N-[3-(2-Carboxyethoxy)-4-methoxyphenyl]-3-
 (2,4,6-trimethoxyphenyl)-2-propenamide 865786-39-6P,
 (E)-N-[3-[2-(Morpholino)ethoxy]-4-methoxyphenyl]-3-(2,4,6-
 trimethoxyphenyl)-2-propenamide 865786-40-9P, (E)-4-[2-[5-[[[2,4,6-
 Trimethoxystyryl)sulfonyl]amino]-2-methoxyphenoxy]ethyl]morpholine
 865786-41-0P, 2-[(3-Mercapto-4-methoxybenzyl)sulfinyl]acetic acid
 865786-42-1P, 2-[[3-[(tert-Butyldimethylsilyl)oxy]-4-
 methoxybenzyl]sulfinyl]acetic acid 865786-43-2P, 2-[[3-[(tert-
 Butyldimethylsilyl)sulfanyl]-4-methoxybenzyl]sulfinyl]acetic acid
 865786-44-3P, O-2-Methoxy-5-[[[carboxymethyl]sulfinyl]methyl]phenyl
 dihydrogen phosphate 865786-45-4P, O-2-Methoxy-5-
 [[[carboxymethyl]sulfinyl]methyl]phenyl dimethyl phosphate 865786-46-5P,
 O-2-Methoxy-5-[[[carboxymethyl]sulfinyl]methyl]phenyl diethyl phosphate
 865786-47-6P, O-2-Methoxy-5-[[[carboxymethyl]sulfinyl]methyl]phenyl
 dibenzyl phosphate 865786-48-7P, S-2-Methoxy-5-
 [[[carboxymethyl]sulfinyl]methyl]phenyl-O,O-dihydrogen phosphorothioate
 865786-49-8P, S-2-Methoxy-5-[[[carboxymethyl]sulfinyl]methyl]phenyl-O,O-
 dimethyl phosphorothioate 865786-50-1P, S-2-Methoxy-5-
 [[[carboxymethyl]sulfinyl]methyl]phenyl-O,O-diethyl phosphorothioate
 865786-51-2P, S-2-Methoxy-5-[[[carboxymethyl]sulfinyl]methyl]phenyl-O,O-
 dibenzyl phosphorothioate 865786-52-3P, 2-[(3-Mercapto-4-
 methoxybenzyl)sulfonyl]acetic acid 865786-53-4P, 2-[[3-[(tert-
 Butyldimethylsilyl)oxy]-4-methoxybenzyl]sulfonyl]acetic acid
 865786-54-5P, 2-[[3-[(tert-Butyldimethylsilyl)sulfanyl]-4-
 methoxybenzyl]sulfonyl]acetic acid 865786-55-6P, O-2-Methoxy-5-

[[(carboxymethyl)sulfonyl)methyl]phenyl dihydrogen phosphate
 865786-56-7P, O-2-Methoxy-5-[[(carboxymethyl)sulfonyl)methyl]phenyl
 dimethyl phosphate 865786-57-8P, O-[2-Methoxy-5-
 [[(carboxymethyl)sulfonyl)methyl]phenyl] diethyl phosphate 865786-58-9P,
 O-[2-Methoxy-5-[[(carboxymethyl)sulfonyl)methyl]phenyl] dibenzyl phosphate
 865786-59-0P, S-[2-Methoxy-5-[[(carboxymethyl)sulfonyl)methyl]phenyl]
 O,O-dihydrogen phosphorothioate 865786-60-3P, S-[2-Methoxy-5-
 [[(carboxymethyl)sulfonyl)methyl]phenyl] O,O-dimethyl phosphorothioate
 865786-61-4P, S-2-Methoxy-5-[[(carboxymethyl)sulfonyl)methyl]phenyl
 O,O-diethyl phosphorothioate 865786-62-5P, S-2-Methoxy-5-
 [[(carboxymethyl)sulfonyl)methyl]phenyl-O,O-dibenzyl phosphorothioate
 865786-63-6P, O-[2-Methoxy-5-[[(carboxymethyl)sulfanyl)methyl]phenyl]
 dihydrogen phosphate 865786-64-7P, O-[2-Methoxy-5-
 [[(carboxymethyl)sulfanyl)methyl]phenyl] dimethyl phosphate
 865786-65-8P, O-2-Methoxy-5-[[(carboxymethyl)sulfanyl)methyl]phenyl
 diethyl phosphate 865786-66-9P, O-2-Methoxy-5-
 [[(carboxymethyl)sulfanyl)methyl]phenyl dibenzyl phosphate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

- (drug candidate; preparation of substituted phenoxy- and
 phenylthio- derivs. for treating proliferative
disorders and as radioprotectants and chemoprotectants)
- IT 97315-18-9P, 3-(tert-Butyldimethylsilyloxy)-4-methoxybenzaldehyde
 97315-19-0P, 3-(tert-Butyldimethylsilyloxy)-4-methoxybenzyl alcohol
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of substituted phenoxy- and phenylthio-
 derivs. for treating proliferative disorders and as
 radioprotectants and chemoprotectants)
- IT 621-59-0, 3-Hydroxy-4-methoxybenzaldehyde 830-79-5, 2,4,6-
 Trimethoxybenzaldehyde 18162-48-6, tert-Butyldimethylsilyl chloride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of substituted phenoxy- and phenylthio- derivs. for
 treating proliferative disorders and as
 radioprotectants and chemoprotectants)
- IT 51-21-8, 5-Fluorouracil 57-22-7, Vincristine 7689-03-4, Camptothecin
 15663-27-1, Cisplatin 23214-92-8, Doxorubicin 33069-62-4, Paclitaxel
 33419-42-0, Etoposide 65271-80-9, Mitoxantrone
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (use of substituted phenoxy- and phenylthio- derivs. for protecting
 normal human fibroblasts from anticancer agent cytotoxicity)
- IT 852283-22-8P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-
 methoxyphenol 865784-06-1P, (E)-5-[[(2,4,6-
 Trimethoxystyryl)sulfinyl)methyl]-2-methoxybenzenethiol
865784-16-3P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-
 methoxyphenyl dihydrogen phosphate 865784-17-4P,
 (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl dimethyl
 phosphate 865784-18-5P, (E)-5-[[(2,4,6-
 Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl diethyl phosphate
865784-19-6P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-
 methoxyphenyl dibenzyl phosphate 865784-20-9P,
 (E)-(S)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl-O,O-
 dihydrogen phosphorothioate 865784-21-0P, (E)-(S)-5-[[(2,4,6-
 Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl-O,O-dimethyl
 phosphorothioate 865784-22-1P, (E)-(S)-5-[[(2,4,6-
 Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl-O,O-diethyl
 phosphorothioate 865784-23-2P, (E)-(S)-5-[[(2,4,6-
 Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl-O,O-dibenzyl
 phosphorothioate 865784-81-2P, (E)-2-[[5-[[(2,4,6-

Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenoxy]carbonyl]ethanoic acid
865784-82-3P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 3,5-dinitrobenzoate 865784-84-5P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 3,5-diaminobenzoate 865784-85-6P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-chloroacetate
865784-86-7P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-(4-methylpiperazin-1-yl)acetate 865784-87-8P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl benzoate 865784-88-9P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 4-nitrobenzoate 865784-89-0P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 4-aminobenzoate
865784-90-3P, (E)-(R)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2,6-diaminohexanoate 865784-91-4P,
 (E)-(R)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-amino-3-hydroxypropanoate 865784-92-5P 865784-93-6P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl carbamate 865784-94-7P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-(dimethylamino)acetate 865784-95-8P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 4-(4-methylpiperazin-1-yl)benzoate 865784-96-9P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-hydroxyacetate 865784-97-0P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-(pyridinium-1-yl)acetate 865784-98-1P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-acetoxyacetate
865784-99-2P 865785-00-8P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-(triethylammonium)acetate 865785-01-9P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-[tris(2-hydroxyethyl)ammonium]acetate 865785-02-0P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-hydroxy-2-methylpropanoate 865785-03-1P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-acetoxy-2-methylpropanoate 865785-04-2P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2,2,2-trifluoroacetate
865785-05-3P, (E)-3-[[[5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenoxy]carbonyl]propanoic acid 865785-06-4P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 3-(chlorocarbonyl)propanoate 865785-07-5P 865785-08-6P,
 (E)-4-[[[5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenoxy]carbonyl]butanoic acid 865785-09-7P,
 (E)-[[[5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenoxy]carbonyl]methyl dihydrogen phosphate 865785-10-0P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl methyl carbonate 865785-11-1P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-acetoxypropanoate
865785-12-2P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl methyl succinate 865785-13-3P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl ethyl malonate 865785-14-4P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2,2,3,3,3-pentafluoropropanoate 865785-15-5P, (E)-1-[5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl] 3-methyl 2,2-difluoromalate 865785-16-6P, (E)-3-[[[5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenoxy]carbonyl]-2,2,3,3-tetrafluoropropanoic acid 865785-17-7P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenyl 2-aminoacetate
865785-18-8P, (E)-2-[[[5-[[[(2,4,6-Trimethoxystyryl)sulfinyl)methyl]-2-methoxyphenoxy]carbonyl]-2,2-difluoroethanoic acid 865785-19-9P


, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl
 2-(dimethylamino)-2,2-difluoroacetate **865785-20-2P**,
 5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl
 2-(dimethylamino)acetate **865786-03-4P**, (E)-5-[[(2,4,6-
 Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl carboxymethanesulfonate
865786-04-5P, (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-
 methoxyphenyl 2,4-dinitrobenzenesulfonate **865786-05-6P**,
 (E)-5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl
 2,4-diaminobenzenesulfonate **865786-06-7P**, (E)-5-[[(2,4,6-
 Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl
 trifluoromethanesulfonate **865786-07-8P**, (E)-5-[[(2,4,6-
 Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl 4-
 methoxybenzenesulfonate **865786-08-9P**, (E)-5-[[(2,4,6-
 Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl 4-methylbenzenesulfonate
865786-25-0P, (E)-2-[5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-
 2-methoxyphenoxy]ethanoic acid **865786-26-1P**,
 (E)-2-[5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-
 methoxyphenoxy]propanoic acid **865786-27-2P**, (E)-4-[5-[[(2,4,6-
 Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenoxy]butanoic acid
865786-28-3P, (E)-3-[5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-
 2-methoxyphenoxy]propanoic acid **865786-30-7P**,
 (E)-4-[2-[5-[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-
 methoxyphenoxy]ethyl]morpholine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(**drug** candidate; **preparation** of substituted phenoxy- and
 phenylthio- derivs. for treating **proliferative**
disorders and as radioprotectants and chemoprotectants)

RN 852283-22-8 HCAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]met
 hyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-06-1 HCAPLUS

CN Benzenethiol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfin
 yl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-16-3 HCAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, dihydrogen phosphate (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-17-4 HCAPLUS

CN Phosphoric acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl dimethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-18-5 HCAPLUS

CN Phosphoric acid, diethyl 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-19-6 HCAPLUS

CN Phosphoric acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-20-9 HCAPLUS

CN Benzenethiol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl-, dihydrogen phosphate (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-21-0 HCAPLUS

CN Phosphorothioic acid, S-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] O,O-dimethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-22-1 HCAPLUS

CN Phosphorothioic acid, O,O-diethyl S-[2-methoxy-5-(((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfinyl)methyl]phenyl] ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-23-2 HCAPLUS

CN Phosphorothioic acid, S-[2-methoxy-5-(((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfinyl)methyl]phenyl] O,O-bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 865784-81-2 HCAPLUS

CN Propanedioic acid, mono[2-methoxy-5-(((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfinyl)methyl]phenyl] ester (9CI) (CA INDEX NAME)

NAME)


Double bond geometry as shown.



RN 865784-82-3 HCAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, 3,5-dinitrobenzoate (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-84-5 HCAPLUS

CN Benzoic acid, 3,5-diamino-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 865784-85-6 HCAPLUS

CN Acetic acid, chloro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-

10/574,993

trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-86-7 HCAPLUS

CN 1-Piperazineacetic acid, 4-methyl-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-87-8 HCAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 865784-88-9 HCAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)

hyl]-, 4-nitrobenzoate (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-89-0 HCAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, 4-aminobenzoate (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 865784-90-3 HCAPLUS

CN D-Lysine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 865784-91-4 HCAPLUS

CN D-Serine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 865784-92-5 HCAPLUS

CN L-Serine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 865784-93-6 HCAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-94-7 HCAPLUS

CN Glycine, N,N-dimethyl-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-95-8 HCAPLUS

CN Benzoic acid, 4-(4-methyl-1-piperazinyl)-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-96-9 HCAPLUS


CN Acetic acid, hydroxy-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 865784-97-0 HCAPLUS
 CN Pyridinium, 1-[2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 865784-98-1 HCAPLUS
 CN Acetic acid, (acetyloxy)-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 865784-99-2 HCAPLUS
 CN Propanoic acid, 2-hydroxy-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-00-8 HCAPLUS

CN Ethanaminium, N,N,N-triethyl-2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]-2-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-01-9 HCAPLUS

CN Ethanaminium, N,N,N-tris(2-hydroxyethyl)-2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]-2-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-02-0 HCAPLUS

CN Propanoic acid, 2-hydroxy-2-methyl-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-03-1 HCAPLUS

CN Propanoic acid, 2-(acetyloxy)-2-methyl-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-04-2 HCAPLUS

CN Acetic acid, trifluoro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-05-3 HCAPLUS

CN Butanedioic acid, mono[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-06-4 HCAPLUS

CN Butanoic acid, 4-chloro-4-oxo-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-07-5 HCAPLUS

CN Hexanedioic acid, 3-oxo-, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 865785-08-6 HCAPLUS

CN Pentanedioic acid, mono[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (9CI) (CA INDEX NAME)

NAME)


Double bond geometry as shown.



RN 865785-09-7 HCAPLUS

CN Acetic acid, (phosphonoxy)-, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-10-0 HCAPLUS

CN Carbonic acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 865785-11-1 HCAPLUS

CN Propanoic acid, 2-(acetyloxy)-, 2-methoxy-5-[[[(1E)-2-(2,4,6-

trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-12-2 HCAPLUS

CN Butanedioic acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-13-3 HCAPLUS

CN Propanedioic acid, ethyl 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-14-4 HCAPLUS

CN Propanoic acid, pentafluoro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-15-5 HCAPLUS

CN Propanedioic acid, difluoro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-16-6 HCAPLUS

CN Butanedioic acid, tetrafluoro-, mono[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-17-7 HCAPLUS

CN Glycine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-18-8 HCAPLUS

CN Propanedioic acid, difluoro-, mono[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 865785-19-9 HCAPLUS

CN Acetic acid, (dimethylamino)difluoro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 865785-20-2 HCAPLUS
 CN Glycine, N,N-dimethyl-, 2-methoxy-5-[[[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 865786-03-4 HCAPLUS
 CN Acetic acid, [[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]sulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 865786-04-5 HCAPLUS
 CN Benzenesulfonic acid, 2,4-dinitro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 865786-05-6 HCAPLUS
 CN Benzenesulfonic acid, 2,4-diamino-, 2-methoxy-5-[[[(1E)-2-(2,4,6-

10/574,993

trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-06-7 HCAPLUS

CN Methanesulfonic acid, trifluoro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-07-8 HCAPLUS

CN Benzenesulfonic acid, 4-methoxy-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-08-9 HCAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-25-0 HCAPLUS

CN Acetic acid, 2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-26-1 HCAPLUS

CN Propanoic acid, 2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-27-2 HCAPLUS

CN Butanoic acid, 4-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-28-3 HCAPLUS

CN Propanoic acid, 3-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-30-7 HCAPLUS

CN Morpholine, 4-[2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L134 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2005:451126 HCAPLUS Full-text

DOCUMENT NUMBER: 143:1247

TITLE: α,β -Unsaturated sulfoxides for treating proliferative disorders and as radioprotective and chemoprotective agents

INVENTOR(S): Reddy, Premkumar E.; Reddy, Ramana M. V.; Bell, Stanley C.

PATENT ASSIGNEE(S): Temple University of the Commonwealth System of Higher Education, USA; Onconova

SOURCE: Therapeutics Inc.
PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046599	A2	20050526	WO 2004-US37293	20041108
WO 2005046599	A3	20051006		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004289281	A1	20050526	AU 2004-289281	20041108
CA 2546495	A1	20050526	CA 2004-2546495	20041108
EP 1689706	A2	20060816	EP 2004-816944	20041108
R: AT, BE, CH, LI, CY, BG, CZ				
US 2006280746	A1	20061214	US 2006-574993	20060406
PRIORITY APPLN. INFO.:			US 2003-520523P	P 20031114
			WO 2004-US37293	W 20041108

OTHER SOURCE(S): CASREACT 143:1247; MARPAT 143:1247

ED Entered STN: 27 May 2005

AB $\alpha\beta$ -Unsatd. sulfoxides Ar1[CH(R1)]nS(O)CH=CHAr2 [Ar1, Ar2 = (un)substituted (hetero)aryl (when Ar1 and Ar2 are both Ph, at least one of Ar1 and Ar2 is substituted); n = 0, 1; R1 = H, C1-8 hydrocarbyl, CN, etc.; conformation of substituents on carbon-carbon double bond is E or Z; conformation of substituents on sulfoxide S atom is R-, S- or any mixture of R- and S-; when R1 other than H, conformation of substituents on carbon atom to which R1 is attached is R-, S- or any mixture of R- and S-] are disclosed which are useful as antiproliferative agents including e.g. anticancer agents and as radioprotective and chemoprotective agents. Processes or preg. compds. of the invention are also disclosed.

IC ICM A61K

CC 1-6 (Pharmacology)

Section cross-reference(s): 8, 25

ST unsatd sulfoxide prepn proliferative disorder treatment; antitumor radioprotectant chemoprotectant unsatd sulfoxide

IT Bone, disease

(Paget's; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT Fibrosis

(Peronies and Duputren's fibrosis; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT Radioprotectants

(and chemoprotectants; α,β -unsatd. sulfoxides for treatment

- of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Antiarteriosclerotics
(antiatherosclerotics; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Neoplasm
(bone marrow; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Intestine, neoplasm
(colorectal; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, with α,β -unsatd. sulfoxides; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Disease, animal
(degenerative, chronic progressive myelodegenerative disease; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Disease, animal
(ganglioneuromatosis; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Disease, animal
Newborn
(hemangiomatosis in newborn; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Mitosis
(mitotic phase cell cycle inhibitor; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, conjugates, with α,β -unsatd. sulfoxides; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Nervous system, neoplasm
(neurofibromatosis type 1; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Lung, neoplasm
(non-small-cell carcinoma; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Disease, animal
(proliferative; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

- IT Carcinoma
(pulmonary non-small-cell; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Artery, disease
(restenosis; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Multiple sclerosis
(secondary progressive; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Alkaloids, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(vinca; α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Antitumor agents
Apoptosis
Atherosclerosis
Bone marrow, neoplasm
Brain, neoplasm
Cardiovascular agents
Cirrhosis
Cystic fibrosis
Cytotoxic agents
Drug delivery systems
Drug toxicity
Human
Ionizing radiation
Keloid
Kidney, neoplasm
Leukemia
Lung, neoplasm
Mammary gland, neoplasm
Neoplasm
Nervous system agents
Ovary, neoplasm
Oxidizing agents
Prostate gland, neoplasm
Radiotherapy
Sarcoidosis
Skin, neoplasm
Testis, neoplasm
(α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Macrolides
Taxanes
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)
- IT Sulfoxides
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and

- chemoprotectants)
- IT Sulfides, reactions
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (α,β -unsatd. sulfoxides for treatment of
proliferative disorders and as radioprotectants and
 chemoprotectants)
- IT 80449-01-0, Topoisomerase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; α,β -unsatd. sulfoxides for treatment of
proliferative disorders and as radioprotectants and
 chemoprotectants)
- IT 57-22-7, Vincristine 64-86-8, Colchicine 64-86-8D, Colchicine, derivs.
 7689-03-4, Camptothecin 33069-62-4, Paclitaxel 33419-42-0, Etoposide
 65271-80-9, Mitoxantrone
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (α,β -unsatd. sulfoxides for treatment of
proliferative disorders and as radioprotectants and
 chemoprotectants)
- IT 852283-21-7P 852283-22-8P 852283-23-9P
852283-75-1P 852283-91-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (α,β -unsatd. sulfoxides for treatment of
proliferative disorders and as radioprotectants and
 chemoprotectants)
- IT 852283-15-9 852283-16-0 852283-17-1
852283-18-2 852283-19-3 852283-20-6
852283-24-0 852283-25-1 852283-26-2
852283-27-3 852283-28-4 852283-29-5
852283-30-8 852283-31-9 852283-32-0
852283-33-1 852283-34-2 852283-35-3
852283-36-4 852283-37-5 852283-38-6
852283-39-7 852283-40-0 852283-41-1
852283-42-2 852283-43-3 852283-44-4
852283-45-5 852283-46-6 852283-47-7
852283-48-8 852283-49-9 852283-50-2
852283-51-3 852283-52-4 852283-53-5
852283-54-6 852283-55-7 852283-56-8
852283-57-9 852283-58-0 852283-59-1
852283-60-4 852283-61-5 852283-62-6
852283-63-7 852283-64-8 852283-65-9
852283-66-0 852283-67-1 852283-68-2
852283-69-3 852283-70-6 852283-71-7
852283-72-8 852283-73-9 852283-74-0
852283-76-2 852283-77-3 852283-78-4
852283-79-5 852283-80-8 852283-81-9
852283-82-0 852283-83-1 852283-84-2
852283-85-3 852283-86-4 852283-87-5
852283-88-6 852283-89-7 852283-90-0
852283-92-2 852283-93-3 852283-94-4
852283-95-5 852283-96-6 852283-97-7
852283-98-8 852283-99-9 852284-00-5
852284-01-6 852284-02-7 852284-03-8
852284-04-9 852284-05-0 852284-06-1
852284-07-2 852284-08-3 852284-09-4
852284-10-7 852284-11-8 852284-12-9
852284-13-0 852284-14-1 852284-15-2
852284-16-3 852284-17-4 852284-18-5

<u>852284-19-6</u>	<u>852284-20-9</u>	<u>852284-21-0</u>
<u>852284-22-1</u>	<u>852284-23-2</u>	<u>852284-24-3</u>
<u>852284-25-4</u>	<u>852284-26-5</u>	<u>852284-27-6</u>
<u>852284-28-7</u>	<u>852284-29-8</u>	<u>852284-30-1</u>
<u>852284-31-2</u>	<u>852284-32-3</u>	<u>852284-33-4</u>
<u>852284-34-5</u>	<u>852284-35-6</u>	<u>852284-36-7</u>
<u>852284-37-8</u>	<u>852284-38-9</u>	<u>852284-39-0</u>
<u>852284-40-3</u>	<u>852284-41-4</u>	<u>852284-42-5</u>
<u>852284-43-6</u>	<u>852284-44-7</u>	<u>852284-45-8</u>
<u>852284-46-9</u>	<u>852284-47-0</u>	<u>852284-48-1</u>
<u>852284-49-2</u>	<u>852284-50-5</u>	<u>852284-51-6</u>
<u>852284-52-7</u>	<u>852284-53-8</u>	<u>852284-54-9</u>
<u>852284-55-0</u>	<u>852284-56-1</u>	<u>852284-57-2</u>
<u>852284-58-3</u>	<u>852284-59-4</u>	<u>852284-60-7</u>
<u>852284-61-8</u>	<u>852284-62-9</u>	<u>852284-63-0</u>
<u>852284-64-1</u>	<u>852284-65-2</u>	<u>852284-66-3</u>
<u>852284-67-4</u>	<u>852284-68-5</u>	<u>852284-69-6</u>
<u>852284-70-9</u>	<u>852284-71-0</u>	<u>852284-72-1</u>
<u>852284-73-2</u>	<u>852284-74-3</u>	<u>852284-75-4</u>
<u>852284-76-5</u>	<u>852284-77-6</u>	<u>852284-78-7</u>
<u>852284-79-8</u>	<u>852284-80-1</u>	<u>852284-81-2</u>
<u>852284-82-3</u>	<u>852284-83-4</u>	<u>852284-84-5</u>
<u>852284-85-6</u>	<u>852284-86-7</u>	<u>852284-87-8</u>
<u>852284-88-9</u>	<u>852284-89-0</u>	<u>852284-90-3</u>
<u>852284-91-4</u>	<u>852284-92-5</u>	<u>852284-93-6</u>
<u>852284-94-7</u>	<u>852284-95-8</u>	<u>852284-96-9</u>
<u>852284-97-0</u>	<u>852284-98-1</u>	<u>852284-99-2</u>
<u>852285-00-8</u>	<u>852285-01-9</u>	<u>852285-02-0</u>
<u>852285-03-1</u>	<u>852285-04-2</u>	<u>852285-05-3</u>
<u>852285-06-4</u>	<u>852285-07-5</u>	<u>852285-08-6</u>
<u>852285-09-7</u>	<u>852285-10-0</u>	<u>852285-11-1</u>
<u>852285-12-2</u>	<u>852285-13-3</u>	<u>852285-14-4</u>
<u>852285-15-5</u>	<u>852285-16-6</u>	<u>852285-17-7</u>
<u>852285-18-8</u>	<u>852285-19-9</u>	<u>852285-20-2</u>
<u>852285-21-3</u>	<u>852285-22-4</u>	<u>852285-23-5</u>
<u>852285-24-6</u>	<u>852285-25-7</u>	<u>852285-26-8</u>
<u>852285-27-9</u>	<u>852285-28-0</u>	<u>852285-29-1</u>
<u>852285-30-4</u>	<u>852285-31-5</u>	<u>852285-32-6</u>
<u>852285-33-7</u>	<u>852285-34-8</u>	<u>852285-35-9</u>
<u>852285-36-0</u>	<u>852285-37-1</u>	<u>852285-38-2</u>
<u>852285-39-3</u>	<u>852285-40-6</u>	<u>852285-41-7</u>
<u>852285-42-8</u>	<u>852285-43-9</u>	<u>852285-44-0</u>
<u>852285-45-1</u>	<u>852285-46-2</u>	<u>852285-47-3</u>
<u>852285-48-4</u>	<u>852285-49-5</u>	<u>852285-50-8</u>
<u>852285-51-9</u>	<u>852285-52-0</u>	<u>852285-53-1</u>
<u>852285-54-2</u>	<u>852285-55-3</u>	

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α,β -unsatd. sulfoxides for treatment of
proliferative disorders and as radioprotectants and
chemoprotectants)

IT	<u>852285-56-4</u>	<u>852285-57-5</u>	<u>852285-58-6</u>
	<u>852285-59-7</u>	<u>852285-60-0</u>	<u>852285-61-1</u>
	<u>852285-62-2</u>	<u>852285-63-3</u>	<u>852285-64-4</u>
	<u>852285-65-5</u>	<u>852285-66-6</u>	<u>852285-67-7</u>
	<u>852285-68-8</u>	<u>852285-69-9</u>	<u>852285-70-2</u>
	<u>852285-71-3</u>	<u>852285-72-4</u>	<u>852285-73-5</u>
	<u>852285-74-6</u>	<u>852285-75-7</u>	<u>852285-76-8</u>
	<u>852285-77-9</u>	<u>852285-80-4</u>	

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(α,β -unsatd. sulfoxides for treatment ofproliferative disorders and as radioprotectants and chemoprotectants)IT 68-11-1, Mercaptoacetic acid, reactions 104-83-6 619-66-9

824-94-2 830-79-5 6378-19-4 529502-39-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(α,β -unsatd. sulfoxides for treatment ofproliferative disorders and as radioprotectants and chemoprotectants)

IT 28203-55-6P 125174-87-0P 852285-78-0P 852285-79-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(α,β -unsatd. sulfoxides for treatment ofproliferative disorders and as radioprotectants and chemoprotectants)IT 852283-21-7P 852283-22-8P 852283-23-9P852283-75-1P 852283-91-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(α,β -unsatd. sulfoxides for treatment ofproliferative disorders and as radioprotectants and chemoprotectants)

RN 852283-21-7 HCAPLUS

CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-22-8 HCAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-23-9 HCAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[[4-methoxy-3-nitrophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-75-1 HCAPLUS

CN Benzoic acid, 4-[(1E)-2-[[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-91-1 HCAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT	<u>852283-15-9</u>	<u>852283-16-0</u>	<u>852283-17-1</u>
	<u>852283-18-2</u>	<u>852283-19-3</u>	<u>852283-20-6</u>
	<u>852283-24-0</u>	<u>852283-25-1</u>	<u>852283-26-2</u>
	<u>852283-27-3</u>	<u>852283-28-4</u>	<u>852283-29-5</u>
	<u>852283-30-8</u>	<u>852283-31-9</u>	<u>852283-32-0</u>
	<u>852283-33-1</u>	<u>852283-34-2</u>	<u>852283-35-3</u>
	<u>852283-36-4</u>	<u>852283-37-5</u>	<u>852283-38-6</u>
	<u>852283-39-7</u>	<u>852283-40-0</u>	<u>852283-41-1</u>
	<u>852283-42-2</u>	<u>852283-43-3</u>	<u>852283-44-4</u>
	<u>852283-45-5</u>	<u>852283-46-6</u>	<u>852283-47-7</u>

852283-48-8	852283-49-9	852283-50-2
852283-51-3	852283-52-4	852283-53-5
852283-54-6	852283-55-7	852283-56-8
852283-57-9	852283-58-0	852283-59-1
852283-60-4	852283-61-5	852283-62-6
852283-63-7	852283-64-8	852283-65-9
852283-66-0	852283-67-1	852283-68-2
852283-69-3	852283-70-6	852283-71-7
852283-72-8	852283-73-9	852283-74-0
852283-76-2	852283-77-3	852283-78-4
852283-79-5	852283-80-8	852283-81-9
852283-82-0	852283-83-1	852283-84-2
852283-85-3	852283-86-4	852283-87-5
852283-88-6	852283-89-7	852283-90-0
852283-92-2	852283-93-3	852283-94-4
852283-95-5	852283-96-6	852283-97-7
852283-98-8	852283-99-9	852284-00-5
852284-01-6	852284-02-7	852284-03-8
852284-04-9	852284-05-0	852284-06-1
852284-07-2	852284-08-3	852284-09-4
852284-10-7	852284-11-8	852284-12-9
852284-13-0	852284-14-1	852284-15-2
852284-16-3	852284-17-4	852284-18-5
852284-19-6	852284-20-9	852284-21-0
852284-22-1	852284-23-2	852284-24-3
852284-25-4	852284-26-5	852284-27-6
852284-28-7	852284-29-8	852284-30-1
852284-31-2	852284-32-3	852284-33-4
852284-34-5	852284-35-6	852284-36-7
852284-37-8	852284-38-9	852284-39-0
852284-40-3	852284-41-4	852284-42-5
852284-43-6	852284-44-7	852284-45-8
852284-46-9	852284-47-0	852284-48-1
852284-49-2	852284-50-5	852284-51-6
852284-52-7	852284-53-8	852284-54-9
852284-55-0	852284-56-1	852284-57-2
852284-58-3	852284-59-4	852284-60-7
852284-61-8	852284-62-9	852284-63-0
852284-64-1	852284-65-2	852284-66-3
852284-67-4	852284-68-5	852284-69-6
852284-70-9	852284-71-0	852284-72-1
852284-73-2	852284-74-3	852284-75-4
852284-76-5	852284-77-6	852284-78-7
852284-79-8	852284-80-1	852284-81-2
852284-82-3	852284-83-4	852284-84-5
852284-85-6	852284-86-7	852284-87-8
852284-88-9	852284-89-0	852284-90-3
852284-91-4	852284-92-5	852284-93-6
852284-94-7	852284-95-8	852284-96-9
852284-97-0	852284-98-1	852284-99-2
852285-00-8	852285-01-9	852285-02-0
852285-03-1	852285-04-2	852285-05-3
852285-06-4	852285-07-5	852285-08-6
852285-09-7	852285-10-0	852285-11-1
852285-12-2	852285-13-3	852285-14-4
852285-15-5	852285-16-6	852285-17-7
852285-18-8	852285-19-9	852285-20-2
852285-21-3	852285-22-4	852285-23-5
852285-24-6	852285-25-7	852285-26-8
852285-27-9	852285-28-0	852285-29-1

852285-30-4	852285-31-5	852285-32-6
852285-33-7	852285-34-8	852285-35-9
852285-36-0	852285-37-1	852285-38-2
852285-39-3	852285-40-6	852285-41-7
852285-42-8	852285-43-9	852285-44-0
5-45-1	852285-46-2	852285-47-3
852285-48-4	852285-49-5	852285-50-8
852285-51-9	852285-52-0	852285-53-1
852285-54-2	852285-55-3	

85228


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α,β -unsatd. sulfoxides for treatment of
proliferative disorders and as radioprotectants and
 chemoprotectants)

RN 852283-15-9 HCAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]- (9CI)
 (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-16-0 HCAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]- (9CI)
 (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-17-1 HCAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfinyl]methyl]- (9CI)
 (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-18-2 HCAPLUS

CN Naphthalene, 1-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfinyl]methyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852283-19-3 HCAPLUS

CN Naphthalene, 1-[[[(1E)-2-(3-nitrophenyl)ethenyl]sulfinyl]methyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852283-20-6 HCAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852283-24-0 HCAPLUS

CN Acetic acid, [[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-25-1 HCAPLUS

CN Propanoic acid, 3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-26-2 HCAPLUS

CN Guanidine, [2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-27-3 HCAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-28-4 HCAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-3,5-dinitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-29-5 HCAPLUS

CN Benzamide, 3,5-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-30-8 HCAPLUS

CN Acetamide, 2-chloro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-31-9 HCAPLUS

CN 1-Piperazineacetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-32-0 HCAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-33-1 HCAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-34-2 HCAPLUS

CN Benzamide, 4-amino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-35-3 HCAPLUS

CN Benzenamine, 2-methoxy-N-[(4-nitrophenyl)methylene]-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, [N(Z)]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852283-36-4 HCAPLUS

CN Hexanamide, 2,6-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 852283-37-5 HCAPLUS

CN Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 852283-38-6 HCAPLUS

CN Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-

trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 852283-39-7 HCAPLUS

CN Urea, [2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-40-0 HCAPLUS

CN Benzenamine, 2-methoxy-N-methyl-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852283-41-1 HCAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

yl)methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-42-2 HCAPLUS

CN Benzenesulfonamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-2,4-dinitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-43-3 HCAPLUS

CN Benzenesulfonamide, 2,4-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-44-4 HCAPLUS

CN Acetamide, 2-(dimethylamino)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-45-5 HCAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 852283-46-6 HCAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-47-7 HCAPLUS

CN Acetamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-48-8 HCAPLUS

CN 2-Pyridineacetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-49-9 HCAPLUS

CN Acetamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-50-2 HCAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-51-3 HCAPLUS

CN Ethanaminium, N,N,N-triethyl-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-2-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-52-4 HCAPLUS

CN Ethanaminium, N,N,N-tris(2-hydroxyethyl)-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-2-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-53-5 HCAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-54-6 HCAPLUS

CN Butanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-55-7 HCAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-56-8 HCAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-57-9 HCAPLUS

CN β -Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-58-0 HCAPLUS

CN Propanoyl chloride, 3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-59-1 HCAPLUS

CN Butanedioic acid, mono[2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-2-oxoethyl] ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-60-4 HCAPLUS

CN Pentanoic acid, 5-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-5-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-61-5 HCAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-2-(phosphonooxy)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-62-6 HCAPLUS

CN Butanoic acid, 4-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-63-7 HCAPLUS

CN Carbamic acid, [2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-64-8 HCAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-65-9 HCAPLUS

CN Propanamide, 3-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-66-0 HCAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-67-1 HCAPLUS

CN Propanoic acid, 3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-68-2 HCAPLUS

CN Propanamide, 2,2,3,3,3-pentafluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-69-3 HCAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-70-6 HCAPLUS

CN Butanoic acid, 2,2,3,3-tetrafluoro-4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-71-7 HCAPLUS

CN Acetamide, 2-amino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-72-8 HCAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-73-9 HCAPLUS

CN Acetamide, 2-(dimethylamino)-2,2-difluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-74-0 HCAPLUS

CN Benzoic acid, 4-[(1E)-2-[[[4-fluorophenyl]methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-76-2 HCAPLUS

CN Ethanone, 1-[5-[(1E)-2-[[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-2-fluorophenyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-77-3 HCAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl)methyl]sulfinyl]ethenyl]-2,4-difluoro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-78-4 HCAPLUS

CN Benzenamine, 5-[(1E)-2-[[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-2-fluoro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-79-5 HCAPLUS

CN Benzene, pentafluoro[(1E)-2-[[4-(4-fluorophenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-80-8 HCAPLUS

CN Benzene, [(1E)-2-[[4-(4-chlorophenyl)methyl]sulfinyl]ethenyl]pentafluoro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-81-9 HCAPLUS

CN Benzene, [(1E)-2-[[4-(4-bromophenyl)methyl]sulfinyl]ethenyl]pentafluoro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-82-0 HCAPLUS

CN Benzene, pentafluoro[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-83-1 HCAPLUS

CN Benzene, [[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]pentafluoro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-84-2 HCAPLUS

CN Benzene, [[[(1E)-2-(4-bromophenyl)ethenyl]sulfinyl]methyl]pentafluoro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-85-3 HCAPLUS

CN Benzene, [(1E)-2-[[[(3,4-dichlorophenyl)methyl]sulfinyl]ethenyl]pentafluoro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-86-4 HCAPLUS

CN Benzene, pentafluoro[(1E)-2-[[[(4-iodophenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-87-5 HCAPLUS

CN Phenol, 2-[(1E)-2-[[[(4-fluorophenyl)methyl]sulfinyl]ethenyl]-4,6-dinitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-88-6 HCAPLUS

CN Phenol, 2-[(1E)-2-[(4-bromophenyl)methyl]sulfinyl]ethenyl]-4,6-dinitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-89-7 HCAPLUS

CN Phenol, 2-[(1E)-2-[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-4,6-dinitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-90-0 HCAPLUS

CN Phenol, 2-[(1E)-2-[(2,4-dichlorophenyl)methyl]sulfinyl]ethenyl]-4,6-
dinitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-92-2 HCAPLUS

CN Benzene, 1,3-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl]methyl]sulfinyl]ethenyl]-2-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-93-3 HCAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl]methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-94-4 HCAPLUS

CN Benzene, 5-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl]methyl]sulfinyl]ethenyl]-1,2,3-trimethoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-95-5 HCAPLUS

CN Benzene, 2-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfinyl]ethenyl]-1,3,5-trimethoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-96-6 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfinyl]ethenyl]-2,4-dimethoxy-3-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-97-7 HCAPLUS

CN Benzene, 1,2,3-trifluoro-4-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-98-8 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-2,3,4-trifluoro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-99-9 HCAPLUS

CN Phenol, 3,5-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-00-5 HCAPLUS

CN Benzene, 1,2,4,5-tetrafluoro-3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-01-6 HCAPLUS

CN Benzene, 1,2,4-trimethoxy-5-[(1E)-2-[[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-02-7 HCAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[(1E)-2-[[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-03-8 HCAPLUS

CN Phenol, 2-methoxy-4-[(1E)-2-[[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-6-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-04-9 HCAPLUS

CN Benzene, 1,2-dimethoxy-4-[(1E)-2-[[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-5-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-05-0 HCAPLUS

CN Benzene, 1-iodo-2,3-dimethoxy-5-[(1E)-2-[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-06-1 HCAPLUS

CN Benzene, 5-fluoro-1,3-dimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-07-2 HCAPLUS

CN Phenol, 3,5-dimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-08-3 HCAPLUS

CN Benzene, 2-[(1E)-2-[[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-1,3,5-trimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-09-4 HCAPLUS

CN Benzene, 2-[(1E)-2-[[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-1,3,5-trimethoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-10-7 HCAPLUS

CN Benzene, 2-[(1E)-2-[[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-5-fluoro-1,3-dimethoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-11-8 HCAPLUS

CN Phenol, 4-[(1E)-2-[[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-12-9 HCAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]-1,3,5-trimethoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-13-0 HCAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]-5-fluoro-1,3-dimethoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-14-1 HCAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-15-2 HCAPLUS

CN Benzene, 1-[[[(1E)-2-(2,6-dimethoxyphenyl)ethenyl]sulfinyl]methyl]-2,3,4-trimethoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-16-3 HCAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-17-4 HCAPLUS

CN Benzene, 5-[[[(1E)-2-(2,6-dimethoxyphenyl)ethenyl]sulfinyl]methyl]-1,2,3-trimethoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-18-5 HCAPLUS

CN Benzene, 5-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-1,2,3-trimethoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-19-6 HCAPLUS

CN Benzene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-20-9 HCAPLUS

CN Benzene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-21-0 HCAPLUS

CN Benzene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfinyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-22-1 HCAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-23-2 HCAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-24-3 HCAPLUS

CN Benzene, 1,2-dichloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-25-4 HCAPLUS

CN Benzene, 1,2-dichloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-26-5 HCAPLUS

CN Benzene, 4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfinyl]methyl]-1,2-dichloro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-27-6 HCAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-(nitrophenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-28-7 HCAPLUS

CN Benzonitrile, 4-[(1E)-2-[[4-(fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-29-8 HCAPLUS

CN Benzonitrile, 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-30-1 HCAPLUS

CN Benzonitrile, 4-[(1E)-2-[[(4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-31-2 HCAPLUS

CN Benzene, 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-1,2-difluoro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-32-3 HCAPLUS

CN Benzene, 2-chloro-4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-1-fluoro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-33-4 HCAPLUS

CN Benzene, 2-chloro-1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-4-fluoro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-34-5 HCAPLUS

CN Benzene, 2,4-dichloro-1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-35-6 HCAPLUS

CN Benzene, 1,2-dichloro-4-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-36-7 HCAPLUS

CN Benzene, 1,2-dichloro-3-[(1E)-2-[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-37-8 HCAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[(4-iodophenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-38-9 HCAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-39-0 HCAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-40-3 HCAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfinyl]methyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-41-4 HCAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-42-5 HCAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-iodophenyl]methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-43-6 HCAPLUS

CN Benzene, 1-iodo-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-44-7 HCAPLUS

CN Benzene, 1-[(1E)-2-[[[(4-iodophenyl)methyl]sulfinyl]ethenyl]-2-nitro- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-45-8 HCAPLUS

CN Benzene, 1-iodo-4-[(1E)-2-[[[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-46-9 HCAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-47-0 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl]methyl]sulfinyl]ethenyl]-2-nitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-48-1 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl]methyl]sulfinyl]ethenyl]-3-nitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-49-2 HCAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852284-50-5 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl]methyl]sulfinyl]ethenyl]-2-

(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-51-6 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-52-7 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-53-8 HCAPLUS

CN Benzene, 4-fluoro-1-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-54-9 HCAPLUS

CN Benzene, 1-[(1E)-2-[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-2-nitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-55-0 HCAPLUS

CN Benzene, 1-[(1E)-2-[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-3-nitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-56-1 HCAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-57-2 HCAPLUS

CN Benzene, 1-[(1E)-2-[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-2-
(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-58-3 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-59-4 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-60-7 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-4-fluoro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852284-61-8 HCAPLUS

CN Benzene, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-1-fluoro-2-

methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-62-9 HCAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-63-0 HCAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-[4-fluoro-2-(trifluoromethyl)phenyl]ethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-64-1 HCAPLUS


CN Benzene, 1-[(1E)-2-[[[(4-bromophenyl)methyl]sulfinyl]ethenyl]-2-nitro-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852284-65-2 HCAPLUS
 CN Benzene, 1-[(1E)-2-[[[4-bromophenyl)methyl]sulfinyl]ethenyl]-3-nitro-
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852284-66-3 HCAPLUS
 CN Benzene, 1-bromo-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]-
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852284-67-4 HCAPLUS
 CN Benzene, 1-[(1E)-2-[[[4-bromophenyl)methyl]sulfinyl]ethenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 852284-68-5 HCAPLUS
 CN Benzene, 1-[(1E)-2-[[[4-bromophenyl)methyl]sulfinyl]ethenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-69-6 HCAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfinyl]methyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-70-9 HCAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-nitrophenyl)ethenyl]sulfinyl]methyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-71-0 HCAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 852284-72-1 HCAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[[(4-methylphenyl)methyl]sulfinyl]ethenyl]-

(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-73-2 HCAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-methylphenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-74-3 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4-methylphenyl)methyl]sulfinyl]ethenyl]-2-nitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-75-4 HCAPLUS

CN Benzene, 1-[(1E)-2-[[4-methylphenyl)methyl]sulfinyl]ethenyl]-3-nitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-76-5 HCAPLUS

CN Benzene, 1-methyl-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-77-6 HCAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-78-7 HCAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-79-8 HCAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-80-1 HCAPLUS

CN Benzene, 1-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]-2-nitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-81-2 HCAPLUS

CN Benzene, 1-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]-3-nitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-82-3 HCAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852284-83-4 HCAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[(4-nitrophenyl)methyl]sulfinyl]ethenyl]-

(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-84-5 HCAPLUS

CN Benzene, 1-chloro-2-[(1E)-2-[(phenylmethyl)sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-85-6 HCAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-86-7 HCAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-87-8 HCAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-88-9 HCAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-89-0 HCAPLUS

CN Benzene, 2,4-difluoro-1-[(1E)-2-[(4-fluorophenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-90-3 HCAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-91-4 HCAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-92-5 HCAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[(4-fluorophenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-93-6 HCAPLUS

CN Benzene, [[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-94-7 HCAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-95-8 HCAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-96-9 HCAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-97-0 HCAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(phenylmethyl)sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-98-1 HCAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-99-2 HCAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-00-8 HCAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(4-fluorophenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-01-9 HCAPLUS

CN Benzene, 1-fluoro-4-[(1Z)-2-[(phenylmethyl)sulfinyl]ethenyl]- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 852285-02-0 HCAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-03-1 HCAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-04-2 HCAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-05-3 HCAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(phenylmethyl)sulfinyl]ethenyl]- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 852285-06-4 HCAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[[[4-chlorophenyl]methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-07-5 HCAPLUS

CN Benzene, 1-[[[(1Z)-2-(4-bromophenyl)ethenyl]sulfinyl]methyl]-2-chloro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-08-6 HCAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[[4-(4-fluorophenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-09-7 HCAPLUS

CN Benzene, 1-methyl-4-[(1Z)-2-[(phenylmethyl)sulfinyl]ethenyl]- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 852285-10-0 HCAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-11-1 HCAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-12-2 HCAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfinyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-13-3 HCAPLUS

CN Benzene, 1-fluoro-4-[(1Z)-2-[[[4-iodophenyl]methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-14-4 HCAPLUS

CN Pyridine, 2-[(1E)-2-[[[4-fluorophenyl]methyl]sulfinyl]ethenyl]- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 852285-15-5 HCAPLUS

CN Pyridine, 3-[(1E)-2-[[[4-fluorophenyl]methyl]sulfinyl]ethenyl]- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 852285-16-6 HCAPLUS

CN Pyridine, 4-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-17-7 HCAPLUS

CN Pyridine, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-18-8 HCAPLUS

CN Pyridine, 3-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-19-9 HCAPLUS

CN Pyridine, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-20-2 HCAPLUS

CN Pyridine, 2-[(1E)-2-[(4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-21-3 HCAPLUS

CN Pyridine, 3-[(1E)-2-[(4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-22-4 HCAPLUS

CN Pyridine, 4-[(1E)-2-[(4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852285-23-5 HCAPLUS

CN Thiophene, 2-[(1E)-2-[(4-fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI)

(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-24-6 HCAPLUS

CN Thiophene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-25-7 HCAPLUS

CN Thiophene, 4-bromo-2-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-26-8 HCAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-27-9 HCAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-28-0 HCAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[[(4-bromophenyl)methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-29-1 HCAPLUS

CN Thiophene, 2-[(1E)-2-[[(4-fluorophenyl)methyl]sulfinyl]ethenyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-30-4 HCAPLUS

CN Thiophene, 2-[(1E)-2-[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-31-5 HCAPLUS

CN Thiophene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-32-6 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-33-7 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-34-8 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-35-9 HCAPLUS

CN Thiophene, 3-[(1E)-2-[(4-iodophenyl)methylsulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-36-0 HCAPLUS

CN Thiophene, 3-[(1E)-2-[(4-methylphenyl)methylsulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-37-1 HCAPLUS

CN Thiophene, 3-[(1E)-2-[(4-methoxyphenyl)methylsulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-38-2 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[[4-(trifluoromethyl)phenyl]methyl]sulfinyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-39-3 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[[2,4-dichlorophenyl]methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-40-6 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[[3,4-dichlorophenyl]methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-41-7 HCAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-thienyl)ethenyl]sulfinyl]methyl]- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 852285-42-8 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[4-nitrophenyl]methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-43-9 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[4-fluorophenyl]methyl]sulfinyl]ethenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-44-0 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[4-chlorophenyl]methyl]sulfinyl]ethenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-45-1 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[[4-bromophenyl)methyl]sulfinyl]ethenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-46-2 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-47-3 HCAPLUS

CN Thiophene, 3-[(1E)-2-[[[2,4-dichlorophenyl)methyl]sulfinyl]ethenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-48-4 HCAPLUS

CN Furan, 2-[(1E)-2-[[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-49-5 HCAPLUS

CN Furan, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-50-8 HCAPLUS

CN Furan, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-51-9 HCAPLUS

CN Furan, 3-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 852285-52-0 HCAPLUS

CN Furan, 3-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)

INDEX NAME)


Double bond geometry as shown.



RN 852285-53-1 HCAPLUS

CN Furan, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-54-2 HCAPLUS

CN Furan, 3-[(1E)-2-[[4-iodophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-55-3 HCAPLUS

CN Furan, 3-[(1E)-2-[[4-methylphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 852285-56-4 852285-57-5 852285-58-6
852285-59-7 852285-60-0 852285-61-1
852285-62-2 852285-63-3 852285-64-4
852285-65-5 852285-66-6 852285-67-7
852285-68-8 852285-69-9 852285-70-2
852285-71-3 852285-72-4 852285-73-5
852285-74-6 852285-75-7 852285-76-8
852285-77-9 852285-80-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

RN 852285-56-4 HCAPLUS

CN Furan, 3-[(1E)-2-[[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-57-5 HCAPLUS

CN Furan, 3-[(1E)-2-[[[4-(trifluoromethyl)phenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-58-6 HCAPLUS

CN Furan, 3-[(1E)-2-[[[2,4-dichlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-59-7 HCAPLUS

CN Furan, 3-[(1E)-2-[(3,4-dichlorophenyl)methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-60-0 HCAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-furanyl)ethenyl]sulfinyl]methyl]- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 852285-61-1 HCAPLUS

CN Furan, 3-[(1E)-2-[(4-nitrophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 852285-62-2 HCAPLUS

CN Thiazole, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-63-3 HCAPLUS

CN 1H-Pyrrole, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-64-4 HCAPLUS

CN 1H-Pyrrole, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-65-5 HCAPLUS

CN Thiophene, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-2-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-66-6 HCAPLUS

CN Thiophene, 4-[(1E)-2-[[4-iodophenyl)methylsulfinyl]ethenyl]-2-nitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-67-7 HCAPLUS

CN Thiophene, 4-[(1E)-2-[[2,4-dichlorophenyl)methylsulfinyl]ethenyl]-2-nitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-68-8 HCAPLUS

CN Thiophene, 4-[(1E)-2-[[4-methoxyphenyl)methylsulfinyl]ethenyl]-2-nitro-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-69-9 HCAPLUS

CN Naphthalene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-70-2 HCAPLUS

CN Naphthalene, 2-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-71-3 HCAPLUS

CN Naphthalene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-72-4 HCAPLUS

CN Naphthalene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-73-5 HCAPLUS

CN Naphthalene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-74-6 HCAPLUS

CN Naphthalene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-75-7 HCAPLUS


CN Anthracene, 9-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 852285-76-8 HCAPLUS
 CN Anthracene, 9-[(1E)-2-[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.




RN 852285-77-9 HCAPLUS
 CN Anthracene, 9-[(1E)-2-[[(4-bromophenyl)methyl]sulfinyl]ethenyl]- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.



RN 852285-80-4 HCAPLUS
 CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L134 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:638614 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:149136

TITLE: Protection of tissues and cells from cytotoxic effects of ionizing radiation by ABL inhibitors

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana; Cosenza, Stephen C.; Gumireddy, Kiranmai

PATENT ASSIGNEE(S): Temple University of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 151 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065074	A2	20050721	WO 2004-US28654	20040902
WO 2005065074	A3	20060223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-501783P P 20030909

OTHER SOURCE(S): MARPAT 143:149136

ED Entered STN: 22 Jul 2005

AB Pre-treatment with ABL protein kinase inhibitors protects normal cells from the toxic side effects of ionizing radiation. Administration of one or more radioprotectant to a patient prior to anticancer radiotherapy reduces the cytotoxic side effects of the radiation on normal cells. The radioprotective effect allows for safely increasing the dosage of anticancer radiation. Amelioration of toxicity following inadvertent radiation exposure may also be mitigated.

IC ICM A61K

CC 8-9 (Radiation Biochemistry)
Section cross-reference(s): 21

L134 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:423713 HCAPLUS Full-text

DOCUMENT NUMBER: 142:459275

TITLE: Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana; Cosenza, Stephen C.; Gumireddy, Kiranmai

PATENT ASSIGNEE(S): Temple University of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2005044181 A2 20050519 WO 2004-US28658 20040902
 WO 2005044181 A3 20060309

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-501748P P 20030909

OTHER SOURCE(S): MARPAT 142:459275

ED Entered STN: 19 May 2005

AB Pre-treatment with benzyl or styryl sulfonyl compds. protects normal cells from the toxic side effects of ionizing radiation. Administration of one or more radioprotective compds. to a patient prior to anticancer radiotherapy reduces the cytotoxic side effects of the radiation on normal cells. The radioprotective effect of the compds. allows for the safe increase of the dosage of anticancer radiation. Amelioration of toxicity following inadvertent radiation exposure may also be mitigated with administration of one or more of the compds.

IC ICM A61K

CC 8-9 (Radiation Biochemistry)
 Section cross-reference(s): 63

=> d ibib ab hitrn fhitr 7

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, WPIX' - CONTINUE? (Y)/N:y

L134 ANSWER 7 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2006:327543 USPATFULL Full-text

TITLE: Alpha, beta-unsaturated sulfoxides for treating proliferative disorders

INVENTOR(S): Reddy, E. Premkumar, Villanova, PA, UNITED STATES

Reddy, M. V. Ramana, Upper Darby, PA, UNITED STATES

Bell, Stanley C., Narberth, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006280746	A1	20061214
APPLICATION INFO.:	US 2004-574993	A1	20041108 (10)
	WO 2004-US37293		20041108
			20060406 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-520523P	20031114 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DRINKER BIDDLE & REATH, ATTN: INTELLECTUAL PROPERTY GROUP, ONE LOGAN SQUARE, 18TH AND CHERRY STREETS, PHILADELPHIA, PA, 19103-6996, US	
NUMBER OF CLAIMS:	77	

EXEMPLARY CLAIM: 1

LINE COUNT: 3952

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB $\alpha\beta$ -Unsaturated sulfoxides of Formula I: ##STR1## are useful as antiproliferative agents including, for example, anticancer agents, and as radioprotective and chemoprotective agents.

IT 852283-21-7P 852283-22-8P 852283-23-9P
852283-75-1P 852283-91-1P

(α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT 852283-15-9 852283-16-0 852283-17-1
852283-18-2 852283-19-3 852283-20-6
852283-24-0 852283-25-1 852283-26-2
852283-27-3 852283-28-4 852283-29-5
852283-30-8 852283-31-9 852283-32-0
852283-33-1 852283-34-2 852283-35-3
852283-36-4 852283-37-5 852283-38-6
852283-39-7 852283-40-0 852283-41-1
852283-42-2 852283-43-3 852283-44-4
852283-45-5 852283-46-6 852283-47-7
852283-48-8 852283-49-9 852283-50-2
852283-51-3 852283-52-4 852283-53-5
852283-54-6 852283-55-7 852283-56-8
852283-57-9 852283-58-0 852283-59-1
852283-60-4 852283-61-5 852283-62-6
852283-63-7 852283-64-8 852283-65-9
852283-66-0 852283-67-1 852283-68-2
852283-69-3 852283-70-6 852283-71-7
852283-72-8 852283-73-9 852283-74-0
852283-76-2 852283-77-3 852283-78-4
852283-79-5 852283-80-8 852283-81-9
852283-82-0 852283-83-1 852283-84-2
852283-85-3 852283-86-4 852283-87-5
852283-88-6 852283-89-7 852283-90-0
852283-92-2 852283-93-3 852283-94-4
852283-95-5 852283-96-6 852283-97-7
852283-98-8 852283-99-9 852284-00-5
852284-01-6 852284-02-7 852284-03-8
852284-04-9 852284-05-0 852284-06-1
852284-07-2 852284-08-3 852284-09-4
852284-10-7 852284-11-8 852284-12-9
852284-13-0 852284-14-1 852284-15-2
852284-16-3 852284-17-4 852284-18-5
852284-19-6 852284-20-9 852284-21-0
852284-22-1 852284-23-2 852284-24-3
852284-25-4 852284-26-5 852284-27-6
852284-28-7 852284-29-8 852284-30-1
852284-31-2 852284-32-3 852284-33-4
852284-34-5 852284-35-6 852284-36-7
852284-37-8 852284-38-9 852284-39-0
852284-40-3 852284-41-4 852284-42-5
852284-43-6 852284-44-7 852284-45-8
852284-46-9 852284-47-0 852284-48-1
852284-49-2 852284-50-5 852284-51-6
852284-52-7 852284-53-8 852284-54-9
852284-55-0 852284-56-1 852284-57-2
852284-58-3 852284-59-4 852284-60-7
852284-61-8 852284-62-9 852284-63-0
852284-64-1 852284-65-2 852284-66-3
852284-67-4 852284-68-5 852284-69-6

<u>852284-70-9</u>	<u>852284-71-0</u>	<u>852284-72-1</u>
<u>852284-73-2</u>	<u>852284-74-3</u>	<u>852284-75-4</u>
<u>852284-76-5</u>	<u>852284-77-6</u>	<u>852284-78-7</u>
<u>852284-79-8</u>	<u>852284-80-1</u>	<u>852284-81-2</u>
<u>852284-82-3</u>	<u>852284-83-4</u>	<u>852284-84-5</u>
<u>852284-85-6</u>	<u>852284-86-7</u>	<u>852284-87-8</u>
<u>852284-88-9</u>	<u>852284-89-0</u>	<u>852284-90-3</u>
<u>852284-91-4</u>	<u>852284-92-5</u>	<u>852284-93-6</u>
<u>852284-94-7</u>	<u>852284-95-8</u>	<u>852284-96-9</u>
<u>852284-97-0</u>	<u>852284-98-1</u>	<u>852284-99-2</u>
<u>852285-00-8</u>	<u>852285-01-9</u>	<u>852285-02-0</u>
<u>852285-03-1</u>	<u>852285-04-2</u>	<u>852285-05-3</u>
<u>852285-06-4</u>	<u>852285-07-5</u>	<u>852285-08-6</u>
<u>852285-09-7</u>	<u>852285-10-0</u>	<u>852285-11-1</u>
<u>852285-12-2</u>	<u>852285-13-3</u>	<u>852285-14-4</u>
<u>852285-15-5</u>	<u>852285-16-6</u>	<u>852285-17-7</u>
<u>852285-18-8</u>	<u>852285-19-9</u>	<u>852285-20-2</u>
<u>852285-21-3</u>	<u>852285-22-4</u>	<u>852285-23-5</u>
<u>852285-24-6</u>	<u>852285-25-7</u>	<u>852285-26-8</u>
<u>852285-27-9</u>	<u>852285-28-0</u>	<u>852285-29-1</u>
<u>852285-30-4</u>	<u>852285-31-5</u>	<u>852285-32-6</u>
<u>852285-33-7</u>	<u>852285-34-8</u>	<u>852285-35-9</u>
<u>852285-36-0</u>	<u>852285-37-1</u>	<u>852285-38-2</u>
<u>852285-39-3</u>	<u>852285-40-6</u>	<u>852285-41-7</u>
<u>852285-42-8</u>	<u>852285-43-9</u>	<u>852285-44-0</u>
<u>852285-45-1</u>	<u>852285-46-2</u>	<u>852285-47-3</u>
<u>852285-48-4</u>	<u>852285-49-5</u>	<u>852285-50-8</u>
<u>852285-51-9</u>	<u>852285-52-0</u>	<u>852285-53-1</u>
<u>852285-54-2</u>		

(α , β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

IT 852285-55-3 852285-56-4 852285-57-5
852285-58-6 852285-59-7 852285-60-0
852285-61-1 852285-62-2 852285-63-3
852285-64-4 852285-65-5 852285-66-6
852285-67-7 852285-68-8 852285-69-9
852285-70-2 852285-71-3 852285-72-4
852285-73-5 852285-74-6 852285-75-7
852285-76-8 852285-77-9 852285-80-4

(α , β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)


IT 852283-21-7P

(α , β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

RN 852283-21-7 USPATFULL

CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> d iall abeq tech abex hitstr 8

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, WPIX' - CONTINUE? (Y)/N:y

L134 ANSWER 8 OF 8 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2006-212802 [22] WPIX
 DOC. NO. CPI: C2006-070118 [22]
 TITLE: Treatment of an individual for a proliferative disorder
 involves administration of alpha, beta-
unsaturated sulfones, sulfoxides,
 sulfonamides, sulfinimides, acylsulfonamides and
 acylsulfinamide compounds
 DERWENT CLASS: B05
 INVENTOR: REDDY P E; REDDY R M V
 PATENT ASSIGNEE: (UTEM-C) UNIV TEMPLE
 COUNTRY COUNT: 109

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2006025924	A2	20060309	(200622)*	EN	87[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2006025924	A2	WO 2005-US22394	20050623

PRIORITY APPLN. INFO: US 2004-583009P 20040624

INT. PATENT CLASSIF.:

IPC ORIGINAL: A61K0031-18 [I,A]; A61K0031-18 [I,C]; A61K0031-4427 [I,C]
 ; A61K0031-4439 [I,A]

BASIC ABSTRACT:

WO 2006025924 A2 UPAB: 20060331

NOVELTY - Treatment of an individual for a proliferative disorder involves administration of alpha, beta-unsaturated sulfones, sulfoxides, sulfonamides, sulfinimides, acylsulfonamides and acylsulfinamide compounds or their salts.

DETAILED DESCRIPTION - Treatment of a proliferative disorder involves administration of alpha, beta-unsaturated sulfones, sulfoxides, sulfonamides, sulfinimides, acylsulfonamides and acylsulfinamide compounds of formula (I), or their salts.

(R1)n-Q1-E1-M1-L(R2)-M2-E2-Q2-(R1)n (I)

Q1 and Q2 = (hetero)aryl;

R1 = halo, 1-8C hydrocarbyl, -C(O)-Ry, -N(Rw)2, -N(Rw)C(O)-Ry, -N(Rw)C(Rz)C(O)-Ry, -N(Rw)SO2Ry, -N(Rw)-1-4C alkylene-CO2Rw, -NO2, -CN, -ORw, -OC(O)Ry, -OC(Rz)C(O)Ry, -OSO2Ry, -O-1-4C alkylene-CO2Rw, -OP(O)(ORw)2, -O-2-6C alkylene-N(CH3)2, -O-1-6C haloalkyl, -P(O)(ORw)2, -SO2N(Rw)Rx, -NHC(=NH)NHRx, 1-6C haloalkyl or heteroalkyl;

Rw = H or 1-8C hydrocarbyl;

Rx = H, 1-8C hydrocarbyl or -C(O)(1-8C)hydrocarbyl;

Ry = H, 1-8C hydrocarbyl, -O-1-8C hydrocarbyl, substituted phenyl, substituted heterocyclyl(1-3C alkyl), heteroaryl(1-3C alkyl), 2-10C heteroalkyl, 1-6C haloalkyl, -C(Rz)NHRx, -N(Rw)Rx, -1-3C alkylene-NH2, -1-3C

alkylene-N(CH₃)₂, -1-3C perfluoroalkylene-N(CH₃)₂, -1-3C alkylene-N+(1-3C)₃, -1-3C alkylene-N+(CH₂CH₂OH)₃, -1-3C alkylene-OR_x, -1-4C alkylene-CO₂R_w, -1-4C alkylene-CO₂N(R_w)R_x, -1-4C alkylene-C(O)halo, halo(1-3C)alkyl or -1-4C perfluoroalkylene-CO₂R_w;

R_z = H, 1-6C alkyl, -(CH₂)₃-NH-C(NH₂) (=NH), -CH₂C(=O)NH₂, -CH₂COOH, -CH₂SH, -(CH₂)₂C(O)-NH₂, -(CH₂)₂CO₂H, -CH₂-(2-imidazolyl), -(CH₂)₄-NH₂, -(CH₂)₂-S-CH₃, phenyl, -CH₂-phenyl, -CH₂-OH, -CH(OH)-CH₃, -CH₂-(3-indolyl) or -CH₂-(4-hydroxyphenyl);

n = 0-5;

M₁ and M₂ = -SO₂-, -S(O)- or -C(O)-;

L = CH or N;

R₂ = H or 1-6C alkyl;

E₁ and E₂ = carbon-carbon double bond in the (E)- or (Z)-conformation.

Provided that:

(1) when one of M₁ and M₂ is -SO₂-, then the other of M₁ and M₂ is other than -S(=O)-;

(2) when one of M₁ and M₂ is -C(=O)-, then the other of M₁ and M₂ is other than -C(=O)-; and

(3) when one of E₁ and E₂ is carbon-carbon double bond in the (Z)-conformation, then the other of E₁ and E₂ is carbon-carbon double bond in the (E)-conformation.

INDEPENDENT CLAIMS are also included for the following:

(1) new compounds (I), or their salts, with the additional proviso that when L is CH, R₂ is -H, M₁, M₂ are -SO₂-, and Q₁ and Q₂ are phenyl; then at least one n is greater than 0, and at least one substituent of R₁ is other than -OH, -OC(=O)CH₃, -C(O)CH₃, -OCH₃, -Br, -I, -NO₂, -CO₂(1-8C)hydrocarbyl, -SO₃(1-8C)hydrocarbyl, -P(O)(OR_w)₂ or -OP(O)(OR_w)₂; and

(2) the preparation of (I).

ACTIVITY - Cytostatic; Neuroprotective; Antiarteriosclerotic; Vulnerary; Osteopathic; Antiinflammatory; Vasotropic; Ophthalmological; Antiangiogenic; Nootropic; Antidiabetic; Gastrointestinal-Gen.; Antiulcer; Gynecological.

MECHANISM OF ACTION - Vascular endothelial growth factor receptor (VEGFR) (preferably VEGFR-1 (FLT-1) and VEGFR-2 (Flk-1/KDR)) inhibitor; Tumor cell growth inhibitor.

The inhibition of FLT1 by 4-((1E)-2-((E)-4-hydroxy-2,6-dimethoxystyrylsulfonyl)methylsulfonyl)-vinyl)-3,5-dimethoxyphenol (A1) was assessed by employing an in vitro filter assay for FLT-1. (A1) Was prepared as 10 mmol stock solution in dimethylsulfoxide. Curcumin was also prepared as 10 mmol stock solution for testing in the FLT-1 assay. Five units of recombinant FLT1 active protein was incubated with (A1) in reaction mixture (15 mul) (4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) (50 mM), MgCl₂ (10 mM), EDTA (1 mM), dithiothreitol (2 mM) 0.01% NP-40 pH 7.5) for 30 minutes at room temperature (25degreesC). Kinase reactions were performed for 20 minutes at 30degreesC in a volume of 20 mul (enzyme (15 mul)+(A1) (2 muM), ATP (1 mM), gamma32pATP (2 mul) and IGF-1Rtide (250 microns)). Aliquots (10 mul) of the kinase reaction were spotted onto the center of filter. After 30 seconds, the filters were washed with 0.75% phosphoric acid and once with acetone (5 minutes). The IC50 value of (A1) was found to be 0.077 muM.

USE - Compounds (I) are used for the treatment of a proliferative disorder e.g. hemangiomas in newborn, secondary progressive multiple sclerosis, atherosclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Paget's disease of the bone, fibrocystic disease of the breast, uterine fibroids, peronies and Duputren's fibrosis, restenosis, benign proliferative breast disease, benign prostatic hyperplasia, X-linked lymphoproliferative disorder, post-transplantation lymphoproliferative disorder, macular degeneration, retinopathies, proliferative vitreoretinopathy, non-cancerous lymphoproliferative disorders and cancer (such as ovarian, cervical, breast, prostate, testicular, lung, renal, colorectal, skin, brain, leukemia

(including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoid leukemia and chronic lymphoid leukemia)); for angiogenesis mediated disorder; and for age related senile dementia.

Compounds (I) are also used for inducing apoptosis of tumor cell (e.g. ovarian, cervical, breast, prostate, testicular, lung, renal, colorectal, skin or brain tumor cells) (all claimed). (I) are further used for treating metastasis, corneal graft rejection, ocular neovascularization, retinal neovascularization, diabetic retinopathy, retrolental fibroplasias, neovascular glaucoma, gastric ulcer, infantile hemangiomas, angiofibroma of the nasopharynx, avascular necrosis of bone and endometriosis.

ADVANTAGE - The compounds selectively kill various tumor cell types without killing normal cells; and activate the c-Jun NH2 terminal kinase (JNK) pathway.

MANUAL CODE:

CPI: B05-B01E; B05-B01F; B05-B01M; B05-B01N; B06-H;
B07-H; B10-A08; B10-A09B; B10-A10; B10-A15; B10-A17;
B10-A24; B10-A25; B14-E08; B14-F01G; B14-F02F2; B14-F07;
B14-G02C; B14-H01; B14-H01A; B14-H01B; B14-H04; B14-H05;
B14-J01A4; B14-L06; B14-N01; B14-N03; B14-N14; B14-N17B;
B14-S01; B14-S16

TECH

ORGANIC CHEMISTRY - Preparation (claimed): Preparation of (I) involves:
(1) either process (A): reacting a compound of formula (R1)_n-Q1-C(O)-H (Ia) with a compound of formula RO-C(O)-CH₂-M1-L(R2)-M2-CH₂-C(O)-OR (Ib); and isolating (I) (where E1 and E2 is carbon-carbon double bonds having (E)-conformation; Q1 is same as Q2; and R1 substituents on Q1 are same as R1 substituents on Q2); or
(2) process (B): reacting a compound of formula (R1)_n-Q2-C(O)-H (Ic) with a compound of formula (R1)_n-Q1-E1-M1-L(R2)-M2-CH₂-C(O)-OR (Id); and isolating (I) (where E2 is carbon-carbon double bonds having (E)-conformation).

R = H or 1-7C hydrocarbyl.

ABEX DEFINITIONS - Preferred Definitions: - Q1, Q2 = phenyl or heteroaryl; - L = CH; - M1 = -SO₂-; - M2 = -SO₂- or -C(O)-; and - R2 = -H.

ADMINISTRATION - The dosage of (I) is 0.05-50 mg/kg/day and administered parenterally (including intravenously, intramuscularly, intraarterially, intraperitoneally, intranasally, rectally, intravaginally, intravesically, intradermally, topically or subcutaneously) or orally.

SPECIFIC COMPOUNDS - 316 Compounds are specifically claimed as (I), e.g. 4-((1E)-2-((E)-4-hydroxy-2,6-dimethoxystyrylsulfonyl)methylsulfonyl)-vinyl)-3,5-dimethoxyphenol of formula (I-A).

EXAMPLE - To a round bottom flask containing 2,2'-(methylenedithio)diacetic acid (0.1 mol) dissolved in glacial acetic acid (25 ml) was added hydrogen peroxide (0.2 mol, 30% solution). The resulting mixture was heated at reflux temperature for 2 hours. When the reaction was complete, the mixture was allowed to cool room temperature (22-25degreesC). Volatiles were removed under vacuum and the rest residue was purified by column chromatography to obtain carboxymethanesulfonylmethanesulfonyl acetic acid (a1). - A solution of 4-hydroxy-2,6-dimethoxybenzaldehyde (2 mmol) and (a1) (1 mmol) was dissolved in (40-50degreesC) acetic acid (10 ml) and three drops of piperidine was added. The resulting mixture was heated to obtain 4-((1E)-2-((E)-4-hydroxy-2,6-dimethoxystyrylsulfonyl)methylsulfonyl)-vinyl)-3,5-dimethoxyphenol (yield 62%).

=> fil hcap

FILE 'HCAPLUS' ENTERED AT 09:23:19 ON 13 APR 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Apr 2007 VOL 146 ISS 17
 FILE LAST UPDATED: 12 Apr 2007 (20070412/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1 not l83

L135 0 L1 NOT L83

=> d que nos

L1	1	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	US2006-574993/APPS
L6			STR			
L7			STR			
L9	547	SEA	FILE=REGISTRY	SSS	FUL	L7
L12	339	SEA	FILE=REGISTRY	SUB=L9	SSS	FUL L6
L32		QUE	ABB=ON	PLU=ON	REDDY, E?/AU	
L33		QUE	ABB=ON	PLU=ON	REDDY, P?/AU	
L34		QUE	ABB=ON	PLU=ON	REDDY, M?/AU	
L35		QUE	ABB=ON	PLU=ON	REDDY, R?/AU	
L36		QUE	ABB=ON	PLU=ON	BELL, S?/AU	
L37		QUE	ABB=ON	PLU=ON	(TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)	
)/CS,SO,PA	
L39		QUE	ABB=ON	PLU=ON	PROLIFER?	
L40		QUE	ABB=ON	PLU=ON	DISEAS? OR DISORDER? OR SYNDROM? OR	
					MALADY OR SICKNESS OR ILLNESS OR CONDITION	
L41		QUE	ABB=ON	PLU=ON	HEMANGIOMAT?	
L42		QUE	ABB=ON	PLU=ON	MULTIPLE (W) SCLERO?	
L43		QUE	ABB=ON	PLU=ON	MS	
L44		QUE	ABB=ON	PLU=ON	MYELODEGENER?	
L45		QUE	ABB=ON	PLU=ON	?DEGENER? (3A) ?MYELO?	
L46		QUE	ABB=ON	PLU=ON	GANGLIONEUROMATO?	
L47		QUE	ABB=ON	PLU=ON	KELOID?	
L48		QUE	ABB=ON	PLU=ON	PAGET?	
L49		QUE	ABB=ON	PLU=ON	FIBROCYS?	
L50		QUE	ABB=ON	PLU=ON	COLORECT?	
L51		QUE	ABB=ON	PLU=ON	SKIN OR DERM? OR EPIDER?	
L52		QUE	ABB=ON	PLU=ON	BRAIN?	
L53		QUE	ABB=ON	PLU=ON	LEUKEM? OR LEUKAEM?	
L54		QUE	ABB=ON	PLU=ON	IONIZ? OR IONIS?	

L55 QUE ABB=ON PLU=ON RADIATION
 L56 QUE ABB=ON PLU=ON OPTIC?
 L57 QUE ABB=ON PLU=ON ISOMER?
 L58 QUE ABB=ON PLU=ON THERAP? OR DRUG OR PHARM? OR MEDIC?
 L59 QUE ABB=ON PLU=ON SARCOID?
 L60 QUE ABB=ON PLU=ON PERONIES
 L61 QUE ABB=ON PLU=ON DUPUTREN
 L62 QUE ABB=ON PLU=ON FIBROSIS
 L63 QUE ABB=ON PLU=ON CIRRHOSIS
 L64 QUE ABB=ON PLU=ON ?ATHEROSCLERO? OR ANIATHEROSCLER?
 L65 QUE ABB=ON PLU=ON ?VASCULAR?
 L66 QUE ABB=ON PLU=ON RESTENO?
 L67 QUE ABB=ON PLU=ON ?CANCER? OR ?CARCIN? OR ?ONCO? OR ?S
 ARCOM? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLAS? OR ?MALIGN? OR
 ?DYPLAS?
 L68 QUE ABB=ON PLU=ON ANTICANCER? OR ANTICARCIN? OR ANTISA
 RCOM? OR ANTITUM? OR ANTINEOPLAS?
 L69 QUE ABB=ON PLU=ON OVARY OR OVARIAN
 L70 QUE ABB=ON PLU=ON BREAST OR MAMMAR?
 L71 QUE ABB=ON PLU=ON PROSTAT?
 L72 QUE ABB=ON PLU=ON TESTIS OR TESTIC?
 L73 QUE ABB=ON PLU=ON LUNG
 L74 QUE ABB=ON PLU=ON PULMONAR?
 L75 QUE ABB=ON PLU=ON KIDNEY OR RENAL?
 L77 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L12
 L78 '6 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 AND (L39 OR L40 OR L41 OR
 L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
 L51 OR L52 OR L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR L59 OR
 L60 OR L61 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68 OR
 L69 OR L70 OR L71 OR L72 OR L73 OR L74 OR L75)
 L79 QUE ABB=ON PLU=ON SYNTHES? OR SYNTH OR PREP? OR REACT?
 L80 QUE ABB=ON PLU=ON MANUFACT?
 L81 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 AND (L79 OR L80)
 L82 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 OR L78 OR L81
 L83 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L82 AND (L32 OR L33 OR L34 OR
 L35 OR L36 OR L37)
 L135 0 SEA FILE=HCAPLUS ABB=ON PLU=ON L1 NOT L83

=> fil wpix

FILE 'WPIX' ENTERED AT 09:23:29 ON 13 APR 2007
 COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE LAST UPDATED: 11 APR 2007 <20070411/UP>
 MOST RECENT THOMSON SCIENTIFIC UPDATE: 200724 <200724/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> New reloaded DWPI Learn File (LWPI) available as well <<<

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> New display format FRAGHITSTR available <<<
 SEE ONLINE NEWS and

http://www.stn-international.de/archive/stn_online_news/fraghitstr_ex.pdf

>>> IPC Reform backfile reclassification has been loaded to 31 December
 2006. No update date (UP) has been created for the reclassified
 documents, but they can be identified by 20060101/UPIC and
 20061231/UPIC. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
<http://scientific.thomson.com/media/scpdf/ipcrdwpf.pdf>

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX
PLEASE SEE

http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<
'BIX BIEX ABEX TT' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> s 12 not 1108

L136 0 L2 NOT L108

=> d que nos

```

L2      1 SEA FILE=WPIX ABB=ON PLU=ON US2006-574993/APPS
L6      STR
L32     QUE ABB=ON PLU=ON REDDY, E?/AU
L33     QUE ABB=ON PLU=ON REDDY, P?/AU
L34     QUE ABB=ON PLU=ON REDDY, M?/AU
L35     QUE ABB=ON PLU=ON REDDY, R?/AU
L36     QUE ABB=ON PLU=ON BELL, S?/AU
L37     QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA)
        )/CS,SO,PA
L104    112 SEA FILE=WPIX SSS FUL L6
L105    4 SEA FILE=WPIX ABB=ON PLU=ON L104/DCR
L106    4 SEA FILE=WPIX ABB=ON PLU=ON (RAI110/DCN OR RAI11Q/DCN OR
        RAI11R/DCN OR RAI11S/DCN OR RAI11T/DCN OR RAI11U/DCN OR
        RAI12A/DCN OR RAI12B/DCN OR RAI12C/DCN OR RAI12D/DCN OR
        RAI12E/DCN OR RAI12F/DCN OR RAI12G/DCN OR RAI12H/DCN OR
        RAI2CA/DCN OR RAI2CB/DCN OR RAI2CC/DCN OR RAI2CD/DCN OR
        RAI2CE/DCN OR RAI2CF/DCN OR RAI2CG/DCN OR RAI2CH/DCN OR
        RAI2CJ/DCN OR RAI2CK/DCN OR RAI2CL/DCN OR RAI2CM/DCN OR
        RAI2CN/DCN OR RAI2CO/DCN OR RAI2CP/DCN OR RAI2CQ/DCN OR
        RAI2CR/DCN OR RAI2CS/DCN OR RAI2CT/DCN OR RAI2CU/DCN OR
        RAI2CV/DCN OR RAI2CW/DCN OR RAI2CX/DCN OR RAI2CY/DCN OR
        RAI2CZ/DCN OR RAI2C5/DCN OR RAI2C6/DCN OR RAI2C7/DCN OR
        RAI2C8/DCN OR RAI2C9/DCN OR RAI2DA/DCN OR RAI2DB/DCN OR
        RAI2DC/DCN OR RAI2DD/DCN OR RAI2DE/DCN OR RAI2DF/DCN OR
        RAI2DG/DCN OR RAI2DH/DCN OR RAI2DI/DCN OR RAI2DJ/DCN OR
        RAI2DK/DCN OR RAI2DL/DCN OR RAI2DM/DCN OR RAI2DN/DCN OR
        RAI2DO/DCN OR RAI2DP/DCN OR RAI2DQ/DCN OR RAI2DR/DCN OR
        RAI2DS/DCN OR RAI2DT/DCN OR RAI2DU/DCN OR RAI2DV/DCN OR
        RAI2DX/DCN OR RAI2DY/DCN OR RAI2DZ/DCN OR RAI2D0/DCN OR
        RAI2D1/DCN OR RAI2D2/DCN OR RAI2D3/DCN OR RAI2D4/DCN OR
        RAI2D5/DCN OR RAI2D6/DCN OR RAI2D7/DCN OR RAI2D8/DCN OR
        RAI2D9/DCN OR RAI2EA/DCN OR RAI2E0/DCN OR RAI2E1/DCN OR
        RAI2E2/DCN OR RAI2E3/DCN OR RAI2E4/DCN OR RAI2E5/DCN OR
        RAI2E6/DCN OR RAI2E7/DCN OR RAI2E8/DCN OR RAI2E9/DCN OR
        RAJKMO/DCN OR RAJKMP/DCN OR RAJKN1/DCN OR RAJKN2/DCN OR
        RAJKN3/DCN OR RAJKOB/DCN OR RAJKOC/DCN OR RAJKOD/DCN OR
        RAJKOE/DCN OR RAJKOF/DCN OR RAJKOG/DCN OR RAJKOH/DCN OR
        RAJKOI/DCN OR RAJKOO/DCN OR RANXKV/DCN OR RANXKW/DCN OR
        RANXKX/DCN OR RANXKY/DCN OR RANXKZ/DCN OR RANXL0/DCN OR

```

10/574,993

RANXL1/DCN OR RANXL2/DCN)

L107 4 SEA FILE=WPIX ABB=ON PLU=ON L105 OR L106
L108 4 SEA FILE=WPIX ABB=ON PLU=ON L107 AND (L32 OR L33 OR L34 OR
L35 OR L36 OR L37)
L136 0 SEA FILE=WPIX ABB=ON PLU=ON L2 NOT L108

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 09:23:42 ON 13 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Apr 6, 2007 (20070406/UP).

=> d his ful

(FILE 'HOME' ENTERED AT 06:44:18 ON 13 APR 2007)

FILE 'HCAPLUS' ENTERED AT 06:44:40 ON 13 APR 2007
ACT NWA993HCAAPP/A

L1 1 SEA ABB=ON PLU=ON US2006-574993/APPS

FILE 'WPIX' ENTERED AT 06:44:50 ON 13 APR 2007
ACT NWA993WPIAPP/A

L2 1 SEA ABB=ON PLU=ON US2006-574993/APPS

FILE 'REGISTRY' ENTERED AT 06:45:00 ON 13 APR 2007
ACT NWA993REGAPP/A

L3 (1)SEA ABB=ON PLU=ON US2006-574993/APPS
L4 SEL PLU=ON L3 1- RN : 282 TERMS
L5 282 SEA ABB=ON PLU=ON L4

FILE 'LREGISTRY' ENTERED AT 06:45:10 ON 13 APR 2007
D SAVED
ACT NWA993STRQ/Q

L6 STR

L7 STR L6

FILE 'REGISTRY' ENTERED AT 06:47:44 ON 13 APR 2007
L8 2 SEA SSS SAM L7
D SCAN

FILE 'STNGUIDE' ENTERED AT 06:48:01 ON 13 APR 2007
D QUE STAT

FILE 'REGISTRY' ENTERED AT 06:50:46 ON 13 APR 2007
D QUE STAT

L9 547 SEA SSS FUL L7
SAVE TEMP L9 NWA993PSET1/A
L10 18 SEA ABB=ON PLU=ON L5 NOT L9
D SCAN

FILE 'LREGISTRY' ENTERED AT 06:52:13 ON 13 APR 2007
D QUE L6

FILE 'REGISTRY' ENTERED AT 06:52:44 ON 13 APR 2007
L11 18 SEA SUB=L9 SSS SAM L6
D QUE STAT

FILE 'STNGUIDE' ENTERED AT 06:53:16 ON 13 APR 2007

FILE 'REGISTRY' ENTERED AT 06:55:13 ON 13 APR 2007
D QUE STAT

L12 339 SEA SUB=L9 SSS FUL L6
SAVE TEMP L12 NWA993RSET1/A

FILE 'STNGUIDE' ENTERED AT 06:56:12 ON 13 APR 2007

L13 FILE 'LREGISTRY' ENTERED AT 07:11:32 ON 13 APR 2007
STR

L14 FILE 'CASREACT' ENTERED AT 07:14:40 ON 13 APR 2007
1 SEA SSS SAM L13 (1 REACTIONS)
D SCAN

L15 FILE 'LREGISTRY' ENTERED AT 07:15:22 ON 13 APR 2007
STR L13

L16 FILE 'CASREACT' ENTERED AT 07:15:40 ON 13 APR 2007
0 SEA SSS SAM L15 (0 REACTIONS)

FILE 'STNGUIDE' ENTERED AT 07:15:50 ON 13 APR 2007
D QUE STAT

L17 FILE 'CASREACT' ENTERED AT 07:18:29 ON 13 APR 2007
3 SEA SSS FUL L15 (8 REACTIONS)
SAVE TEMP L17 NWA993CRXP/A
D SCAN

FILE 'STNGUIDE' ENTERED AT 07:19:58 ON 13 APR 2007
D SAVED

L18 FILE 'CHEMINFORMRX' ENTERED AT 07:20:41 ON 13 APR 2007
0 SEA SSS SAM L15 (0 REACTIONS)

L19 1 SEA SSS FUL L15 (1 REACTIONS)
SAVE TEMP L19 NWA993CHMP/A
D SCAN

FILE 'STNGUIDE' ENTERED AT 07:22:35 ON 13 APR 2007

L20 FILE 'HCAPLUS' ENTERED AT 07:22:56 ON 13 APR 2007
15 SEA ABB=ON PLU=ON L12

FILE 'STNGUIDE' ENTERED AT 07:23:41 ON 13 APR 2007

L21 FILE 'REGISTRY' ENTERED AT 07:24:34 ON 13 APR 2007
264 SEA ABB=ON PLU=ON L5 AND L12

L22 18 SEA ABB=ON PLU=ON L5 NOT L12
D SCAN

FILE 'STNGUIDE' ENTERED AT 07:25:21 ON 13 APR 2007

L23 FILE 'LREGISTRY' ENTERED AT 07:26:27 ON 13 APR 2007
STR L15

FILE 'STNGUIDE' ENTERED AT 07:27:49 ON 13 APR 2007
SET NOTICE 110
D SET
SET NOTICE 500

L24 FILE 'BEILSTEIN' ENTERED AT 07:30:09 ON 13 APR 2007
1 SEA SSS SAM L7

L25 0 SEA SSS SAM L6

L26 11 SEA SSS FUL L6
SAVE TEMP L26 NWA993BEIP/A

L27 6 SEA ABB=ON PLU=ON L26 NOT BABSAN/FA
SELECT L26 1- BABSAN

FILE 'BABS' ENTERED AT 07:32:22 ON 13 APR 2007

L28 8 SEA ABB=ON PLU=ON (6121948/AN OR 6011603/AN OR 5521334/AN OR
5542760/AN OR 6443896/AN OR 5571926/AN OR 6282045/AN OR
6294163/AN)
SAVE TEMP L28 NWA993BABS/A

FILE 'STNGUIDE' ENTERED AT 07:32:55 ON 13 APR 2007
D SAVED

FILE 'CHEMINFORMRX' ENTERED AT 07:33:46 ON 13 APR 2007

L29 0 SEA SSS SAM L7 (0 REACTIONS)
L30 0 SEA SSS SAM L6 (0 REACTIONS)
L31 3 SEA SSS FUL L6 (5 REACTIONS)
SAVE TEMP L31 NWA993CHMP2/A
D SCAN

FILE 'STNGUIDE' ENTERED AT 07:35:49 ON 13 APR 2007
D SAVED

FILE 'ZCAPLUS' ENTERED AT 07:53:07 ON 13 APR 2007

L32 QUE ABB=ON PLU=ON REDDY, E?/AU
L33 QUE ABB=ON PLU=ON REDDY, P?/AU
L*** DEL QUE REDDY, M?
L34 QUE ABB=ON PLU=ON REDDY, M?/AU
L35 QUE ABB=ON PLU=ON REDDY, R?/AU
L36 QUE ABB=ON PLU=ON BELL, S?/AU
L37 QUE ABB=ON PLU=ON (TEMPLE OR ONCONOVA OR (ONCO(W)NOVA))/CS,SO
PA
D HIS10
L38 QUE ABB=ON PLU=ON (REDDY OR BELL)/AU
L39 QUE ABB=ON PLU=ON PROLIFER?
L40 QUE ABB=ON PLU=ON DISEAS? OR DISORDER? OR SYNDROM? OR MALADY
OR SICKNESS OR ILLNESS OR CONDITION
L41 QUE ABB=ON PLU=ON HEMANGIOMAT?
L42 QUE ABB=ON PLU=ON MULTIPLE (W) SCLERO?
L43 QUE ABB=ON PLU=ON MS
L44 QUE ABB=ON PLU=ON MYELODEGENER?
L45 QUE ABB=ON PLU=ON ?DEGENER? (3A) ?MYELO?
L46 QUE ABB=ON PLU=ON GANGLIONEUROMATO?
L47 QUE ABB=ON PLU=ON KELOID?
L48 QUE ABB=ON PLU=ON PAGET?
L49 QUE ABB=ON PLU=ON FIBROCYS?
L50 QUE ABB=ON PLU=ON COLORECT?
L51 QUE ABB=ON PLU=ON SKIN OR DERM? OR EPIDER?
L52 QUE ABB=ON PLU=ON BRAIN?
L53 QUE ABB=ON PLU=ON LEUKEM? OR LEUKAEM?
L54 QUE ABB=ON PLU=ON IONIZ? OR IONIS?
L55 QUE ABB=ON PLU=ON RADIATION
L56 QUE ABB=ON PLU=ON OPTIC?
L57 QUE ABB=ON PLU=ON ISOMER?
L58 QUE ABB=ON PLU=ON THERAP? OR DRUG OR PHARM? OR MEDIC?
L59 QUE ABB=ON PLU=ON SARCOID?
L60 QUE ABB=ON PLU=ON PERONIES
L61 QUE ABB=ON PLU=ON DUPUTREN
L62 QUE ABB=ON PLU=ON FIBROSIS
L63 QUE ABB=ON PLU=ON CIRRHOS?
L64 QUE ABB=ON PLU=ON ?ATHEROSCLERO? OR ANIATHEROSCLER?

L65 QUE ABB=ON PLU=ON ?VASCULAR?
 L66 QUE ABB=ON PLU=ON RESTENO?
 L67 QUE ABB=ON PLU=ON ?CANCER? OR ?CARCIN? OR ?ONCO? OR ?SARCOM?
 OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLAS? OR ?MALIGN? OR ?DYPLAS?
 L68 QUE ABB=ON PLU=ON ANTICANCER? OR ANTICARCIN? OR ANTISARCOM?
 OR ANTITUM? OR ANTINEOPLAS?
 L69 QUE ABB=ON PLU=ON OVARY OR OVARIAN
 L70 QUE ABB=ON PLU=ON BREAST OR MAMMAR?
 L71 QUE ABB=ON PLU=ON PROSTAT?
 L72 QUE ABB=ON PLU=ON TESTIS OR TESTIC?
 L73 QUE ABB=ON PLU=ON LUNG
 L74 QUE ABB=ON PLU=ON PULMONAR?
 L75 QUE ABB=ON PLU=ON KIDNEY OR RENAL?

FILE 'HCAPLUS' ENTERED AT 08:04:02 ON 13 APR 2007

L76 149 SEA ABB=ON PLU=ON L9
 L77 15 SEA ABB=ON PLU=ON L12
 L78 6 SEA ABB=ON PLU=ON L77 AND (L39 OR L40 OR L41 OR L42 OR L43
 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52
 OR L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR L59 OR L60 OR L61
 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68 OR L69 OR L70
 OR L71 OR L72 OR L73 OR L74 OR L75)

FILE 'ZCAPLUS' ENTERED AT 08:05:13 ON 13 APR 2007

L79 QUE ABB=ON PLU=ON SYNTHES? OR SYNTH OR PREP? OR REACT?

FILE 'HCAPLUS' ENTERED AT 08:05:53 ON 13 APR 2007

L80 QUE ABB=ON PLU=ON MANUFACT?
 L81 14 SEA ABB=ON PLU=ON L77 AND (L79 OR L80)
 L82 15 SEA ABB=ON PLU=ON L77 OR L78 OR L81
 L83 4 SEA ABB=ON PLU=ON L82 AND (L32 OR L33 OR L34 OR L35 OR L36
 OR L37)
 SAVE TEMP L83 NWA993HCAINV/A

FILE 'ZCAPLUS' ENTERED AT 08:07:07 ON 13 APR 2007

L84 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY<2004
 OR REVIEW/DT
 L85 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004

FILE 'HCAPLUS' ENTERED AT 08:08:08 ON 13 APR 2007

L86 11 SEA ABB=ON PLU=ON L82 NOT L83
 L87 11 SEA ABB=ON PLU=ON L86 AND L84
 L88 11 SEA ABB=ON PLU=ON L86 OR L87
 D SCAN TI HIT

FILE 'STNGUIDE' ENTERED AT 08:09:13 ON 13 APR 2007

FILE 'HCAPLUS' ENTERED AT 08:09:52 ON 13 APR 2007
 SAVE TEMP L88 NWA993HCCAM/A

FILE 'STNGUIDE' ENTERED AT 08:10:15 ON 13 APR 2007

FILE 'REGISTRY' ENTERED AT 08:10:33 ON 13 APR 2007
 L89 ANALYZE PLU=ON L12 1- LC : 7 TERMS
 D 1-7

FILE 'STNGUIDE' ENTERED AT 08:11:34 ON 13 APR 2007

FILE 'REGISTRY' ENTERED AT 08:12:36 ON 13 APR 2007
 L90 264 SEA ABB=ON PLU=ON L12 AND USPATFULL/LC

FILE 'USPATFULL' ENTERED AT 08:12:50 ON 13 APR 2007

L91 1 SEA ABB=ON PLU=ON L90

L92 1 SEA ABB=ON PLU=ON L91 AND (L32 OR L33 OR L34 OR L35 OR L36 OR L37)

L93 0 SEA ABB=ON PLU=ON L91 NOT L92

FILE 'TOXCENTER' ENTERED AT 08:14:19 ON 13 APR 2007

FILE 'REGISTRY' ENTERED AT 08:14:21 ON 13 APR 2007

L94 323 SEA ABB=ON PLU=ON L12 AND TOXCENTER/LC

FILE 'TOXCENTER' ENTERED AT 08:14:34 ON 13 APR 2007

L95 3 SEA ABB=ON PLU=ON L94

L96 3 SEA ABB=ON PLU=ON L95 AND (L32 OR L33 OR L34 OR L35 OR L36 OR L37)

L97 0 SEA ABB=ON PLU=ON L95 NOT L96

FILE 'REGISTRY' ENTERED AT 08:15:16 ON 13 APR 2007

L98 13 SEA ABB=ON PLU=ON L12 AND CASREACT/LC

FILE 'CASREACT' ENTERED AT 08:15:31 ON 13 APR 2007

L99 6 SEA ABB=ON PLU=ON L98

FILE 'REGISTRY' ENTERED AT 08:15:50 ON 13 APR 2007

L100 1 SEA ABB=ON PLU=ON L12 AND CAOLD/LC

FILE 'CAOLD' ENTERED AT 08:16:01 ON 13 APR 2007

L101 1 SEA ABB=ON PLU=ON L100
SELECT L101 1- AN

FILE 'HCAPLUS' ENTERED AT 08:16:26 ON 13 APR 2007

L102 2 SEA ABB=ON PLU=ON "CA59:5004B"/OREF

FILE 'STNGUIDE' ENTERED AT 08:16:40 ON 13 APR 2007

FILE 'WPIX' ENTERED AT 08:18:03 ON 13 APR 2007

L103 12 SEA SSS SAM L6
D TRI 1-12
D QUE STAT

L104 112 SEA SSS FUL L6
SAVE TEMP L104 NWA993WPIS/A

L105 4 SEA ABB=ON PLU=ON L104/DCR
SELECT L104 1- SDCN

L*** DEL 0 S E10-E121/DNC

L106 4 SEA ABB=ON PLU=ON (RAI110/DCN OR RAI11Q/DCN OR RAI11R/DCN OR RAI11S/DCN OR RAI11T/DCN OR RAI11U/DCN OR RAI12A/DCN OR RAI12B/DCN OR RAI12C/DCN OR RAI12D/DCN OR RAI12E/DCN OR RAI12F/DCN OR RAI12G/DCN OR RAI12H/DCN OR RAI2CA/DCN OR RAI2CB/DCN OR RAI2CC/DCN OR RAI2CD/DCN OR RAI2CE/DCN OR RAI2CF/DCN OR RAI2CG/DCN OR RAI2CH/DCN OR RAI2CJ/DCN OR RAI2CK/DCN OR RAI2CL/DCN OR RAI2CM/DCN OR RAI2CN/DCN OR RAI2CO/DCN OR RAI2CP/DCN OR RAI2CQ/DCN OR RAI2CR/DCN OR RAI2CS/DCN OR RAI2CT/DCN OR RAI2CU/DCN OR RAI2CV/DCN OR RAI2CW/DCN OR RAI2CX/DCN OR RAI2CY/DCN OR RAI2CZ/DCN OR RAI2C5/DCN OR RAI2C6/DCN OR RAI2C7/DCN OR RAI2C8/DCN OR RAI2C9/DCN OR RAI2DA/DCN OR RAI2DB/DCN OR RAI2DC/DCN OR RAI2DD/DCN OR RAI2DE/DCN OR RAI2DF/DCN OR RAI2DG/DCN OR RAI2DH/DCN OR RAI2DI/DCN OR RAI2DJ/DCN OR RAI2DK/DCN OR RAI2DL/DCN OR RAI2DM/DCN OR RAI2DN/DCN OR RAI2DO/DCN OR

RAI2DP/DCN OR RAI2DQ/DCN OR RAI2DR/DCN OR RAI2DS/DCN OR
 RAI2DT/DCN OR RAI2DU/DCN OR RAI2DV/DCN OR RAI2DX/DCN OR
 RAI2DY/DCN OR RAI2DZ/DCN OR RAI2D0/DCN OR RAI2D1/DCN OR
 RAI2D2/DCN OR RAI2D3/DCN OR RAI2D4/DCN OR RAI2D5/DCN OR
 RAI2D6/DCN OR RAI2D7/DCN OR RAI2D8/DCN OR RAI2D9/DCN OR
 RAI2EA/DCN OR RAI2E0/DCN OR RAI2E1/DCN OR RAI2E2/DCN OR
 RAI2E3/DCN OR RAI2E4/DCN OR RAI2E5/DCN OR RAI2E6/DCN OR
 RAI2E7/DCN OR RAI2E8/DCN OR RAI2E9/DCN OR RAJKMO/DCN OR
 RAJKMP/DCN OR RAJKN1/DCN OR RAJKN2/DCN OR RAJKN3/DCN OR
 RAJKOB/DCN OR RAJKOC/DCN OR RAJKOD/DCN OR RAJKOE/DCN OR
 RAJKOF/DCN OR RAJKOG/DCN OR RAJKOH/DCN OR RAJKOI/DCN OR
 RAJKOO/DCN OR RANXKV/DCN OR RANXKW/DCN OR RANXKX/DCN OR
 RANXKY/DCN OR RANXKZ/DCN OR RANXL0/DCN OR RANXL1/DCN OR
 RANXL2/DCN)

L107 4 SEA ABB=ON PLU=ON L105 OR L106
 L108 4 SEA ABB=ON PLU=ON L107 AND (L32 OR L33 OR L34 OR L35 OR L36
 OR L37)
 L109 0 SEA ABB=ON PLU=ON L107 NOT L108

FILE 'STNGUIDE' ENTERED AT 08:20:54 ON 13 APR 2007
 D COST

FILE 'LREGISTRY' ENTERED AT 08:22:14 ON 13 APR 2007
 L110 STR L6

FILE 'MARPAT' ENTERED AT 08:23:53 ON 13 APR 2007
 L111 1 SEA SSS SAM L110
 D SCAN

FILE 'STNGUIDE' ENTERED AT 08:24:37 ON 13 APR 2007
 D QUE STAT

FILE 'MARPAT' ENTERED AT 08:27:50 ON 13 APR 2007
 D QUE STAT
 D SCAN
 D QUE STAT
 L112 52 SEA SSS FUL L110
 SAVE TEMP L112 NWA993MARPA

FILE 'HCAPLUS' ENTERED AT 08:30:56 ON 13 APR 2007
 L113 52 SEA ABB=ON PLU=ON L112
 L114 6 SEA ABB=ON PLU=ON L113 AND (L32 OR L33 OR L34 OR L35 OR L36
 OR L37)
 L115 46 SEA ABB=ON PLU=ON L113 NOT L114
 L116 34 SEA ABB=ON PLU=ON L115 AND L85
 L117 34 SEA ABB=ON PLU=ON L116 AND ((L39 OR L40 OR L41 OR L42 OR L43
 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52
 OR L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR L59 OR L60 OR L61
 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68 OR L69 OR L70
 OR L71 OR L72 OR L73 OR L74 OR L75) OR (L79 OR L80))
 L118 1 SEA ABB=ON PLU=ON L117 AND ATHEROSCLER?/TI
 D IBIB

FILE 'STNGUIDE' ENTERED AT 08:33:56 ON 13 APR 2007

FILE 'HCAPLUS' ENTERED AT 08:34:03 ON 13 APR 2007
 L119 34 SEA ABB=ON PLU=ON L117 NOT L88
 L120 2 SEA ABB=ON PLU=ON L114 NOT L83

FILE 'STNGUIDE' ENTERED AT 08:35:02 ON 13 APR 2007

FILE 'MEDLINE, BIOSIS, EMBASE, CABA, AGRICOLA, DRUGU, VETU, BIOTECHNO'
ENTERED AT 08:35:44 ON 13 APR 2007

FILE 'REGISTRY' ENTERED AT 08:35:50 ON 13 APR 2007

SET SMARTSELECT ON
L121 SEL PLU=ON L12 1- CHEM : 412 TERMS
SET SMARTSELECT OFF

FILE 'MEDLINE, BIOSIS, EMBASE, CABA, AGRICOLA, DRUGU, VETU, BIOTECHNO'
ENTERED AT 08:35:55 ON 13 APR 2007

L122 0 SEA ABB=ON PLU=ON L121

FILE 'STNGUIDE' ENTERED AT 08:47:15 ON 13 APR 2007

FILE 'ZCAPLUS' ENTERED AT 08:48:24 ON 13 APR 2007

L123 QUE ABB=ON PLU=ON UNSAT? OR ?ALKENYL?

L124 QUE ABB=ON PLU=ON ?SULFOXID?

FILE 'STNGUIDE' ENTERED AT 08:48:57 ON 13 APR 2007

FILE 'JAPIO' ENTERED AT 08:49:24 ON 13 APR 2007

L125 16 SEA ABB=ON PLU=ON L123(7A)L124

L126 0 SEA ABB=ON PLU=ON L125 AND (L37 OR L38)

FILE 'STNGUIDE' ENTERED AT 08:50:00 ON 13 APR 2007

FILE 'MEDLINE, BIOSIS, EMBASE, PASCAL, CABA, AGRICOLA, LIFESCI, BIOENG,
BIOTECHNO, BIOTECHDS, DRUGU, DRUGB, VETU, VETB, SCISEARCH, CONFSCI,
DISSABS' ENTERED AT 08:50:48 ON 13 APR 2007

L127 364 SEA ABB=ON PLU=ON L123 (5A) L124

L128 0 SEA ABB=ON PLU=ON L127 AND (L32 OR L33 OR L34 OR L35 OR L36
OR L37)
D QUE\

FILE 'MEDLINE, BIOSIS, EMBASE, PASCAL, CABA, AGRICOLA, LIFESCI, BIOENG,
BIOTECHNO, BIOTECHDS, DRUGU, DRUGB, VETU, VETB, SCISEARCH, CONFSCI,
DISSABS, WPIX' ENTERED AT 08:53:12 ON 13 APR 2007

L129 438 SEA ABB=ON PLU=ON L123 (5A) L124

L130 4 SEA ABB=ON PLU=ON L129 AND (L32 OR L33 OR L34 OR L35 OR L36
OR L37)

FILE 'STNGUIDE' ENTERED AT 08:54:31 ON 13 APR 2007

D SAVED

D QUE STAT L9

D QUE STAT L12

D QUE NOS L89

D L89 1-7

D QUE STAT L17

D QUE STAT L19

D QUE STAT L29

D QUE STAT L30

D QUE STAT L31

D QUE STAT L26

D QUE NOS L27

D QUE L28

D QUE L88

D QUE NOS L93

D QUE NOS L97

D QUE NOS L99

D QUE NOS L100
 D QUE NOS L102
 D QUE STAT L104
 D QUE NOS L109
 D QUE NOS L122

FILE 'BEILSTEIN' ENTERED AT 09:01:55 ON 13 APR 2007

D L27 IDE 1
 D L27 RX 1
 D L27 IDE 2
 D L27 RX 2
 D L27 IDE 3
 D L27 RX 3
 D L27 IDE 4
 D L27 RX 4
 D L27 IDE 5
 D L27 RX 5
 D L27 IDE 6
 D L27 RX 6

FILE 'HCAPLUS, CASREACT, CHEMINFORMRX, BABS, REGISTRY' ENTERED AT
 09:04:56 ON 13 APR 2007

L131 21 DUP REM L88 L17 L19 L31 L28 L93 L97 L99 L100 L102... (14 DUPLI
 ANSWERS '1-11' FROM FILE HCAPLUS
 ANSWERS '12-14' FROM FILE CASREACT
 ANSWERS '15-18' FROM FILE CHEMINFORMRX
 ANSWERS '19-20' FROM FILE BABS
 ANSWER '21' FROM FILE REGISTRY

FILE 'STNGUIDE' ENTERED AT 09:05:20 ON 13 APR 2007

FILE 'HCAPLUS, CASREACT, CHEMINFORMRX, BABS, REGISTRY' ENTERED AT
 09:06:56 ON 13 APR 2007

L132 21 DUP REM L88 L17 L19 L31 L28 L93 L97 L99 L100 L102... (14 DUPLI
 ANSWERS '1-11' FROM FILE HCAPLUS
 ANSWERS '12-14' FROM FILE CASREACT
 ANSWERS '15-18' FROM FILE CHEMINFORMRX
 ANSWERS '19-20' FROM FILE BABS
 ANSWER '21' FROM FILE REGISTRY

FILE 'STNGUIDE' ENTERED AT 09:07:09 ON 13 APR 2007

D QUE L100
 D QUE NOS L101

FILE 'HCAPLUS, CASREACT, CHEMINFORMRX, BABS, CAOLD' ENTERED AT 09:09:24
 ON 13 APR 2007

L133 21 DUP REM L88 L17 L19 L31 L28 L93 L97 L99 L101 L102... (14 DUPLI
 ANSWERS '1-11' FROM FILE HCAPLUS
 ANSWERS '12-14' FROM FILE CASREACT
 ANSWERS '15-18' FROM FILE CHEMINFORMRX
 ANSWERS '19-20' FROM FILE BABS
 ANSWER '21' FROM FILE CAOLD

FILE 'STNGUIDE' ENTERED AT 09:09:29 ON 13 APR 2007

FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' ENTERED AT 09:10:04
 ON 13 APR 2007

D IBIB ED AB HITIND HITSTR

FILE 'STNGUIDE' ENTERED AT 09:10:11 ON 13 APR 2007

FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' ENTERED AT 09:10:23
ON 13 APR 2007

D IBIB ED AB HITIND HITSTR 2-11

FILE 'STNGUIDE' ENTERED AT 09:10:26 ON 13 APR 2007

FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' ENTERED AT 09:10:53
ON 13 APR 2007

D IBIB AB FHIT 12

FILE 'STNGUIDE' ENTERED AT 09:10:55 ON 13 APR 2007

FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' ENTERED AT 09:11:21
ON 13 APR 2007

D IBIB AB FHIT 13-14

FILE 'STNGUIDE' ENTERED AT 09:11:26 ON 13 APR 2007

FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' ENTERED AT 09:11:47
ON 13 APR 2007

D BIB AB FHIT 15

FILE 'STNGUIDE' ENTERED AT 09:11:49 ON 13 APR 2007

FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' ENTERED AT 09:11:59
ON 13 APR 2007

D BIB AB FHIT 16-18

FILE 'STNGUIDE' ENTERED AT 09:12:03 ON 13 APR 2007

FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' ENTERED AT 09:12:47
ON 13 APR 2007

D IBIB AB 19-20

FILE 'STNGUIDE' ENTERED AT 09:12:48 ON 13 APR 2007

FILE 'CASREACT, CHEMINFORMRX, BABS, HCAPLUS, CAOLD' ENTERED AT 09:13:13
ON 13 APR 2007

D IDE HITSTR 21

FILE 'STNGUIDE' ENTERED AT 09:13:31 ON 13 APR 2007

D QUE STAT L112

D QUE NOS L119

FILE 'HCAPLUS' ENTERED AT 09:14:30 ON 13 APR 2007

D IBIB ED AB HITIND L119

FILE 'STNGUIDE' ENTERED AT 09:14:30 ON 13 APR 2007

FILE 'HCAPLUS' ENTERED AT 09:14:48 ON 13 APR 2007

D IBIB ED AB HITIND L119 2-34

FILE 'STNGUIDE' ENTERED AT 09:15:18 ON 13 APR 2007

D QUE NOS L83

D QUE NOS L92

D QUE NOS L96

D QUE NOS L108

D QUE NOS L126

D QUE NOS L120

D QUE L130

FILE 'HCAPLUS, USPATFULL, TOXCENTER, WPIX' ENTERED AT 09:19:16 ON 13 APR 2007

L134 8 DUP REM L83 L92 L96 L108 L120 L126 L130 (10 DUPLICATES REMOVED)
 ANSWERS '1-6' FROM FILE HCAPLUS
 ANSWER '7' FROM FILE USPATFULL
 ANSWER '8' FROM FILE WPIX

FILE 'STNGUIDE' ENTERED AT 09:19:28 ON 13 APR 2007

FILE 'HCAPLUS, USPATFULL, WPIX' ENTERED AT 09:19:48 ON 13 APR 2007
 D IBIB ED AB HITIND HITSTR

FILE 'STNGUIDE' ENTERED AT 09:19:50 ON 13 APR 2007

FILE 'HCAPLUS, USPATFULL, WPIX' ENTERED AT 09:20:17 ON 13 APR 2007
 D IBIB ED AB HITIND HITSTR 2-6

FILE 'STNGUIDE' ENTERED AT 09:20:37 ON 13 APR 2007

FILE 'HCAPLUS, USPATFULL, WPIX' ENTERED AT 09:22:16 ON 13 APR 2007
 D IBIB AB HITRN FHITSTR 7

FILE 'STNGUIDE' ENTERED AT 09:22:18 ON 13 APR 2007

FILE 'HCAPLUS, USPATFULL, WPIX' ENTERED AT 09:22:51 ON 13 APR 2007
 D IALL ABEQ TECH ABEX HITSTR 8

FILE 'STNGUIDE' ENTERED AT 09:22:55 ON 13 APR 2007

L135 FILE 'HCAPLUS' ENTERED AT 09:23:19 ON 13 APR 2007
 0 SEA ABB=ON PLU=ON L1 NOT L83
 D QUE NOS

L136 FILE 'WPIX' ENTERED AT 09:23:29 ON 13 APR 2007
 0 SEA ABB=ON PLU=ON L2 NOT L108
 D QUE NOS

FILE 'STNGUIDE' ENTERED AT 09:23:42 ON 13 APR 2007

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Apr 2007 VOL 146 ISS 17
 FILE LAST UPDATED: 12 Apr 2007 (20070412/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIX

FILE LAST UPDATED: 11 APR 2007 <20070411/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200724 <200724/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> New reloaded DWPI Learn File (LWPI) available as well <<<

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> New display format FRAGHITSTR available <<<

SEE ONLINE NEWS and

http://www.stn-international.de/archive/stn_online_news/fraghitstr_ex.pdf

>>> IPC Reform backfile reclassification has been loaded to 31 December 2006. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC and 20061231/UPIC. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

http://www.stn-international.de/stndatabases/details/ipc_reform.html and
<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf>

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX PLEASE SEE

http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 APR 2007 HIGHEST RN 929960-62-3

DICTIONARY FILE UPDATES: 12 APR 2007 HIGHEST RN 929960-62-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE LREGISTRY

LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Apr 6, 2007 (20070406/UP).

FILE CASREACT

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 7 Apr 2007 VOL 146 ISS 16

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
*
*      CASREACT now has more than 12 million reactions      *
*
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1999) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE CHEMINFORMRX

FILE LAST UPDATED: 8 MAR 2007 <20070308/UP>

>>> CAS Registry Numbers are available for
substances prior to 1995 <<<

FILE BEILSTEIN

FILE LAST UPDATED ON JANUARY 10, 2007

FILE COVERS 1771 TO 2006.

FILE CONTAINS 9,780,003 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

```
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.      *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
```


* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
 * ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
 * FOR PRICE INFORMATION SEE HELP COST *

NEW

* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.

* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

FILE BABS

FILE LAST UPDATED: 10 JAN 2007 <20070110/UP>

FILE COVERS 1980 TO DATE.

FILE ZCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 13 Apr 2007 VOL 146 ISS 17

FILE LAST UPDATED: 12 Apr 2007 (20070412/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 12 Apr 2007 (20070412/PD)

FILE LAST UPDATED: 12 Apr 2007 (20070412/ED)

HIGHEST GRANTED PATENT NUMBER: US7203969

HIGHEST APPLICATION PUBLICATION NUMBER: US2007083964

CA INDEXING IS CURRENT THROUGH 12 Apr 2007 (20070412/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 12 Apr 2007 (20070412/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

FILE TOXCENTER

FILE COVERS 1907 TO 10 Apr 2007 (20070410/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2007 MeSH terms. and See HELP RLOAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2007 vocabulary.

FILE CAOLD

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

FILE MARPAT

FILE CONTENT: 1961-PRESENT VOL 146 ISS 15 (20070406/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES (COVERAGE TO THESE DATES IS NOT COMPLETE):

US	2007043092	22	FEB	2007
DE	102006011317	15	FEB	2007
EP	1754791	21	FEB	2007
JP	2007048464	22	FEB	2007
WO	2007023141	01	MAR	2007
GB	2428675	07	FEB	2007
FR	2889846	23	FEB	2007
RU	2293746	20	FEB	2007
CA	2555098	09	FEB	2007

Expanded G-group definition display now available.

FILE MEDLINE

FILE LAST UPDATED: 12 Apr 2007 (20070412/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 11 April 2007 (20070411/ED)

FILE EMBASE

FILE COVERS 1974 TO 12 Apr 2007 (20070412/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE CABA

10/574,993

FILE COVERS 1973 TO 5 Apr 2007 (20070405/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The CABA file was reloaded 7 December 2003. Enter HELP RLOAD for details.

FILE AGRICOLA

FILE COVERS 1970 TO 3 Apr 2007 (20070403/ED)

Compiled and distributed by the National Agricultural Library of the Department of Agriculture of the United States of America. It contains copyrighted material. All rights reserved. (2007)

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE DRUGU

FILE LAST UPDATED: 10 APR 2007 <20070410/UP>

>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<

>>> THESAURUS AVAILABLE IN /CT <<<

FILE VETU

FILE LAST UPDATED: 02 JAN 2002 <20020102/UP>

FILE COVERS 1983-2001

FILE BIOTECHNO

FILE LAST UPDATED: 7 JAN 2004 <20040107/UP>

FILE COVERS 1980 TO 2003.

>>> BIOTECHNO IS NO LONGER BEING UPDATED AS OF 2004 <<<

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN /CT AND BASIC INDEX <<<

FILE JAPIO

FILE LAST UPDATED: 2 APR 2007 <20070402/UP>

FILE COVERS APRIL 1973 TO DECEMBER 28, 2006

>>> GRAPHIC IMAGES AVAILABLE <<<

FILE PASCAL

FILE LAST UPDATED: 10 APR 2007 <20070410/UP>

FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE IN THE BASIC INDEX (/BI) FIELD <<<

FILE LIFESCI

FILE COVERS 1978 TO 21 Mar 2007 (20070321/ED)

FILE BIOENG

FILE LAST UPDATED: 29 MAR 2007 <20070329/UP>

FILE COVERS 1982 TO DATE

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
THE BASIC INDEX <<<

FILE BIOTECHDS

FILE LAST UPDATED: 11 APR 2007 <20070411/UP>

FILE COVERS 1982 TO DATE

>>> USE OF THIS FILE IS LIMITED TO BIOTECH SUBSCRIBERS <<<

FILE DRUGB

>>> FILE COVERS 1964 TO 1982 - CLOSED FILE <<<

FILE VETB

FILE LAST UPDATED: 25 SEP 94 <940925/UP>

FILE COVERS 1968-1982

FILE SCISEARCH

FILE COVERS 1974 TO 12 Apr 2007 (20070412/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE CONFSCI

FILE COVERS 1973 TO 3 Jan 2007 (20070103/ED)

CSA has resumed updates, see NEWS FILE

FILE DISSABS

FILE COVERS 1861 TO 2 APR 2007 (20070402/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

=>